

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2013208895 B2

(54) Title
Dual antigen-induced bipartite functional complementation

(51) International Patent Classification(s)
C07K 16/28 (2006.01) **C07K 16/46** (2006.01)
C07K 16/30 (2006.01)

(21) Application No: **2013208895** (22) Date of Filing: **2013.01.14**

(87) WIPO No: **WO13/104804**

(30) Priority Data

(31) Number
12151125.7 (32) Date
2012.01.13 (33) Country
EP

(43) Publication Date: **2013.07.18**
(44) Accepted Journal Date: **2017.07.06**

(71) Applicant(s)
Julius-Maximilians-Universitat Wurzburg

(72) Inventor(s)
Stuhler, Gernot

(74) Agent / Attorney
Davies Collison Cave Pty Ltd, Level 15 1 Nicholson Street, MELBOURNE, VIC, 3000, AU

(56) Related Art
WO 2007/062466 A1

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2013/104804 A3

(43) International Publication Date

18 July 2013 (18.07.2013)

WIPO | PCT

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 16/46 (2006.01)
C07K 16/30 (2006.01)

HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2013/050603

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

14 January 2013 (14.01.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

12151125.7 13 January 2012 (13.01.2012) EP

(71) Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG [DE/DE]; Sanderring 2, 97070 Würzburg (DE).

(72) Inventor: STUHLER, Gernot; Hasenbühlsteige 1/2, 72070 Tübingen (DE).

(74) Agent: JÜRGEN, Meier; Vossius & Partner, Siebertstraße 4, 81675 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

21 November 2013



WO 2013/104804 A3

(54) Title: DUAL ANTIGEN-INDUCED BIPARTITE FUNCTIONAL COMPLEMENTATION

(57) Abstract: The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety "T" binding to an antigen "A" and a fragment of "F" of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has "A" at (on) its surface and wherein, upon dimerization of "F", the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.

Dual Antigen-Induced Bipartite Functional Complementation

The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “A” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.

The last years have seen a number of landmark papers reporting outstanding efficacy of bispecific antibody constructs for immune therapy of tumours *in vitro* and in pre-clinical and early clinical trials. Today, a substantial number of different bispecific constructs are available that differ in size, composition, pharmacokinetics and ability to directly eliminate neoplastic cells or to engage immune effector cells for tumour cell lysis.

Antibody-based cancer immune strategies are highly promising therapeutic options due to their excellent sensitivity and specificity towards target structures.

The modular structural and functional organisation of antibodies allows extensive manipulation by genetic engineering. Different immunoglobulin-like domains can be separated and/or joined without losing specific domain-associated functional features. Moreover, they can be combined and linked with heterologous protein domains but also with non-peptidic moieties. It is therefore possible to develop fusion constructs in a rational way devoid of the natural limitations of conventional antibodies.

Antibody- based fusion proteins can be generated with novel biological and/or pharmaceutical properties. There are promising efforts to modify the capability of the Fc domain to elicit ADCC (antibody dependent cell mediated cytotoxicity) and CDC (complement-dependent cytotoxicity) by mutagenesis, dependent on the intended application, either to reduce side effects (inhibitory mutations) or to enhance therapeutic efficacy (activating mutations). New applications that become possible by genetic engineering are even more variate when the antigen binding domain of antibodies is considered.

The antigen recognizing variable domains of the heavy (V_H) and light chain (V_L) of an antibody can be joined by a peptide linker via genetic engineering while preserving the antigen binding capability. Such antigen binding single chain variable fragments (scFvs) can be used as small antibody surrogates with high tissue penetrating capability and low serum retention time for clinical imaging procedures and radiotherapy and other applications. Importantly, these scFv moieties can be easily employed as antigen specific modules in the development of novel recombinant therapeutics.

Recent reports indicate a tremendous potential of recombinant bispecific antibodies in anti-tumour therapy. Such bispecific antibodies recognise two antigens, one of which is expressed by the tumour, whereas the other is usually found on an immune cell. Most bispecific antibodies in anti-tumour therapy target a tumour-associated lineage marker on the one hand and CD3 ϵ , an invariant molecule of the T-cell receptor/CD3 complex on the other hand, thus recruiting T cells to destroy the tumour [Müller and Kontermann, Bispecific antibodies for cancer immunotherapy: Current perspectives. *BioDrugs* 2010, 24(2):89-98].

Despite the extensive options for manipulating antibody structure and function, the therapeutic efficacy of such antibody-based reagents is limited by the nature of the addressed antigen, the accessibility of the antigen in tumour and tumour-associated tissues and the aptitude of the antibody to elicit or mediate the desired cell death inducing function.

For example, when patients are treated with bispecific constructs directed against antigens also expressed on tissues with vital functions, severe side effects are observed. This is a severe problem, since, with the exception of an unknown number of individually mutated cell surface molecules and the monoclonal B- or T- cell receptor in case of lymphomas, tumour specific antigens that discriminate a transformed cell from its healthy progenitor are

not available.

Since therapeutic concepts based on the use of bispecific antibodies usually rely on the recruitment of effector cells, it appears that the more effective the tool (bispecific construct), the more likely side effects do occur, and even minute expression of antigen on non-transformed tissue can cause uncontrollable off-target effects.

In 2008, SCIENCE published the first report on the clinical efficacy of the single-chain bispecific T cell engaging (BiTE) antibody MT103/blinatumomab; it induces remissions in about 80% of lymphoma patients relapsed or refractory to standard immune-chemotherapy at serum levels about 5 orders of magnitude lower than serum levels reported for the monoclonal antibody rituximab (Bargou, R. et al *Science* 321, 974-977, 2008). This publication and subsequent reports on confirmatory phase II trials in acute lymphatic leukemia (ALL) ushered in a new era of bispecific antibodies, until then in grave demise for almost two decades due to systemic toxicity and little or no therapeutic activity. Mainly in the wake of that SCIENCE paper, bispecific antibodies became a burgeoning field again in which more than 35 different formats were counted (Reichert, *Drug Discov Today*. **17** (2012) 954-963). These formats differ in size and are optimized for affinity to the antigen, stability, ability to recruit effector cells (mostly T cells) and pharmacokinetics. Affinity or avidity of the constructs are manipulated by affinity maturation using diverse techniques or simply by joining multiple scFv domains in line in order to create a multivalent construct. Even trispecific antibodies are reported that are designed to display enhance binding capabilities by addressing two instead of one target molecule. Stability of the formats can be optimized by adding immunoglobulin-like domains in order to mimic naturally occurring antibodies and to simultaneously enhance pharmacokinetic properties like prolonged half life in serum and protection from proteolytic digestion by proteases. Moreover, stability of the formats can be enhanced by optimizing the production. Since linker sequences which are utilized to covalently join scFv domains often leads to aggregates, production lines have been established that first produce two or three polypeptides that can be easily reassembled in order to generate a functional drug. Such techniques utilize directed disulphid-bridges or crosslinking reagents to covalently join two different polypeptides. Other techniques make use of hetero- or homo-dimerization domains like leucine-zipper domains, Fc-domains and others like knob into hole technologies (see, for example, WO 2007/062466). Moreover, V_H and V_L interactions, which can be stabilized by the binding of the antigen, have been used in

so called open-sandwich immunoassays for the detection of the antigen (Ueda, *Nature Biotechnology* 14 (1996), 1714-1718; Ohmuro-Matsuyama (2012) *Detection of Protein Phosphorylation by*

Open-Sandwich Immunoassay, Integrative Proteomics, Dr. Hon-Chiu Leung (Ed.), ISBN: 978-953-51-0070-6; WO 2004/016782/EP-A1 1536005.)

However, bi/tri-specific and bi-or multivalent constructs described in the art have disadvantages. First, the absence of truly specific tumor antigens that can be addressed as target molecule. In fact, the more potent the bispecific antibody format, the more severe are collateral damages, because the target antigens addressed so far are differentiation antigens shared by tumors and non-malignant cells. In consequence, bi- or tri-specific formats of the prior art cannot discriminate malignant from non-malignant cells. In this respect, tri-specific constructs, developed for high avidity binding to target cells, may turn out to confer a high degree of off-target effects because binding of one target molecule in general suffice to recruit immune cells for destruction of a cell which express either target molecule. Thus, tri-specific construct enhance avidity on the cost of specificity. Recent multi-parameter analyses indicate that tumor cells can be distinguished from their respective non-transformed tissues of origin because of the expression of aberrant antigen signatures. Today, these findings constitute an integral part of the World Health Organization (WHO) classification system of hematopoietic neoplasms, and also hold true for cancer and cancer stem or cancer initiating cells of other provenance. Thus, it would be advantageous to target cells that simultaneously express a combination of antigens that together signify a malignant state. None of the antibodies disclosed by prior art is able to discriminate between cells that express a combination of target antigens from single antigen positive cells. Second, a major problem of bi-specific antibody technologies using, for example, complete CD3 modules (e.g. a anti Cd3 scFv) is the inherent ability of these proteins to stimulate or pre-stimulate T cells irrespective of binding to the target antigen on target cells and many side effects observed so far appear to be associated with errant T cell function.

Thus, there is a need in the art for more specific treatment options in cancer treatment, in particular there is a need for improved ways to identify and/or eliminate cancer cells with higher specificity and reduce side-effects.

Similar needs exist in the field of allogeneic stem cell transplantation, i.e. the transplantation

of stem cells obtained from another person to a patient. A patient suffering from relapsed or refractory leukaemia or another haematological disease may be treated by chemotherapy/irradiation (to eliminate the malignant haematopoietic cells) in combination with a transplantation of healthy haematopoietic cells from a donor. If elimination of malignant cells is incomplete, the tumour may grow back from the surviving malignant recipient cells despite the presence of healthy cells provided by the transplantation. As a result, survival rates among patients undergoing tumour treatment and allogeneic transplantation are significantly reduced.

However, it is difficult to eliminate (and, similarly, to identify) the surviving malignant cells with high specificity, and thus despite various attempts, good solutions to this problem have not been found. Accordingly, there exists a need in the art to provide improved ways to specifically identify and/or eliminate such malignant recipient cells with minimal side effects on other cells.

The graft (allogenic stem cells), given shortly after the conditioning therapy (radiation/chemotherapy) can replace and reconstitute hematopoiesis. The graft is harvested from either bone marrow or from stimulated peripheral blood cells and contains about one percent of hematopoietic stem cells which are the source of newly built blood cells. In addition, the graft normally contains a huge number of immune cells, especially T lymphocytes, that are part of the adoptive immune system and that can be very beneficial in cases where these T cells mount an immune attack against leukemic cells. This situation is well described and known as graft versus leukemia effect. On the other side, an errant immune response which directs T cells against the patient, known as graft versus host disease, is also frequently observed.

To minimize graft versus host disease, grafts are usually selected on the basis of HLA (human leukocyte antigen) or MHC (major histocompatibility complex). The closer the antigens between donor and recipient match the lower is the probability of severe graft versus host disease. However, for many patients, a full matched graft cannot be found. In these cases, a bone marrow or peripheral blood stem cells are utilized that differ in one or even more HLA molecules. These clinical situations require a strict immunosuppressive regimen after transplantation to keep the T cell system strictly under control.

It is therefore one object of the present invention to provide for improved ways to

specifically identify and/or eliminate specific kinds of cells. Moreover, it is an object of the present invention to provide for improved ways to specifically identify and/or eliminate cells that have a specific combination of two specific antigens at their cell surface. Furthermore, it is an object of the present invention to provide for improved ways to specifically identify and/or eliminate cancerous cells. Furthermore, it is an object of the present invention to provide for improved ways to specifically identify and/or eliminate cells that (1) are of a certain origin (such as, in the situation of a tissue or cell transplantation, cells originating from the recipient or from the donor) and that (2) belong to a specific cell type or cell lineage (such as haematopoietic cells).

The objects of the present invention are solved by a set of polypeptides comprising:

a first polypeptide P1 comprising

(i) a targeting moiety T1,

wherein said targeting moiety T1 specifically binds to an antigen A1, and

(ii) a fragment F1 of a functional domain F,

wherein neither said fragment F1 by itself nor said polypeptide P1 by itself is functional with respect to the function of said domain F,

and

a second polypeptide P2 comprising

(i) a targeting moiety T2,

wherein said targeting moiety T2 specifically binds to an antigen A2, and

(ii) a fragment F2 of said functional domain F,

wherein neither said fragment F2 by itself nor said polypeptide P2 by itself is functional with respect to the function of said domain F,

wherein said antigen A1 is different from said antigen A2,

wherein said polypeptide P1 and said polypeptide P2 are not associated with each other in the absence of a substrate that has both antigens A1 and A2 at or on its surface, more specifically a cell that carries both antigens A1 and A2 at or on its cell surface, and

wherein, upon dimerization of said fragment F1 of said polypeptide P1 with said fragment F2 of said polypeptide P2, the resulting dimer is functional with respect to the function of said domain F.

The objects of the present invention are also solved by a set of polypeptides comprising:

a first polypeptide P1 comprising

(i) a targeting moiety T1,

wherein said targeting moiety T1 specifically binds to an antigen A1, and

(ii) a fragment F1 of a functional domain F,

wherein neither said fragment F1 by itself nor said polypeptide P1 by itself is functional with respect to the function of said domain F,

and

a second polypeptide P2 comprising

(i) a targeting moiety T2,

wherein said targeting moiety T2 specifically binds to an antigen A2, and

(ii) a fragment F2 of said functional domain F,

wherein neither said fragment F2 by itself nor said polypeptide P2 by itself is functional with respect to the function of said domain F,

wherein said antigen A1 is different from said antigen A2,

wherein

(a) said fragment F1 comprises a V_L domain of an antibody and said fragment F2 comprises a V_H domain of the same antibody; or wherein said fragment F1 comprises a V_H domain of an antibody and said fragment F2 comprises a V_L domain of the same antibody; or

(b) said fragment F1 comprises a V_L domain of an antibody and said fragment F2 comprises a V_H domain of the same antibody; or wherein said fragment F1 comprises a V_H domain of an antibody and said fragment F2 comprises a V_L domain of the same antibody; and

wherein said polypeptide P1 and said polypeptide P2 are not associated with each other in the absence of a substrate that has both antigens A1 and A2 at or on its surface, more specifically a cell that carries both antigens A1 and A2 at or on its cell surface, and

wherein, upon dimerization of said fragment F1 of said polypeptide P1 with said fragment F2 of said polypeptide P2, the resulting dimer is functional with respect to the function of said domain F.

The objects of the present invention are also solved by a set of polypeptides comprising:

a first polypeptide P1 comprising

(i) a targeting moiety T1,

wherein said targeting moiety T1 specifically binds to an antigen A1, and

- (ii) a fragment F1 of a functional domain F,

wherein neither said fragment F1 by itself nor said polypeptide P1 by itself is functional with respect to the function of said domain F,

and

a second polypeptide P2 comprising

- (i) a targeting moiety T2,

wherein said targeting moiety T2 specifically binds to an antigen A2, and

- (ii) a fragment F2 of said functional domain F,

wherein neither said fragment F2 by itself nor said polypeptide P2 by itself is functional with respect to the function of said domain F,

wherein said antigen A1 is different from said antigen A2,

wherein

(c) said fragment F1 comprises a V_L domain of an antibody and said fragment F2 comprises a V_H domain of the same antibody; or wherein said fragment F1 comprises a V_H domain of an antibody and said fragment F2 comprises a V_L domain of the same antibody;

(d) said polypeptide P1 and said polypeptide P2 are not associated with each other in the absence of a substrate that has both antigens A1 and A2 at its surface, more specifically a cell that carries both antigens A1 and A2 at its cell surface; or

(e) said fragment F1 comprises a V_L domain of an antibody and said fragment F2 comprises a V_H domain of the same antibody; or wherein said fragment F1 comprises a V_H domain of an antibody and said fragment F2 comprises a V_L domain of the same antibody; and

wherein said polypeptide P1 and said polypeptide P2 are not associated with each other in the absence of a substrate that has both antigens A1 and A2 at its surface, more specifically a cell that carries both antigens A1 and A2 at its cell surface, and

wherein, upon dimerization of said fragment F1 of said polypeptide P1 with said fragment F2 of said polypeptide P2, the resulting dimer is functional with respect to the function of said domain F, and wherein said polypeptides P1 and P2, in particular said fragments F1 and F2, have, in the absence of a substrate or cell, with each other a dissociation constant K_D in the range of 10⁻⁸ M to 10⁻² M.

The present invention further refers to the following items:

1. A set of polypeptides comprising:
 - a first polypeptide P1 comprising
 - (i) a targeting moiety T1,
wherein said targeting moiety T1 specifically binds to an antigen A1, and
 - (ii) a fragment F1 of a functional domain F,
wherein neither said fragment F1 by itself nor said polypeptide P1 by itself is functional with respect to the function of said domain F,

and

 - a second polypeptide P2 comprising
 - (i) a targeting moiety T2,
wherein said targeting moiety T2 specifically binds to an antigen A2, and
 - (ii) a fragment F2 of said functional domain F,
wherein neither said fragment F2 by itself nor said polypeptide P2 by itself is functional with respect to the function of said domain F,

wherein said antigen A1 is different from said antigen A2,
wherein said polypeptide P1 and said polypeptide P2 are not associated with each other in the absence of a substrate that has both antigens A1 and A2 at its surface, more specifically a cell that carries both antigens A1 and A2 at its cell surface, and
wherein, upon dimerization of said fragment F1 of said polypeptide P1 with said fragment F2 of said polypeptide P2, the resulting dimer is functional with respect to the function of said domain F.
2. The set of polypeptides according to item 1, wherein a cell carrying both antigens A1 and A2 at its cell surface induces dimerization of the fragment F1 of said polypeptide P1 with the fragment F2 of said polypeptide P2, whereas a cell which does not carry both antigens A1 and A2 at its cell surface does not induce dimerization of the fragment F1 of said polypeptide P1 with the fragment F2 of said polypeptide P2.
3. The set of polypeptides according to item 1 or 2, wherein said targeting moiety T1 comprises an immunoglobulin module, preferably an immunoglobulin module I1 comprising a V_L domain linked to a V_H domain, more preferably an immunoglobulin module I1 that comprises a scFv (single-chain variant fragment) of an antibody, or an

immunoglobulin module comprising a variable domain $V_{H}H$ of a llama antibody, camel antibody or shark antibody,

and/or said targeting moiety T2 comprises an immunoglobulin module, preferably an immunoglobulin module I2 comprising a V_L domain linked to a V_H domain, more preferably an immunoglobulin module I2 that comprises a scFv (single-chain variant fragment) of an antibody, or an immunoglobulin module comprising a variable domain $V_{H}H$ of a llama antibody, camel antibody or shark antibody,

or wherein said targeting moiety T1 and/or said targeting moiety T2 comprises an aptamer or a natural ligand of said antigen A1 or antigen A2, respectively

4. The set of polypeptides according to any of the preceding items, wherein said antigen A1 and/or said antigen A2 is an antigen expressed on the surface of cells of a tumour or on the surface of progenitor/precursor cells of a tumour, preferably an antigen expressed on the surface of cells of a haematologic tumour or an antigen expressed on the surface of cells of a non-haematologic tumour.
5. The set of polypeptides according to any of the preceding items, wherein the combination of antigen A1 and antigen A2 is only found on cancerous cells, and not on cells that are not cancerous, and wherein, preferably, the combination of antigen A1 and antigen A2 is specific for cancerous cells of a certain type of cancer.
6. The set of polypeptides according to any of the preceding items, wherein said antigen A1 is an MHC antigen, preferably an allelic variant of any of HLA-A, HLA-B, HLA-C, HLA-DQ, HLA-DR, or HLA-DM, more preferably an allelic variant of an MHC class I molecule, more preferably an allelic variant selected from the group consisting of HLA-A1, HLA-A2, HLA-A3, HLA-A25, HLA-B7, HLA-B8, HLA-B35, HLA-B44, HLA-Cw3, HLA-Cw4, and HLA-Cw7, and/or said antigen A2 is an antigen that is specific for a certain cell type or cell lineage.
7. The set of polypeptides according to any of the preceding items, wherein said functional domain F is an immunoglobulin module, preferably a scFv (single-chain variant fragment) of an antibody, or a fluorescent molecule, preferably GFP or a GFP variant, or a molecule capable of mediating bioluminescence, preferably *Gaussia* luciferase.

8. The set of polypeptides according to any of the preceding items, wherein said functional domain F is a domain that specifically binds to a carrier molecule, preferably a carrier molecule that is a peptide or a carbohydrate molecule, or an affinity tag, preferably an affinity tag selected from the group consisting of a FLAG-tag, a myc-tag, a glutathione-S-transferase(GST)-tag, a hemagglutinin(HA)-tag, a polyhistidine(His)-tag and a maltose binding protein(MBP)-tag.
9. The set of polypeptides according to any of the preceding items, wherein said functional domain F is a domain that specifically binds to a radioactive compound, a domain that specifically binds to a toxin molecule that by itself is not capable of penetrating through the cell membrane of a human cell and that is internalized into a human cell upon association with the cell membrane of said cell, a domain that specifically binds to a fluorescent molecule, or a domain that specifically binds to a molecule capable of mediating bioluminescence.
10. The set of polypeptides according to any of the preceding items, wherein said fragment F1 comprises a V_L domain of an antibody and said fragment F2 comprises a V_H domain of the same antibody, wherein, preferably, said antibody is an anti-CD3 antibody, or wherein said fragment F1 comprises a V_H domain of an antibody and said fragment F2 comprises a V_L domain of the same antibody, wherein, preferably, said antibody is an anti-CD3 antibody.
11. The set of polypeptides according to any of the preceding items for use in the treatment of a patient who is suffering from a tumour or for diagnostic use in a patient who is suffering from a tumour, preferably for use in the treatment of a patient who is suffering from a tumour and undergoing allogeneic tissue or cell transplantation or meant to undergo such transplantation or for diagnostic use in a patient who is suffering from a tumour and undergoing or meant to undergo allogeneic tissue or cell transplantation, wherein, preferably, said set of polypeptides is administered to said patient.
12. A nucleic acid molecule or a set of nucleic acid molecules encoding the set of polypeptides or one of the polypeptides of the set of polypeptides according to any of the preceding items.

13. A vector comprising the nucleotide sequence of the nucleic acid molecule according to item 12 or the sequence of one of the nucleic acid molecules of the set of nucleic acid molecules according to item 12.
14. A pharmaceutical composition comprising either the set of polypeptides according to any of items 1 to 11 or the nucleic acid molecule/set of nucleic acid molecules according to item 12 or the vector according to item 13, wherein, preferably, said pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
15. A kit comprising the set of polypeptides according to any of items 1-11.

Preferably, said antigen A1 is a cell surface molecule. Preferably, said antigen A2 is a cell surface molecule. Preferably, said antigen A1 is specific for the malignant state of a cell. Preferably, said antigen A2 is specific for a certain cell type or cell lineage or for the malignant state of a cell. Preferably, said antigen A1 is specific for a malignant cell type. Preferably, said antigen A2 is specific for a malignant cell type.

In one aspect, the present invention relates to the set of polypeptides as defined and described herein, wherein, however, the antigen A1 is the same as the antigen A2. Hence, in such a set of polypeptides P1 and P2, the F1 fragment may be linked to the targeting moiety T1 and the F2 fragment may be linked to the targeting moiety T2, whereas both T1 and T2 specifically bind to the same antigen. In this context, the epitope on antigen A1, to which the targeting moiety T1 binds, may be the same or a different epitope as the epitope on the antigen A2, to which the targeting moiety T2 binds. In case the epitope on antigen A1 is the same as the epitope on the antigen A2, polypeptide P1 may comprise a targeting moiety which is identical to the targeting moiety comprised in P2. Also this aspect of the invention is based on the advantage that the set of polypeptides P1 and P2 with the disrupted F domain displays no off target effects (for example no pre-activation of CD3-displaying T cells and, hence, less toxic properties and/or side effects, for example as compared to conventional bispecific antibodies).

In one embodiment, said fragment F1 and said fragment F2 together are said functional domain F.

In one embodiment, said polypeptide P1 and said polypeptide P2 are not covalently linked to each other in the absence of a substrate that has both antigens A1 and A2 at its surface, more

specifically a cell that carries both antigens A1 and A2 at its cell surface.

In one embodiment, said polypeptide P1 and said polypeptide P2 are not covalently linked to each other.

Said polypeptide P1 and polypeptide P2 and/or, in particular, said fragment F1 and fragment F2 as comprised therein, more particular the V_H and V_L which may be comprised therein, are not associated with each other, in particular when administered to a subject in need of medical intervention. i.e. in need of therapy and/or diagnosis. Accordingly, the pharmaceutical or diagnostic means provided herein comprise the two polypeptides P1 and P2 as comprised in the herein defined “set of polypeptides” in non-associated form. The association of said two polypeptides take place in vivo under the presence of said substrate or cell. Under the presence of said substrate or cell, the association of said two polypeptides may be (further) stabilized by a stabilizing agent (for example an antigen, like, for example, CD3, HIS or DIG as described herein). Preferably, they are not associated with each other in the absence of said substrate or cell and/or do not dimerizise in the absence of said substrate or cell. More preferably, they are not associated with each other in the absence of said substrate or cell and/or do not dimerizise in the absence of said substrate or cell even if an agent is present which stabilizes association and/or dimerization of polypeptide P1 and polypeptide P2 and/or, in particular, fragment F1 and fragment F2, i.e. even if said polypeptide P1 and polypeptide P2 and/or, in particular, said fragment F1 and fragment F2 is present in an stabilizing agent/P1(F1)/P2(F2)-trimeric complex (for example in an antigen/VH/VL-trimeric complex).

In one specific embodiment, said polypeptide P1 and polypeptide P2 and/or, in particular, said fragment F1 and fragment F2 as comprised therein, more particular the V_H and V_L which may be comprised therein, are associated with each other and/or dimerizise into a three-part-complex-formation, preferably by an interaction mediated by an agent which stabilizes association and/or dimerization of polypeptide P1 and polypeptide P2 and/or, in particular, fragment F1 and fragment F2 (for example by an antigen-mediated interaction). Most preferably, however, this association and/or dimerization only occurs in the presence of said substrate or cell.

The affinity strength with which, for example, leucine-zippers and/or constant domains, like immunoglobulin CH3 or Fc fragments, hetero- and homodimerize is estimated to be at a

dissociation constant K_D in the range of $\sim 10^{-8}$ to 10^{-11} M (see, for example, Zhu (1997) Protein Sci. 6, 781-8; Plückthun (1997) Immunotech. 3, 83-105). This K_D range is clearly below the K_D with which, in the absence of said substrate or cell, association and/or dimerization of said polypeptides P1 and P2, in particular of said fragments F1 and F2, of this invention might occur. Hence, in one embodiment, polypeptide P1 and polypeptide P2 and/or, in particular, fragment F1 and fragment F2 as comprised therein, more particular the V_H and V_L which may be comprised therein, associate with each other and/or dimerize in the absence of said substrate or cell only with a K_D which is above the K_D of, for example, hetero- and homodimerization of leucine-zippers and/or constant domains, like immunoglobulin CH3 or Fc fragments. In the presence of said substrate or cell, it is envisaged that polypeptide P1 and polypeptide P2 and/or, in particular, fragment F1 and fragment F2 as comprised therein, more particular the V_H and V_L which may be comprised therein, associate with each other and/or dimerize with a K_D which is in the range of the K_D of, for example, hetero- and homodimerization of leucine-zippers and/or constant domains, like immunoglobulin CH3 or Fc fragments, or even below this range.

The interaction strength of, for example, isolated VH and VL domains in general is of low affinity. Using calorimetric, fluorometric or ultraviolet difference spectroscopy and/or circular dichroism techniques, dissociation constants K_D of 10^{-9} to 10^{-6} M have been determined (see, for example, Wörn JMB (2001) 305, 989-1010; Plückthun (1992) Immunological Reviews No 130). Using surface plasmon resonance techniques (SPR biosensor BIACore or BIACore 2000, Pharmacia) and an anti HEL-Antibody system (anti-hen egg lysozyme antibody HyHEL-10), Ueda (loc. cit.) and Ohmuro-Matsuyama (loc. cit.) found that isolated VH and VL domains do not dimerize at all ($K_a < 10^5/M$, below detection limit). However, association of the VH and VL peptides was significantly enhanced in the presence of cognate antigens ($K_a \sim 10^9/M$) with a remarkable reduction of the dissociation rate of the antigen/VH/VL-trimeric complex with a calculated $K_d \sim 2.73 \times 10^{-5} \pm 1.43 \times 10^{-6}$ /s at $1.4 \mu M$ of the antigen. Hence, it is particularly envisaged in the context of this invention that the K_D with which, in the absence of said substrate or cell, association and/or dimerization of said polypeptides P1 and P2, in particular of said fragments F1 and F2, of this invention might occur is only at, or even above, the K_D or range of K_D of isolated VH and VL domains, for example as has been estimated in the context of Wörn (loc. cit.), Plückthun (1992; loc. cit.), Ueda (loc. cit.) and Ohmuro-Matsuyama (loc. cit.), in particular above the K_D or range of K_D of the antigen/VH/VL-trimeric complex as has been estimated

in the context of Wörn (loc. cit.), Plückthun (1992;loc. cit.), Ueda (loc. cit.) and Ohmuro-Matsuyama (loc. cit.). In the presence of said substrate or cell, it is envisaged that polypeptide P1 and polypeptide P2 and/or, in particular, fragment F1 and fragment F2 as comprised therein, more particular the V_H and V_L which may be comprised therein, associate with each other and/or dimerize with a K_D which is (far) below the K_D or range of K_D of isolated VH and VL domains, for example as has been estimated in the context of Wörn (loc. cit.), Plückthun (1992;loc. cit.), Ueda (loc. cit.) and Ohmuro-Matsuyama (loc. cit.), preferably at, or even below, the K_D or range of K_D of the antigen/ VH / VL -trimeric complex as has been estimated in the context of Plückthun (loc. cit.), Ueda (loc. cit.) and Ohmuro-Matsuyama (loc. cit.)

In one aspect, polypeptide P1 and polypeptide P2 and/or, in particular, fragment F1 and fragment F2 as comprised therein, more particular the V_H and V_L which may be comprised therein, are not associated in the absence of said substrate or cell and/or do not dimerize in the absence of said substrate or cell. If at all, they associate with each other and/or dimerize in the absence of said substrate or cell only with a K_D above 10^{-8} M, preferably above 10^{-6} M, more preferably above 10^{-5} M and more preferably above 10^{-4} M. In another aspect, if at all, they associate with each other and /or dimerize in the absence of said substrate or cell only with a K_D in the range of 10^{-8} M to 10^{-2} M, preferably 10^{-7} M to 10^{-3} M, more preferably 10^{-6} M to 10^{-3} M and even more preferably 10^{-5} M to 10^{-3} M. In another aspect, polypeptide P1 and polypeptide P2 and/or, in particular, fragment F1 and fragment F2 as comprised therein, more particular the V_H and V_L which may be comprised therein, are associated in the presence of said substrate or cell and/or dimerize in the presence of said substrate or cell. In particular, they associate with each other and /or dimerize in the presence of said substrate or cell with a K_D below 10^{-6} M, preferably below 10^{-7} M, more preferably below 10^{-8} M and more preferably below 10^{-9} M. They may also associate with each other and/or may dimerize in the presence of said substrate or cell with a K_D in the range of 10^{-11} M to 10^{-6} M, more preferably 10^{-11} M to 10^{-7} M and even more preferably 10^{-11} M to 10^{-8} M.

In a preferred embodiment, the above even applies in case an agent is present which stabilizes association and/or dimerization of polypeptide P1 and polypeptide P2 and/or, in particular, fragment F1 and fragment F2. For example, such an stabilizing agent in accordance with this invention may be an antigen, like, for example, CD3, HIS or DIG as

described herein, capable to bind to the domain F which, for example, may comprise a V_H and a V_L of an antibody (F1 and F2, respectively, or F2 and F3, respectively).

Being “present”, in the context of this invention and, in particular, in the context of the above (i.e. with respect to said agent and/or said substrate or cell and/or said antigens A1 and A2), particularly means being present at a concentration in a range of 0.01 μM to 1 mM, in a range of 0.1 to 500 μM , in a range of 0.1 to 300 μM , in a range of 0.1 to 100 μM , in a range of 1 to 500 μM , in a range of 10 to 500 μM . Being “absent”, in the context of this invention and, in particular, in the context of above (i.e. with respect to said agent and/or said substrate or cell and/or said antigens A1 and A2), particularly means being present at a concentration below the above ranges or below 1 mM, 500 μM , 300 μM , 100 μM , 10 μM , 1 μM , 0.1 μM , 0.01 μM , 0.001 μM or 1 nM wherein the lower values are preferred.

The person skilled in the art is readily in the position to measure the K_D of dimerization, in particular, of P1 and P2, more particular of F1 and F2 as comprised therein, more particular of the V_H and V_L which may be comprised therein. Examples of respective measuring methods are x-ray crystallography; nuclear magnet resonance (NMR); isothermal calorimetry (ITC); cryo-electro microscopy (CEM); mass spectrometry (MS); surface Plasmon resonance (SPR). Such methods are, for example, described in Protein Surface Recognition: Approaches for Drug Discovery: Approaches for the Inhibition of Protein-Protein Interactions for Drug Discovery (Eds: Ernest Giralt, Mark Peczuh, Xavier Salvatella John Wiley & Sons; 12. November 2010). Further examples of respective measuring methods are circular Dichroism Analysis; small Zone Gel Filtration Chromatography; Fluorescence Gel Retardation; Sedimentation Equilibrium; Fluorescence Polarization Assay; Blot Overlay or Far Western Blot Analysis; Affinity Capillary Electrophoresis Analysis; Fluorescence Resonance Energy Transfer (FRET); such methods are, for example described in Protein-Protein Interactions: Methods and Applications: 261 (Methods in Molecular Biology); Haian Fu (Editor); Humana Press; 1 (23. März 2004). A preferred method to measure the K_D in accordance with this invention is Fluorescence Correlation Spectroscopy (FCS). This method is, for example, described in Douglas Magde (Physical Review Letters 29, 11, 1972, S. 705–708).

In one particular aspect, the K_D s referred to herein (i) apply to, (ii) are at or (iii) are to be measured at a temperature of 4 to 38 °C, preferably 4 to 20 °C (for example 10°C) or 20 to 38 °C (for example 30°C), and/or a pH of 4,5 to 8 (for example a pH of 7),

“Not associated” in the context of the present invention particularly means not functionally associated with respect of the function of the domain F, i.e. not allowing F1 and F2 to form a functional F. Hence, in one aspect of the invention, P1 and P2 may be bound to each other (for example covalently) as far as no functional domain F is formed by F1 and F2. It is, however, preferred that P1 and P2 are separated.

In one embodiment, said antigen A1 and/or said antigen A2 is a molecule.

In one embodiment, said antigen A1 and/or said antigen A2 is proteinaceous.

In one embodiment, said antigen A1 and/or said antigen A2 is non-proteinaceous.

In one embodiment, said targeting moiety T1 binds non-covalently to said antigen A1.

In one embodiment, said targeting moiety T2 binds non-covalently to said antigen A2.

In one embodiment, a substrate having both antigens A1 and A2 at its surface induces dimerization of the fragment F1 of said polypeptide P1 with the fragment F2 of said polypeptide P2, whereas a substrate which does not have both antigens A1 and A2 at its cell surface does not induce dimerization of the fragment F1 of said polypeptide P1 with the fragment F2 of said polypeptide P2.

In one embodiment, a cell carrying both antigens A1 and A2 at its cell surface induces dimerization of the fragment F1 of said polypeptide P1 with the fragment F2 of said polypeptide P2, whereas a cell which does not carry both antigens A1 and A2 at its cell surface does not induce dimerization of the fragment F1 of said polypeptide P1 with the fragment F2 of said polypeptide P2. In this context “induces dimerization” particularly means “allows juxtaposition and subsequent dimerization”.

In one embodiment, said targeting moiety T1 comprises an immunoglobulin module and/or said targeting moiety T2 comprises an immunoglobulin module.

In one embodiment, said targeting moiety T1 comprises an immunoglobulin module I1 which comprises a V_L domain linked to a V_H domain, preferably an immunoglobulin module I1 that comprises a scFv (single-chain variant fragment) of an antibody, a Fab or a F(ab')₂ (for example with additional parts of, for example, an Fc domain) of an antibody or a complete antibody.

and/or said targeting moiety T2 comprises an immunoglobulin module I2 which comprises a V_L domain linked to a V_H domain, preferably an immunoglobulin module I2 that comprises a scFv (single-chain variant fragment) of an antibody a Fab or a F(ab')₂ (for example with additional parts of, for example, an Fc domain) of an antibody or a complete antibody.

In one embodiment, said targeting moiety T1 and/or said targeting moiety T2 comprises an immunoglobulin module which comprises a variable domain V_HH of a llama antibody, a camel antibody, or a shark antibody.

In one embodiment, said targeting moiety T1 and/or said targeting moiety T2 is an aptamer, or a natural ligand of said antigen A1 or antigen A2, respectively.

In one embodiment, said targeting moiety T1 and/or said targeting moiety T2 comprises a Fv or scFv ((single-chain) variant fragment) of an antibody.

In one embodiment, the immunoglobulin module comprised in the targeting moiety T1 and T2 comprises a V domain selected from the group consisting of:

- (i) a V domain of an anti-HLA-A2 antibody comprising a V_L domain comprising SEQ ID NOS: 78 and 79 (CDRs 1 and 3) and DAS (CDR 2) and/or a V_H domain comprising SEQ ID NOS: 75-77 (CDRs 1-3);
- (ii) a V domain of an anti-HLA-Cw6 antibody comprising a V_L domain comprising SEQ ID NOS: 83 and 84 (CDRs 1 and 3) and DDS (CDR 2) and/or a V_H domain comprising SEQ ID NOS: 80-82 (CDRs 1-3);
- (iii) a V domain of an anti-EpCAM antibody comprising a V_L domain comprising SEQ ID NOS: 88 and 89 (CDRs 1 and 3) and WAS (CDR 2) and/or a V_H domain comprising SEQ ID NOS: 85-87 (CDRs 1-3);
- (iv) a V domain of an anti-Her2 antibody comprising a V_L domain comprising SEQ ID NOS: 93 and 94 (CDRs 1 and 3) and SAS (CDR 2) and/or a V_H domain comprising SEQ ID NOS: 90-92 (CDRs 1-3);
- (v) a V domain of an anti-EGFR1 antibody comprising a V_L domain comprising SEQ ID NOS: 98 and 99 (CDRs 1 and 3) and DAS (CDR 2) and/or a V_H domain comprising SEQ ID NOS: 95-97 (CDRs 1-3);

- (vi) a V domain of an anti-CEA antibody comprising a V_L domain comprising SEQ ID NOS: 103 and 104 (CDRs 1 and 3) and SAS (CDR 2) and/or a V_H domain comprising SEQ ID NOS:100-102 (CDRs 1-3);
- (vii) a V domain of an anti-CD45 antibody comprising a V_L domain comprising SEQ ID NOS: 107 and 108 (CDRs 1 and 3) and LAS (CDR 2) and/or a V_H domain comprising SEQ ID NOS: 105 and 106 (CDRs 1 and 2) and CDR3 or SEQ ID NOS:132-134 (CDRs 1-3);
- (viii) a V domain of an anti-CD138 antibody comprising a V_L domain comprising SEQ ID NOS: 112 and 113 (CDRs and 1 and 3) and YTS (CDR 2) and/or a V_H domain comprising SEQ ID NOS: 109-111 (CDRs 1-3); and
- (ix) a V domain of an anti-CD19 antibody comprising a V_L domain comprising SEQ ID NOS: 158 and 159 (CDRs 1 and 3) and DAS (CDR 2) and/or a V_H domain comprising SEQ ID NOS: 155-157 (CDRs 1-3).

In a further, preferred, embodiment, the immunoglobulin module comprised in the targeting moiety T1 and/or T2 comprises a V domain selected from the group consisting of:

- (i) a V domain of an anti-HLA-A2 antibody comprising a V_L domain comprising SEQ ID NO: 52 and/or a V_H domain comprising SEQ ID NO: 51;
- (ii) a V domain of an anti-HLA-Cw6 antibody comprising a V_L domain comprising SEQ ID NO: 54 and/or a V_H domain comprising SEQ ID NO: 53;
- (iii) a V domain of an anti-EpCAM antibody comprising a V_L domain comprising SEQ ID NO: 56 and/or a V_H domain comprising SEQ ID NO: 55;
- (iv) a V domain of an anti-Her2 antibody comprising a V_L domain comprising SEQ ID NO: 58 and/or a V_H domain comprising SEQ ID NO: 57;
- (v) a V domain of an anti-EGFR1 antibody comprising a V_L domain comprising SEQ ID NO: 60 and/or a V_H domain comprising SEQ ID NO: 59;
- (vi) a V domain of an anti-CEA antibody comprising a V_L domain comprising SEQ ID NO: 62 and/or a V_H domain comprising SEQ ID NO: 61;
- (vii) a V domain of an anti-CD45 antibody comprising a V_L domain comprising SEQ ID NO: 64 and/or a V_H domain comprising SEQ ID NO: 63; and
- (viii) a V domain of an anti-CD138 antibody comprising a V_L domain comprising SEQ ID NO: 66 and/or a V_H domain comprising SEQ ID NOS: 65;
- (ix) a V domain of an anti-CD19 antibody comprising a V_L domain comprising SEQ ID NO: 153 and/or a V_H domain comprising SEQ ID NO: 152.

In a further, preferred, embodiment, the immunoglobulin module comprised in the targeting moiety T1 and/or T2 comprises a V domain comprising any one of SEQ ID NOS: 67-74 and 154.

In one embodiment, polypeptide P1 has the general structure F1-T1 and/or polypeptide P2 has the general structure F2-T2. The F fragment and T moieties may be separated by a linker (e.g. F1-linker-T1 and/or F2-linker-T2) and/or flanked by (an) additional amino acid stretche(s) 1 and/or 2 (stretch-F1-(linker)-T1-stretch2 and/or stretch1-F2-(linker)-T2-stretch2). It is preferred that the above general structure is from the N terminus to the C terminus of the polypeptides, i.e. N-F1-T1-C and/or N-F2-T2-C, N-F1-linker-T1-C and/or N-F2-linker-T2-C and N-stretch1-F1-(linker)-T1-stretch2-C and/or N-stretch1-F2-(linker)-T2-stretch2-C. In case the targeting moiety is or comprises an immunoglobulin module I, like an Fv or scFv, polypeptide P1 may have the general structure F1-VH1-VL1 and/or polypeptide P2 may have the general structure F2-VH2-VL2 or polypeptide P1 may have the general structure F1-VL1-VH1 and/or polypeptide P2 may have the general structure F2-VL2-VH2. Also in these cases the F fragment and T moieties may be separated by a linker (e.g. F1-linker-VH/VL1-VL/VH1 and/or F2-linker-VH/VL2-VL/VH2) and/or flanked by (an) additional amino acid stretche(s) 1 and/or 2 (stretch1-F1-(linker)-VH/VL1-VL/VH1-stretch2 and/or stretch1-F2-(linker)-VH/VL2-VL/VH2-stretch2). Also in this case, it is preferred that the above general structure is from the N terminus to the C terminus of the polypeptides, i.e. N-F1-VH/VL1-VL/VH1-C and/or N-F2-VH/VL2-VL/VH2-C, N-F1-linker-VH/VL1-VL/VH1-C and/or N-F2-linker-VH/VL2-VL/VH2-C and N-stretch1-F1-(linker)-VH/VL1-VL/VH1-stretch2-C and/or N-stretch1-F2-(linker)-VH/VL2-VL/VH2-stretch2-C. There may also a linker be present between VH and VL or VL and VH.

The above described linker, in particular the between the V domains, may comprise 1 to 25 amino acids, preferably 12 to 20 amino acids, preferably 12 to 16 or 15 to 20 amino acids. The above described linker may comprise one or more (G₃S) and/or (G₄S) motives, in particular 1, 2, 3, 4, 5 or 6 (G₃S) and/or (G₄S) motives, preferably 3 or 4 (G₃S) and/or (G₄S) motives, more preferably 3 or 4 (G₄S) motives.

In one embodiment, said immunoglobulin module I1 and said fragment F1 are separated by a linker comprising 1 to 12, preferably 3 to 12, amino acids, and/or said immunoglobulin module I2 and said fragment F2 are separated by a linker comprising 1 to 12, preferably 3 to

12, amino acids.

In one embodiment, the V_L domain of I1 is linked to the V_H domain of I1 by a linker comprising 12 to 25 amino acids, preferably a linker with the sequence $(G_3S)_3$ or $(G_3S)_4$ or $(G_4S)_3$ or $(G_4S)_4$ and/or the V_L domain of I2 is linked to the V_H domain of I2 by a linker comprising 12 to 25 amino acids, preferably a linker with the sequence $(G_3S)_3$ or $(G_3S)_4$ or $(G_4S)_3$ or $(G_4S)_4$.

As mentioned, the linker as described above may comprise (G_3S) and/or (G_4S) motives. Alternative linkers may consist of or comprise the GEGTSTGSGGSGGSGGAD motive. The person skilled in the art can without further ado find and use further (peptide) linker known in the art.

The said additional amino acid stretches 1 and/or 2 may consist of or comprise 1 to 200, 1 to 100, 1 to 70, 1 to 65, 1 to 50, 1 to 25 or 1 to 20 amino acids.

In one embodiment, said antigen A1 and/or said antigen A2 is an antigen expressed on the surface of cells of a tumour or on the surface of progenitor/precursor cells of a tumour, preferably an antigen expressed on the surface of cells of a haematologic tumour, more preferably an antigen expressed on the surface of cells selected from the group consisting of acute myeloid leukemia cells, chronic myeloid leukemia cells, acute lymphatic leukemia cells, chronic lymphatic leukemia cells, lymphoma cells, myeloproliferative syndrome cells, myelodysplastic cells, more preferably myeloma cells, or said antigen A1 and/or said antigen A2 is an antigen expressed on the surface of cells of a non-haematologic tumour, preferably a cell selected from the group consisting of renal cell carcinoma cells, bladder cancer cells, lung cancer cells, mesothelioma cells, prostate cancer cells, brain cancer cells, bone cancer cells, sarcoma cells, soft tissue cancer cells, ovarian cancer cells, cervix cancer cells, breast cancer cells, endometrial cancer cells, uterine cancer cells, germ cell tumour cells, anal cancer cells, rectal carcinoma cells, colon carcinoma cells, small intestine carcinoma cells, gastric carcinoma cells, gastrointestinal stroma tumour cells, liver carcinoma cells, pancreas carcinoma cells, bile duct carcinoma cells, gall bladder carcinoma cells, head and neck cancer cells, hypopharyngeal cancer cells, laryngeal cancer cells, cells of a cancer of the esophagus, skin cancer cells, preferably melanoma cells, cells of a childhood cancer, cells of an endocrine tumour, cells of a carcinoid tumour, thymoma cells, thyroid cancer cells, cells of an islet cell tumour, cells of an adrenal cell tumour, cells of a neuroendocrine tumour and

cells of a cancer of unknown primary (cancer of unknown primary origin). Detailed information on such cancers can be found in the relevant literature, such as "Cancer Medicine", JF Holland, E Frei (editors), McGraw-Hill Professional, 8th edition (2010) and references cited therein.

In one embodiment, the combination of antigen A1 and antigen A2 is only found on blood cells or precursor cells of blood cells, preferably on only one type of blood cells.

In one embodiment, the combination of antigen A1 and antigen A2 is only found on target, in particular, cancerous cells, and not (or only to a negligible extent) on cells that are not target cells, in particular, that are not cancerous. In a preferred embodiment, the combination of antigen A1 and antigen A2 is specific for cancerous cells of a certain type of cancer.

In one embodiment, the combination of antigen A1 and antigen A2 distinguishes a certain kind of cells, preferably a certain type of cancer cells, from any other cells.

"Certain type of cancer" in this context may mean type of cancer characterized by the same organ in which the cancer is formed or, preferred, type cancer characterized by the same pair of (aberrant) antigens A1 and A2.

In one embodiment, the combination of antigen A1 and antigen A2 is found on progenitor/precursor cells that are progenitor/precursor cells of a tumour and not on progenitor/precursor cells that are not progenitor/precursor cells of a tumour.

In one embodiment, said antigen A1 is an antigen that is specific for the malignant state of a cell and said antigen A2 is an antigen that is specific for the cell type or cell lineage of said cell.

In one embodiment,

- a) antigen A1 is EpCAM (epithelial cell adhesion molecule) and antigen A2 is CD10 (cluster of differentiation 10), HER2/neu (human epidermal growth factor receptor 2), VEGF-R (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor; also called HER1 (human epidermal growth factor receptor 1) or ErbB1) or MDR (multidrug resistance protein), or
- b) antigen A1 is MCSP (melanoma-associated chondroitin sulfate proteoglycan) and antigen A2 is melanoferrin or EpCAM, or
- c) antigen A1 is CA125 (cancer antigen 125/carbohydrate antigen 125) and antigen A2

- is CD227 (PEM (polymorphic epithelial mucin) or MUC1 (mucin-1)), or
- d) antigen A1 is CD56 and antigen A2 is CD140b (PDGFR β (platelet-derived growth factor receptor beta)) or GD3 ganglioside, or
- e) antigen A1 is EGFR and antigen 2 is HER2, or
- f) antigen A1 is PSMA (prostate-specific membrane antigen) and antigen 2 is HER2, or
- g) antigen 1 is Sialyl Lewis and antigen 2 is EGFR, or
- h) antigen 1 is CD44 and antigen 2 is ESA (epithelial surface antigen) (CD326, EpCAM), CD24, CD133, MDR (multidrug resistance protein) or CD117, or
- i) antigen 1 is CD34 and antigen 2 is CD19, CD79a, CD2, CD7, HLA-DR (human leukocyte antigen DR), CD13, CD117, CD33 or CD15, or
- j) antigen 1 is CD33 and antigen 2 is CD19, CD79a, CD2, CD7, HLA-DR (human leukocyte antigen DR), CD13, CD117 or CD15, or
- k) antigen 1 is MUC1 and antigen 2 is CD10, CEA or CD57, or
- l) antigen 1 is CD38 and antigen 2 is CD138, or
- m) antigen 1 is CD 24 and antigen 2 is CD29 or CD49f, or
- n) antigen 1 is carbonic anhydrase IX and antigen 2 is aquaporin, preferably aquaporin-2.

In one embodiment, said antigen A1 and/or said antigen A2 is selected from the group consisting of HLA-A (HLA-A major histocompatibility complex, class I, A [Homo sapiens]; Gene ID: 3105 updated on 13-Jan-2013; DAQB-90C11.16-002; Chromosome: 6; NC_000006.11 (29910247..29913661); for HLA-A2: 1. mRNA = LOCUS NM_001242758 = Version NM_001242758.1 GI:337752169 = GenBank: AY191309.1 PRI 13-JAN-2013; 2. Protein = P79495 [UniParc]. Last modified May 1, 1997. Version 1.; for HLA-Cw6: mRNA = LOCUS HUMMHCCW6A = GenBank: VERSION M28160.1 GI:531197PRI (18-AUG-1994); Protein = Q29963 [UniParc]. Last modified August 22, 2003. Version 2.); EpCAM (EPCAM epithelial cell adhesion molecule [Homo sapiens]; also known as ESA; KSA; M4S1; MK-1; DIAR5; EGP-2; EGP40; KS1/4; MIC18; TROP1; EGP314; HNPCC8; TACSTD1.; Gene ID: 4072, updated on 6-Jan-2013; mRNA = VERSION NM_002354.2 GI:218505669PRI 06-JAN-2013; Protein = P16422 [UniParc]. last modified November 13, 2007. Version 2.); CD45 (PTPRC protein tyrosine phosphatase, receptor type, C [Homo sapiens]; also known asLCA; LY5; B220; CD45; L-CA; T200; CD45R; GP180; Gene ID: 5788, updated on 13-Jan-2013; mRNA = VERSION NM_002838.4 GI:392307006 PRI 13-JAN-2013; Protein = P08575-1 = Isoform 1, Last modified July 19, 2003. Version 2.;

Protein = P08575-2 = Isoform 2); Her2 (ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) [Homo sapiens]; also known asNEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu; gene ID: 2064, updated on 13-Jan-2013; mRNA transcript variant 1 = VERSION NM_004448.2 GI:54792095, PRI 06-JAN-2013; mRNA transcript variant 2 = VERSION NM_001005862.1 GI:54792097, PRI 06-JAN-2013; Protein = P04626-1 = Isoform 1 , Last modified August 13, 1987. Version 1.; Protein = P04626-2= Isoform 2; Protein = P04626-3= Isoform 3; Protein = P04626-4= Isoform 4); EGFR (EGFR epidermal growth factor receptor [Homo sapiens]; also known asERBB; HER1; mENA; ERBB1; PIG61; Gene ID: 1956, updated on 13-Jan-2013; mRNA transcript variant 1 = VERSION NM_005228.3 GI:41327737, PRI 13-JAN-2013; mRNA transcript variant 2 = VERSION NM_201282.1 GI:41327731, PRI 13-JAN-2013; mRNA transcript variant 3 = VERSION NM_201283.1 GI:41327733, PRI 13-JAN-2013; mRNA transcript variant 4 = VERSION NM_201284.1 GI:41327735, PRI 13-JAN-2013; Protein = P00533-1 = Isoform 1, Last modified November 1, 1997. Version 2.; Protein = P00533-2 = Isoform 2; Protein = P00533-3 = Isoform 3; Protein = P00533-4 = Isoform 4); CD138 (SDC1 syndecan 1 [Homo sapiens]; Gene ID: 6382, updated on 6-Jan-2013; mRNA transcript variant 1 = VERSION NM_001006946.1 GI:55749479, PRI 06-JAN-2013; mRNA transcript variant 2 = VERSION NM_002997.4 GI:55925657, PRI 06-JAN-2013; Protein = P18827 [UniParc]. Last modified May 5, 2009. Version 3.); CEA (CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 [Homo sapiens]; also known asCEA; CD66e; Gene ID: 1048, updated on 13-Jan-2013; mRNA = VERSION NM_004363.2 GI:98986444, PRI 13-JAN-2013; P06731, Last modified January 11, 2011. Version 3.); and CD19 (CD19 CD19 molecule [Homo sapiens]; also known asB4; CVID3; Gene ID: 930, updated on 5-Jan-2013; mRNA transcript 1 = VERSION NM_001178098.1 GI:296010920, PRI 06-JAN-2013; mRNA transcript 2 = VERSION NM_001770.5 GI:296010919, PRI 06-JAN-2013; Protein = P15391 [UniParc]. Last modified November 13, 2007. Version 6).

In one embodiment, said antigen A1 and/or said antigen A2 is an MHC antigen, preferably an allelic variant of any of HLA-A, HLA-B, HLA-C, HLA-DQ, HLA-DR, or HLA-DM, more preferably an allelic variant of an MHC class I molecule, more preferably an allelic variant selected from the group consisting of HLA-A1, HLA-A2, HLA-A3, HLA-A25, HLA-B7, HLA-B8, HLA-B35, HLA-B44, HLA-Cw3, HLA-Cw4, HLA-Cw6, and HLA-Cw7.

In one embodiment, said antigen A1 is HLA-A2.

In one embodiment, said antigen A1 and/or said antigen A2 is selected from the group consisting of CD45, aquaporin, preferably aquaporin-2, scavenger receptor class B member 1 (SCARB1), CD34, CD33, CD138, CD15, CD1a, CD2, CD3, CD4, CD5, CD8, CD20, CD23, CD31, CD43, CD56, CD57, CD68, CD79a, CD146, synaptophysin, CD56, CD57, nicotinic acetylcholine receptor, muscle-specific kinase (MUSK), voltage-gated calcium channel (P/Q-type), voltage-gated potassium channel (VGKC), N-methyl-D-aspartate receptor (NMDA), TSH (thyroid stimulating hormone) receptor, amphiphysin, HepPar-1, ganglioside GQ1B, ganglioside GD3, ganglioside GM1 and glycophorin-A.

In a preferred embodiment, said antigen A1 is an MHC antigen and said antigen A2 is an antigen that is specific for a certain cell type or cell lineage.

In one embodiment, said functional domain F is an immunoglobulin module, preferably a scFv (single-chain variant fragment) of an antibody more preferably a Fv (variant fragment) of an antibody, or a fluorescent molecule, preferably a bimolecular fluorescence complementation molecule, more preferably GFP or a GFP variant, or a molecule capable of mediating bioluminescence, preferably a luciferase molecule, more preferably *Gaussia* luciferase.

In one embodiment, said functional domain F is a Fv (variant fragment) of an antibody.

In one embodiment, said functional domain F specifically binds or is capable of specifically binding to an antigen. In a specific aspect, said antigen may be an antigen that is present on cells of the human immune system. In a preferred embodiment, said binding activates said cells of the human immune system.

In one embodiment, said functional domain F is a T cell engaging domain, preferably a T cell engaging domain specifically binding to CD2, CD3, CD5, T cell receptor or CD28, more preferably a T cell engaging domain specifically binding to CD3ε, an NK cell (natural killer cell) engaging domain, preferably a NK cell engaging domain specifically binding to CD1a, CD16a or CD56, a domain engaging macrophage cells, preferably a domain engaging macrophage cells specifically binding to CD16a, CD32a, CD32b, CD89 or CD64, a monocyte engaging domain, preferably a monocyte engaging domain specifically binding to CD32a, CD32b, CD64 or CD89, a granulocyte engaging domain, preferably a granulocyte

engaging domain specifically binding to CD16b, CD32a, CD32b, CD64, or CD89, a domain engaging neutrophil granulocytes, preferably a domain engaging neutrophil granulocytes that specifically binds to CD89 (Fc α RI), or a domain engaging activated neutrophil granulocytes, monocytes and/or macrophages, preferably a domain engaging activated neutrophil granulocytes, monocytes and/or macrophages that specifically binds to CD64 (Fc γ RI).

In one embodiment, said functional domain F is a domain that specifically binds to an antigen linked to a diagnostic or therapeutic compound.

In one embodiment, said functional domain F is a domain that specifically binds to a carrier molecule or an affinity tag. Preferably, said carrier molecule is linked to a diagnostic or therapeutic compound. Preferably, said affinity tag is linked to a diagnostic or therapeutic compound.

Preferably, said affinity tag is selected from the group consisting of a FLAG-tag, a myc-tag, a glutathione-S-transferase(GST)-tag, a hemagglutinin(HA)-tag, a polyhistidine(His)-tag, a digoxigenin (DIG)-tag and a maltose binding protein(MBP)-tag.

Preferably, said carrier molecule is a peptide or a carbohydrate molecule. In a preferred embodiment, said functional domain F is a domain that specifically binds to a carrier molecule, preferably a carrier molecule linked to a diagnostic or therapeutic compound, wherein said carrier molecule is selected from the group consisting of gelatine, inulin, dextrane and hydroxyethyl starch.

In one embodiment, said therapeutic compound is a radioactive compound, preferably a radioactive compound comprising ^{90}Y , ^{177}Lu , ^{131}I , ^{32}P , ^{10}B , or ^{213}Bi . In one embodiment, said therapeutic compound is a toxin. Preferably, said toxin is selected from the group consisting of *B. anthracis* edema factor, *B. anthracis* lethal factor, *C. perfringens* iota toxin, *C. botulinum* C2 toxin, *C. difficile* ADP-ribosyltransferase, *C. diphtheriae* diphtheria toxin fragment A, *Burgholderia* sp. shiga toxin (subunit A), *Clostridium perfringens* str. 13 toxin pfoA perfringolysin O, Ricin A chain, plant RIP bouganin, Human RNASE3 ribonuclease (RNase A family, 3) and anthrax lethal factor endopeptidase. A further non-limiting example of a toxin in accordance with this invention is a toxin being or comprising an amino acid sequence selected from the group consisting of SEQ ID NOS 160 to 168.

In one embodiment, said diagnostic compound is a radioactive compound, preferably a

radioactive compound comprising ^{99m}Tc , ^{111}In , ^{82}Rb or ^{201}Tl . In one embodiment, said diagnostic compound is a fluorescent compound, preferably GFP, a GFP variant, or a fluorescent small-molecule compound such as FITC (fluorescein isothiocyanate), PE (phycoerythrin), an alexa fluor dye (such as AlexaFluor488 or related dyes) or a cyanine dye (such as Cy3 (Indocarbocyanine) or Cy5 (Indodicarbocyanine) or related dyes), In one embodiment, said diagnostic compound is a molecule capable of mediating bioluminescence, preferably a luciferase molecule, more preferably *Gaussia* luciferase.

In one embodiment, said fragment F1 comprises a V_L domain of an antibody and said fragment F2 comprises a V_H domain of the same antibody, wherein, preferably, said antibody is an anti-CD3 antibody, more preferably an anti-CD3 ε antibody, or an anti-His or anti-DIG antibody or said fragment F1 comprises a V_H domain of an antibody and said fragment F2 comprises a V_L domain of the same antibody, wherein, preferably, said antibody is an anti-CD3 antibody, more preferably an anti-CD3 ε antibody, or an anti-His or anti-DIG antibody.

In another embodiment, the V_L and V_H domains as comprised in the F1 and F2 fragment, respectively, or in the F2 and F1 fragment, respectively may also of two different antibodies, either specific for the same Antigen (and for the same or a different epitope) or for different Antigen. This is, for example, envisaged to be employed where new specifications are to be created (for example in phage-display approaches).

In another embodiment, the immunoglobulin module comprised in the F domain comprises a V domain selected from the group consisting of:

- (i) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NOS: 18-20 (CDRs 1-3) and/or a V_H domain comprising SEQ ID NOS: 15-17 (CDRs 1-3);
- (ii) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NOS: 24-26 (CDRs 1-3) and/or a V_H domain comprising SEQ ID NOS: 21-23 (CDRs 1-3);
- (iii) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NOS: 30-32 (CDRs 1-3) and/or a V_H domain comprising SEQ ID NOS: 27-29 (CDRs 1-3);

- (iv) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NOS: 36 and 37 (CDRs 1 and 3) and DTS (CDR 2) and/or a V_H domain comprising SEQ ID NOS: 33-35 (CDRs 1-3);
- (v) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NOS: 41 and 42 (CDRs 1 and 3) and YTN (CDR 2) and/or a V_H domain comprising SEQ ID NOS: 38-40 (CDRs 1-3); and
- (vi) a V domain of an anti-His antibody comprising a V_L domain comprising SEQ ID NOS: 46 and 47 (CDRs 1 and 3) and KVS (CDR 2) and/or a V_H domain comprising SEQ ID NOS: 43-45 (CDRs 1-3);
- (vii) a V domain of an anti-DIG antibody comprising a V_L domain comprising SEQ ID NOS: 50 and 131 (CDRs 1 and 3) and YSS (CDR 2) and/or a V_H domain comprising SEQ ID NOS: 48 and 49 (CDRs 1 and 2) and A (CDR 3).

In another, preferred embodiment, the immunoglobulin module comprised in the F domain comprises a V domain selected from the group consisting of:

- (i) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NO: 2 and/or a V_H domain comprising SEQ ID NO: 1;
- (ii) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NO: 4 and/or a V_H domain comprising SEQ ID NO: 3;
- (iii) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NO: 6 and/or a V_H domain comprising SEQ ID NO: 5;
- (iv) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NO: 8 and/or a V_H domain comprising SEQ ID NO: 7;
- (v) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NO: 10 and/or a V_H domain comprising SEQ ID NO: 9; and
- (vi) a V domain of an anti-His antibody comprising a V_L domain comprising SEQ ID NO: 12 and/or a V_H domain comprising SEQ ID NO: 11;
- (vii) a V domain of an anti-DIG antibody comprising a V_L domain comprising SEQ ID NO: 14 and/or a V_H domain comprising SEQ ID NO: 30.

In one embodiment, said functional domain F is a domain that specifically binds to a toxin molecule, preferably a toxin molecule that by itself is not capable of penetrating through the cell membrane of a human cell and that, preferably, is internalized into a human cell upon

association with the cell membrane of said cell, wherein, preferably, said association with the cell membrane of said cell is mediated by specifically binding to a heterodimer formed from two molecules, preferably two molecules associated with said cell membrane, wherein, preferably, said two molecules are the polypeptides P1 and P2 as described herein.. In one embodiment, said functional domain F is a domain that specifically binds to the A-component (active component) of a bacterial two-component A-B toxin. In one embodiment said functional domain F is a domain that specifically binds to a toxin selected from the group consisting of *B. anthracis* edema factor, *B. anthracis* lethal factor, *C. perfringens* iota toxin, *C. botulinum* C2 toxin, *C. difficile* ADP-ribosyltransferase, *C. diphtheriae* diphtheria toxin fragment A, *Burgholderia* sp. shiga toxin (subunit A), *Clostridium perfringens* str. 13 toxin pfoA perfringolysin O, Ricin A chain, plant RIP bouganin, Human RNASE3 ribonuclease (RNase A family, 3) and anthrax lethal factor endopeptidase. A further non-limiting example of a toxin in accordance with this invention is a toxin being or comprising an amino acid sequence selected from the group consisting of SEQ ID NOS 160 to 168.

In one embodiment, said functional domain F is a domain that specifically binds to a fluorescent molecule, preferably a fluorescent molecule that by itself is not capable of penetrating through the cell membrane of a human cell. Preferably, said fluorescent molecule is GFP or a GFP variant or a molecule that is or comprises a fluorescent small-molecule compound such as FITC (fluorescein isothiocyanate), PE (phycoerythrin), an alexa fluor dye (such as AlexaFluor488 or related dyes) or a cyanine dye (such as Cy3 (Indocarbocyanine) or Cy5 (Indodicarbocyanine) or related dyes).

In one embodiment, said functional domain F is a domain that specifically binds to a molecule capable of mediating bioluminescence, preferably to a luciferase molecule, more preferably to *Gaussia* luciferase.

In one embodiment, said functional domain F is a fluorescent molecule, preferably a bimolecular fluorescence complementation molecule, more preferably GFP or a GFP variant, such as YFP, CFP, Venus, or Cerulean.

Examples of particular polypeptides P1 or P2 comprised in the set of polypeptides according to this invention are polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 114-129 and 197.

In general, the present invention relates to the treatment or elimination of any undesired cell

population and the treatment or prevention of any disorder or disease which comes along with this undesired cell population. For this purpose, the set of polypeptides of this invention is to be used.

In one embodiment, said set of polypeptides is a set of polypeptides for use in the treatment of a patient who is suffering from a tumour or cancer or for diagnostic use in a patient who is suffering from a tumour or cancer, preferably for use in the treatment of a patient who is suffering from a tumour or cancer and undergoing allogeneic tissue or cell transplantation or meant to undergo such transplantation, or for diagnostic use in a patient who is suffering from a tumour or cancer and undergoing or meant to undergo allogeneic tissue or cell transplantation, wherein, preferably, said set of polypeptides is administered to said patient.

Examples of tumours to be treated or diagnosed are those for which the tumour or cancer cells are described herein above with respect to the antigens A1 and/or A2.

In one embodiment, said treatment involves the elimination of recipient tissue/cells of a certain cell type, preferably a cancerous cell type, or recipient precursor cells giving rise to a certain cell type, preferably to a cancerous cell type, optionally after or in parallel to transplantation to the recipient of donor tissue/cells of said same cell type or donor precursor cells giving rise to said same cell type.

In one embodiment, the set of polypeptides of the invention is for use in an allogeneic transplantation setting for haematopoietic neoplasias, for example, with mismatched HLA antigens, in particular for use in therapeutically exploiting this mismatch situation. In this exemplary situation, the dual information of recipient HLA haplotype (HLA_{patient}) and haematopoietic lineage origin (CD45) is displayed exclusively on leukemic blasts and other haematopoietic cells of the patient. All other cells of recipient origin express the recipient haplotype but not the hematopoietic lineage antigen CD45 (e.g. recipient non-hematopoietic cells are positive for HLA-A2 but negative for CD45). Likewise, all donor hematopoietic cells express donor HLA haplotype molecules that means that they are CD45 positive but HLA-A2 negative in the situation a mismatch transplantation where the patient but not the donor is positive for HLA-A2. Consequently, the present invention also relates to bimolecular and complementing single-chain antibody constructs directed against HLA-A2, in cases where the patient but not the donor is HLA-A2 positive, and a second construct specific for the haematopoietic lineage marker CD45 to specifically target all hematopoietic

cells of the patient including all hematologic neoplasms. Hence, the first polypeptide P1 may comprise a single-chain variable fragment antibody construct directed against the HLA of the patient (targeting moiety T1) fused to the V_L fragment of F1 antiCD3 (for example, fragment F1). The second polypeptide P2 may comprise a single-chain variable fragment construct specific for a haematopoietic lineage marker (for example, CD45; targeting moiety T2), fused to the V_H split-fragment of F2 anti CD3-Fv (fragment F2).

In one embodiment, said elimination involves the destroying of said recipient tissue/cells or said recipient precursor cells by cells of the immune system, by a toxin or by a radioactive compound.

In one embodiment, said set of polypeptides is a set of polypeptides for diagnostic use in a patient undergoing allogeneic tissue or cell transplantation, wherein, preferably, said patient is a patient suffering from a tumour.

In one embodiment, said diagnostic use involves the specific detection of recipient cells of a certain cell type or cell lineage among recipient cells of different cell type or cell lineage and donor cells of the same or different type or cell lineage.

In one embodiment, said diagnostic use involves the specific detection of recipient cells that are malignant cells among recipient cells that are not malignant and among donor cells. In one embodiment, said set of polypeptides is administered to a patient.

Preferably, said patient is a mammal, more preferably a human being.

In one embodiment, said administration occurs by bolus administration or by continuous administration.

In one embodiment, the polypeptides P1 and P2 of said set of polypeptides are administered in parallel. In another embodiment, the polypeptides P1 and P2 of said set of polypeptides are administered sequentially.

In one embodiment, one of the polypeptides P1 or P2 of said set of polypeptides is administered by bolus administration, whereas the other one is administered by continuous administration.

In one embodiment, the amount of polypeptide administered is in the range of from

0.5 $\mu\text{g}/\text{m}^2$ per day to 500 $\mu\text{g}/\text{m}^2$ per day for the polypeptide P1 or for the polypeptide P2 or for each of the polypeptides P1 and P2, preferably in the range of from 5 $\mu\text{g}/\text{m}^2$ per day to 200 $\mu\text{g}/\text{m}^2$ per day for the polypeptide P1 or for the polypeptide P2 or for each of the polypeptides P1 and P2, more preferably in the range of from 10 $\mu\text{g}/\text{m}^2$ per day to 80 $\mu\text{g}/\text{m}^2$ per day for the polypeptide P1 or for the polypeptide P2 or for each of the polypeptides P1 and P2.

In one embodiment, the amount of polypeptide administered is in the range of from 0.05 $\mu\text{g}/\text{m}^2$ per day to 0.5 $\mu\text{g}/\text{m}^2$ per day for the polypeptide P1 or for the polypeptide P2 or for each of the polypeptides P1 and P2.

In one embodiment, the amount of polypeptide P1 administered is different from the amount of polypeptide P2 administered.

In one embodiment, the amount of polypeptide administered is in the range of from 0.5 $\mu\text{g}/\text{m}^2$ per day to 50 $\mu\text{g}/\text{m}^2$ per day for the polypeptide P1 or for the polypeptide P2 or for each of the polypeptides P1 and P2. In one embodiment, the amount of polypeptide administered is in the range of from 50 $\mu\text{g}/\text{m}^2$ per day to 100 $\mu\text{g}/\text{m}^2$ per day for the polypeptide P1 or for the polypeptide P2 or for each of the polypeptides P1 and P2. In one embodiment, the amount of polypeptide administered is in the range of from 100 $\mu\text{g}/\text{m}^2$ per day to 200 $\mu\text{g}/\text{m}^2$ per day for the polypeptide P1 or for the polypeptide P2 or for each of the polypeptides P1 and P2. In one embodiment, the amount of polypeptide administered is in the range of from 200 $\mu\text{g}/\text{m}^2$ per day to 300 $\mu\text{g}/\text{m}^2$ per day for the polypeptide P1 or for the polypeptide P2 or for each of the polypeptides P1 and P2. In one embodiment, the amount of polypeptide administered is in the range of from 300 $\mu\text{g}/\text{m}^2$ per day to 400 $\mu\text{g}/\text{m}^2$ per day for the polypeptide P1 or for the polypeptide P2 or for each of the polypeptides P1 and P2. In one embodiment, the amount of polypeptide administered is in the range of from 400 $\mu\text{g}/\text{m}^2$ per day to 500 $\mu\text{g}/\text{m}^2$ per day for the polypeptide P1 or for the polypeptide P2 or for each of the polypeptides P1 and P2. In one embodiment, the amount of polypeptide administered is in the range of from 500 $\mu\text{g}/\text{m}^2$ per day to 1 mg/m^2 per day for the polypeptide P1 or for the polypeptide P2 or for each of the polypeptides P1 and P2.

Further reference points for deriving the amounts of the polypeptides P1 and P2 to be administered can also be obtained by consulting studies carried out with bispecific antibody constructs (e.g. Bargou R et al., Tumor regression in cancer patients by very low doses of a

T cell-engaging antibody. *Science*. 2008; 321(5891):974-7; and Topp MS et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. *J Clin Oncol*. 2011, 29:2493-8).

In one embodiment, said administration occurs continuously for at least 12 hours or for at least 1 day or for at least 2 days or for at least 3 days or for at least 4 days or for at least 5 days or for at least 6 days or for at least 7 days or for at least 8 days or for at least 9 days or for at least 10 days or for at least 11 days or for at least 12 days or for at least 13 days or for at least 14 days or for at least 15 days or for at least 16 days or for at least 17 days or for at least 18 days or for at least 19 days or for at least 20 days or for at least 21 days or for at least 22 days or for at least 23 days or for at least 24 days or for at least 25 days or for at least 26 days or for at least 27 days or for at least 28 days or for at least 29 days or for at least 30 days or for at least 5 weeks or for at least 6 weeks.

In one embodiment, said administration of said set of polypeptides or of one of the polypeptides of said set of polypeptides occurs intravenously, preferably by intravenous injection.

In one embodiment, said administration of said set of polypeptides or of one of the polypeptides of said set of polypeptides occurs subcutaneously, preferably by subcutaneous injection.

In one embodiment, said set of polypeptides is administered in combination with one or more drugs selected from the group consisting of an immunomodulatory drug, and/or a steroid, preferably prednisolone or prednisone.

In one embodiment, said set of polypeptides is administered in combination with a radioactive compound, preferably a radioactive compound linked to an antigen, a carrier molecule or an affinity tag, wherein said radioactive compound, said antigen, said carrier molecule or said affinity tag is specifically bound by said functional domain F.

In one embodiment, said set of polypeptides is administered in combination with a toxin, preferably a toxin linked to an antigen, a carrier molecule or an affinity tag, wherein said toxin, said antigen, said carrier molecule or said affinity tag is specifically bound by said functional domain F.

In one embodiment, said set of polypeptides is administered in combination with a fluorescent molecule, preferably a fluorescent molecule linked to an antigen, a carrier molecule or an affinity tag, wherein said fluorophore, said antigen, said carrier molecule or said affinity tag is specifically bound by said functional domain F.

In one embodiment, said functional domain F is a domain that specifically binds to an antigen which is not recognized as foreign by the immune system of said patient to whom said set of polypeptides is administered.

In one embodiment two sets of polypeptides as described above (a first set of polypeptides and a second set of polypeptides) are administered simultaneously or sequentially. In one preferred embodiment, said first set of polypeptides has different fragments F1 and F2 than said second set of polypeptides. In one preferred embodiment, said first set of polypeptides has the same fragments F1 and F2 as said second set of polypeptides. In one preferred embodiment, the targeting moieties T1 and T2 of said first set of polypeptides bind to the same antigens as the targeting moieties T1 and T2, respectively, of said second set of polypeptides. In one preferred embodiment, the targeting moieties T1 and T2 of said first set of polypeptides bind to different antigens than the targeting moieties T1 and T2 of said second set of polypeptides.

In one embodiment, said patient has undergone cancer treatment before treatment with said set of polypeptides, said cancer treatment preferably being chemotherapy, radiation therapy or operative removal of the tumour, or undergoes cancer treatment parallel to treatment with said set of polypeptides, said cancer treatment preferably being chemotherapy, radiation therapy or operative removal of the tumour.

In one embodiment, said set of polypeptides or one of the polypeptides of said set of polypeptides has been produced by means of a prokaryotic or eukaryotic expression system or by de novo peptide synthesis.

In one embodiment, said set of polypeptides or one of the polypeptides of said set of polypeptides is generated inside said patient by protein expression from a nucleic acid introduced into said patient.

Many patients suffer from allergic or auto-immune diseases. In many of these cases, a clonal B cell population produce an errant antibody that reacts with antigens expressed by the

patients' tissues or complex with an allergen, causing anaphylactic reactions. In both cases, it is desirable to specifically eliminate the errant B cell clone.

To this end, one may modify the combinatorial system in a way so that one arm (P1 or P2, in particular T1 or T2) recognizes a B cell associated antigen (e.g. CD19, CD20, CD38 or CD138) and the other arm (P2 or P1, in particular T2 or T1, respectively) is the allergen or the substrate bound by the antibody that causes the autoimmune disease. When these two constructs bind to a B cell that is CD19 (CD20, CD38 or CD138) positive and simultaneously displays the clonotypic antibody on the surface, the attached anti-CD3 VH and VL can interact and reconstitute the CD3 binding site exactly on the B cell. This allergen-specific or antigen-specific assembly will ultimately result in the clonal depletion of the Target B cells.

Hence, in accordance with this invention, any of said antigens A1 and A2 may also be a clonotypic antibody on the surface of a B cell, in particular a B cell that causes an autoimmune disorder.

In this context, for example, one of said antigens A1 and A2 may be CD19 and the other one may be a clonotypic antibody on the surface of a B cell, in particular a B cell that causes an autoimmune disorder.

In accordance with this aspect of the invention, any one of said targeting moiety T1 and T2 may comprise an allergen or substrate which binds to the clonotypic antibody on the surface of the B cell and/or which is, upon binding to the clonotypic antibody, capable to cause an autoimmune disorder. Non-limiting examples of an allergen comprised in any one of said targeting moiety T1 and T2 are hair allergens, like, for example, dog-hair, cat-hair (e.g. Fel d 1, Feld d1A, Feld d1B) or guinea-pig-hair allergens, or pollen allergens, like, for example, birch, grass, pollen allergens. Further non-limiting examples are mite allergens (for example Tyr p 2, Der P1, Der f 2), cat allergens (for example Fel d 1, Feld d1A, Feld d1B), peanut allergens (for example Conglutin-7), rot fungus allergens (for example Alt a 1), dog allergens (for example Can f 1), sprue wheat allergens (for example Alpha/beta-gliadin), german cockroach allergens (for example Bla g 1.02 variant allergen), birch tree or (major) pollen allergens (for example Cyn d 1, Pha a 1, Dac g 3, Phl p 2, Phl p 1, Profilin, Bet v 1-L, Bet v 1-A), major apple allergens (for example Mal d 1), cow's milk allergens (for example alpha-lactalbumin, alpha-S1-casein), chicken egg allergens (for example lysozyme C,

ovalbumin) and Horse allergens (for example latherin, Equ c 1), and the like. A further non-limiting and preferred example of an allergen comprised in any one of said targeting moiety T1 and T2 is the antigen for human myeloma cell line U266 antibody IgE-ND. A further non-limiting and preferred example of an allergen comprised in any one of said targeting moiety T1 and T2 is an allergen being or comprising an amino acid sequence selected from the group consisting of SEQ ID NOS 169 to 195.

In this context, the inventions also relates to the set of polypeptides as described herein, and, in particular in the above aspect, for use in treating or preventing a disorder selected from the group consisting of

- (i) an autoimmune disorder; and
- (ii) a hypersensitivity disorder.

Non-limiting examples of an autoimmune disorder to be treated or prevented in accordance with this invention are selected from the group consisting of

- (i) allergic disorders;
- (ii) Multiple Sclerosis;
- (iii) Psoriasis;
- (iv) Systemic Lupus Erythematosus;
- (v) Sjögren's syndrome;
- (vi) Rheumatoid Arthritis;
- (vii) Idiopathic Thrombocytopenic Purpura;
- (viii) Diabetes;
- (xi) Vasculitis;
- (x) Crohn's disease; and
- (xi) Amyloidosis.

Non-limiting examples of a hypersensitivity disorder to be treated or prevented in accordance with this invention are selected from the group consisting of allergies (type I hypersensitivity reaction according to Coombs and Gell classification), an antibody dependent cytotoxic reaction (type II hypersensitivity reaction), a immune complex disease (type III hypersensitivity reaction), delayed type hypersensitivity (type IV hypersensitivity reaction) and a receptor mediated autoimmune disease (type V hypersensitivity reaction).

In a preferred embodiment, said autoimmune or hypersensitivity disorder comes along with or is triggered by allogenic stem cell transplantation (i.e. any of type I to type V hypersensitivity disorder according to the Coombs and Gell classification).

Many cells which are infected by a pathogen (for example a virus, like, for example, HIV, EBV, CMV) express pathogen-encoded proteins on their cell surface. Hence, in accordance with this invention, any of said antigens A1 and A2 may also be such a pathogen-encoded protein, like, for example, a HIV, EBV or CMV protein on the surface of a cell. In this context, the inventions also relates to the set of polypeptides as described herein for use in treating or preventing an infectious disease, for example a viral infectious disease. Particular examples of pathogen-encoded proteins can be derived from <http://www.uniprot.org/uniprot/> and are HIV gp120 (Q78706); EBV LMP-2 (P13285); CMV gB (P06473); HBV HBS (Q9JG36); HCV E1 (C4B751); HCV E2 (Q6TRB1); Human adenovirus C serotype 2 HAdV-2 (P03276).

The objects of the present invention are also solved by a nucleic acid molecule or a set of nucleic acid molecules encoding the set of polypeptides or one of the polypeptides of the set of polypeptides as defined in the embodiments above, wherein, preferably, said nucleic acid molecule or the nucleic acid molecules of said set of nucleic acid molecules comprises an export signal that mediates secretion of the encoded polypeptide(s) by a bacterial or eukaryotic cell.

A non-limiting example of the nucleic acid molecule or set of nucleic acid molecules according to this invention comprises one or more of the nucleotide sequences as depicted in any one of SEQ ID NOS: 135-150 and 196.

The objects of the present invention are also solved by a vector comprising the nucleotide sequence of the nucleic acid molecule as defined above or the sequence of one of the nucleic acid molecules of the set of nucleic acid molecules as defined above.

The objects of the present invention are also solved by a cell comprising said nucleic acid/set of nucleic acids or said vector.

The objects of the present invention are also solved by a pharmaceutical composition comprising either the set of polypeptides as defined above or the nucleic acid molecule/set of

nucleic acid molecules as defined above or the vector as defined above, wherein, preferably, said pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

The objects of the present invention are also solved by a kit comprising the set of polypeptides as defined above and/or the nucleic acid molecule or the set of nucleic acid molecules according the invention and/or the vector according the invention.

In one embodiment, the polypeptides of said set of polypeptides comprised by said kit are contained in a single vial.

In one preferred embodiment, the polypeptides of said set of polypeptides comprised by said kit are contained in separate vials.

In one embodiment, one or more of the polypeptides of said set of polypeptides comprised by said kit are freeze-dried.

In one embodiment, one or more of the polypeptides of said set of polypeptides comprised by said kit are in solution.

The objects of the present invention are also solved by a method for treatment of a patient who is suffering from a

- (i) tumour or cancer and/or who is undergoing allogeneic cell or tissue transplantation;
- (ii) an autoimmune disorder; or
- (iii) a hypersensitivity disorder.

Said method may comprise the steps:

- obtaining a set of polypeptides, said set of polypeptides comprising
 - a first polypeptide P1 comprising
 - (i) a targeting moiety T1,
wherein said targeting moiety T1 specifically binds to an antigen A1, and
 - (ii) a fragment F1 of a functional domain F,
wherein neither said fragment F1 by itself nor said polypeptide P1 by itself is functional with respect to the function of said domain F,

and

- a second polypeptide P2 comprising
 - (i) a targeting moiety T2,
wherein said targeting moiety T2 specifically binds to an antigen A2, said

antigen A2 being a cell surface molecule that is specific for a certain cell type or cell lineage, and

(ii) a fragment F2 of said functional domain F,

wherein neither said fragment F2 by itself nor said polypeptide P2 by itself is functional with respect to the function of said domain F,

wherein said antigen A1 is different from said antigen A2,

wherein said polypeptide P1 and said polypeptide P2 are not associated with each other in the absence of a substrate that has both antigens A1 and A2 at its surface, more specifically a cell that carries both antigens A1 and A2 at its cell surface, and

wherein, upon dimerization of said fragment F1 of said polypeptide P1 with said fragment F2 of said polypeptide P2, the resulting dimer is functional with respect to the function of said domain F,

- administering said set of polypeptides to said patient.

In such method of treatment, said set of polypeptides is as defined in the embodiments above.

The objects of the present invention are also solved by a method of using the set of polypeptides as described above for treatment of a patient undergoing cell or tissue transplantation.

The objects of the present invention are also solved by the use of a set of proteins as defined in the embodiments above for the manufacture of a medicament for the treatment of a patient suffering from the above defined and described diseases a disorder or, for example, a patient suffering from cancer and/or undergoing cell or tissue transplantation.

As used herein, the term "polypeptide" refers to a linear molecular chain of amino acids containing more than 30 amino acids. Optionally, a polypeptide may include one or more disulfide bonds or be chemically modified. Moreover, optionally a non-proteinaceous element (such as a fluorophore, RNA-aptamer, DNA-aptamer, or small molecule) may be attached to said linear molecular chain of amino acids. Such polypeptides can be produced by any known method. The polypeptide can for example be generated by expression from a nucleic acid coding for said polypeptide, or can be synthesized by solid phase synthesis methods, or be produced by conjugation or linkage of existing molecules, e.g., by chemical linkage.

The term "polypeptide P1" is used to refer to a polypeptide comprising (i) a targeting moiety, wherein said targeting moiety specifically binds to an antigen, and (ii) a fragment of a functional domain, wherein neither said fragment by itself nor said polypeptide P1 by itself is functional with respect to the function of said functional domain. The term "polypeptide P2" is used to refer to a polypeptide comprising (i) a targeting moiety, wherein said targeting moiety specifically binds to an antigen, and (ii) a fragment of a functional domain, wherein neither said fragment by itself nor said polypeptide P2 by itself is functional with respect to the function of said functional domain.

The term "domain", as used herein, refers to a linear molecular chain of amino acids that includes the amino acid sequence of an entire polypeptide or a portion of a polypeptide. Optionally, a domain may include one or more disulfide bonds or be chemically modified. Moreover, optionally a domain may comprise a non-proteinaceous element (such as a fluorophore). In one embodiment, however, the term "domain" does not comprise compounds that are chemically modified or comprise non-proteinaceous element(s).

A "functional domain", as used herein, is a domain that is capable of fulfilling a certain function, such as specific binding to a certain binding partner or antigen, specific activation of a certain receptor, mediation of toxic effects, or fluorescence upon excitation with light of an appropriate wavelength.

The term "functional domain F" is preferably meant to also include compounds that are non-proteinaceous. In one embodiment, however, it refers to a proteinaceous compound or a functional part thereof.

The term "a fragment of a domain", as used herein, refers to a linear molecular chain of amino acids that corresponds to a part of a domain, but not the entire domain. Optionally, a fragment of a domain may include one or more disulfide bonds or be chemically modified. Moreover, optionally a domain may comprise a non-proteinaceous element or part of such a non-proteinaceous element.

The term "fragment F1" is used to refer to a fragment of a functional domain. The term "fragment F2" is used to refer to a fragment of a functional domain.

The pairwise abbreviations P1, P2; T1, T2; F1, F2; A1, A2; and I1, I2, as used herein, are meant to designate different polypeptides, targeting moieties, fragments, antigens, and immunoglobulin modules, respectively. They are synonymous to first polypeptide, second

polypeptide; first targeting moiety, second targeting moiety; first fragment, second fragment; first antigen, second antigen; and first immunoglobulin module, second immunoglobulin module, respectively.

The term "moiety", as used herein, refers to a linear molecular chain of amino acids that includes the amino acid sequence of an entire polypeptide or a portion of a polypeptide. Optionally, a moiety may include one or more disulfide bonds or be chemically modified. Moreover, optionally a moiety may comprise a non-proteinaceous element (such as an oligonucleotide). In one embodiment, however, the term "moiety" does not comprise compounds that are chemically modified or comprise non-proteinaceous element(s).

The term "targeting moiety T1" is used to refer to a moiety that specifically binds to an antigen, for example antigen A1. The term "targeting moiety T2" is used to refer to a moiety that specifically binds to an antigen, for example antigen A2.

As used herein, a "linker" is a sequence of amino acids within a polypeptide that connects two parts of said polypeptide or two domains comprised by said polypeptide.

The term "nucleic acid molecule", as used by the present invention, defines a linear molecular chain consisting of more than 30 nucleotides. The term includes DNA, such as cDNA or genomic DNA, and RNA.

The term "construct", as used herein, refers to a nucleic acid molecule comprising one or more recombinant nucleotide sequences. The term also includes polypeptides that are expressed from a recombinant nucleotide sequence or that are artificially made or recombinant molecules that comprise two or more amino acid sequences that are not naturally found within the same protein.

The term "specifically binds to" or "specifically binds", as used by the present invention in the context of a molecule or domain that specifically binds to an interaction partner or antigen or that specifically binds an interaction partner or antigen, means that a molecule or domain binds to said interaction partner or antigen, preferably by non-covalent binding, or is capable of binding said interaction partner or antigen, preferably by non-covalent binding, and does not or essentially not cross-react with any other interaction partner or antigen with a structure similar to that of the interaction partner or antigen.

In the context of a targeting moiety (such as targeting moiety T1 or T2) specifically binding to an antigen (such as antigen A1 or A2), the term "specifically binds to" is meant to refer to

a situation where either said targeting moiety is capable of specifically binding to said antigen, or where it actually binds thereto.

In the context of a T cell engaging domain, an NK cell engaging domain, domain engaging macrophage cells, a monocyte engaging domain, a granulocyte engaging domain, a domain engaging neutrophil granulocytes, or a domain engaging activated neutrophil granulocytes, monocytes and/or macrophages, the term "specifically binding to" an antigen or molecule or "specifically binds to" an antigen or molecule is meant to refer to a situation where either the respective domain is capable of specifically binding to said antigen or molecule, or where it actually binds thereto.

In the context of a functional domain being a domain that "specifically binds to" an antigen, a molecule, a compound, a carrier molecule or an affinity tag, the term "specifically binds to" is meant to refer to a situation where either said functional domain is capable of specifically binding to said antigen, molecule, compound, carrier molecule or affinity tag, or where it actually binds thereto.

In the context of a toxin, fluorophore, antigen, carrier molecule or affinity tag being "specifically bound by" a functional domain, this is meant to refer to a situation where either said functional domain is capable of specifically binding to said toxin, fluorophore, antigen, carrier molecule or affinity tag, or where it actually binds thereto.

As used in the present application, a molecule or antigen is "specific for a certain cell type or cell lineage" if it is expressed by said cell type/cells of said cell lineage, but not (or only to a negligible extent) by other cell types or cells of other cell lineage. In some embodiments, a molecule or antigen is "specific for a certain cell type or cell lineage" if it is expressed by said cell type/cells of said cell lineage, and not more than a few other cell types or cells of other cell lineage besides said cell type/cells of said cell lineage express said antigen as well, while most other cell types or cells of other cell lineage besides said cell type/cells of said cell lineage do not express said antigen (or only to a negligible extent). The term "specific for a certain cell type or cell lineage" may also mean that said molecule or antigen is expressed by said cell type/cells of said cell lineage at a higher rate or at a higher proportion or amount than by other cell types/cells of other cell lineages, in the sense that there may be a small but detectable expression of said molecule also in other cell types/cells of other cell lineages. The term "marker", as used herein in the context of a marker for a certain cell type or cell lineage, can refer to a molecule or antigen that is specific for a cell type or cells of a cell lineage, respectively, as described above.

As used herein, the term "aptamer" refers to a small compound composed of oligonucleic acid (such as RNA or DNA) or peptidic or non-peptidic molecule that binds to a specific target molecule with high affinity.

As used herein, the term "carrier molecule" refers to a molecule or part of a molecule that is not recognized as foreign by the immune system of a patient to whom the set of polypeptides according to the invention is administered or that causes no or only a weak immune reaction by a patient to whom the set of polypeptides according to the invention is administered. Preferably, such a "carrier molecule" is being bound by or capable of being bound by another molecule, such as an antibody. In some embodiments, a "carrier molecule" is a molecule or part of a molecule that in certain embodiments, the carrier molecule is attached covalently or non-covalently to a second molecule or part of a second molecule, for example a fluorophore or toxin.

The term "MHC" refers to the Major Histocompatibility Complex, which is a set of genes encoding a group of molecules comprising cell-surface molecules that are required for antigen presentation to T-cells and that are also responsible for rapid graft rejections. In humans, the MHC includes the genes HLA-A, HLA-B, HLA-C, HLA-DP, HLA-HQ, and HLA-DR. In the present application, the term is used to refer to the genes of the Major Histocompatibility Complex as well to the gene products encoded by these genes. The term "HLA" refers to Human Leukocyte Antigens. As used herein, "HLA" is the human form of "MHC".

The term "allelic variant", as used herein, denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. For example, HLA-A1, HLA-A2, and HLA-A3 are three of the allelic variants of HLA-A. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.

The term "antigen", as used herein, refers to a molecule known to be specifically bound by or capable of being specifically bound by an antibody or the antigen-binding part of an antibody. In its broadest meaning, "antigen A1" refers to an antigen as defined above. In its broadest meaning "antigen A2" refers to an antigen as defined above. The designations "antigen A1" and "antigen A2" have been chosen in order to allow for distinction between "antigen A1" and "antigen A2". An "MHC antigen" is an antigen that is also a molecule belonging to the major histocompatibility complex. MHC antigens include MHC class I

antigens (in humans, the antigens HLA-A, -B, and -C) and MHC class II antigens (in humans, the antigens HLA-DP, -DQ, and -DR). The phrase that a cell "carries an antigen" or "carries an antigen at its cell surface" is meant to refer to a situation where a cell expresses an antigen that is present at the cell surface of said cell and accessible for an antibody from outside said cell. The phrase that a substrate "has an antigen at its surface" is meant to refer to a situation where said antigen is present at the surface of said substrate and accessible for an antibody applied to said substrate.

The term "an antigen that is specific for the malignant state of a cell", as used herein, refers to an antigen that a malignant cell of a certain cell type (such as a malignant B-cell tumour cell) carries at its cell surface, but that a cell of the same cell type that is not malignant (such as a non malignant B-cell) does not (or only to a negligible extent) carry at its cell surface.

The term "an antigen/molecule that is specific for a malignant cell type", as used herein, refers to an antigen/molecule that a malignant cell of a certain cell type (such as malignant B-cell tumour cell) carries at its cell surface, but that a cell of the same cell type that is not malignant (such as a non malignant B-cell) or cells of other cell types (such as T-cells or hepatocytes) do not (or only to a negligible extent) carry at their cell surface. In some embodiments, the term "an antigen/molecule that is specific for a malignant cell type" refers to an antigen/molecule that a malignant cell of a certain cell type (such as malignant B-cell tumour cell) carries at its cell surface, but that a cell of the same cell type that is not malignant (such as a non malignant B-cell) does not (or only to a negligible extent) carry at its cell surface, and that only cells of a few other cell types besides that certain cell type carry at their cell surface, while cells of most other cell types do not (or only to a negligible extent). The term "an antigen/molecule that is specific for a malignant cell type" may also mean that said antigen/molecule is expressed by said malignant cell of a certain cell type at a higher rate or at a higher proportion or amount than by a cell of the same cell type that is not malignant, in the sense that there may be a small but detectable expression of said molecule also in a cell of the same cell type that is not malignant. The term "marker", as used herein in the context of a marker for the malignant state of a certain cell or for a malignant cell type, can refer to a molecule or antigen that is specific for the malignant state of a certain cell or for a malignant cell type, respectively, as described above.

The term "immunoglobulin domain", as used herein, refers to a domain that essentially consists of a globular region of an antibody chain. Immunoglobulin domains are characterized in that they retain the immunoglobulin fold characteristic of antibody

molecules. Immunoglobulins, such as IgG, IgE, or IgM, are composed of a varying number of heavy and light chains. Each heavy and light chain contains a constant region and a variable region. Each light chain variable region (V_L) and each heavy chain variable region (V_H) contains three hypervariable regions, also called "complementarity-determining regions" or "CDRs". The CDRs are primarily responsible for binding of the immunoglobulin to an antigen.

The terms " V_H " or " V_H domain" are used interchangeably and refer to the variable region of an immunoglobulin heavy chain of an antibody. The terms " V_L " or " V_L domain" are used interchangeably and refer to the variable region of an immunoglobulin light chain of an antibody.

The term "immunoglobulin module", as used herein, refers to a molecule, part of a molecule or molecular assembly which comprises one or more, preferably two or more, immunoglobulin domains and which is capable of binding to an antigen. Preferably, an "immunoglobulin module" comprises a linear molecular chain of amino acids that includes the amino acid sequence of one or more, preferably two or more, immunoglobulin domains. Optionally, an "immunoglobulin module" comprises one or more, preferably two or more, disulfide bonds. Included in the term "immunoglobulin module" are molecules or parts of a molecule that comprise or consist of a "single-chain variant fragment" of an antibody. Included in the term "immunoglobulin module" are also molecules or parts of a molecule that comprise or consist of a V_H H domain of a llama antibody, a camel antibody, or a shark antibody.

The term "immunoglobulin module I1" is used to refer to an immunoglobulin module comprising a V_L domain linked to a V_H domain. Preferably, said V_L domain and said V_H domain of said immunoglobulin module I1 are derived from the same antibody. Preferably, said V_L domain and said V_H domain of said immunoglobulin module I1 form a dimer. Preferably, said dimer is capable of specifically binding to an antigen. Said antigen may be, for example, the antigen A1. In one embodiment, said "immunoglobulin module I1" comprises a "single-chain variant fragment" of an antibody that is capable of specifically binding to an antigen, for example the antigen A1.

The term "immunoglobulin module I2" is used to refer to an immunoglobulin module comprising a V_L domain linked to a V_H domain. Preferably, said V_L domain and said V_H domain of said immunoglobulin module I2 are derived from the same antibody. Preferably, said V_L domain and said V_H domain of said immunoglobulin module I2 form a dimer. Preferably, said dimer is capable of specifically binding to an antigen. Said antigen may be,

for example, the antigen A2. In one embodiment, said "immunoglobulin module I2" comprises a "single-chain variant fragment" of an antibody that is capable of specifically binding to an antigen, for example the antigen A2.

Within a construct of an immunoglobulin module comprising a V_L domain linked to a V_H domain, the V_L domain may be positioned N- or C-terminally of the corresponding V_H domain. The skilled person is able to determine which arrangement of the V_H and V_L domains is more suitable for a specific single-chain variant fragment domain.

The terms "Fv" and "variant fragment", as used herein, refers to a fragment of an antibody that is the minimum antibody fragment which contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy and one light chain variable region in a tight, non-covalent association (V_H - V_L dimer). In this configuration, the V_H and V_L domain together define an antigen binding site with antigen binding specificity on the surface of the V_H - V_L dimer.

The terms "scFv", "single chain Fv", and "single-chain variant fragment" are used interchangeably and are meant to designate an antibody or portion of an antibody in which the variable region of the heavy chain (V_H) and the variable region of the light chain (V_L) of a traditional two chain antibody have been joined to form one chain. Typically, a linker is inserted between the two chains to allow for proper folding and creation of an active binding site.

The term "llama antibody", as used herein, refers to an antibody or part of an antibody derived from llama. The term "camel antibody", as used herein, refers to an antibody or part of an antibody derived from camel. The term "shark antibody", as used herein, refers to an antibody or part of an antibody derived from shark. Llama, camel and shark antibodies have an antigen binding moiety that is built up by one single domain, V_HH , (rather than a V_H and a V_L chain).

The expression "T cell engaging domain", as used herein, is meant to refer to a domain that specifically binds to an antigen that is present on the cell surface of T cells. Preferably, binding of said T cell engaging domain to said antigen activates said T cell. Similarly, the expression "NK cell engaging domain" refers to a domain that specifically binds to an antigen that is present on the cell surface of Natural Killer cells. Preferably, binding of said NK cell engaging domain to said antigen activates said Natural Killer cells. The expression

"domain engaging macrophage cells" refers to a domain that specifically binds to an antigen that is present on the cell surface of macrophage cells. Preferably, binding of said domain engaging macrophage cells to said antigen activates said macrophage cells. The expression "monocyte engaging domain" refers to a domain that specifically binds to an antigen that is present on the cell surface of monocytes. Preferably, binding of said monocyte engaging domain to said antigen activates said monocytes. The expression "granulocyte engaging domain" refers to a domain that specifically binds to an antigen that is present on the cell surface of granulocytes. Preferably, binding of said granulocyte engaging domain to said antigen activates said granulocytes. The expression "domain engaging neutrophil granulocytes" refers to a domain that specifically binds to an antigen that is present on the cell surface of neutrophil granulocytes. Preferably, binding of said domain engaging neutrophil granulocytes to said antigen activates said neutrophil granulocytes. The expression "domain engaging activated neutrophil granulocytes, monocytes and/or macrophages" refers to a domain that specifically binds to an antigen that is present on the cell surface of activated neutrophil granulocytes, monocytes and/or macrophages. Preferably, binding of said domain engaging activated neutrophil granulocytes, monocytes and/or macrophages to said antigen activates said monocytes and/or macrophages.

The term "molecule capable of mediating bioluminescence", as used herein, refers to a molecule (or functional part of a molecule) that has an enzymatic activity which in the presence of the appropriate substrate(s) catalyzes a reaction that causes bioluminescence. The term includes luciferases, such as the luciferases of firefly or *Gaussia*.

The term "GFP variant", as used herein, refers to a molecule that has an amino acid sequence derived from the amino acid sequence of green fluorescent protein from *Aequorea victoria* by introducing alterations resulting in greater fluorescence or fluoresce in different colors. The term is meant to include, among others, YFP (yellow fluorescent protein), CFP (cyan fluorescent protein), Venus (Nagai T et al., A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. *Nat Biotechnol.* 2002 Jan;20(1):87-90), Cerulean (Enhanced CFP with S72A, Y145A and H148D substitutions).

"Enhanced GFP" (and, analogously, "enhanced YFP", "enhanced CFP") refers to a GFP (YFP, CFP) which has been "humanized", as reported in Kain et al. (1995) *Biotechniques* 19(4):650-55. "Humanized" refers to changes made to the GFP (YFP, CFP) nucleic acid sequence to optimize the codons for expression of the protein in human cells.

The term "bimolecular fluorescence complementation molecule", as used herein, refers to a fluorescent molecule that can be provided as two fragments which by themselves are not fluorescent, but which upon heterodimerization between the two fragments form a dimer that is capable of fluorescence.

The term "therapeutic compound", as used herein, refers to a compound suited for preventing, treating, alleviating or curing a disease or disease state. Preferably, a "therapeutic compound" is a compound that, upon entry into a cell, is capable of causing the death of that cell. In some embodiments, a therapeutic compound can be a chemical or radioactive compound that damages vital cellular structures or interrupts vital cellular processes.

The term "diagnostic compound", as used herein, refers to a compound that can be detected by common detection methods, such as methods used in the clinic or in biochemical or medical diagnostic laboratories, for example a fluorescent compound, a radioactive compound, or a molecule mediating bioluminescence.

The term "progenitor/precursor cells" is meant to refer to immature, undifferentiated or partially differentiated cells that are typically found in post-natal animals/humans and have the potential to differentiate into a specific cell type or into specific cell types. The term "progenitor/precursor cells of a tumour" designates progenitor/precursor cells with altered properties (e.g. regarding their proliferation behaviour or gene expression pattern) that give rise to tumour cells. Examples for such progenitor/precursor cells of a tumour are e.g. leukemic precursor or progenitor cells.

The term "cancer", as used herein, refers to a malignant cell, group of cells, or malignant neoplasia. The term is meant to comprise carcinomas, sarcomas, lymphomas, leukemias, germ cell tumours, and blastomas. A "cancerous cell" is a cell that is part of or derived from a cancer. The term "tumour" is used interchangeably with the term "cancer".

As used herein, the term "haematologic tumour" refers to a cancer of the blood or blood building system (such as bone marrow cells, blood-building cells, and precursor cells of mature blood cells). In some embodiments, the term "haematologic tumour" refers to a haematologic neoplasia. As used herein, the term "non-haematologic tumour" refers to a tumour that is not a haematologic tumour.

The term "a patient who is undergoing allogeneic tissue or cell transplantation", as used

herein, refers to a situation where a patient receives or has received transplanted cells or transplanted tissue that has/have been obtained from another person. A preferred situation as to this aspect is the situation with mismatched HLA antigens. The unit " $\mu\text{g}/\text{m}^2$ ", as used herein in the context of an amount of a polypeptide administered, refers to a certain amount of polypeptide per square meter of body surface of the patient to whom said polypeptide is administered (the peptide may be administered by any adequate route of administration, such as by intravenous or subcutaneous injection). For example, the expression "The amount of polypeptide administered is $50 \mu\text{g}/\text{m}^2$ per day for the polypeptide P1." is meant to refer to a situation where the amount of polypeptide P1 administered per day is $50 \mu\text{g}$ per square meter of body surface of the patient to whom the polypeptide P1 is administered. In the case of a patient having a body surface of 2 m^2 this would mean that $100 \mu\text{g}$ of polypeptide P1 are administered per day.

The present inventors have surprisingly found that with a set of polypeptides according to the invention the above-indicated problems of the prior art can be overcome and the above-described objects can be accomplished. Moreover, the present inventors have surprisingly found that with a set of polypeptides according to the invention, cells with a specific combination of two antigens can be identified and/or eliminated with high specificity and reduced side-effects.

It is one advantage of the combinatorial strategy of the invention that no preformed F units (for example anti-CD3 units) are used. The F1 and CD3 V_H and V_L) do not heterodimerize *per se*, not even in the presence of an agent which stabilizes their dimerization (for example an antigen capable to bind to the domain F, like for example, CD3, HIS or DIG), and thus do not result in a functional F domain (for example do not stimulate T cells). Exclusively in situations where both complementary constructs P1 and P2 simultaneously bind on the surface of a given cell, the two components F1 and F2 reconstitute the F domain (for example, the CD3 binding site). Thus, function of the F domain (for example T cell activation) takes place precisely where needed but not systemically. Hence, it can be assumed that the combinatorial strategy of the invention has less toxic effects, for example as compared to normal bispecific antibody strategies. This is also evidenced by the appended examples, in particular by the *in vivo* model for allogeneic transplantation, where HLA-A2 positive mice did not suffer any clinical effects after infusion of HLA-A2 reactive constructs.

In particular, to tag cells that express a predefined antigen signature, two single-chain

polypeptides were designed as parts of the final bipartite (bi-molecular) construct (bi-molecular/trispecific antibody construct), each composed of an antigen-binding single-chain variable fragment (scFv) and either the variable light (VL) or variable heavy chain (VH) domain of an antibody. When these two hybrid fragments bind their respective antigens on the surface of a single cell, the VL and VH domains interact with each other to reconstitute the original antigen binding site and thus fulfill the desired requirements.

As mentioned, it is one advantage of the set of polypeptides of the invention that binding of both target antigens on the cell surface is requisite for functional heterodimerization. Self-assembly of the two complementary parts and subsequent T cell stimulation after binding of only one arm to its antigen can be ruled out, thus corroborating published data showing that V_H or V_L binding by itself is of low affinity and that V_H/V_L heterodimers tend to dissociate rapidly in the absence of antigen (Colman, 1987, *Nature* 326, 358-363; Amit, 1986, *Science* 233, 747-753; Law, 2002, *Int Immunol* 14, 389-400; Ueda, 1996, *Nat Biotechnol* 14, 1714-1718).

In contrast to the homo- or hetero-dimerization domains well known in the art (leucine-zipper, Fc-domains, knob in the hole etc), VH and HL interactions are of low affinity. However, it has been shown that VH/VL interaction can be stabilized after binding to the specific antigen. Without being bound by theory, VH/VL interaction in accordance with this invention takes place only in situations after both fragments have previously bound to their cognate target antigens, for example on the surface of a target cell. Also without being bound by theory, after simultaneous on-target binding, the constructs are brought into close proximity so that they can form a trimeric complex with the antigen. The thus on-target complemented trispecific heterodimer of the invention is functional with respect to the function of the domain F, for example, engages and stimulates T cells for tumor cell destruction if anti CD3 is reconstituted.

Beside one advantage of the constructs of the invention P1 and P2, e.g. the combinatorial nature of the immune response elicited, it was surprisingly found in the context of this invention that the bi-molecular construct with the disrupted F domain, for example scFv-anti CD3, displays no off target effects.

The set of polypeptides according to this invention, in particular the polypeptides P1 and P2 comprised therein, have the further advantage to be more stable and/ or have an improved

shelf life (in particular at 4°C) as compared to conventional bispecific constructs like BiTE constructs. These conventional bispecific constructs tend to aggregate (in particular at 4°C).

It is envisaged that the polypeptides of this invention P1 and P2, more particular of F1 and F2 as comprised therein, more particular of the V_H and V_L which may be comprised therein, due to their hydrophobic interface, are capable to bind albumin. This leads to an improved retention time; i.e. longer bioavailability in vivo but also in vitro, like, for example, in serum or blood samples.

The set of polypeptides according to the present invention comprises a first polypeptide P1 and a second polypeptide P2. The first polypeptide P1 comprises a first targeting moiety T1 (which is capable of specifically binding to an antigen A1) fused to a first fragment F1 of a functional domain F (see Figure 1A, top). The second polypeptide P2 comprises a second targeting moiety T2 (which is capable of specifically binding to an antigen A2) linked to a second fragment F2 of the functional domain F (see Figure 1A, bottom). Importantly, the fragments F1 resp. F2 of the functional domain are non-toxic by their own and unable to exert any biological function unless there is partnering between the two polypeptides P1 and P2. When both polypeptides P1 and P2 simultaneously bind to their antigens on the surface of a single cell that expresses both antigens A1 and A2, the fragments F1 and F2 of the functional domain F are brought together in close proximity, they hetero-dimerize and thus complement the desired biological function (see Figure 1B). On the other hand, a cell that expresses either only antigen A1 (Figure 1C) or only antigen A2 (Figure 1D) or none of the antigens does not cause complementation of the biological function. Thus, the biological function is achieved with high specificity only in the presence of cells having both antigens A1 and A2 at their cell surface upon simultaneous binding of both polypeptides P1 and P2 to such a cell. Depending on the nature of the functional domain F, different objects, such as specific identification/detection or elimination of cells that express both antigens A1 and A2, can be accomplished.

In one exemplary embodiment, this inventive principle is applied for the specific elimination of tumour cells:

Novel histopathological and flow cytometry analyses have revealed that tumour cells can be detected and distinguished from their non-transformed counterparts not by single surface markers but by the expression of aberrant antigen combinations/profiles, as is known for

haematopoietic neoplasias and cancer and cancer stem cells of various other provenience. Thus, while a single antigen may not be sufficient to specifically identify a certain tumour cell, a specific combination of two antigens may allow discriminating the tumour cell from any other type of cell.

For example, the set of polypeptides according to the invention may be used to specifically eliminate cancer cells characterized by the simultaneous expression of the antigens CD33 and CD19 at their cell surface. This combination of antigens is found on certain types of acute leukemia cells and distinguishes these cells from any other cells (such as non-malignant cells), which may carry either CD33 or CD19 at their cell surface, but do not carry both CD33 and CD19 at their cell surface (Ossenkoppele et al., Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol 2011, 153(4):421-36).

To specifically eliminate these leukemic cells carrying both CD33 and CD19 at their cell surface, the first targeting moiety T1 of the first polypeptide P1 may be a single chain variable Fragment (scFv) specific for CD33. As fragment F1 of the functional domain F, the light chain variable domain V_L of an anti CD3 antibody may be chosen. The second targeting moiety T2 of the second polypeptide P2 may be a scFv specific for CD19. As the fragment F2 of the functional domain F the heavy chain variable domain V_H of that anti CD3 antibody may be chosen. The light chain variable domain V_L and the heavy chain variable domain V_H of the anti CD3 antibody are each non-toxic by their own. They are also unable to exert their biological function (i.e. to effectively bind the CD3 antigen) unless there is partnering between the polypeptides P1 and P2.

In the presence of a leukemic cell having both CD33 and CD19 at its cell surface, both polypeptides P1 and P2 simultaneously bind to that cell. As a consequence, the fragments F1 and F2 of the functional group F (i.e. the heavy and light chain of the Fv anti CD3 variable domain of that anti-CD3 antibody) are brought together in close proximity, they heterodimerize and thus complement the desired biological function, enabling the dimer of P1 and P2 to specifically bind to CD3.

CD3 is a cell surface molecule that is present on the surface of T cells. The molecule is part of the T cell signalling complex, and cross-linking of CD3 molecules on the surface of a T cell after binding of a CD3-specific antibody leads to activation of the T cell. By engaging

CD3 antigens on the surface of T cells, heterodimers of polypeptides P1 and P2 are capable of recruiting T cells and activating them. As a result, typical effector mechanisms of a cytotoxic T cell response are elicited, leading to cell lysis: release of lytic granules containing the cytotoxic proteins perforin, granzymes, and granzysin. Perforin forms pores into the membrane of the target cell through which the granzymes can enter and induce apoptosis. These effects lead to specific destruction of leukemic cells that carry both CD33 and the CD19 antigen at their cell surface.

Other cells than the leukemic cells do not have both the CD33 and CD19 antigen at their cell surface. Therefore, they cannot recruit both polypeptides P1 and P2, and no complementation of the CD3 binding capability and engagement of CD3 positive T lymphocytes is achieved. Consequently, other cells besides the leukemic cells are unaffected, and destruction of the malignant cells with exquisite specificity is achieved.

This is in stark contrast to conventional bispecific antibodies. A conventional bispecific construct that engages T cells and has specificity for cells expressing CD33 would mediate the destruction of all CD33 positive cells. Since CD33 is myeloid lineage marker which is expressed on many myeloid cells and myeloid progenitor cells, the destruction of these cells would result in long lasting aplasia and probably death of the patient. A conventional bispecific construct that engages T cells and has specificity for CD19 positive cells would lead to the elimination of all cells carrying the CD19 antigen at their cell surface. CD19 is expressed on a significant subset of B-lymphocytes. Destruction of these cells would lead to a severe defect of the immune system. Thus, besides eliminating leukemic cells that simultaneously express CD33 and CD19 on the surface, the application of conventional bispecific antibodies with specificity for CD33 and CD19 would lead to elimination of myeloid cells and a substantial subset of B-lymphocytes.

Thus, while conventional bispecific antibodies recognize only one antigen on the cell to be eliminated, effector activation according to the present invention requires the simultaneous recognition of two specific antigens on the surface of the cell to be identified/eliminated. In consequence, the present invention achieves significantly improved specificity and reduced side effects.

It is clear to a person of skill in the art that, within the principle of the present invention, diverse variations to the exemplary embodiment described above are possible.

For example, the approach described in the above exemplary embodiment can easily be adapted for the identification/elimination of other types of tumour cells besides CD33 and CD19 positive acute leukemia cells simply by choosing appropriate targeting moieties T1 and T2 that specifically bind to antigens A1 and A2, respectively, that are present simultaneously on the cells to be identified/eliminated, but not present simultaneously on other cell types. As quoted above, many if not all cancer cells (but also progenitor/precursor cells of cancer cells) express a number of cell surface molecules which *per se* are widely expressed on normal tissues, but are indicative for the malignant phenotype if expressed in a non-physiological combination. For example, CD34 is a marker for haematopoietic stem cells and CD7 can be detected on a subset of lymphoid cells. The combination of CD34 and CD7, however, is strongly associated with malignancy, and aberrant co-expression of the two antigens can be detected on a substantial proportion of acute myelogenous leukemias (Ossenkoppele et al., Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. *Br J Haematol* 2011, 153(4):421-36.). Similarly, aberrant co-expression of CD44 and CD117 has been described for ovarian cancer stem cells, CD44 and CD24 for pancreas cancer initiating cells and the combination of EpCAM and CD44 in colon and breast cancer stem cells (Natasha Y. Frank, Tobias Schatton, Markus H. Frank; The therapeutic promise of the cancer stem cell concept. *J Clin Invest.* 2010; 120:41–50). Expression of CD24 and CD29, as well as CD24 and CD49f has been found to be specific for breast carcinoma (Vassilopoulos A et al. Identification and characterization of cancer initiating cells from BRCA1 related mammary tumours using markers for normal mammary stem cells. *Int J Biol Sci* 2008; 4:133-142). Moreover, combinations with highly expressed antigen levels are indicative for a number of malignancies, like CD38 and CD138 for myeloma.

In addition to the cancer-specific antigen combinations listed above and those known from the scientific literature, additional combinations of two antigens that are expressed simultaneously on specific tumour cells but not on other cells can be derived in a straightforward manner by the person of skill in the art.

Firstly, the skilled person may arrive at an antigen combination that is specific for a certain cancer by combining an antigen that is specific for the malignant state of the respective cell type with an appropriate cell type marker or cell lineage marker. For example, carbonic anhydrase IX is a marker strongly associated with renal cell carcinoma and metastases of

renal cell carcinoma and thus represents a marker for the malignant state of renal cells. This membrane located marker, however, is also expressed on normal cells of the intestinal tract. By selecting as second antigen a renal lineage marker like aquaporin, the resulting combination of two antigens is specific for renal cell carcinoma cells and cells resulting from metastasis of renal cell carcinoma, while neither non-malignant kidney cells (which do not express carbonic anhydrase IX) nor cells from the intestinal tract (which do not express aquaporins) are characterized by the selected pair of antigens.

Detailed information on markers for the malignant state of various cell types and on markers for numerous cell types or cell lineages is available from the literature and web-based resources (see below for details) or can be obtained by straight-forward experimentation (see below).

Examples for markers for the malignant state of a cell include: E-cadherin for epithelial cells and ductal-type breast carcinoma cells; Ca-125 for Epithelial malignancies and ovary cancer cells, adenocarcinoma cells and breast cancer cells; Her-2/neu for breast cancer cells; gross cystic disease fluid protein (BRST-2 protein) for breast cancer cells; BCA-225 (breast carcinoma associated glycoprotein) for lung and breast cancer cells; CA 19-9 (carbohydrate antigen 19-9) for pancreas, bile duct and intestinal tract cancer cells; CEA for colorectal cancer cells; CD117 (c-kit) for gist (gastrointestinal stromal tumour) cells (and myeloid and mast cells); CD30 for Reed-Sternberg cells (and Ki-1 activated T-cells and B-cells); Epithelial antigen (BER-EP4), Epithelial membrane antigen, and Epithelial Related Antigen (MOC-31) for epithelial cancer cells; Epidermal growth factor receptor (HER1) for cells of various cancers; Platelet derived growth factor receptor (PDGFR) alpha for cells of various cancers; Melanoma associated marker/Mart 1/Melan-A for melanoma cells; CD133 for cancer stem cell populations and others; TAG 72 (tumour associated gp 72) for adenocarcinoma cells.

Further examples for markers for a malignant state of a cell/cells include: EpCAM, CD19, HER-2, HER-3, HER-4, PSMA, MUC-1 (mucin), MUC2, MUC3, MUC4, MUC5AC, MUC5B, MUC7, Lewis-Y, CD20, CD33, CD44v6, Wue-1, Plasma Cell Antigen, (membrane-bound) IgE, Melanoma Chondroitin Sulfate Proteoglycan (MCSP), STEAP, mesothelin, Prostate Stem Cell Antigen (PSCA), sTn (sialylated Tn antigen), FAP (fibroblast activation antigen), EGFRvIII, Ig α , Ig β , MT-MMPs, Cora antigen, EphA2, L6 and CO-29, CCR5, β HCG, ganglioside GD3, 9-O-Acetyl-GD3, GM2, Globo H, fucosyl GM1, Poly SA,

GD2, Carboanhydrase IX (MN/CA IX), Sonic Hedgehog (Shh), CCR8, TNF-alpha precursor, A33 Antigen, Ly-6, desmoglein 4, E-cadherin neoepitope, Fetal Acetylcholine Receptor, CD25, Muellerian inhibitor Substance (MIS) Receptor type II, endosialin, SAS, CD63, TF-antigen, CD7, CD22, Ig α (CD79a), Ig β (CD79b), G250, gp100, F19-antigen and EphA2.

Examples for antigens that are specific for a certain cell type/cell lineage or for a few cell types/cell lineages (cell type markers/cell lineage markers) include: CD45 for hematopoietic cells; CD34 for endothelial cells, stem cells, and stromal cells; CD33 for myeloid cells; CD138 for plasma cells and a subset of epithelial cells; CD15 for epithelial, myeloid, and Reed-Sternberg cells; CD1a for cortical thymocytes and Langerhans cells; CD2 for thymic cells, T-cells, and Natural Killer (NK) cells; CD3 for T-cells; CD4 for helper T-cells; CD5 for T-cells, a subset of B-cells, and thymic carcinoma cells; CD8 for cytotoxic T-cells; CD20 for B-cells; CD23 for activated B-cells; CD31 for endothelial cells; CD43 for T-cells, myeloid cells, a subset of B-cells, histiocytes, and plasma cells; CD56 for NK cells; CD57 for neuroendocrine cells, and NK cells; CD68 for macrophages; CD79a for B-cells and plasma cells; CD146 for the endothelial cell lineage; surfactant proteins for lung cells; synaptophysin, CD56 or CD57 for neuroendocrine cells; nicotinic acetylcholine receptor or muscle-specific kinase (MUSK) for muscle cells; voltage-gated calcium channel (P/Q-type) or voltage-gated potassium channel (VGKC) or N-methyl-D-aspartate receptor (NMDA) for muscle cells and neurons; TSH (thyroid stimulating hormone) receptor for thyroid gland; amphiphysin for muscle cells; HepPar-1 for hepatocytes; ganglioside GQ1B, GD3 or GM1 for neuronal cells; and glycophorin-A for cells of the erythropoietic cell lineage.

It should be noted that there are situations where it may be advantageous to rely for the purposes of the present invention on an antigen with a less than perfect specificity for the cell type or cell lineage of interest. For example in situations where no antigen is known that is found exclusively on the cell type/cell lineage of interest and not on any other cell types/lineages or in situations where it is not possible to confirm the exclusive specificity of an antigen, also antigens that are present on one or more other cell types/cell lineages besides the cell type/cell lineage of interest may be considered. Similar consideration apply for markers for the malignant state of a cell, or even for the specificity of the combination of two antigens. Thus, there are for example situations where for the purposes of the present invention a combination of two antigens is selected that is specific not only for the cells of

interest, but also for one or more (a few) other cell types/cell lineages/kinds of malignant cells.

Secondly, the skilled person may arrive at an antigen combination that is specific for a certain cancer by straightforward experimentation. This may comprise the steps of (1) determining the surface antigens on the tumour cells to be eliminated and (2) identifying among these tumour cell surface antigens two antigens that are not present simultaneously on other cell types (or, in some embodiments, present on only a few other cell types).

Often, experimentation may not be necessary to determine the surface antigens on tumour cells to be eliminated, because such information may already be available for the respective type of cancer from the printed literature (see, e.g. David J. Dabbs, Diagnostic immunohistochemistry, Churchill Livingstone, 3rd edition (2010); or F Lin and J Prichard, Handbook of Practical Immunohistochemistry: Frequently Asked Questions, Springer, New York, 1st edition (2011)). Even more extensive information is available through web-based resources. For example, the Cancer Genome Anatomy Project (CGAP) of the U.S. National Cancer Institute (NCI) has systematically determined the gene expression profiles of various normal, precancer, and cancer cells (Strausberg RL. The Cancer Genome Anatomy Project: building a new information and technology platform for cancer research. In: Molecular Pathology of Early Cancer, 1999, (Srivastava, S., Henson, D.E., Gazdar, A., eds. IOS Press), pp. 365-370). The resources generated by the CGAP initiative are freely available (<http://cgap.nci.nih.gov/>) and include access to all CGAP data and the necessary analysis tools. Similarly, the Cancer Genome Characterization Initiative (CGCI) of the National Cancer Institute focuses on tools for characterizing the genomic changes involved in different tumours, for example genomic characterization methods including exome and transcriptome analysis using second generation sequencing. The data generated by CGCI is available through a publicly accessible database (<http://cgap.nci.nih.gov/cgci.html>). Thus, in many cases information about the presence or absence of various known cell surface proteins on the tumour cells of interest can be derived by simply checking these publicly accessible databases. If desired, this information may then be verified in a second step by immunocytochemical/immunohistochemical analysis of tumour cells/tissue according to the methods described below.

If there is no information available on the proteins expressed by the tumour cells/tissue of interest, the skilled person can carry out a characterization of the antigens on the tumour

cells/tissue by immunocytochemical/immunohistochemical methods with a panel of antibodies (see, e.g., "Handbook of Practical Immunohistochemistry: Frequently Asked Questions" by F Lin and J Prichard, Springer New York, 1st edition (2011); or "Using Antibodies: A Laboratory Manual" by E Harlow and D Lane, Cold Spring Harbor Laboratory Press (1998)). In brief, a histological preparation or cells isolated from the tumour are incubated with a first antibody directed at a potential surface antigen and, after a washing step, incubation of a second antibody directed against the Fc domain of the first antibody. This second antibody is labelled with a fluorophore or an enzyme like HRP (horse radish peroxidase), in order to visualize expression of the targeted antigen. Panels of antibodies that can be used for high throughput antigen profiling purposes of cell surface antigens are commercially available from numerous manufacturers.

In addition, tools specifically dedicated to high throughput proteomic cell characterization to identify and analyze cell surface protein expression are commercially available, such as the FACS (Fluorescence-activated cell sorting)-based high throughput array technology BD FACSTM CAP (Combinational Antibody Profile) of Becton, Dickinson & Company.

The immunocytochemical/immunohistochemical/proteomic analysis described above may be preceded (or, in some cases, replaced) by genome-wide gene expression profiling of tumour cells or by mass spectrometric analysis of the proteins expressed by the tumour cells/tissue of interest. For example, genome-wide gene expression profiling of tumour cells can be carried out to check for the expression of various cell surface molecules, and the presence of such antigens on the cell surface of the tumour cells may then be confirmed through antibody-based staining methods as described above.

Further information about approaches to characterize the surface antigens of (cancer) cells is available in the relevant scientific literature (e.g. Zhou J, Belov L, Huang PY, Shin JS, Solomon MJ, Chapuis PH, Bokey L, Chan C, Clarke C, Clarke SJ, Christopherson RI. Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. *J Immunol Methods.* 2010;355:40-51; or Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. *Endocr Relat Cancer.* 2004;11:659-87).

In a next step, the skilled person may identify among the cell surface antigens of the tumour cells a combination of two antigens which is not expressed simultaneously on other cell types.

Often, already the literature or publicly available databases may provide detailed information about the presence or absence of antigens from other cell types:

The expression of various cell surface molecules on diverse cell types has been studied systematically by researchers in the past decades by immunophenotyping and gene expression profiling of almost any cell type of the body. For example, detailed information on the expression of more than 360 "cluster of differentiation" antigens (or CD antigens) is available in print (e.g. "Leukocyte and Stromal Cell Molecules: The CD Markers" by Zola H, Swart B, Nicholson I, and Voss E; John Wiley & Sons, 1st ed. (2007)) and in online depositories (e.g. www.hcdm.org/MoleculeInformation/tabid/54/Default.aspx), and includes information on tissue distribution and expression levels of antigens, as well as information about antigen reactive antibodies and the epitopes these antibodies bind to.

Moreover, there are publicly available databases which provide access to a large amount of genomic data generated by the scientific community. For example, the Gene Expression Omnibus (GEO) platform of the National Center for Biotechnology Information (NCBI) of the United States (Barrett T et al., NCBI GEO: archive for functional genomics data sets--10 years on. *Nucleic Acids Res.* 2011;39(Database issue):D1005-10) archives and gives access to an enormous collection of microarray, next-generation sequencing, and other forms of high-throughput functional genomic data, and further provides web-based interfaces and applications for easy access to this information (<http://www.ncbi.nlm.nih.gov/geo/>).

Once a pair of two antigens has been identified through these resources that appears to be absent from other cell types besides the tumour cells of interest, a person skilled in the art can easily validate the suitability of the antigen combination for further development of P1 and P2-polypeptide constructs. Such validation that the identified combination of two antigens is indeed not expressed simultaneously on other cell types besides the tumour cells can be carried out by immunohistochemical/immunocytochemical analysis of a (optimally large) collection of assorted cell types and/or tissues with antibodies against the two antigens. Cells and tissues of any kind can be obtained from ATCC (American Type Culture Collection), from pathology departments and from tissue banks associated with universities and research institutions. A suitable antigen combination is defined as a pair of antibodies that stains exclusively the tumour cells, but not healthy tissues or healthy cells (i.e. both antibodies of the pair stain the tumour cells, but no other tissues/cells are stained by both antibodies).

It should be noted that, while in many situations the highest degree of specificity (preferably absolute specificity) is of course desirable, there are situations where a lower degree of specificity is acceptable. For example, if the set of polypeptides is used for diagnostic purposes, some degree of crossreactivity with other cell types or tissues may be acceptable (especially in the case of solid tumours, since the additional positional information helps to distinguish tumour cells from crossreacting cells). Moreover, if the set of polypeptides is used for therapeutic purposes, some degree of crossreactivity with other cell types or tissues may also be acceptable, depending on the severity the disease in a treated patient and on the cell types/tissues affected by the crossreactivity. Other situations where a lower degree of specificity may be acceptable may arise in the context of a transplantation setting (see below).

In cases where no hint about a suitable antigen combination can be derived from the literature or public databases, the presence/absence of the cell surface antigens of the tumour cells from other cell types can be checked by straightforward experimentation. To this end, a variety of cell types and/or tissues obtainable from the sources indicated above may be subjected to proteomic cell characterization, immunocytochemical/immunohistochemical analysis and/or gene expression profiling. (It should be noted that such analysis of non-tumour cells/tissues has to be carried out only once in order to obtain data that can be used for the design of various constructs according to the invention that may be adapted to diverse different therapeutic or diagnostic situations.) Upon comparison of the obtained results with the information about cell surface antigens of the tumour cells of interest, a combination of two antigens that is not present on any other cells besides the tumour cells of interest can be easily identified.

A similar systematic approach to identify a pair of two antigens that is specific for tumour cells is also described in a recent publication by Balagurunathan, which relies on genome-wide gene expression profiling followed by immunohistochemistry (Yoganand Balagurunathan, Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. *Mol Cancer Ther* 2008;7: 3071-3080). Using DNA microarrays, the authors of that manuscript generated databases of mRNA gene expression profiles for a substantial number of pancreatic cancer specimens and normal tissue samples. The expression data for genes encoding cell-surface molecules were analyzed by a multivariate rule-based computational approach in order to identify gene combinations

that are preferentially expressed on tumour cells but not in normal tissues. Aberrant co-expression of antigens constituting a tumour-specific antigen combination was then confirmed using standard immunohistochemistry techniques on pancreatic tumour tissue and normal tissue microarrays.

Having identified and validated such a combination of antigens that is specific for the tumour cells of interest, the constructs of polypeptide P1 and polypeptide P2 can be engineered by standard protein engineering techniques and methods of molecular biology (see, e.g. G Howard and M Kaser, *Making and Using Antibodies: A Practical Handbook*, CRC Press, 1st edition (2006); Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York (2001)).

For many cell surface molecules, specific monoclonal antibodies are characterized and therefore readily available. Thus, in many cases the skilled person may have access to hybridoma cells of monoclonal antibodies that are specific for the antigens of the identified combination of antigens. Having the option to choose from a panel of antibodies specific for a given antigen, a person skilled in the art may choose a reactive antibody which binds an epitope close to the membrane, in order to minimize the distance of the antigen expressing cell from the effector cell (Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, Kufer P. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. *Cancer Immunol Immunother.* 2010 Aug;59(8):1197-209). If no such antibody is available against one or both antigens of the identified combination of antigens, monoclonal antibodies against the antigens can be generated by standard techniques (e.g. G Howard and M Kaser, *Making and Using Antibodies: A Practical Handbook*, CRC Press, 1st edition (2006)). Moreover, various companies offer full services for the generation of custom-made monoclonal antibodies and hybridoma cells.

DNA or mRNA coding for the variable domains of the monoclonal antibodies of interest can be obtained from hybridomas by PCR amplification or cloning (Orlandi R, Gussow PT, Jones: Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. *Proc Natl Acad Sci U S A* 1989, 86(10):3833-3837; Wang Z, Raifu M, Howard M, Smith L, Hansen D, Goldsby R, Ratner D: Universal PCR amplification of mouse immunoglobulin gene variable regions: the design of degenerate primers and an assessment of the effect of DNA polymerase 3' to 5' exonuclease activity. *J Immunol Methods* 2000,

233(1-2):167-177; Essono S, Frobert Y, Grassi J, Cremino C, Boquet D: A general method allowing the design of oligonucleotide primers to amplify the variable regions from immunoglobulin cDNA. *J Immunol Methods* 2003, 279:251-266; G Howard and M Kaser, *Making and Using Antibodies: A Practical Handbook*, CRC Press, 1st edition (2006)) or from already established vectors comprising the DNA sequence of the variable fragment of the respective antibody. Often, the sequence can be extracted from public databases, where many sequences are deposited, and then the construct may even be generated by gene synthesis as it is offered by various commercial service providers (e.g. Creative Biolabs, Shirley, USA).

To form the construct of polypeptide P1, the sequence coding for the variable fragment Fv of an antibody specific for the first antigen of the identified pair of antigens (or, optionally, the sequence of a single chain variable fragment derived from that sequence) is used for the first targeting moiety (T1) and linked via a suitable linker (coding, e.g., for less than 12 aa) to a sequence coding for the first fragment F1 of a functional domain (e.g. the V_L domain of an anti CD3 antibody). Likewise, to form the construct of polypeptide P2 the sequence coding for the variable fragment Fv of an antibody specific for the second antigen of the identified pair of antigens (or, optionally, the sequence of a single chain variable fragment derived from that sequence) is used for the second targeting moiety (T2) and linked via a suitable linker to a sequence coding for the second fragment F2 of that functional domain (e.g. the V_H domain of an anti CD3 antibody).

For any construct of a polypeptide P1 or P2 according to the invention, modifications to the construct or to the sequences used for forming the construct are considered in order to adapt the construct to specific needs. For example, a construct can be modified in a way that reduces or abolishes its immunogenicity in humans. In case a sequence is derived from a non-human parent antibody, such as a murine antibody, modifications to the sequence can be carried out that result in a reduced immunogenicity in humans while retaining or substantially retaining the antigen-binding properties of the parent antibody (known to the skilled person as "humanizing" an antibody/construct).

Various modifications of the above-described procedure and adaptions in order to accommodate the embodiments and variations described in this application are evident to the person of skill in the art.

In addition to variations with respect to the antigens that the targeting moieties T1 and T2 specifically bind to, various other modifications are possible. For example, instead of single chain variant fragments (scFv) as targeting moiety T1 and/or T2 other types of monovalent antibodies or antibody-like structures can be employed. For example, an antibody/antibody-like structure derived from a llama, camel or shark antibody can be used. Since llama, camel and shark antibodies have an antigen binding moiety that is built up by one single domain (rather than a V_H and a V_L chain), the resulting polypeptide P1 or P2 is much smaller and may thus better penetrate into tumour tissues.

Furthermore, since many tumour-relevant antigens are cell surface-bound receptors, the single chain Fv of targeting moiety T1 and/or T2 can be replaced by the natural or artificial ligand of such a cell surface-bound receptor. Like antibodies, these natural or artificial ligands confer excellent specificity towards the target receptor. Alternatively, the targeting moiety T1 and/or T2 can be an aptamer.

Moreover, in order to enhance binding affinity of a targeting moiety towards the antigen, the targeting moiety can be multimerized and/or altered by glycosylation or other types of posttranslational or chemical modification or be optimized through site directed mutagenesis or a phage display selection process.

Moreover, the fragments F1 and F2 (i.e. the V_L and V_H fragments of anti CD3 Fv in the above-described exemplary embodiment) can be replaced by fragments of a different functional domain F, resulting in a different biological effect upon complementation of the two fragments. By using fragments of anti CD56, anti CD1a, or anti CD16a, natural killer cells can be recruited and activated. By using fragments of anti CD16, natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages can be recruited and activated. By using fragments of anti CD32a, anti CD32b, anti CD89, anti CD16a, or anti CD64, macrophages can be recruited and activated. By using fragments of anti CD32a, anti CD32b, anti CD64, or anti CD89, monocytes can be recruited and activated. By using fragments of anti CD16b, anti CD89, anti CD32a, anti CD32b, or anti CD64, granulocytes can be recruited and activated. Moreover, alternatively to anti CD3, T cells can also be recruited and activated by using fragments of anti CD2, anti CD5, anti CD28, or anti TCR (T cell receptor). Further information or additional options regarding the recruitment and activation of effector cells through antibody binding are available from the published literature, e.g. "Bispecific Antibodies" by Roland E. Kontermann (editor), Springer Berlin

Heidelberg; 1st Edition. (2011).

An additional option is to use a set of polypeptides P1 and P2 with fragments F1 and F2 of a functional domain F that binds an antigen on an effector cell upon complementation of the two fragments, but wherein binding to this antigen of the effector cell does not cause activation of said effector cell. This set of polypeptides ("first set of polypeptides") is then used (e.g. administered to a patient) in combination with a second set of polypeptides with fragments of a functional domain F that upon complementation binds to a second, different antigen on the same effector cell, but wherein again binding to this antigen of the effector cell does not cause activation of the effector cell. The antigens to which the first and the second sets of polypeptides bind are chosen in a way that, while binding of only one of the two antigens on the effector cells does not result in activation of the effector cell, binding of both antigens on the effector cell simultaneously leads to activation of the effector cell. This has the advantages that (1) antigens on effector cells can be used that do not function individually, but require costimulation of a second antigen, and (2) the number of different antigens that dictates the specificity with which a certain cell (such as a cancer cell) is differentiated from other cells can be increased from two (if the first and second set of polypeptides have the same targeting moieties T1 and T2, respectively) to up to four different antigens (if the first and second set of polypeptides have no targeting moiety in common).

Similar effects may be achieved with two sets of polypeptides with different targeting moieties, but the same functional domain: These sets of polypeptides are designed to have a functional domain directed against an effector cell antigen that normally allows each set of polypeptides by itself to activate the effector cell. However, both sets of polypeptides are used in a concentration that is just too low to cause efficient effector cell activation. If both sets of polypeptides are present simultaneously (e.g. upon simultaneous administration to a patient) each set of polypeptides by itself is not capable of activating the effector cell (due to its low concentration), while the combination of both sets of polypeptides is (because the effects of the two sets of polypeptides act synergistically and thus the sum of the effects caused by the two sets of polypeptides is sufficient to activate the effector cell).

As another alternative to recruitment/activation of effector cells, a "pretargeting" approach can be pursued, as it is well established for bispecific antibody constructs (Cancer Imaging and Therapy with Bispecific Antibody Pretargeting. Goldenberg DM, Chatal JF, Barbet J,

Boerman O, Sharkey RM. Update Cancer Ther. 2007 Mar;2(1):19-31). To this end, F1 and F2 are substituted by V_H and V_L fragments of an antibody specific for an antigen, a carrier molecule (i.e. a molecule/part of a molecule that is not recognized as foreign by the immune system of the patient to whom said set of polypeptides is administered or a molecule that causes no or only a weak immune reaction by a patient to whom it is administered) or an affinity tag. Subsequently (or simultaneously) to administering the polypeptides P1 and P2, a therapeutic or diagnostic compound coupled to said antigen, carrier molecule or affinity tag is administered. Only cells which carry both the antigens A1 and A2 at their surface are bound by both polypeptide P1 and polypeptide P2. Consequently, only at these cells functional complementation leads to generation of a binding site capable of recruiting the therapeutic or diagnostic compound through said antigen, carrier molecule or affinity tag. This approach allows exclusive addressing of target cells combined with the possibility of precise administration and dosing of therapeutic compounds like toxins or radioactive substances or diagnostic compounds, while cells that do not express the antigens or do express only one of the antigens are not affected.

A suitable carrier molecule may for example be a peptide or a carbohydrate molecule. Preferably, the carrier molecule may be gelatine, dextrane, or hydroxyethyl starch, which are common plasma expanders that are metabolically inert, remain in the blood and are, if they are small enough, renally eliminated. Alternatively, the carrier molecule may be inulin, a metabolically inert molecule that is used routinely in the clinic for determination of glomerular clearance (and, in addition, antibodies exist that specifically recognize inulin). A suitable affinity tag may be, for example, a Flag-tag, a myc-tag, a glutathione-S-transferase(GST)-tag, a hemagglutinin(HA)-Tag, a polyhistidine(His)-tag, or a maltose binding protein(MBP)-tag, a digoxigenin(DIG)-tag.

The therapeutic compound coupled to the antigen, carrier molecule or affinity tag may for example be a radioactive compound or a toxin.

Suitable radioactive compounds are for example compounds comprising ⁹⁰Y, ¹⁷⁷Lu, ¹³¹I, ³²P, ¹⁰B, or ²¹³Bi. Recruitment of the antigen, carrier molecule or affinity tag linked to the radioactive compound to cells that express both the first and the second antigen leads to accumulation of radioactivity onto the tumour site, resulting in specific destruction of tumour cells/tissue.

Alternatively, the therapeutic compound coupled to the antigen, carrier molecule or affinity tag may for example be a toxic compound that is not able to cross the cell membrane without

prior binding to the cell surface.

This prerequisite is fulfilled by the A components of classical AB-toxins derived from a number of pathogenic bacteria like *Clostridium perfringens*, *C. botulinum*, *C. difficile*, *B. anthracis* and others. AB-toxins are two-component protein complexes that interfere with internal cell functions. The A component is the "active" component (i.e. it kills a cell upon membrane penetration), but is not able to cross the cell membrane on its own. The B component is the "binding" component that by itself is non-toxic, but is essential for uptake and membrane penetration of component A.

For example, *Bacillus anthracis* protective antigen (PA) is a classical toxin B component which mediates the uptake of the actual anthrax exotoxins edema factor and lethal factor (LF). LF without the PA-component is non-toxic since LF by its own does not penetrate membranes and thus cannot execute its pathogenic capabilities (Pezard C, Berche P, Mock M. "Contribution of individual toxin components to virulence of *Bacillus anthracis*" 1991 Infect. Immun. 59 (10): 3472). However, when bound to cell surface molecules, LF is internalised and highly toxic to the cell.

Upon dimerization of the polypeptides P1 and P2, the function of the functional domain F is reconstituted. Through interaction of the reconstituted functional domain with the antigen, carrier molecule or affinity tag coupled to the toxin, the toxin is recruited to the cell membrane of the target cells, incorporated into the cells and kills the cells.

This principle is easily adapted to the purposes of the invention by the skilled person, since it is already widely used in so called immunotoxins, where a targeting moiety, mostly an antibody-like domain or natural ligand, is coupled to the toxin component (see, e.g., Immunotoxins for targeted cancer therapy. Kreitman RJ, AAPS J. 2006 Aug 18;8(3):E532-51). Examples include immunotoxins based on diphtheria toxin (such as Denileukin diftitox (U.S. trade name Ontak) which has been approved by FDA for the treatment of some T cell lymphomas) or based on *B. anthracis* Lethal Factor (Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ (2007). "Immunotoxin treatment of cancer". Annu. Rev. Med. 58: 221-37).

Suitable A components of AB-toxins may for example be *B. anthracis* edema factor, *B. anthracis* lethal factor, *C. perfringens* iota toxin, *C. botulinum* C2 toxin, *C. difficile* ADP-ribosyltransferase *C. diphtheriae* diphtheria toxin fragment A.

Alternatively, the therapeutic compound may for example be a cytotoxic compound that is toxic upon entry into a cell and that is capable of crossing the cell membrane by itself without prior binding to the cell surface. In this case, the antigen, carrier molecule or affinity tag that the therapeutic compound is coupled to is selected such that it prevents the resulting

conjugate (i.e. the therapeutic compound linked to the antigen/carrier molecule/affinity tag) from crossing cell membranes and entering cells without prior binding of the conjugate to the cell surface (a suitable carrier molecule may for example be a hydroxyethyl starch carrier). Thus, such a conjugate does not enter cells without prior binding to their cell surface; once such a conjugate binds to the cell surface, however, it is internalized into the cell and the toxic compound kills the cell. The conjugate does not bind to cells, unless it is recruited in the presence of the inventive set of polypeptides to cells that simultaneously express both antigens A1 and A2 at their cell surface. Such cells bind and recruit both polypeptides P1 and P2, and the reconstituted functional domain specifically binds to and recruits the antigen/carrier molecule/affinity tag which, in turn, results in internalization of the therapeutic compound. In consequence, a specific killing of cells that carry both antigens A1 and A2 at their cell surface is accomplished. Cytotoxic compounds that may be used in this context include e.g. auristatin, ricin, saponin, bryodin 1, bouganin, gelonin, pokeweed antiviral protein (PAP), antifolates, vinca alkaloides, anthracyclines, calicheamicin, ribonuclease, abrin, modeccin, or Listeriolysin O.

The diagnostic compound coupled to the antigen, carrier molecule or affinity tag may for example be a radioactive compound, a fluorophore, or a compound capable of mediating bioluminescence.

Suitable radioactive compounds are for example compounds comprising ^{99m}Tc , ^{111}In , ^{82}Rb or ^{201}Tl . Such compounds are detected by well-known medical imaging procedures in the clinic.

Alternatively, a fluorescent compound may be used as diagnostic compound, such as GFP (green fluorescent protein) or a GFP variant (e.g. BFP (blue fluorescent protein), CFP (cyan fluorescent protein), or YFP (yellow fluorescent protein)), or a fluorescent small-molecule compound like FITC (fluorescein isothiocyanate) or PE (phycoerythrin), alexa fluor dyes (such as AlexaFluor488 and related dyes sold by Molecular Probes, e.g.) or cyanine dyes (such as Cy3 (Indocarbocyanine) or Cy5 (Indodicarbocyanine) or related dyes).

Alternatively, a compound capable of mediating bioluminescence may be used as diagnostic compound, such as a luciferase, for example *Gaussia* luciferase (Chopra A. *Gaussia princeps* luciferase. In: Molecular Imaging and Contrast Agent Database (MICAD) [database online]. Bethesda (MD): National Library of Medicine (US), NCBI; 2004-2012. Available from: <http://micad.nih.gov.>). The employment of *Gaussia* luciferase for *in vivo* imaging is well established (see, e.g., Santos EB et al. Sensitive *in vivo* imaging of T cells

using a membrane-bound *Gaussia princeps* luciferase. *Nat Med.* 2009 Mar;15(3):338-44. Epub 2009 Feb 15; or Inoue Y et al. *Gaussia luciferase* for bioluminescence tumor monitoring in comparison with firefly luciferase. *Mol Imaging.* 2011 Oct 1;10(5):377-85. doi: 10.2310/7290.2010.00057. Epub 2011 Apr 26; see also below for additional details).

Moreover, the fragments F1 and F2 (i.e. the V_L and V_H fragments of anti CD3 Fv in the above-described exemplary embodiment) can be replaced by V_L and V_H fragments of an antibody that is specific for a therapeutic or diagnostic compound (i.e. in this case the functional domain F is capable of directly binding to the therapeutic or diagnostic compound). Here, the same therapeutic and diagnostic compounds as described above in the context of the "pretargeting" approach may be considered.

Furthermore, the fragments F1 and F2 (i.e. the V_L and V_H fragments of anti CD3 Fv in the above-described exemplary embodiment) can be replaced by fragments of a fluorescent or bioluminescent compound that are biologically inactive on their own, but regain their function (i.e. their ability to mediate fluorescence or bioluminescence) upon association of the two fragments and functional complementation, thus allowing for specific identification of cells that carry both the antigens A1 and A2.

A number of fluorescent molecules that may be used in this context are well known and characterized in the art including, but are not limited to, GFP (green fluorescent protein), GFP derivatives (like YFP (yellow fluorescent protein) and CFP (cyan fluorescent protein), Venus (Nagai T et al., A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. *Nat Biotechnol.* 2002 Jan;20(1):87-90), or Cerulean (Enhanced CFP with S72A, Y145A and H148D substitutions)). For these molecules, split fragments are described that self-assemble in the situation of close proximity in a process called bimolecular fluorescence complementation (BiFC).

For example, GFP, CFP, Venus, Venus with a M153T substitution, or Cerulean may be split after amino acid 155 (i.e., for example, fragment F1 may comprise amino acids 1-155 of GFP, while fragment F2 may comprise amino acids 156-245 of GFP, or vice versa). Alternatively, YFP or Venus may be split after amino acid 173. Further details on split GFP and split GFP variants can be found in Kerppola TK., Visualization of molecular interactions using bimolecular fluorescence complementation analysis: characteristics of protein fragment complementation. *Chem Soc Rev.* 2009;38:2876-86.

An example for a molecule that mediates bioluminescence and that can be used in this

context is split luciferase. Particularly suited is the luciferase of *Gaussia princeps*, which requires no cofactors to be active and catalyzes the oxidation of the substrate coelenterate luciferin (coelenterazine) in a reaction that emits blue light, or derivatives of *Gaussia* luciferase (Remy I and Michnick S, A highly sensitive protein-protein interaction assay based on *Gaussia* luciferase. *Nature Methods* - 3, 977 - 979 (2006)). For example, fragment F1 may comprise a fragment from the N-terminus of *Gaussia* luciferase to Gly-93, while fragment F2 may comprise a fragment from Glu-94 to the C-terminus of *Gaussia* luciferase, or vice versa (see Remy I and Michnick S, *Nature Methods*, 2006 for details). Application of the *Gaussia* split luciferase system *in vivo* has been established (Luker et al., *In vivo* imaging of ligand receptor binding with *Gaussia* luciferase complementation. *Nature Medicine* 2011, doi:10.1038/nm.2590), allowing for straightforward adaptation to the purposes of the present invention by a skilled person.

Intravital imaging of tumour lesions is of eminent importance in cases, where cancer cells infiltrate tissues and the complete elimination of all transformed cells is prerequisite for cure. A surgeon searching for disseminated cancer cells in the operation site may use split GFP or split GFP derivatives fused to the targeting moieties and a laser assisted Multispectral fluorescence camera system for detection of cells aberrantly expressing an addressed antigen profile, similar to the intraoperative use of fluorescence or bioluminescence that is already exploited in some clinical settings (van Dam GM et al., Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor- α targeting: first in-human results. *Nat Med.* 2011 Sep 18;17(10):1315-9; Luker et al., *In vivo* imaging of ligand receptor binding with *Gaussia* luciferase complementation. *Nature Medicine* 2011, doi:10.1038/nm.2590).

For detection of complemented split luciferase, the application of a substrate for luciferase, which can be luciferin or coelenterazine, is mandatory. Coelenterazine is preferred because coelenterazine emits light independent of ATP and is well established for *in vivo* imaging and *in vivo* applications. A surgeon will be able to visualize cancer cells after having tagged the tumor with polypeptide P1 and P2 and injected a non-toxic amount of coelenterazine intravenously.

In another exemplary embodiment, the inventive principle is applied in the context of a patient who suffers from a haematopoietic tumour and who received a transplantation of healthy haematopoietic cells from another person (the donor). Here, the set of polypeptides according to the invention can be used for the specific elimination (or detection) of

remaining malignant haematopoietic cells of the recipient after transplantation of healthy haematopoietic cells from the donor.

To destroy the malignant haematopoietic cells in a patient suffering from a haematopoietic tumour, the patient may be subjected to chemotherapy and/or radiation therapy. Subsequently, the patient receives a transplantation of healthy haematopoietic cells from a donor.

To minimize the risk of transplant rejection or graft versus host disease, transplantation of tissue/cells (e.g. bone marrow) from a donor who has the same set of MHC (major histocompatibility complex) molecules is usually preferred. However, often no donor with the same set of MHC molecules ("HLA-identical donor") can be identified. Therefore, transplant grafts with one or two mismatches in the set of MHC variants, unrelated cord blood with up to three mismatches, or haploidentical transplantations are increasingly employed. Accordingly, it is common that there is at least one distinctive difference between the set of MHC molecules expressed by the cells of the recipient and the cells of the donor.

In the transplantation according to this exemplary embodiment of the invention, donor cells are used that are distinct from the recipient cells with respect to at least one of their HLA variants. This means that there is at least one "distinguishing antigen" that is present at the cell surface of the recipient cells, but not at the cell surface of the donor cells. For example, the distinguishing antigen may be HLA-A2, if the patient (i.e. the recipient) is HLA-A2 positive, while the donor is HLA-A2 negative.

Despite chemotherapy/radiation therapy, individual malignant haematopoietic cells of the recipient may have escaped eradication. Since the surviving malignant haematopoietic cells are recipient cells, they carry the distinguishing antigen that differentiates recipient cells from donor cells. At the same time, they are cells of haematopoietic lineage origin and thus have markers of this cell lineage, such as CD45, at their cell surface. Leukemic blasts and other haematopoietic cells of the patient are the only cells that simultaneously display the distinguishing antigen (here HLA-A2) and markers of haematopoietic cell lineage (here CD45). The set of polypeptides according to the invention exploits this fact to specifically eliminate these cells.

To this end, the first targeting moiety T1 of the first polypeptide P1 may be a scFv specific for the distinguishing antigen which is present only on recipient cells (here HLA-A2). As

fragment F1 of the functional domain F, the variable region of the light chain (V_L) of a CD3ε-specific antibody may be chosen. The second targeting moiety T2 of the second polypeptide P2 may be a single chain variable Fragment (scFv) specific for CD45. As fragment F2 of the functional domain F, the variable region of the heavy chain (V_H) of said CD3ε-specific antibody may be chosen. (Naturally, it is equally possible to use the variable region of the heavy chain (V_H) of a CD3ε-specific antibody as fragment F1 and the variable region of the light chain (V_L) of said CD3ε-specific antibody as fragment F2. As is evident for a person of skill in the art, this is a general principle, and it is generally possible to switch the fragments used for fragment F1 and fragment F2.) Neither is V_L of the CD3ε-specific antibody capable of engaging CD3ε in the absence of V_H, nor is V_H of the CD3ε-specific antibody capable of engaging CD3ε in the absence of V_L. Accordingly, neither P1 nor P2 is by itself capable of binding to CD3ε.

However, if both the distinguishing antigen (e.g. HLA-A2) and the CD45 antigen are present on one single cell, binding to their respective antigens brings the two polypeptides P1 and P2 into close proximity. As a consequence, the unpaired V_H and V_L domains assemble, resulting in heterodimerization of the polypeptides P1 and P2 and in the formation of a functional variable antibody fragment Fv from the V_H and V_L domains that is capable of binding to CD3ε (see Figure 2).

As a result, T cells are recruited and activated through CD3ε, and the cell carrying both HLA-A2 and CD45 at its cell surface is specifically eliminated by a cytotoxic T cell response.

A person of skill in the art understands that, within the principle of the present invention, diverse variations to this exemplary embodiment are possible.

For example, in polypeptide P2 the scFv fragment recognising the haematopoietic cell lineage marker CD45 can be replaced by a scFv fragment recognising a marker of a different cell lineage or cell type, i.e. the targeting moiety T2 may be a domain that specifically binds an antigen that is specific for a cell lineage other than the haematopoietic cell lineage or for a certain cell type (for a detailed list of various cell lineage markers and cell type markers that may be used in this context see David J. Dabbs, Diagnostic immunohistochemistry, Churchill Livingstone, 3rd edition (2010); or F Lin and J Prichard, Handbook of Practical Immunohistochemistry: Frequently Asked Questions, Springer, New York, 1st edition

(2011)). To adapt the set of polypeptides to an alternative cell lineage marker/cell type marker, it is sufficient to replace the targeting moiety T2 of polypeptide P2 with a targeting moiety that has binding specificity for the desired alternative cell lineage marker/cell type marker.

For example, in the situation of metastatic renal cell carcinoma (RCC), a person skilled in the art might consult the above-cited databases for information on cell surface proteins with restricted expression to kidney cells. Among many other molecules, he will learn that expression of certain members of the aquaporin family is confined to kidney cells and erythrocytes. Having obtained this information, a person skilled in the art will construct a polypeptide P2 recognising an aquaporin family member that is confined to kidney cells and erythrocytes fused to the variable region of the heavy chain (V_H) of a CD3 ε -specific antibody. In case that the patient suffering renal cell carcinoma is HLA A2 positive and a kidney transplant from a healthy donor is HLA A2 negative, the clinician treating the patient may utilise the two constructs (anti-aquaporin fused to anti-CD3(V_H) and anti-HLA A2 fused to the light chain (V_L) of said CD3 ε -specific antibody). In this case, all cells simultaneously expressing said aquaporin and HLA A2 will be tagged for lysis by T cells which are renal cell carcinoma cells and metastatic tissues. Kidney cells donated by the healthy donor are HLA A2 negative and will not be attacked. Since erythrocytes loose HLA expression along the process of ontogeny and thus do not carry HLA molecules on their surfaces, they will be spared despite expressing large amounts of aquaporins. Again, a conventional, non-complementing bispecific antibody addressing aquaporin would mediate killing of all kidney cells from donor and recipient as well as erythrocytes. A bispecific antibody addressing HLA A2 in a HLA A2 positive patient most likely would be fatal, since every recipient cell except erythrocytes express HLA A2 and can be attacked by the retargeted T cells.

Another example is hepatocellular carcinoma (HCC). Hepatocytes are largely involved in a number of metabolic processes including the trafficking of lipoproteins. To this end, hepatocytes express receptors for high density lipoproteins (HDL) on their surfaces (scavenger receptor class B member 1, SCARB1). Treatment of an HLA A2 positive patient suffering HCC which expresses SCARB1 on the surface of tumor cells and metastases can be accomplished by a Polypeptide P2 construct comprising a scFv domain addressing SCARB1 fused to the variable region of the heavy chain (V_H) of said CD3 ε -specific

antibody and a Polypeptide P1 (anti-HLA A2 scFv fused to the light chain (V_L) of said CD3 ε -specific antibody) and transplantation of liver cells from a healthy, HLA A2 negative donor. In this case, all hepatocytes and hepatocyte-derived malignant cells expressing both, SCARB1 and HLA A2 will be tagged for lysis by T lymphocytes. Hepatocytes of the donor lacking HLA A2 will be spared as well as normal SCARB1 negative donor cells expressing HLA A2. Since SCARB1 expression is also reported for cells participating in steroid synthesis in the adrenal gland, these cells most likely will also be destroyed by redirected T cells, resulting in Addison's disease.

Various markers that are specific for certain cell types or cell lineages or a few cell types/lineages are known (for a list of examples, see above). More information on lineage markers, differentiation antigens and tissue markers as well as their tissue distribution are easily accessible from published sources (see, e.g. David J. Dabbs, Diagnostic immunohistochemistry, Churchill Livingstone, 3rd edition (2010); or F Lin and J Prichard, Handbook of Practical Immunohistochemistry: Frequently Asked Questions, Springer, New York, 1st edition (2011)) and public databases (such as the Gene Expression Atlas of the European Bioinformatics Institute (EBI), <http://www.ebi.ac.uk/gxa/>; or the Gene Expression Omnibus (GEO) platform, see above). Moreover, such markers can be identified and/or verified in a straightforward manner by a skilled person using similar methods as described above for the identification of tumour-specific combinations of antigens.

In certain preferred embodiments, an antigen with less than perfect specificity for a certain cell type or cell lineage is used (i.e. an antigen is used that is present on more than one, but preferably only a few, cell types or cell lineages). In some embodiments, an antigen is used that is expressed by said cell type/cell lineage at a higher rate or at a higher proportion or amount than by other cell types/cell lineages, in the sense that there may be a small but detectable expression of said antigen also in other cell types/cell lineages.

The concept can further be adapted to any other HLA haplotype besides HLA-A2 used in the exemplary embodiment above, as long as the recipient cells are positive for this HLA antigen and the donor cells are negative for it. Possible HLA antigens include, among others, HLA A1, HLA A2, HLA A3, HLA A25, HLA B7, HLA B8, HLA B35, HLA B44 and HLA Cw3, HLA Cw4, HLA Cw6, HLA Cw7. To adapt the set of polypeptides to an alternative HLA antigen, it is sufficient to replace the targeting moiety T1 of polypeptide P1 with a targeting moiety that has binding specificity for the desired alternative HLA antigen. By an

appropriate choice of the targeting moiety T1, it is of course also possible to specifically eliminate donor cells.

Moreover, instead of a V_L domain and a V_H domain that upon assembly form a domain capable of binding to CD3 ϵ (i.e. fragment F1 and fragment F2 of polypeptides P1 and P2, respectively), the V_L domain and V_H domain can be replaced with domains/fragments that upon assembly confer a different function to the resulting dimer. In this respect, all the variations described above for the exemplary embodiment relating to the elimination/detection of tumour cells identified by a specific combination of two cell surface antigens are equally applicable. For example, upon assembly the complemented functional domain may mediate binding/activation of other effector cells than T cells, may be adapted to a "pretargeting" approach, may bind a therapeutic or diagnostic compound, or may form a fluorescent molecule/molecule capable of mediating bioluminescence.

The diverse options for the choice of the fragments F1 and F2 and for the choice of the targeting moieties T1 or T2 described above in the exemplary embodiment relating to application of the inventive principle for the specific elimination of tumour cells may of course be considered, as well.

From the described exemplary embodiments and variations, it will be clear to a person of skill in the art that the inventive principle described above can not only be used for the highly specific identification/elimination of tumour cells or of remaining malignant recipient cells after a cell transplantation, but also for the identification/elimination of any other type of cell carrying a specific combination of two antigens that distinguishes it from other types of cells.

In the following, reference is made to the figures:

Figure 1 shows the principle of the invention. Figure 1A: Antigens and design of polypeptides P1 and P2. Figure 1B: If a cell expresses both antigens 1 and 2 at its cell surface, simultaneous binding of polypeptide P1 and polypeptide P2 to the surface of this cell brings P1 and P2 in close proximity, causes association of fragments F1 and F2 and restoration of the biological function of domain F by complementation. No restoration of biological function occurs if only antigen A1 (Figure 1C) or antigen A2 (Figure 1D) is present on the cell surface.

Figure 2 shows an exemplary embodiment of the invention in an allogeneic transplantation setting for haematopoietic neoplasias with mismatched HLA antigens. In this situation, the dual information of recipient HLA haplotype (HLA_{patient}) and haematopoietic lineage origin (CD45) is displayed exclusively on leukemic blasts and other haematopoietic cells of the patient. The first polypeptide P1 comprises a single-chain variable fragment antibody construct directed against the HLA of the patient (targeting moiety T1) fused to the V_L fragment of anti CD3 (fragment F1). The second polypeptide P2 comprises a single-chain variable fragment construct specific for the haematopoietic lineage marker CD45 (targeting moiety T2), fused to the V_H split-fragment of anti CD3 Fv (fragment F2).

CD45: antigen specific for haematopoietic cells. HLA_{patient}: HLA-antigen specific for patient cells, i.e. an allelic variant of the human MHC that is present on the surface of patient cells (= cells of the recipient of cell transplantation), but absent from the surface of donor cells. α CD45 scFv: scFv with binding specificity for CD45. α HLA_{patient} scFv: scFv with binding specificity for HLA_{patient}. CD3(V_H): variable region of an immunoglobulin heavy chain of an antibody with binding specificity for CD3. CD3(V_L): variable region of an immunoglobulin light chain of an antibody with binding specificity for CD3.

Upon binding of the two constructs through their α CD45 scFv and α HLA_{patient} scFv, respectively, to a cell carrying both the CD45 and the HLA_{patient} antigen, assembly of CD3(V_H) with CD3(V_L) leads to functional complementation of the antibody with binding specificity for CD3, thus allowing for specific recruitment and activation of T cells through the CD3 molecules at their cell surface.

Figure 3 shows the constructs used in the experiments depicted in Figures 4-9. (Construct 85 differs from construct 71 by the fact that construct 85 has a Flag tag while construct 71 has a myc tag. Construct 75 differs from construct 82 by the fact that construct 75 has a Flag tag while construct 82 has a myc tag.) V_HCD3: variable region of the heavy chain of an anti-CD3 antibody; V_LCD3: variable region of the light chain of an anti-CD3 antibody; V_HA2: variable region of the heavy chain of an anti-HLA-A2 antibody; V_LA2: variable region of the light chain of an anti-HLA-A2 antibody; V_L45: variable region of the heavy chain of an anti-CD45 antibody; V_H45: variable region of the light chain of an anti-CD45 antibody; L18, L7, L15, L6, L19: linker of 18, 7, 15, 6, 19 amino acids, respectively.

Figure 4 shows conventional tandem bispecific single chain scFv constructs used to control the assay system. Briefly, bispecific antibody constructs with specificity for CD3 and HLA

A2 were titrated as indicated to a co-culture of U266, a HLA A2 positive, CD45 positive myeloma cell line, and HLA A2 negative T cells (monocyte depleted peripheral blood mononuclear cells), and production of interleukin 2 by T cells was determined. Substantial T cell stimulatory capacity was detected for the two FvCD3-HLA-A2 constructs 85 and 71, which differ by their respective Flag or Myc-Tags (For domain structure of constructs see Figure 3.). Bispecific tandem Fv constructs in HLA-A2-CD3 configuration were less efficient and single chain constructs addressing either HLA-A2 or CD3 did not stimulate T cells at all. Positive control is conducted using unspecific PHA-L (phytohemagglutinin) stimulation.

Figure 5 shows exquisite and highly specific T cell stimulatory capacity if a pair of complementing constructs according to the invention is used, but not if only one of the two constructs of a pair is used individually. Briefly, V_L CD3-scFvHLA-A2 (construct 42), V_H CD3-scFvCD45(V_L - V_H) (construct 45) and V_H CD3-scFvCD45(V_H - V_L) (construct 55) were titrated separately or in the combinations of constructs 42 and 45, or 42 and 55 to co-cultures of U266 and T cells as described. High T cell stimulatory capacity was demonstrated for the combinations of 42/45 or 42/55 with minute activity, if only one of these constructs was given separately. These results show that the V_L and V_H domains of FvCD3 have to cooperate in order to reconstitute or complement T cell engaging function. Importantly, the scFvCD45 targeting moiety could be switched from (V_L - V_H) to the (V_H - V_L) configuration, clearly indicating that the modular character of the constructs allows replacement of a targeting moiety by another targeting moiety with desired specificity. The assay system was controlled by the use of single chain constructs CD45(V_L - V_H) and CD45(V_H - V_L) which did not stimulate T cells to produce IL2.

Figure 6 shows a first of three competitive blocking experiments. The bispecific tandem construct FvCD3-HLA-A2 (construct 71) was given to co-cultures of U266 and T cells as described and stimulatory function was determined through induced IL2 production by T lymphocytes. The T cell stimulating function was blocked by single chain constructs that occupy the targeted epitope on the HLA A2 molecule (construct 4, concentration *100). Intrinsic stimulation of T cells by the HLA A2 or CD3 specific single chain constructs (construct 4 (concentration *100) or construct 36 (concentration *9)) was ruled out. PHA-L was used as positive control.

Figure 7 shows that "tridomain constructs" (i.e. constructs according to the invention) first

have to bind on the surface of a single cell to dimerize and complement T cell engaging functions the competitive epitope blocking experiments. Briefly, constructs 42 and 45 were given to co-cultures of U266 cells and HLA-A2 negative T lymphocytes and stimulatory capacity was determined by IL2 production of T cells. In experimental situations where the epitopes on HLA A2 or CD45 molecules were competitively blocked by constructs 4 or 46 (both concentrations *100), T cell stimulatory function was abrogated. These results clearly indicate that the two respective "tridomain constructs" have to bind simultaneously onto the surface of a cell in order to restore or to complement T cell engaging function. Intrinsic stimulatory activity of either construct (42, 45, 4, 46 and 36) was ruled out using different concentrations.

Figure 8 shows the analogous experiment to Figure 7 for the combination of constructs 42 and 55. Again, T cell stimulatory capacity of the combination of the two "tridomain constructs" was abrogated by competitive blocking of antigenic epitopes on the HLA A2 or the CD45 molecule. Importantly, these results again show that the targeting module can be easily replaced by another module with appropriate specificity. More importantly, the V_L - V_H - V_L configuration of construct 42 and the V_H - V_H - V_L configuration of construct 55 impede homo- or hetero-dimerization or self-assembling of the constructs without prior binding to a substrate expressing both, HLA A2 and CD45 antigens.

Figure 9 shows lysis of U266 cells by HLA A2 negative T cells in a sample comprising both V_L CD3-scFvHLA-A2 and V_H CD3-scFvCD45(V_H - V_L) constructs ("both constructs"). No significant lysis was observed in control samples comprising only one of the two constructs.

Figure 10 shows the On-target restoration of the polypeptides. Binding of two separate polypeptides (P1 and P2) to their respective antigens on a target cell, each consisting of a specific single-chain variable antibody fragment (scFv, V_H - V_L) fused to the variable light (V_L) or variable heavy chain domain (V_H) of a CD3-specific antibody (Fragment F1 and F2), enables V_H / V_L heterodimerization and the formation of a functional CD3 binding site to engage T cells.

Figure 11 shows that CD3 V_H / V_L dimerization engages T cells and is dual-antigen-restricted. U266 myeloma, primary T cell pro-lymphocytic leukemia (T-PLL), and THP-1 acute myeloid leukemia cells, all HLA-A2-positive and CD45-positive, were probed with HLA-A2-negative donor peripheral blood mononuclear cells (PBMC) and the polypeptides as

indicated. T-cell engagement was assessed by reactive interleukin-2 (IL-2) production (**A**) and target cell lysis (**B**). The bispecific tandem scFv (CD3(V_H-V_L) - HLA-A2(V_H-V_L) antibody was used as a positive control. (**C**), Binding of the polypeptides on THP-1 cells is competitively blocked by an excess of scFvCD45 (left) and scFvHLA-A2 (right) inhibitors (blocking the individual antigen epitopes on the target cell), as indicated, and reactive IL2 production by donor PBMCs was investigated. (**D**), The single or double antigen negative cell lines RAJI and KMS-12-BM were probed with the polypeptides. PHA-L was used as a nonspecific stimulus control for PBMCs.

Figure 12 shows targeted therapy by conditional CD3V_H/V_L complementation *in vivo*. (**A**), Survival of mice (n = 6 per group) after intraperitoneal injection of 5×10^6 THP-1 acute leukemic cells together with 1.25×10^5 CMV-specific, HLA-A2-negative donor T cells and the polypeptides (0.5 μ g) as indicated (tumor cells: T-cell ratio = 40/1). (**B**), Caspase 3 activation was assessed *in vitro* by flow cytometry in HLA-A2/CD45 double-positive THP-1 and CD45-positive but HLA-A2-negative bystander cells after co-culture with donor T cells and the polypeptides (3 nM) as indicated. The bispecific tandem scFv (CD3(V_H-V_L) - HLA-A2(V_H-V_L)) antibody was used as a positive control.

Figure 13 shows that EGFR- and EpCAM-directed polypeptides engage T cells for carcinoma cell destruction. EGFR and EpCAM double-positive human colon cancer cell line COLO-206F and melanoma cell line FM-55 (EGFR-positive but EpCAM-negative) were probed with PBMCs in the presence of polypeptides specific for EGFR (CD3(V_H)-EGFR(V_H-V_L)) and EpCAM (CD3(V_L)-EpCAM(V_H-V_L)) as indicated. T cell engagement was assessed by reactive interferon- γ (IFN γ) production (**A**) and activation of caspase 3 in target cells (**B**).

Figure 14 shows that HLA-A2 and CEA directed polypeptides redirect T cells for tumor cell destruction. Human colon cancer cell line COLO-206F, melanoma cell line FM-55 and ovarian cancer cell line OVCAR were probed with PBMCs in the presence of polypeptides specific for HLA-A2 (CD3(V_L)-HLA-A2(V_H-V_L)) and CEA (CD3(V_H)-CEA(V_H-V_L)) as indicated. T cell engagement was assessed by reactive IFN γ production. Samples were run and analyzed as duplicates.

Figure 15 shows that HLA-A2 and EGFR directed polypeptides redirect T cells for tumor cell destruction. Human cell lines COLO-206F, FM-55 and OVCAR were probed with PBMCs in the presence of polypeptides specific for HLA-A2 (CD3(V_L)-HLA-A2(V_H-V_L)) and EGFR (CD3(V_H)-EGFR(V_H-V_L)) as indicated. T cell engagement was assessed by reactive IFN γ production. Samples were run and analyzed as duplicates.

Figure 16 shows that HLA-A2 and Her2 directed polypeptides redirect T cells for tumor cell destruction. Human cell lines COLO-206F, FM-55 and OVCAR were probed with PBMCs in the presence of polypeptides specific for HLA-A2 (CD3(V_L)-HLA-A2(V_H-V_L)) and Her2 (CD3(V_H)-Her2(V_H-V_L)) as indicated. T cell engagement was assessed by reactive IFN γ production. Samples were run and analyzed as duplicates.

Figure 17 shows that CD45 and HLA-A2 directed polypeptides redirect T cells for tumor cell destruction. In this experiment the split antiCD3 fragments (CD3(V_H) and CD3(V_L)) for the anti-CD45 and anti-HLA-A2 targeting moieties were exchanged, compared to the CD45 and HLA-A2 polypeptides used in Fig. 5,7-9, 11,12, 14-16. Human myeloma cell line U266 was probed with PBMCs in the presence of polypeptides specific for CD45 (CD3(V_L)-CD45(V_H-V_L)) and HLA-A2 (CD3(V_H)-HLA-A2(V_H-V_L)) as indicated. T cell engagement was assessed by reactive IFN γ production. Samples were run and analyzed as duplicates.

Figure 18 shows that EGFR and EpCAM directed polypeptides redirect T cells for tumor cell destruction. Human colon cancer cell lines COLO-206F and CX-1 and ovarian cancer cell line OVCAR were probed with PBMCs in the presence of polypeptides specific for EpCAM (CD3(V_L)-EpCAM(V_H-V_L)) and EGFR (CD3(V_H)-EGFR(V_H-V_L)) as indicated. T cell engagement was assessed by reactive IFN γ production. Samples were run and analyzed as duplicates.

Figure 19 shows that Her2 and EpCAM directed polypeptides redirect T cells for tumor cell destruction. Human ovarian cancer cell line OVCAR were probed with PBMCs in the presence of polypeptides specific for EpCAM (CD3(V_L)-EpCAM(V_H-V_L)) and Her2 (CD3(V_H)-Her2(V_H-V_L)) as indicated. T cell engagement was assessed by reactive IFN γ production. Samples were run and analyzed as duplicates.

Figure 20 shows that CD45 and CD138 directed polypeptides redirect T cells for tumor cell destruction. Human myeloma cell line AMO-1 was probed with PBMCs in the presence of polypeptides specific for CD45 (CD3(V_L)-CD45(V_H-V_L) upper panel, CD3(V_H)-CD45(V_H-

V_L) lower panel) and CD138 (CD3(V_H)-CD138(V_H - V_L) upper panel, CD3(V_L)-CD138(V_H - V_L) lower panel) as indicated. T cell engagement was assessed by reactive IFN γ production. Samples were run and analyzed as duplicates.

Figure 21 shows that targeting a single antigen (CD138) with CD138 directed polypeptides redirect T cells for tumor cell destruction. Human myeloma cell line AMO-1 was probed with PBMCs in the presence of polypeptides specific for CD138 (CD3(V_L)-CD138(V_H - V_L) and (CD3(V_H)-CD138(V_H - V_L)) as indicated. T cell engagement was assessed by reactive IFN γ production. Samples were run and analyzed as duplicates.

Figure 22 shows that targeting a single antigen (CD45) with CD45 directed polypeptides redirect T cells for tumor cell destruction. Human myeloma cell lines AMO-1 and U266 were probed with PBMCs in the presence of polypeptides specific for CD45 (CD3(V_L)-CD45(V_H - V_L) and (CD3(V_H)-CD45(V_H - V_L)) as indicated. T cell engagement was assessed by reactive IFN γ production. Samples were run and analyzed as duplicates.

Figure 23 shows the On-target restoration of two polypeptides directed against a single antigen on the cell surface, targeting two different epitopes (upper part) or the same epitope (lower part) on the antigen. Binding of two separate polypeptides (P1 and P2) to their respective epitope, on the same antigen, on a target cell. For targeting two different epitopes, the targeting moiety of each polypeptide consists of a specific single-chain variable antibody fragment (scFv). For targeting the same epitope, the targeting moiety of each polypeptide consists of the same single-chain variable antibody fragment (scFv). The targeting moieties are fused via peptide linkers to the variable light (V_L) or variable heavy chain domain (V_H) of a CD3-specific antibody (Fragment F1 and F2), enables V_H / V_L heterodimerization and the formation of a functional CD3 binding site (functional domain) to engage T cells.

Figure 24 shows the possibility to use different effector ways to kill a target cell with a kit of polypeptide parts. To this end, the anti-CD3 module (F1 and F2) is replaced by an anti-HIS (hexa-histidine) module which, after simultaneous binding of polypeptide 1 and 2, complements a hexa-histidine binding site and thus binds histidine labeled payloads (eg. a HIS-tagged toxin). The targeting moiety T1 (V_H - V_L) of polypeptide P1 specifically binds to HLA-A2, the targeting moiety T2 (V_H - V_L) of polypeptide P2 specifically binds to CD45. The fragment F1 of polypeptide P1 comprises of a V_H domain of an antibody against a hexahistidine-tag and fragment F2 of polypeptide P2 comprises a V_L domain of the same

antibody. Human myeloid leukemia cell line THP-1 was probed with a histidine (His) tagged Clostridium perfringens Iota toxin component Ia at 0.01 μ g/ml in combination with indicated polypeptides. After 48 hours in culture the cell viability was measured using the alamarBlue® assay. The results show a reduction of viability against the background of the assay for cells probed with the combination, but not with individual polypeptides. Control THP-1 cells were grown simultaneously in culture without toxin. Samples were run and analyzed as duplicates.

Figure 25 shows that HLA-A2 and CD45 directed polypeptides, comprising of a split antibody against a His-tag, kill tumor cells using a histidine (His) tagged Shiga toxin subunit A at a concentration of 0.01 μ g/ml. The same experimental setup was used as in figure F24.

Figure 26 shows that HLA-A2 and CD45 directed polypeptides, comprising of a split antibody against a His-tag, kill tumor cells using a histidine (His) tagged Shiga toxin subunit A at a concentration of 0.1 μ g/ml. The same experimental setup was used as in figure F24/25.

Figure 27 shows that EGFR and EpCAM directed polypeptides, comprising of a functional domain F with F1 and F2 are V_H and V_L of a antibody specific for digoxigenin (aDig), mark tumor cells using a digoxigenin labeled horse radish peroxidase (HRP) molecule. The targeting moiety T1 (V_H-V_L) of polypeptide P1 specifically binds to EGFR, the targeting moiety T2 (V_H-V_L) of polypeptide P2 specifically binds to EpCAM. The fragment F1 of polypeptide P1 comprises of a V_H domain of an antibody against digoxigenin and fragment F2 of polypeptide P2 comprises a V_L domain of the same antibody. Human colon cancer cell line Colo-206F was first probed with indicated polypeptides followed by probing with digoxigenin labeled HRP. The samples were analyzed using the (Invitrogen™, ELISA Kit) and the absorbance was read with a BioRAD-micro plate reader. For analysis the chromogen blank sample (no Digoxigenin-HRP) was set to 0. Samples were run and analyzed as duplicates.

Figure 28 shows that CD45 and HLA-CW6 directed polypeptides redirect T cells for patient cell destruction. Primary patient cells with known HLA-haplotypes were used. A51 = cells of a patient with MDS (myelodysplastic syndrom), homozygous for the HLA-Cw6 haplotype. A49 = cells of a patient after allogeneic bone marrow transplantation, heterozygous for the HLA-Cw6 haplotype. Patient cells were incubated with healthy PBMCs for 30 hours, in the presence of polypeptides specific for CD45 (CD3(V_L)-CD45(V_H-V_L) and

HLA-Cw6 (CD3(V_H)-HLA-CW6(V_H-V_L)) as indicated. T cell engagement was assessed by reactive IFN γ production. Samples were run and analyzed as duplicates.

Figure 29 shows that EGFR and EpCAM directed polypeptides redirect T cells for primary cancer patient cell destruction. A44 tumor cells were collected from the malignant ascites of a 48 years old male patient with metastatic pancreatic cancer. Patient tumor cells were incubated with patients own PBMCs (collected by phlebotomy) for 30 hours, in the presence of polypeptides specific for EpCAM (CD3(V_L)-EpCAM(V_H-V_L) and EGFR (CD3(V_H)-EGFR(V_H-V_L)) as indicated. T cell engagement was assessed by reactive IFN γ production. Samples were run and analyzed as duplicates.

Figure 30 shows that CD45 and HLA-A2 directed polypeptides redirect CMV restricted CD8+ T cells for tumor cell destruction. Human tumor cells THP-1 and U266 were incubated with CMV restricted T-cells from a HLA-A2 negative healthy donor for 30 hours, in the presence of polypeptides specific for HLA-A2 (CD3(V_L)-HLA-A2(V_H-V_L) and CD45 (CD3(V_H)-CD45(V_H-V_L)) as indicated. The bispecific tandem scFv (CD3(V_H-V_L) x HLA-A2(V_H-V_L))-antibody was used as a positive control. T cell engagement was assessed by reactive IFN γ production. Samples were run and analyzed as duplicates.

Figure 31 shows the principle idea to eliminate autoimmune or hypersensitivity disorder causing B-cell clones with a kit of polypeptide parts, consisting of an allergen specific polypeptide and a cell type specific polypeptide. The first polypeptide P1 has at its targeting moiety an allergen (eg. Betv-1A, Der-f2, Conglutin-7, Can-f1, Feld-d1). The second polypeptide P2 has at its targeting moiety a specific single-chain variable antibody fragment (scFv, V_H-V_L) targeting a cell surface protein (eg. CD19, CD138, CD38). Both targeting moieties are fused to either the variable light (V_L) or variable heavy chain domain (V_H) of a CD3-specific antibody (Fragment F1 and F2).

In the following, reference is made to certain (human) genes or proteins also referred to in the specification, the appended examples and figures as well as (partially) in the claims. Herein below, corresponding (exemplary) gene accession numbers are provided. Further accession numbers are also provided in the specification elsewhere herein as well as the appended examples.

CD45: Gene ID: 5788, updated on 13-Jan-2013, 3. Protein = P08575-1 = Isoform 1, Last modified July 19, 2003. Version 2

CD34: Protein: P28906-1/2 Last modified July 15, 1998. Version 2.

CD33: Gene ID: 945, updated on 30-Dec-2012: Protein: P20138 [UniParc]. Last modified October 17, 2006. Version 2. Checksum: 1C73E588240FBAD8

CD138: Gene ID: 6382, updated on 6-Jan-2013, 4. Protein = P18827 [UniParc]. Last modified May 5, 2009. Version 3.

CD15: Gene ID: 2526, updated on 5-Jan-2013

CD1a: Gene ID: 909, updated on 30-Dec-2012, P06126 [UniParc]. Last modified February 9, 2010. Version 4. Checksum: C575C3C538F0AA29

CD2: Gene ID: 914, updated on 5-Jan-2013; P06729 [UniParc]. Last modified October 23, 2007. Version 2. Checksum: A03D853C3B618917

CD3e: Gene ID: 916, updated on 5-Jan-2013, P07766 [UniParc]. Last modified February 1, 1996. Version 2. Checksum: A1603D01CE9957D7

CD4: Gene ID: 920, updated on 13-Jan-2013; P01730 [UniParc]. Last modified November 1, 1988. Version 1. Checksum: 20ED893F9E56D236

CD5: Gene ID: 921, updated on 30-Dec-2012; P06127 [UniParc]. Last modified November 30, 2010. Version 2. Checksum: 9131AEC9683EE1D3

CD8a: Gene ID: 925, updated on 30-Dec-2012; Isoform 1/2 (membrane) P01732-1/2 (mCD8alpha) [UniParc]. Last modified July 21, 1986. Version 1. Checksum: FCCA29BAA73726BB

CD20: Gene ID: 931, updated on 6-Jan-2013; P11836 [UniParc]. Last modified October 1, 1989. Version 1. Checksum: AC5420F8B626BDD1

CD23: Gene ID: 2208, updated on 4-Jan-2013; P06734 [UniParc]. Last modified January 1, 1988. Version 1. Checksum: F86708C0E6515B87

CD31: Gene ID: 5175, updated on 13-Jan-2013; Isoform Long [UniParc]. Last modified April 1, 1990. Version 1. Checksum: C57BBFA200A407A6, P16284-1/2/3/4/5/6 = Isoforms 1-6

CD43: Gene ID: 6693, updated on 30-Dec-2012; P16150 [UniParc]. Last modified April 1, 1990. Version 1. Checksum: C9C9AB8435D5E1FE

CD56: Gene ID: 4684, updated on 30-Dec-2012; Isoform 1 [UniParc]. Last modified July 22, 2008. Version 3. Checksum: FD3B9DE80D802554, P13591-2/1/3/4/4/6, Isoforms 1-6

CD57: Gene ID: 27087, updated on 5-Jan-2013

CD68: Gene ID: 968, updated on 6-Jan-2013; Isoform Long (CD68.1) [UniParc]. Last modified May 15, 2007. Version 2. Checksum: 69E68D69EDE8EFB0, P34810-1/2, Isoform 1/2

CD79a: Gene ID: 973, updated on 5-Jan-2013; Isoform 1 (Long) [UniParc]. Last modified June 1, 1994. Version 2. , Checksum: 6E5B837409969292, P11912-1/2, Isoform 1/2

CD146: Gene ID: 4162, updated on 30-Dec-2012; Isoform 1 [UniParc]. Last modified January 10, 2006. Version 2. Checksum: E46CB8AC7BA0738E, P43121-1/2, Isoform 1/2.

surfactant proteins (A and B):

Gene ID: 6440, updated on 30-Dec-2012 and Gene ID: 6439, updated on 30-Dec-2012, P07988 [UniParc]. Last modified May 1, 1992. Version 3. Checksum: 9FD7F66678A35153, and Isoform 1 [UniParc]. Last modified April 1, 1990. Version 2. Checksum: C26A21E33C60AA78, P11686-1/2, Isoform 1/2

synaptophysin:

Gene ID: 6855, updated on 30-Dec-2012, P08247 [UniParc]. Last modified August 1, 1991. Version 3. Checksum: 592289C43B12EFA7

nicotinic acetylcholine receptors:

Gene ID: 1138, updated on 30-Dec-2012, Gene ID: 1136, updated on 6-Jan-2013, Gene ID: 1139, updated on 13-Jan-2013, Gene ID: 1137, updated on 30-Dec-2012, Gene ID: 1141, updated on 5-Jan-2013

muscle-specific kinase MUSK:

Gene ID: 4593, updated on 8-Jan-2013, Isoform 1 [UniParc]. Last modified January 1, 1998. Version 1. Checksum: 3DDC20E179FA010C, O15146-1/2, Isoform 1/2

voltage-gated calcium channel (P/Q-type):

Gene ID: 773, updated on 5-Jan-2013; Isoform 1 (1A-1) (BI-1-GGCAG) [UniParc]. Last modified July 15, 1999. Version 2. Checksum: 2F2F378ACE02FD56, O00555-1/2/3/4/5/6/7, Isoforms 1-7, Gene ID: 25398, updated on 11-Jan-2013, J3KP41 [UniParc]. Last modified October 3, 2012. Version 1. Checksum: AEDF4D2A5E49263F

voltage-gated potassium channel (VGKC):

Gene ID: 3737, updated on 30-Dec-2012, Gene ID: 3736, updated on 8-Jan-2013, Gene ID: 3742, updated on 8-Jan-2013

N-methyl-D-aspartate receptor (NMDA):

Gene ID: 2904, updated on 5-Jan-2013, Q13224 [UniParc]. Last modified June 20, 2001. Version 3. Checksum: 40AEB12BE6E50CEF; Gene ID: 2902, updated on 30-Dec-2012, Isoform 3 (Long) (NR1-3) [UniParc]. Last modified June 1, 1994. Version 1. Checksum: CDF5402769E530AB, Q05586-1/2/3/4/5, Isoforms 1-5

TSHR: Gene ID: 7253, updated on 4-Jan-2013, Isoform Long [UniParc]. Last modified March 29, 2005. Version 2. Checksum: D2EE9CEBFD64A65F, P16473-1/2/3, Isoforms 1-3

Amphiphysin:

Gene ID: 273, updated on 8-Jan-2013, Isoform 1 (128 kDa) [UniParc]. Last modified February 1, 1996. Version 1., Checksum: 78B4F75AB75BA357, P49418-1/2, Isoform 1-2

ganglioside GQ1B: Gene ID: 29906, updated on 30-Dec-2012

GD3: Gene ID: 117189, updated on 22-Jun-2012

Ca-125: Gene ID: 94025, updated on 30-Dec-2012, Q8WXI7 [UniParc]. Last modified March 1, 2003. Version 2. Checksum: B3E7BDF19997A440

Her-2/neu: Gene ID: 2064, updated on 13-Jan-2013, 4. Protein = P04626-1/2/3/4 = Isoform 1-4 , Last modified August 13, 1987. Version 1. gross cystic disease fluid protein 15; Gene ID: 5304, updated on 30-Dec-2012

CD117: Gene ID: 3815, updated on 6-Jan-2013

CD30: Gene ID: 943, updated on 6-Jan-2013; Isoform Long [UniParc]. Last modified December 1, 1992. Version 1. Checksum: 7A407CC78A6E0BC8, P28908-1/2, Isoform 1/2

Platelet derived growth factor receptor PDGFR alpha:

Gene ID: 5159, updated on 13-Jan-2013, Gene ID: 5156, updated on 13-Jan-2013, Isoform 1 [UniParc]. Last modified April 1, 1990. Version 1. Checksum: 5E3FB9940ACD1BE8, P16234-1/2/3, Isoforms 1-3; P09619 [UniParc]. Last modified July 1, 1989. Version 1. Checksum: 038C15E531D6E89D

Melanoma associated marker/Mart 1:

Gene ID: 2315, updated on 30-Dec-2012; Q16655 [UniParc]. Last modified November 1, 1996. Version 1. Checksum: B755BFF39CFCB16E

CD133: Gene ID: 8842, updated on 13-Jan-2013; Isoform 1 (AC133-1) (S2) [UniParc].

Last modified June 1, 1998. Version 1. Checksum: D21CBC05ADB2DEDF, O43490-1/2/3/4/5/6/7, Isoforms 1-7

In the following, reference is made to the examples which are given to illustrate, not to limit the present invention.

Examples

Example 1

Cloning of recombinant antibody constructs

DNA sequences derived from hybridoma cells and coding for the variable domains of anti-CD3, anti-CD45 and anti-HLA A2 antibodies, respectively, were used to generate the antibody constructs depicted in Figure 3 by standard methods of molecular biology (see, e.g. Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York (2001)). The constructs were designed to carry different affinity tags to facilitate identification and purification upon expression of recombinant proteins (Myc-, Flag, His-Tag). For details on domain arrangement, affinity tags and linkers of the constructs, see Figure 3.

pelB Leader codes for an amino acid sequence that directs a protein expressed in bacteria to the bacterial periplasm. The leader sequence is cleaved by bacterial enzymes and the protein can be isolated.

Example 2

Expression and Purification of Recombinant Antibodies

Periplasmic Protein Expression:

Recombinant antibody constructs were expressed in the periplasm of *E. coli* strain TG1

using an appropriate prokaryotic expression vector. Two litres of 2 × TY medium including 0.1 % glucose and 100 µg/ml ampicillin were inoculated with 20 ml of an overnight culture of transformed TG1 and grown to exponential phase (OD600 0.8 – 0.9) at 37°C. Since the antibody fragments are under control of the lactose promotor, protein expression was induced by addition of 1 mM IPTG followed by incubation at RT (room temperature) with shaking for additional 3 h. Cells were harvested by centrifugation for 10 min at 2,750 × g and 4°C and were resuspended in 100 ml of an appropriate buffer. Cell lysis was performed by adding 50 µg/ml freshly dissolved lysozyme [Roche Diagnostics] and incubating for 25 min on ice. Following, 10 mM MgSO₄ were added to stabilise spheroblasts, and cells were centrifuged for 10 min at 6,200 × g and 4°C. Finally, the supernatant obtained, containing the periplasmic protein, was dialysed against PBS overnight at 4°C and was centrifuged again for 15 min as stated above. Afterwards, recombinant proteins were purified by Ni-NTA-IMAC (Nickel Nitrilo-triacetic acid Immobilised Metal Affinity Chromatography).

Immobilised-Metal Affinity Chromatography (IMAC):

For purification of recombinant proteins with a His₆ tag, an IMAC was performed by means of immobilised nickel-nitrilotriacetic acid (NTA) agarose beads [Qiagen]. First, a column of 1 ml Ni-NTA agarose needed to be equilibrated with approximately 10 ml of sterile PBS or a sodium phosphate buffered solution with 20 mM imidazole. Then, crude protein, either precipitated from cytoplasmic expression or dialysed from periplasmic expression, was gradually applied to the column. After washing with about 20 ml of an appropriate IMAC wash buffer (sodium phosphate buffered solution containing 20 – 35 mM imidazole) until no more protein was detectable in the flow, bound protein was eluted from the column in 500 µl fractions with a sodium phosphate-buffered solution including 250 mM imidazole.

All collected wash and elution fractions were tested for presence of protein by a qualitative Bradford assay by adding 10 µl of each sample to 90 µl of 1 × Bradford solution. Verification of the purification process was performed by an SDS-PAGE analysis. For this purpose, eluted fractions were run in parallel with crude protein, flow, and wash fraction under reducing conditions. Finally, positive fractions determined by the colorimetric reaction were pooled into peak and minor fractions and dialysed against PBS overnight at 4°C. For usage in stimulation assays, purified proteins needed to be sterile filtrated, and their concentration has been determined. In addition, after protein quantification, 2 µg of further used fractions were also analysed by SDS-PAGE and Western blotting under reducing and

non-reducing conditions.

In an alternative of Example 2, DNA coding for (V_H)CD3-EGFR(V_H-V_L), (V_H)CD3-CEA(V_H-V_L), (V_H)CD3-Her2(V_H-V_L), (V_H)CD3-HLA-A2(V_H-V_L), (V_H)CD3-HLA-CW6(V_H-V_L), (V_H)CD3-CD138(V_H-V_L), (V_H)antiDig-EGFR(V_H-V_L), (V_H)antiHis-HLA-A2(V_H-V_L), (V_L)CD3-CEA(V_H-V_L), (V_L)CD3-EpCAM(V_H-V_L), (V_L)antiDig-EpCAM(V_H-V_L), (V_L)antiHis-CD45(V_H-V_L), (V_L)CD3-CD45(V_H-V_L) were synthesised and proteins were produced and isolated by GenScript (Piscataway, NJ, USA). The DNA was codon optimized for E.coli expression (vector E3), expression optimized, grown in 2 litres standard LB-medium, protein was obtained from inclusion bodies or periplasm (pelB leader) in one step by Ni-HiTrap column. Bacterial endotoxins were removed by dialysis against 5 litres 1x phosphate buffered saline (PBS). The concentration was measured by Bradford protein assay with bovine serum albumin (BSA) as standard. The purity was estimated by densitometric analysis of a Coomassie Blue-stained SDS-PAGE gel. Aliquots were stored at -80°C or +4°C. Storage buffer was used 1xPBS, 5% Glycerol, 0.5% sodium lauroyl sarcosine, pH 7.4.

Example 3

Cell Culture Techniques

Cell Cultivation:

Mammalian cells were cultivated in T75 tissue culture flasks in 20 ml of the appropriate culture medium at 37°C with 5 % CO₂. Cells were split every 2 – 3 days. Adherent cells first needed to be detached with 1 × trypsin-EDTA. Cells were counted using a vital stain, eosin or trypan blue. For storage, cells of 60 – 80 % confluence were harvested by centrifugation for 5 min at 450 × g, resuspended in FCS with 10 % DMSO, aliquoted in cryovials, and gradually frozen to a temperature of -80°C. Cells were thawed quickly at 37°C in a water bath and cautiously added to 5 ml medium. In order to remove DMSO, cells were centrifuged again, resuspended in fresh medium and transferred into a tissue culture flask.

Preparation of Peripheral Blood Mononuclear Cells (PBMC):

PBMC, comprising lymphocytes and monocytes, were previously isolated from the buffy coat of a healthy human donor by density centrifugation using the Ficoll based lymphocyte

separation solution LSM 1077 (PAA Laboratories, Pasching, Austria). Since, during usage, these PBMC nevertheless appeared as an inhomogeneous cell population, the separation from remaining erythrocytes, granulocytes, and thrombocytes was repeated as follows. Thawed PBMC, resuspended in 30 ml RPMI 1640 medium containing 10 % FCS and Pen-Strep, were cautiously layered onto 10 ml of LSM 1077 and centrifuged for 5 min at 800 × g without braking. After discarding the upper phase, PBMC concentrated in the interphase were transferred into a fresh tube, resuspended in 30 ml of medium, and centrifuged for 5 min at 450 × g. Monocytes were removed by cultivating PBMC in a Ø 10 cm tissue culture plate overnight, allowing adherence of monocytes to the plate. Finally, PBMC, remaining in solution, were harvested.

In an alternative of Example 3, Primary human cancer cells from a patient with metastatic pancreatic cancer were extracted from the ascites bags of the patient (Figure 29). 4 litres with fresh collected malignant ascites were stored in 2 litres glass bottles at 4°C over night. The next day the cell pellet from the glass bottom was washed in 1xPBS and resuspended in culture medium (DMED supplemented with 200 µM l-glutamine, 10% heat inactivated FBS, penicillin (200 U/mL), streptomycin (200 µg/mL) and sodium pyruvate (1mM) (Gibco®)). Adhering cells were cultured in incubator 36°C, 5%CO₂, 90% humidity. The same day the ascites was collected from the patient, 20ml peripheral blood for PBMC extraction was collected. Primary leukemic cells were obtained from a 71 year old male patient with T-cell-prolymphocytic leukemia (T-PLL) (Figure 11A) relapsing 32 days after matched allogeneic stem cell transplantation. The leukemic T-PLL cells were extracted as PBMCs from the peripheral blood of the patients. At the time the sample was drawn the patient had >90% leukemic blast in his blood count in routine clinic diagnostic. From all patients an informed consent, approved by the University hospital of Würzburg ethical committee, was signed.

In an alternative of Example 3, generation of cytomegalievirus (CMV)-specific human T-cells: Briefly, dendritic cells (DC) were generated from plastic adherent monocytes from PBMC of HLA-A0201 negative, B0702+ donor. After 72h of culture in GM-CSF/IL4-containing DC medium (Cellgenix), DC were matured in medium containing IL4(100ng/ml), GM-CSF(800IU/ml), LPS (10ng/ml) and IFN γ (100U/ml) plus 2.5ug/ml CMV pp65 derived peptide TPRVTGGG. After 16h, DC were irradiated (30Gy) and co-incubated with CD45RO $^-$, CD57 $^-$ naïve CD8 $^+$ T-cells at a 1:4 ratio in medium containing 5% AB serum and IL21 (10ng/ml). Fresh medium, IL7 and IL15 was added on days 3, 5 and 7 of culture,

before evaluation on day 10-12. Cells were cultured in Cellgenix DC medium. Human AB serum was used from PAA. One single batch was used throughout all experiments. IL4, IL7, IL15, IL21 were either purchased from Peprotech or Cellgenix (with identical results). GM-CSF was purchased from Gentaur. LPS (E.coli O:15) was purchased from Sigma. The HLA-B0702-restricted CMV-specific peptide TPRVTGGG was purchased from jpt. For *in vivo* experiments, CMV-specific T-cells were further purified using APC-labelled MHC-multimers (ImmuDex). MHC multimer staining was performed at room temperature, followed by isolation of MHC-multimer+ T-cells with anti-APC-beads (Miltenyi).

Example 4

Functional Assays

Flow Cytometry:

Binding of antibody fusion proteins to antigen-presenting tumour cells and/or T lymphocytes was tested by flow cytometry. For this purpose, $2.5 - 5 \times 10^5$ cells were incubated with 10 $\mu\text{g}/\text{ml}$ of scFv or 0.004 – 4 $\mu\text{g}/\text{ml}$ of titrated fusion proteins in 100 μl of a suitable buffer solution (such as PBS + bovine serum albumin, or other acceptable buffer solution) per well on a 96-well V-shaped plate at 4°C for 2 h. After washing three times with 150 μl of a suitable buffer solution, cells were incubated with FITC-conjugated anti-His₆ tag or anti-Flag Tag or anti-myc Tag antibody at RT for 30 min and washed again two times. For gating and testing for background staining, additionally two samples of each cell type were prepared, one of unstained cells and one stained with FITC-conjugated anti-His₆ tag antibody without any protein. Finally, cells were resuspended in 500 μl of a suitable buffer solution, transferred into FACS tubes, and analysed by flow cytometry.

PBMC Stimulation Assay:

Stimulatory properties of recombinant proteins were tested in a cell-based stimulation assay. Thereby, T-cell activation mediated by bispecific antibodies and "tridomain constructs" was determined by measuring PBMC stimulation in terms of the IL-2 release induced.

Measurement of stimulatory Activity of Constructs:

CD45 pos/HLA A2 myeloma cell line U266 were seeded in a flat-bottomed 96-well cell culture plate at a density of 105 cells per well in 100 μ l of culture medium. Titrated stimulatory proteins were added as indicated in 100 μ l medium per well and were preincubated for 1 h at 37°C and 5 % CO₂ to ensure sufficient binding. Unstimulated PBMC, thawed and isolated the day before, were then added at indicated density and incubated for 24 h at 37°C and 5 % CO₂. Finally, plates were centrifuged for 5 min at 450 \times g to harvest cell-free supernatants for IL-2 quantification in ELISA.

IL-2 Sandwich ELISA:

As an indicator for the stimulatory activity, T-cell activation induced by bispecific antibodies was measured in terms of the IL-2 release. Upon PBMC stimulation, concentration of secreted IL-2 in the supernatant was determined by an IL-2 sandwich ELISA.

First, a 96-well ELISA plate was coated with 400 ng/100 μ l per well of mouse anti-human IL-2 antibody overnight at 4°C, followed by saturation of nonspecific binding sites with a suitable blocking buffer for 2 h at RT. In the meantime, serial 1 : 2 dilutions of an IL-2 standard were prepared in duplicate in reagent diluent starting with a maximum IL-2 concentration of 1,000 pg/ml. Then, supernatants containing IL-2 were 1 : 3 diluted in RPMI 1640 medium containing 10 % FCS and Pen-Strep (Penicillin-Streptomycine). Both diluted supernatants and standards were transferred into the ELISA plate and incubated for 2 h at RT. Following, IL-2 was detected by incubation with 17.5 ng/100 μ l per well of biotinylated goat anti-human IL-2 antibody for 2 h at RT. Finally, 100 μ l of HRP-conjugated streptavidin, 1 : 200 diluted in reagent diluent, was added per well and incubated for 20 min at RT. Each plate was developed using a TMB substrate solution. In order to achieve a background signal, at least 2 wells on each plate were incubated with reagent diluent or medium only and the detecting antibody plus TMB. Between each incubation step, the plate was washed three times with PBS containing 0.05 % Tween-20 and once with PBS only.

A seven point standard curve was created by plotting the absorbance signals of each standard sample against the IL-2 concentration. Thus, the amount of IL-2 of each supernatant could be determined by interpolation of the standard curve fitted with the nonlinear regression

equation for one phase exponential association using GraphPad Prism®.

IFN- γ ELISA (alternative of Example 4):

In 100 μ l cell culture supernatant the IFN- γ concentration was measured using the human IFN- γ ELISA Kit (Invitrogen™) after manufacturer's protocol. Briefly 50 μ L of Incubation Buffer was added to each well of a precoated 96-well plat. 50 μ L of the Standard Diluent Buffer to zero wells. 50 μ L of standards and samples to each well. 50 μ L of biotinylated Hu IFN- γ Biotin Conjugate solution into each well. Taped gently on the side of the plate to mix. Covered plate with plate cover and incubate for 1 hour and 30 minutes at room temperature. Thoroughly aspirated solution from wells and discarded the liquid. Washed wells 4 times. Added 100 μ L Streptavidin-HRP Working Solution to each well. Covered plate with the plate cover and incubated for 45 minutes at room temperature. Thoroughly aspirated solution from wells and discarded the liquid. Added 100 μ L of Stabilized Chromogen to each well. The liquid in wells turned blue. We incubated for 15-30 minutes at room temperature and in the dark. Added 100 μ L of Stop Solution to each well. Taped side of plate gently to mix. The solution in the wells changed from blue to yellow. The absorbance of each well was read with a BioRad plate reader at 450 nm.

Cytotoxicity Assay:

The HLA-A2/CD45 positive cell line U266 or myeloma cell line U266 was labelled with 10 μ M CFSE (Invitrogen Vybrant CFDA SE Cell Tracer Kit) in 350 μ l PBS for 10 min at room temperature (RT) in the dark. The labelling reaction was stopped by the addition of 5 ml fetal calf serum (FCS), followed by a 1-minute incubation at RT. After 2 washes, the CFSE-labelled target cells were resuspended in assay medium and co-incubated with Peripheral Blood Mononuclear Cells (PBMC) from a HLA-A2 negative healthy donor at a ration of 1:10 (5*10⁵ U266 and 5*10⁶ PBMCs in 2 ml) and 27 nM of antibody constructs as indicated. A sample treated with Triton was used as positive control (100% lysis) and a sample without antibody construct as negative control (0% lysis). After 24h, apoptotic cells were visualized by 7AAD stain (Biozol, 10 min at RT) and % specific Lysis of CFSE labelled U266 cells was calculated employing flow cytometry techniques.

Caspase-3 Assay (alternative of Example 4):

Staining was performed after co-incubating of the target cells with T-cells (tumor cells: T-cells ratio 2:1) with or without the specific polypeptides for 4h. Surface staining for HLA-A2 and CD45 was performed first, followed by fixation and permeabilization (Fix+Perm, BD Biosciences). Activated Caspase-3 antibody was then added for 30 min. (BD Biosciences). Cells were washed with 1xPBS +5% human serum (HS, PAA Laboratories) and analyzed on a BD-FACS Canto-II. % specific apoptosis was calculated as (% experimental value - % spontaneous release)/(100% - % spontaneous release)*100.

Alamar blue assay (alternative of Example 4):

The alamarBlue® assay (Abd Serotec) was used to measure proliferation and viability of cells after exposure to toxins. Briefly, cells were grown in 100µl cell culture medium per well (96 well plate). For analysis 10µl alamarBlue was added per well and incubated in the incubator for 30-120 minutes. The absorbance was read with a BioRad plate reader at 570nM and 600nM. For blank media only was used. The percent difference in reduction of cell proliferation between the different polypeptide groups was calculated as indicated by the manufacturer, using cells growing in culture without toxin as control.

Digoxigenin Assay (alternative of Example 4):

First peroxidise from horseradish (HRP, Sigma-Aldrich Chemie gmbH) was labelled with digoxigenin NHS-ester (Sigma-Aldrich Chemie gmbH) in a 1/3 molar ratio. Dig-HRP was cleaned up with micro Bio-Spin™ chromatography columns (BioRad and and stored at 4°C in the dark. Colo-206F cells were first incubated with indicated polypeptides at various concentrations for 90 minutes. Cells were washed with PBS and resuspended in cell culture medium with Dig-HRP and incubated for 30 minutes. Afterward cells were washed twice with PBS and resuspended in 50µl PBS. 50µL of Stabilized Chromogen (Invitrogen™) was added for 15-30 minutes at room temperature in the dark. 50 µL of Stop Solution was added and the absorbance was read with a BioRad plate reader at 450 nm.

Mice (alternative of Example 4):

The HLA.A2 transgenic, immunodeficient mice (NodScid IL-2rg -/- HLA.A2/B2m tg; Stock number 14570, The Jackson Laboratory, Bar Harbor, Maine, USA) for the in vivo experiment (Figure 12A) were maintained in our certified animal facility (ZEMM, Center for experimental molecular medicine, University hospital Würzburg) in accordance with European guidelines. Female Mice, 6-10 weeks old, were divided into five groups, six mice

per group (n=30). 5×10^6 THP-1 cells, $1,25 \times 10^5$ CMV specific CD8+ T-cells (tumour cell: T-cell ratio 40/1) and the 0.5 μ g of the polypeptides were injected intraperitoneally (i.p.) as indicated. After injection, mice were monitored by daily inspection. A second injection of 1.16×10^5 CMV-specific CD8+ T-cells/mouse was given at day 13 and injections of the polypeptides were repeated every three days a week. The animals were sacrificed when the increase in body weight was greater 80% or if they appeared moribund according to institutional guidelines.

Domain structure, affinity tags and linkers of the constructs or polypeptides used in Examples 5-9 or Figures 4-11 are shown in Figure 3. These constructs and all constructs or polypeptides used in Figures 4-30 were prepared as described in Examples 1 and 2. Cell culture and functional assays in Examples 5-9 and culture, functional assays and in vivo work as to Figures 4-30 were carried out as described in Examples 3 and 4.

Example 5

The CD45 and HLA A2 positive myeloma target cell line U266 was co-incubated with HLA A2 negative T cells (monocyte depleted PBMCs (peripheral blood mononuclear cells) from a healthy donor and varying amounts of HLA A2 and CD3 bispecific antibody constructs as indicated (Numbers 85, 82, 75 and 71). PHA-L (phytohemagglutinin, a lectin that causes unspecific stimulation of T cells; 1 μ g/ml final concentration) was used as positive control and single chain scFv constructs with specificity for HLA A2 (Number 4) or CD3 (Number 36) were investigated. IL2 (Interleukin-2) production by T cells was measured by ELISA techniques. No IL2 production was found in experimental situations without any constructs. Data obtained is depicted in Figure 4.

Example 6

The CD45 and HLA A2 positive myeloma target cell line U266 was co-incubated with HLA A2 negative T cells (monocyte depleted PBMCs) from a healthy donor and varying amounts of "tridomain constructs" added either separately (Numbers 42, 45, 55; numbers referring to constructs as depicted in Figure 3) or in combinations (42 + 45 or 42 + 55). PHA-L and single chain scFv constructs with specificity for CD45 (Numbers 46 and 17) were given as controls. IL2 production by T cells was measured by ELISA techniques. No IL production

was found in experimental situations without any constructs. Data obtained is depicted in Figure 5.

Example 7

The CD45 and HLA A2 positive myeloma target cell line U266 was co-incubated with HLA A2 negative T cells (monocyte depleted PBMCs) from a healthy donor and the HLA A2 and CD3 bispecific antibody construct alone (number 71, 27 nM) or in combination with single chain scFv constructs that block the antigenic epitopes on HLA A2 (Number 4, hundredfold excess compared to the concentration of construct 71, i.e. 2700 nM) or CD3 (Number 36, ninefold excess compared to the concentration of construct 71, i.e. 243 nM). IL2 production by T cells was measured by ELISA techniques and PHA-L is given as control. Data obtained is depicted in Figure 6.

Example 8

The CD45 and HLA A2 positive myeloma target cell line U266 was co-incubated with HLA A2 negative T cells (monocyte depleted PBMCs) from a healthy donor and the combination of constructs 42 and 45. T cell stimulatory function was blocked by single chain constructs specific for HLA A2 (number 4) or CD45 (number 46). Complementation of T cell stimulatory function was tested by assaying constructs 42 and 45 separately or the single chain scFv construct directed against CD3 (number 36). IL2 production by T cells was measured by ELISA techniques and PHA-L is given as control. Concentration of constructs was 27 nM, unless indicated otherwise. ("9x" indicates a concentration of 243 nM, "100x" a concentration of 2700 nM.) Data obtained is depicted in Figure 7.

Example 9

The CD45 and HLA A2 positive myeloma target cell line U266 was co-incubated with HLA A2 negative T cells (monocyte depleted PBMCs) from a healthy donor and the combination of constructs 42 and 55. T cell stimulatory function was blocked by single chain constructs specific for HLA A2 (number 4) or CD45 (number 46). Complementation of T cell stimulatory function was tested by assaying constructs 42 and 55 separately or the single chain scFv construct directed against CD3 (number 36). IL2 production by T cells was measured by ELISA techniques and PHA-L is given as control. Concentration of constructs

was 27 nM, unless indicated otherwise. ("9x" indicates a concentration of 243 nM, "100x" a concentration of 2700 nM.) Data obtained is depicted in Figure 8.

The results of the preceding Examples clearly demonstrate that two constructs (42+45) or (42+55) first have to bind their ligands on the surface of a single cell in order to subsequently complement T cell engaging function.

Example 10

Lysis of the CD45 and HLA A2 positive myeloma target cell line U266 by HLA A2 negative T cells (monocyte depleted PBMCS) in the presence of V_LCD3-scFvHLA A2 (27 nMol) or V_H-scFvCD45 (27 nMol) or the combination of both of these constructs (27 nMol each) was determined using flow cytometry based techniques. Percent lysis was calculated by apoptotic U266 cells divided through total U266 cells and background apoptosis was subtracted. Data obtained is depicted in Figure 9.

Example 11

As parts of the final bipartite construct, two polypeptides were designed, each composed of an antigen-binding single-chain variable fragment (scFv) and either the variable light (V_L) or variable heavy chain (V_H) domain of a T cell-activating anti-CD3 antibody (Figure 10). When these two polypeptides bind their respective antigens on the surface of a single cell, the V_L and V_H domains interact with each other to reconstitute the original anti-CD3 binding site. The thus on-target formed trispecific heterodimer engages and stimulates T cells for tumor cell destruction.

This scenario is fully validated *in vitro* when T lymphocytes are confronted with target cells that have been incubated with the two different polypeptides. As proof of principle, major histocompatibility antigen HLA-A2 and the hematopoietic lineage marker CD45 were targeted as first and second antigens, which both are expressed on U266 myeloma cells, primary cells from a patient with pro-lymphocytic leukemia of the T cell lineage (T-PLL), and THP-1 acute myeloid leukemic blasts (Figure 11). Due to the described V_L/V_H interaction, the now trispecific heterodimer potently stimulates T cells to secrete interleukin-2 (IL-2) (Figure 11a) and to lyse the labeled tumor cells at nanomolar concentration (Figure 11b), the cytotoxic efficacy being quite similar to that of a bispecific T cell-activating antibody, which was employed as a positive control (Figure 11A, left panel), Mack, 1995,

Proc Natl Acad Sci **92**, 7021-7025. When the polypeptides were added separately from each other, they did not induce T lymphocytes to lyse target cells. These results are in line with structural data indicating that both, V_H and V_L domains are required to confer sufficient affinity to the target antigen (Figure 11A, B), Colman, 1987, *Nature* **326**, 358-363; Amit, 1986, *Science* **233**, 747-753. Moreover, the results reveal that possible homodimerization of either V_H or V_L arms results in a negligible measurable biological effect.

To demonstrate that the two molecules must first bind their antigens on the surface of the target cell for V_H/V_L heterodimerization to occur, single-chain variable fragments specific for HLA-A2 and CD45 were used to block the respective epitopes on the target. As shown in Figure 11c, when present in great excess, these inhibitors prevented the two polypeptides from triggering T cells in a dose-dependent manner. Furthermore, T cells were not stimulated when the target cells were omitted (data not shown) or when target cells were probed that express CD45 only (RAJI cells, Fig. 11D) or neither target molecule (KMS-12-BM, Fig. 11D).

Example 12

For *in vivo* proof of concept, a model of allogeneic mismatch stem cell transplantation was resorted in which a patient's residual leukemic and hematopoietic cells, all HLA-A2 and CD45-positive, must be eliminated to give the allogeneic donor stem cells (HLA-A2-negative, CD45-positive) a chance to engraft and to reconstitute hematopoiesis (see Figure 2). To put the specificity of the bipartite construct to the test, immunodeficient mice expressing the human HLA-A2 transgene on virtually all nucleated cells were used, the question being whether HLA-A2-positive but CD45-negative murine tissues would suffer collateral damage. THP-1 cells were injected intraperitoneally with or without CD8 T lymphocytes from an HLA-A2-negative donor, which had been selected for specificity to cytomegalovirus (CMV) to avoid human anti-murine immune reactivity. Intraperitoneal tumors developed rapidly in mice that did not receive the polypeptides, and in mice treated either with single molecule types or with the combination of both polypeptides but without T cells. In all instances, fatal disseminated disease developed within 3 to 4 weeks (Fig. 12A). In stark contrast, all tumor-bearing mice treated with T cells and repeated injections of both polypeptides survived the end of the experiment on day 31, albeit with palpable tumors at the injection site. These results clearly show that the bipartite construct truly redirects T cells irrespective of their specificity at tumor cells that simultaneously express both target

molecules (HLA-A2 and CD45) in vivo. As an aside, a T cell recruiting bispecific antibodies against HLA-A2 would wreak havoc by redirecting T cells against all HLA-A2 positive murine tissues. Likewise, a CD45-binding bispecific antibody would have mediated lysis of all hematopoietic cells, including THP-1 leukemic blasts and T cells from the donor. In our set-up, however, injection of HLA-A2-specific polypeptide into the HLA-A2 transgenic animals caused no apparent toxicity.

To further examine possible toxicity to bystanders, we employed a highly sensitive apoptosis assay on THP-1 cells and HLA-A2-negative but CD45-positive monocytes, the latter representing the healthy bystander compartment. As depicted in Figure 12B, we observed caspase-3 activation in THP-1 cells but not in monocytes treated in the same well with the combination of the polypeptides or the bispecific positive control and donor T cells. THP-1 cells cultured with T cells and individual polypeptides were unaffected. These observations again clearly show initiation of apoptosis exclusively in the double antigen positive target population, while the HLA-A2-negative bystander cells are spared. These experiments model quite accurately the dire clinical situation of leukemia patients with a HLA-mismatched stem cell transplant. The combinatorial approach of using a distinctive HLA molecule and CD45 aims at enhancing the desired graft versus leukemia effects by retargeting the donor's T cells against leukemic blasts of both, myeloid and lymphoid origin.

Example 13

To venture into solid tumors, we targeted the combinatorial approach to epithelial cell adhesion molecule (EpCAM) and epidermal growth factor receptor (EGFR) antigens. Both antigens are over-expressed in various carcinomas and have been extensively studied in clinical phase II and III trials. The expression of EGFR is closely associated with cell proliferation, while EpCAM is present at the basolateral surface of virtually all simple epithelia and was recently found to act like a signaling protein in the *Wnt* pathway, Maetzel, 2009, *Nat Cell Biol* **11**, 162-171. As Figure 13a illustrates, the two polypeptides trigger the release of interferon- γ (IFN γ) from co-incubated donor lymphocytes and mediate apoptosis of the double-positive cancer cell line COLO-206F at nanomolar concentrations (Fig. 13a, b), but only when given in combination and not with either part alone. As a descendant of neuroepithelial tissue, the melanoma cell line FM-55 lacks EpCAM, and therefore was completely resistant to the polypeptides (Fig. 13a, b). Though the expression of EGFR and EpCAM overlaps broadly on proliferating carcinoma cells, non-proliferating epithelial cells,

e.g., of liver and pancreas solely expressing EGFR or EpCAM antigens, respectively, should be less susceptible to or protected from the two-pronged attack. Notably, hepatic and pancreatic toxicities have been dose-limiting for high-affinity monoclonal EpCAM antibodies in clinical trials (for review see, Munz, 2010, *Cancer Cell Int* **10**:44).

Example 14

The further validation of the bipartite functional complementation strategy was performed by extensive *in vitro* experiments, using a combination of different polypeptides, targeting various cell surface antigens on different human cell lines.

The HLA A2 positive human tumor cell lines FM-55 (myeloma), Colo-206F (colon cancer) and OVCAR (ovarian cancer) were co-incubated with HLA-A2 negative PBMCs from a healthy donor, polypeptide against HLA-A2 (CD3(V_L) - HLA-A2(V_H-V_L)) and with a second polypeptide targeting either CEA (CD3(V_H) - CEA(V_H-V_L)), EGFR (CD3(VH) - EGFR(VH-VL)) or Her2 (CD3(V_H) - Her2(V_H-V_L)). IL2 or IFN- γ production by lymphocytes was measured by ELISA techniques. These data demonstrate that (i) a specific combination of antigens, an antigen signature, can be expressed on carcinomas of various origin (skin, neuroepithelial, gut and ovary tissue), (ii) the antigen signature is approachable with our bipartite functional complementation strategy using a set of polypeptides specific for the antigen signature. Data obtained are depicted in Figures 14, 15 and 16.

Example 15

To demonstrate the exchangeability of the functional domain, the fragments F1 and F2 of a set of polypeptides were exchanged with each other, retaining their specific complementation ability for on target restoration of their original antibody domain to engage T cells. Therefore the set of polypeptides against the CD45 and HLA-A2 target antigen was used. The polypeptide against CD45 had CD3(V_L) as fragment F1 and the polypeptide against HLA-A2 had CD3(V_H) as fragment F2. The CD45 and HLA-A2 positive myeloma cell line U266 was co-incubated with HLA-A2 negative T cells from a healthy donor and polypeptides against CD45 (CD3(V_L) - CD45(V_H-V_L)) and HLA-A2 (CD3(V_H) – HLA-A2(V_H-V_L)) in varying amounts. T cell engagement was assessed by reactive IFN γ production, measured by ELISA techniques. No IFN γ production was found in experimental situations without any polypeptides. Data obtained is depicted in Figure 17.

Example 16

The bipartite functional complementation strategy was further tested by targeting a set of antigens, already used as targets for antibody therapy of cancer (EGFR, EpCAM and Her2) (Her2 is a target for Trastuzumab in breast cancer, EGFR is a target for Cetuximab in colorectal cancer and EpCAM is a target for Catumazumab for the treatment of neoplastic ascites). The EGFR, EpCAM and Her2 positive cells (Colo-206F, CX-1 and OVCAR) were co-incubated with PBMCs from a healthy donor and the combination of polypeptides against EGFR (CD3(V_H) - EGFR(V_H+V_L)), EpCAM (CD3(V_L) - EpCAM(V_H+V_L)) and Her2 (CD3(V_H) - Her2(V_H+V_L)). Complementation of lymphocyte stimulatory function was assessed by reactive IFN γ production, measured by ELISA techniques. No IFN γ production was found in experimental situations without any polypeptides. Data obtained is depicted in Figures 18 and 19.

Example 17

To test an antigen combination with close clinical correlation, the combination CD45 and CD138 was used to target human multiple myeloma (MM) cells. The majority of human MM cells are positive for CD45 and CD138. A T cell recruiting bispecific antibodies against CD45 would kill all hematopoietic cells of a patient and against CD138 would cause severe side effects because of its expression on various normal tissues (epithelial cells, endothelia, trophoblastic cells and glandular cells of the GI tract, The Human Protein Atlas, Version: 10.0, Atlas updated: 2012-09-12). In contrast the combination of CD45 and CD138 is found exclusively on plasma cells and MM cells and is therefore a good antigen signature for the targeted therapy approach. The CD45 and CD138 positive human multiple myeloma cell line AMO-1 was co-incubated with PBMCs from a healthy donor and the combination of polypeptides against CD45 (CD3(V_L) - CD45(V_H+V_L)) and CD138 (CD3(V_H) - CD138(V_H+V_L)). Complementation of lymphocyte stimulatory function was assessed by reactive IFN γ production, measured by ELISA techniques. No IFN γ production was found in experimental situations with single polypeptides or without any polypeptides. Data obtained is depicted in Figure 20.

Example 18

A further application of the bipartite functional complementation strategy is to target single antigens on the cell surface and to kill single antigen positive tumor cells. One major

drawback for T cell recruiting bispecific antibodies with functional antiCD3 binding sides are severe side effects caused by unspecific T-cell activation and cytokine release (Linke, R. et al. Catumaxomab: clinical development and future directions. *MAbs* 2, 129-136 (2010)). The advantage of this bipartite functional complementation strategy is the fact, antibodies that the T-cell activating antiCD3 functional domain is exclusively restored on the target cell. Without the target cell, no T-cell activating domain is present. The CD45 and CD138 positive human multiple myeloma cells AMO-1 and U266 were co-incubated with PBMCs from a healthy donor and the combination of polypeptides against a single target antigen, either CD138 (CD3(V_H) - CD138(V_H+V_L) + CD3(V_L) - CD138(V_H+V_L)) or CD45 (CD3(V_H) - CD45(V_H+V_L) + CD3(V_L) - CD45(V_H+V_L)). Complementation of lymphocyte stimulatory function was assessed by reactive IFN γ production, measured by ELISA techniques. No IFN γ production was found in experimental situations with single polypeptides or without any polypeptides. Data obtained are depicted in Figure 21 and 22. In Figure 23 the single antigen approach is illustrated, by using a set of polypeptides targeting two different epitopes (upper part) or the same epitope (lower part) on the target antigen A1.

Example 19

This is an example to demonstrate that the functional complementation strategy can be further elaborated for targeted payload delivery and that different effector ways are possible to kill a target cell. By complementing the F1 and F2 fragments of a set of bound polypeptides on target, the newly formed antibody binding site can bind any molecule it is specific for. In order to direct a HIS-tagged payload precisely to a target cell, the V_H and V_L fragments of an anti-HIS(hexa-histidine)-antibody were used. After simultaneous binding of polypeptide 1 (antiHis(V_L)-CD45(V_H-V_L) and polypeptide 2 (antiHis(V_H)-HLA-A2(V_H-V_L) to their specific target antigens CD45 and HLA-A2, a hexa-histidine binding site is complemented on target that binds histidine labeled payloads with high affinity. The payload be a HIS-tagged toxin as given in this example here. The CD45 and HLA-A2 positive cells THP-1 were co-incubated with a histidine(His)-tagged Clostridium perfringens Iota toxin component Ia (Figure 24) or a histidine(His)-tagged Shiga toxin subunit A (Figures 25, 26) in combination with polypeptides against CD45 (antiHis(V_L)-CD45(V_H-V_L)) and HLA-A2 (antiHis(V_H)-HLA-A2(V_H-V_L)). Complementation of his-tagged toxin binding and subsequent target cell killing was assessed by measuring cell viability using an

alamarBlue® assay. At the highest concentration of polypeptides used (80nM), a clear difference in target cell killing, measured as reduction in cell viability, was found in experimental situations with a combination of both polypeptides compared to single polypeptides.

Example 20

To further demonstrate the versatility, flexibility and the exchangeability of the bipartite functional complementation strategy, the V_H and V_L fragments of an anti-Digoxigenin antibody were used to identify and mark double antigen positive cells with Digoxigenin-labeled HRP (horse raddish peroxidase). EGFR and EpCAM positive Colo-206F cells were co-incubated with polypeptides against EGFR (antiDig(V_H) - EGFR(V_H+V_L)) and EpCAM (antiDig(V_L) - EpCAM(V_H+V_L)). On target complementation of the functional domain anti-Digoxigenin, indicated by Digoxigenin-HRP labelling of Colo-206F cells, was assessed by measuring the peroxidase activity, using a standard ELISA Kit (Invitrogen™). A clear difference in Dig-HRP labeled target cells was found in experimental situation with a combination of both polypeptides compared to single polypeptides. Data obtained are depicted in Figure 27.

Example 21

Using the human leucocytic antigens (HLA) as one arm for dual antigen restricted bipartite functional complementation, this haplotype strategy was further validated by exchanging the functional domains of the polypeptides with V_H and V_L fragments of an anti-HLA-Cw6 antibody. HLA-Cw6 positive primary patient PBMCs were co-incubated with HLA-Cw6 negative PBMCs from a healthy donor, polypeptide against CD45 (CD3(V_L) – CD45(V_H-V_L)) and HLA-Cw6 (CD3(V_H) – HLA-Cw6(V_H-V_L)). IFN γ production by lymphocytes was measured by ELISA techniques. These data demonstrate that hematopoietic cells of patients with other haplotypes than HLA-A2 can be targeted simply by exchanging one targeting domain (anti HLA-A2, Figure 5, 7-9, 11-12) by another (anti HLA-Cw6). Data obtained are depicted in Figures 28.

Example 22

The dual antigen-induced bipartite functional complementation strategy was further validated in an *in vitro* patient assay, using freshly isolated primary patient cancer cells and antigen targets already used for cancer therapy in clinic or clinical trials (EGFR, EpCAM,

CEA and Her2). Malignant cells of a 48 years old male patient with metastatic pancreatic cancer were co-incubated with the patients own peripheral blood lymphocytes and the combination of polypeptides against EGFR (CD3(V_H) - EGFR(V_H+V_L)), EpCAM (CD3(V_L) - EpCAM(V_H+V_L)), Her2 (CD3(V_H) - Her2(V_H+V_L)), CEA (CD3(V_H) - CEA(V_H-V_L)) and HLA-A2 (CD3(V_L) - HLA-A2(V_H-V_L)). Complementation of lymphocyte stimulatory function was assessed by reactive IFN γ production, measured by ELISA techniques. No IFN γ production was found in experimental situations without any polypeptides. These data demonstrate the potential of this strategy to use patients own immune cells to target and kill his malignant transformed cells. Data obtained are depicted in Figures 29.

Example 23

A highly enriched CD3/CD8 positive CMV restricted T-cell population was used to show that any T cell, irrespective of its specificity, can serve as effector cell and kill double antigen positive tumor cells by this complementation strategy. The CD45 and HLA-A2 positive U266 and THP-1 cells were co-incubated with cytomegalievirus (CMV) specific T-cells from a HLA-A2 negative healthy donor and polypeptides against CD45 (CD3(V_H) - CD45(V_H-V_L)) and HLA-A2 (CD3(V_L) - HLA-A2(V_H-V_L)) in varying amounts. The bispecific tandem scFv (CD3(V_H-V_L) x HLA-A2(V_H-V_L))-antibody was used as a positive control. T cell engagement was assessed by reactive IFN γ production, measured by ELISA techniques. No IFN γ production was found in experimental situations with single polypeptides or without any polypeptides. Data obtained are depicted in Figure 30. Cells from the same frozen aliquot batch, CMV specific T-cells and THP-1 cells, were used for the *in vivo* murine model (Figure 12A).

Example 24

This illustration depicts the potential to target allergen/ autoimmune specific B-cell clones with the bipartite functional complementation strategy. By using a synthetic allergen as targeting moiety, the allergen linked polypeptide will bind specifically to its clonotypic B-cell receptor expressed on the surface of the allergen specific B-cell clone. The second arm of the bipartite strategy will use a B-cell specific polypeptide (CD19, CD20, CD38, CD138), restricting the followed complementation of the effector domain with subsequent target cell killing to the allergen specific B-cell clone. The ultimate goal of this strategy is to eliminate the B cell clone that causes an allergic or autoimmune disease (upper part of Figure 31)

2013208895 26 Sep 2014

whilst sparing B cells with other specificities or cells other than B cells (eg. mast cells or basophilic cells) which bind the antibody responsible for the disease via Fc-receptors (lower part of Figure 31).

The features of the present invention disclosed in the specification, the claims, and/or in the accompanying drawings may, both separately and in any combination thereof, be material for realizing the invention in various forms thereof.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

Claims

1. A set of polypeptides comprising:
a first polypeptide P1 comprising
 - (i) a targeting moiety T1,
wherein said targeting moiety T1 specifically binds to an antigen A1, and
 - (ii) a fragment F1 of a functional domain F,
wherein neither said fragment F1 by itself nor said polypeptide P1 by itself is functional with respect to the function of said domain F,
and
a second polypeptide P2 comprising
 - (i) a targeting moiety T2,
wherein said targeting moiety T2 specifically binds to an antigen A2, and
 - (ii) a fragment F2 of said functional domain F,
wherein neither said fragment F2 by itself nor said polypeptide P2 by itself is functional with respect to the function of said domain F,
wherein said antigen A1 is different from said antigen A2,
wherein said polypeptide P1 and said polypeptide P2 are not associated with each other in the absence of a cell that has both antigens A1 and A2 at its cell surface,
wherein, upon dimerization of said fragment F1 of said polypeptide P1 with said fragment F2 of said polypeptide P2, the resulting dimer is functional with respect to the function of said domain F and
wherein said fragment F1 comprises a V_L domain of an antibody and said fragment F2 comprises a V_H domain of the same antibody; or wherein said fragment F1 comprises a V_H domain of an antibody and said fragment F2 comprises a V_L domain of the same antibody.
2. The set of polypeptides according to claim 1, wherein a cell carrying both antigens A1 and A2 at its cell surface induces dimerization of the fragment F1 of said polypeptide P1 with the fragment F2 of said polypeptide P2, whereas a cell which does not carry both antigens A1 and A2 at its cell surface does not induce dimerization of the fragment F1 of said polypeptide P1 with the fragment F2 of said polypeptide P2.

3. The set of polypeptides according to claim 1 or 2, wherein said polypeptides P1 and P2 have, in the absence of said substrate or cell, with each other a dissociation constant K_D in the range of 10^{-8} M to 10^{-2} M, in the range of 10^{-7} M to 10^{-3} M or in the range of 10^{-6} M to 10^{-3} M; and /or said polypeptides P1 and P2 have, in the presence of said substrate or cell, with each other a dissociation constant K_D below 10^{-6} M, below 10^{-7} M below 10^{-8} M or below 10^{-9} M.
4. The set of polypeptides according to any one of claims 1 to 3, wherein said antigen A1 and/or said antigen A2 is an antigen expressed on the surface of cells of a tumour or on the surface of progenitor/precursor cells of a tumour.
5. The set of polypeptides according to any one of claims 1 to 4, wherein the combination of antigen A1 and antigen A2 is only found on cancerous cells, and not on cells that are not cancerous.
6. The set of polypeptides according to claim 5, wherein the combination of antigen A1 and antigen A2 is specific for cancerous cells of a certain type of cancer.
7. The set of polypeptides according to any one of claims 1 to 6, wherein said antigen A1 is an MHC antigen being an allelic variant selected from the group consisting of: HLA-A2, HLA-Cw6, HLA-A1, HLA-A3, HLA-A25, HLA-B7, HLA-B8, HLA-B35, HLA-B44, HLA-Cw3, HLA-Cw4, and HLA-Cw7; and/or said antigen A2 is an antigen that is specific for a certain cell type or cell lineage selected from the group consisting of: CD45; CD34; CD33; CD138; CD15; CD1a; CD2; CD3; CD4; CD5; CD8; CD20; CD23; CD31; CD43; CD56; CD57; CD68; CD79a; CD146; surfactant proteins; synaptophysin; CD56; CD57; nicotinic acetylcholine receptor; muscle-specific kinase MUSK; voltage-gated calcium channel (P/Q-type); voltage-gated potassium channel (VGKC); N-methyl-D-aspartate receptor (NMDA); TSH; amphiphysin; HepPar-1; ganglioside GQ1B, GD3 or GM1; and glycophorin-A.
8. The set of polypeptides according to any one of claims 1 to 7, wherein any of said antigens A1 and A2 is selected from the group consisting of: HLA-A2; HLA-Cw6; EpCAM; CD20; CD33; CD38; CD45; Her2; EGFR; CD138; CEA; CD19; PSMA; E-cadherin; Ca-125; Her-2/neu; gross cystic disease fluid

protein; BCA-225; CA 19-9; CD117; CD30; Epithelial antigen BER-EP4, Epithelial membrane antigen and Epithelial Related Antigen MOC-31; Epidermal growth factor receptor HER1; Platelet derived growth factor receptor PDGFR alpha; Melanoma associated marker/Mart 1/Melan-A; CD133; TAG 72; aquaporin-2 and a clonotypic antibody on the surface of a B cell.

9. The set of polypeptides according to any one of claims 1 to 8, wherein
 - (i) one of said antigens A1 and A2 is EpCAM and the other one is EGFR, HER2/neu, CD10, VEGF-R or MDR;
 - (ii) one of said antigens A1 and A2 is MCSP and the other one is melanoferrin or EpCAM;
 - (iii) one of said antigens A1 and A2 is CA125 and the other one CD227
 - (iv) one of said antigens A1 and A2 is CD56 and the other one is CD140b or GD3 ganglioside;
 - (v) one of said antigens A1 and A2 is EGFR and the other one is HER2;
 - (vi) one of said antigens A1 and A2 is PSMA and the other one is HER2;
 - (vii) one of said antigens A1 and A2 is Sialyl Lewis and the other one is EGFR;
 - (viii) one of said antigens A1 and A2 is CD44 and the other one is ESA, CD24, CD133, MDR or CD117;
 - (ix) one of said antigens A1 and A2 is CD34 and the other one is CD19, CD79a, CD2, CD7, HLA-DR, CD13, CD117, CD33 or CD15;
 - (x) one of said antigens A1 and A2 is CD33 and the other one is CD19, CD79a, CD2, CD7, HLA-DR, CD13, CD117 or CD15;
 - (xi) one of said antigens A1 and A2 is MUC1 and the other one is CD10, CEA or CD57;
 - (xii) one of said antigens A1 and A2 is CD38 and the other one is CD138;
 - (xiii) one of said antigens A1 and A2 is CD 24 and the other one is CD29 or CD49f;
 - (xiv) one of said antigens A1 and A2 is carbonic anhydrase IX and the other one is aquaporin-2;
 - (xv) one of said antigens A1 and A2 is HLA-A2 and the other one is EpCAM;
 - (xvi) one of said antigens A1 and A2 is HLA-A2 and the other one is CD45;
 - (xvii) one of said antigens A1 and A2 is HLA-A2 and the other one is EGFR;
 - (xviii) one of said antigens A1 and A2 is HLA-A2 and the other one is Her2;

- (xix) one of said antigens A1 and A2 is HLA-A2 and the other one is CEA;
- (xx) one of said antigens A1 and A2 is EpCAM and the other one is CEA;
- (xxi) one of said antigens A1 and A2 is CD45 and the other one is CD138;
- (xxii) one of said antigens A1 and A2 is EGFR and the other one is CEA;
- (xxiii) one of said antigens A1 and A2 is Her2 and the other one is CEA; or
- (xxiv) one of said antigens A1 and A2 is CD19 and the other one is a clonotypic antibody on the surface of a B cell.

10. The set of polypeptides according to any one of claims 1 to 9, wherein said targeting moiety T1 and/or T2 comprises an immunoglobulin module; or wherein said targeting moiety T1 and/or T2 comprises an aptamer or a natural ligand of said antigen A1 or antigen A2, respectively.

11. The set of polypeptides according to claim 10, wherein said targeting moiety T1 comprises an immunoglobulin module I1 comprising a V_L domain linked to a V_H domain or comprising a variable domain V_{HH} of a llama antibody, camel antibody or shark antibody; and/or said targeting moiety T2 comprises an immunoglobulin module I2 comprising a V_L domain linked to a V_H domain or comprising a variable domain V_{HH} of a llama antibody, camel antibody or shark antibody.

12. The set of polypeptides according to claim 11, wherein said immunoglobulin module I1 comprises a scFv (single-chain variant fragment), a Fab or a $F(ab')_2$ of an antibody or a complete antibody; and/or said immunoglobulin module I2 comprises a scFv (single-chain variant fragment), a Fab or a $F(ab')_2$ of an antibody or a complete antibody.

13. The set of polypeptides according to any one of claims 1 to 3 and 6 to 12, wherein any one of said targeting moiety T1 and T2 comprises an allergen or substrate which binds to a clonotypic antibody on the surface of a B cell.

14. The set of polypeptides according to any one of claims 1 to 13, wherein said functional domain F is or comprises an immunoglobulin module.

15. The set of polypeptides according to claim 14, wherein said functional domain F is a Fv (variant fragment) or a scFv (single-chain variant fragment) of an antibody.
16. The set of polypeptides according to any one of claims 1 to 15, wherein said fragment F1 comprises a V_L domain of an anti-CD3, anti-His or anti-DIG antibody and said fragment F2 comprises a V_H domain of the same antibody, or wherein said fragment F1 comprises a V_H domain of an anti-CD3 anti-His or anti-DIG antibody and said fragment F2 comprises a V_L domain of the same antibody.
17. The set of polypeptides according to any one of claims 14 to 16, wherein said immunoglobulin module comprises a V domain selected from the group consisting of:
 - (i) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NO: 2 and/or a V_H domain comprising SEQ ID NO: 1;
 - (ii) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NO: 4 and/or a V_H domain comprising SEQ ID NO: 3;
 - (iii) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NO: 6 and/or a V_H domain comprising SEQ ID NO: 5;
 - (iv) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NO: 8 and/or a V_H domain comprising SEQ ID NO: 7;
 - (v) a V domain of an anti-CD3 antibody comprising a V_L domain comprising SEQ ID NO: 10 and/or a V_H domain comprising SEQ ID NO: 9; and
 - (vi) a V domain of an anti-His antibody comprising a V_L domain comprising SEQ ID NO: 12 and/or a V_H domain comprising SEQ ID NO: 11;
 - (vii) a V domain of an anti-DIG antibody comprising a V_L domain comprising SEQ ID NO: 14 and/or a V_H domain comprising SEQ ID NO: 30.
18. The set of polypeptides according to any one of claims 1 to 17, wherein any of the polypeptides P1 and P2 is or comprises an amino acid sequence selected from the group consisting of SEQ ID NOS: 114-129 and 197.
19. The set of polypeptides according to any one of claims 1 to 18 for use in the treatment of a patient who is suffering from cancer and/or a tumour or for use in diagnosis in a patient who is suffering from cancer and/or a tumour.

20. A nucleic acid molecule or a set of nucleic acid molecules encoding the set of polypeptides or one of the polypeptides of the set of polypeptides according to any one of claims 1 to 18.
21. The nucleic acid molecule or set of nucleic acid molecules according to claim 20 comprising a nucleotide sequence as depicted in any one of SEQ ID NOS: 135-150 and 196.
22. A pharmaceutical composition comprising either the set of polypeptides according to any of claims 1 to 18 or the nucleic acid molecule/set of nucleic acid molecules according to claim 20 or 21, said pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
23. A kit comprising the set of polypeptides according to any of claims 1-18 or the nucleic acid molecule or the set of nucleic acid molecules according to claim 20 or 21.



Figure 1A**Figure 1B**







Figure 1C**Figure 1D**

Figure 2



4/30

Figure 3A**85/71 taFvCD3-HLA-A2-****75/82 taFvHLA-A2-CD3-**



■ pelB Leader — Linker aa □ His tag □ FLAG (or myc) tag

42 VLCD3-scFvHLA-A2-**45 VhCD3-scFvCD45(VL-VH)-****55 VhCD3-scFvCD45(VH-VL)-****80/78 VhCD3-scFvHLA-A2-**



■ pelB Leader — Linker aa □ His tag □ FLAG (or myc) tag

Figure 3B**36 scFvCD3-FlagHis****4 scFvHLA-A2-mycHis****17 FlagHis-scFvCD45(V_L-V_H)****46 scFvCD45(V_H-V_L)-FlagHis****42 V_LCD3-scFvHLA-A2-mycHis****45 V_HCD3-scFvCD45(V_L-V_H)- FlagHis****55 V_HCD3-scFvCD45(V_H-V_L)- FlagHis**

6/30

Figure 4**Figure 5**

7/30

Figure 6**Figure 7**

8/30




Figure 8**Figure 9**

Figure 10

10/30



Figure 11

Figure 11

12/30

Figure 12A


A

Figure 12B





Figure 13


Figure 14


Figure 15


Figure 16




Figure 17


Figure 18

20/30

Figure 19

21/30

Figure 20



22/30




Figure 21**Figure 22**

Figure 23

24/30



Figure 24**Figure 25**



Figure 26

Figure 27

27/30

Figure 28





Figure 29




Figure 30

Figure 31

SEQUENCE eol f-seql . txt

<110> Julius-Maximilians-Universität Würzburg
<120> Dual antigen-induced bipartite functional complementation
<130> W1010 PCT S3
<150> EP 12 15 1125.7
<151> 2012-01-13
<160> 198
<170> PatentIn version 3.5
<210> 1
<211> 119
<212> PRT
<213> VH anti-CD3
<400> 1

Asp Val Glu Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Arg Tyr
20 25 30

Thr Met His Trp Val Arg Glu Asp Pro Gly Glu Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Thr Thr Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Glu Gly
100 105 110

Thr Thr Val Thr Val Ser Ser
115

<210> 2
<211> 111
<212> PRT
<213> VL anti -CD3

<400> 2

Asp Ile Val Leu Thr Glu Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15

Gl u Arg Al a Thr 20 Leu Ser Cys Arg 25 Al a Ser Gln Ser Val Ser Tyr Met 30

eof f-seql . txt

Asn Trp Tyr Glu Glu Lys Pro Gly Lys Ala Pro Lys Arg Trp Ile Tyr
35 40 45

Asp Thr Ser Lys Val Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Asn Ser Leu Glu Ala Glu
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Glu Glu Trp Ser Ser Asn Pro Leu Thr
85 90 95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Gly Ser Ala Ala Ala
100 105 110

<210> 3

<211> 119

<212> PRT

<213> VH anti -CD3

<400> 3

Asp Ile Lys Leu Glu Glu Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr
20 25 30

Thr Met His Trp Val Lys Glu Arg Pro Gly Glu Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Glu Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Glu Gly
100 105 110

Thr Thr Leu Thr Val Ser Ser
115

<210> 4

<211> 106

<212> PRT

<213> VL anti -CD3

<400> 4

Asp Ile Glu Leu Thr Glu Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
Page 2

eol f-seql . txt

1

5

10

15

Gl u Lys Val Thr Met Thr Cys Arg Al a Ser Ser Ser Val Ser Tyr Met
 20 25 30

Asn Trp Tyr Gl n Gl n Lys Ser Gl y Thr Ser Pro Lys Arg Trp Ile Tyr
 35 40 45

Asp Thr Ser Lys Val Al a Ser Gl y Val Pro Tyr Arg Phe Ser Gl y Ser
 50 55 60

Gl y Ser Gl y Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Gl u Al a Gl u
 65 70 75 80

Asp Al a Al a Thr Tyr Tyr Cys Gl n Gl n Trp Ser Ser Asn Pro Leu Thr
 85 90 95

Phe Gl y Al a Gl y Thr Lys Leu Gl u Leu Lys
 100 105

<210> 5

<211> 122

<212> PRT

<213> huMAb anti -CD variant 9 VH

<400> 5

Gl u Val Gl n Leu Val Gl u Ser Gl y Gl y Gl y Leu Val Gl n Pro Gl y Gl y
 1 5 10 15

Ser Leu Arg Leu Ser Cys Al a Al a Ser Gl y Tyr Ser Phe Thr Gl y Tyr
 20 25 30

Thr Met Asn Trp Val Arg Gl n Al a Pro Gl y Lys Gl y Leu Gl u Trp Val
 35 40 45

Al a Leu Ile Asn Pro Tyr Lys Gl y Val Ser Thr Tyr Asn Gl n Lys Phe
 50 55 60

Lys Asp Arg Phe Thr Ile Ser Val Asp Lys Ser Lys Asn Thr Al a Tyr
 65 70 75 80

Leu Gl n Met Asn Ser Leu Arg Al a Gl u Asp Thr Al a Val Tyr Tyr Cys
 85 90 95

Al a Arg Ser Gl y Tyr Tyr Gl y Asp Ser Asp Trp Tyr Phe Asp Val Trp
 100 105 110

Gl y Gl n Gl y Thr Leu Val Thr Val Ser Ser
 115 120

<210> 6

<211> 113

eol f-seql . txt

<212> PRT

<213> huMAb anti -CD variant 1 VL

<400> 6

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Tyr Thr Ser Arg Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Gl u Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Gly Asn Thr Leu Pro Trp
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Ile Lys Arg
100 105 110

Thr

<210> 7

<211> 119

<212> PRT

<213> Anti -CD3 VH (L2K)

<400> 7

Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Arg Tyr
20 25 30

Thr Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr Trp Gly Glu Gly
 100 105 110

Thr Thr Leu Thr Val Ser Ser
 115

<210> 8
 <211> 106
 <212> PRT
 <213> Anti -CD3 VL (L2K)

<400> 8

Asp Ile Glu Leu Thr Glu Ser Pro Ala Ile Met Ser Ala Ser Pro Gly
 1 5 10 15

Glu Lys Val Thr Met Thr Cys Arg Ala Ser Ser Ser Val Ser Tyr Met
 20 25 30

Asn Trp Tyr Glu Glu Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr
 35 40 45

Asp Thr Ser Lys Val Ala Ser Gly Val Pro Tyr Arg Phe Ser Gly Ser
 50 55 60

Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu
 65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Glu Glu Trp Ser Ser Asn Pro Leu Thr
 85 90 95

Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
 100 105

<210> 9
 <211> 119
 <212> PRT
 <213> Anti -CD3 VH (145. 2C11)

<400> 9

Glu Val Glu Leu Val Glu Ser Gly Gly Leu Val Glu Pro Gly Lys
 1 5 10 15

Ser Leu Lys Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Gly Tyr
 20 25 30

Gly Met His Trp Val Arg Glu Ala Pro Gly Arg Gly Leu Glu Ser Val
 35 40 45

Ala Tyr Ile Thr Ser Ser Ser Ile Asn Ile Lys Tyr Ala Asp Ala Val
 50 55 60

Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Leu Leu Phe
 65 70 75 80

eol f-seql . txt

Leu Glu Met Asn Ile Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys
85 90 95

Ala Arg Phe Asp Trp Asp Lys Asn Tyr Trp Gly Glu Gly Thr Met Val
100 105 110

Thr Val Ser Ser Ala Lys Thr
115

<210> 10
<211> 110
<212> PRT
<213> Anti -CD3 VL (145. 2C11)

<400> 10

Asp Ile Glu Met Thr Glu Ser Pro Ser Ser Leu Pro Ala Ser Leu Gly
1 5 10 15

Asp Arg Val Thr Ile Asn Cys Glu Ala Ser Glu Asp Ile Ser Asn Tyr
20 25 30

Leu Asn Trp Tyr Glu Glu Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Tyr Thr Asn Lys Leu Ala Asp Glu Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Arg Asp Ser Ser Phe Thr Ile Ser Ser Leu Glu Ser
65 70 75 80

Glu Asp Ile Gly Ser Tyr Tyr Cys Glu Glu Tyr Tyr Asn Tyr Pro Trp
85 90 95

Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp
100 105 110

<210> 11
<211> 114
<212> PRT
<213> Anti -HIS VH

<400> 11

Glu Val Glu Leu Glu Glu Ser Gly Pro Glu Asp Val Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Tyr Met Asn Trp Val Lys Glu Ser Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

eof f-seql.txt

Gly Asp Ile Asn Pro Asn Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ser Val Tyr Tyr Cys
85 90 95

Glu Ser Gln Ser Gly Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Val
100 105 110

Ser Ala

<210> 12

<211> 116

<212> PRT

<213> Anti -HIS VL

<400> 12

Asp Tyr Lys Asp Ile Leu Met Thr Gln Thr Pro Ser Ser Leu Pro Val
1 5 10 15

Ser Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Ile
20 25 30

Val His Ser Asn Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro
35 40 45

Gly Gln Ser Pro Lys Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser
50 55 60

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Thr Asp Phe Thr
65 70 75 80

Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys
85 90 95

Phe Gln Gly Ser His Val Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu
100 105 110

Gl u Ile Lys Arg
115

<210> 13

<211> 128

<212> PRT

<213> Anti -DIG VH

<400> 13

Gl u Val Gln Leu Val Glu Ser Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15

eol f-seql . txt

Ser Leu Lys Leu Ser Cys Al a Val Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30

Al a Met Ser Trp Ile Arg Gln Thr Pro Glu Asn Arg Leu Glu Trp Val
35 40 45

Al a Ser Ile Asn Ile Gly Al a Thr Tyr Al a Tyr Tyr Pro Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Al a Lys Asn Thr Leu Phe
65 70 75 80

Leu Gln Met Ser Ser Leu Gly Ser Glu Asp Thr Al a Met Tyr Tyr Cys
85 90 95

Al a Arg Pro Gly Ser Pro Tyr Glu Tyr Asp Lys Al a Tyr Tyr Ser Met
100 105 110

Al a Tyr Trp Gly Pro Gly Thr Ser Val Thr Val Ser Ser Al a Lys Thr
115 120 125

<210> 14
<211> 118
<212> PRT
<213> Anti -DIG VL

<400> 14

Asp Val Gln Met Thr Gln Ser Thr Ser Ser Leu Ser Al a Ser Leu Gly
1 5 10 15

Asp Arg Val Thr Ile Ser Cys Arg Al a Ser Gln Asp Ile Lys Asn Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gly Thr Val Lys Leu Leu Ile
35 40 45

Tyr Tyr Ser Ser Thr Leu Leu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Arg Gly Ser Gly Thr Asp Phe Ser Leu Thr Ile Thr Asn Leu Glu Arg
65 70 75 80

Glu Asp Ile Al a Thr Tyr Phe Cys Gln Gln Ser Ile Thr Leu Pro Pro
85 90 95

Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg Al a Asp Al a Al a
100 105 110

Pro Thr Val Ser Ile Phe
115

eol f-seql . txt

<210> 15
<211> 10
<212> PRT
<213> Anti -CD3 VH CDR1 (WT)

<400> 15

Gly Tyr Thr Phe Thr Arg Tyr Thr Met His
1 5 10

<210> 16
<211> 17
<212> PRT
<213> Anti -CD3 VH CDR2 (VH5)

<400> 16

Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly

<210> 17
<211> 10
<212> PRT
<213> Anti -CD3 VH CDR3 (WT)

<400> 17

Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr
1 5 10

<210> 18
<211> 10
<212> PRT
<213> Anti -CD3 VK CDR1 (WT)

<400> 18

Arg Ala Ser Gln Ser Val Ser Tyr Met Asn
1 5 10

<210> 19
<211> 7
<212> PRT
<213> Anti -CD3 VK CDR2 (WT)

<400> 19

Asp Thr Ser Lys Val Ala Ser
1 5

<210> 20
<211> 9
<212> PRT
<213> Anti -CD3 VK CDR3 (WT)

<400> 20

Gln Gln Trp Ser Ser Asn Pro Leu Thr

eol f-seql . txt

1 5

<210> 21
<211> 10
<212> PRT
<213> Anti -CD3 VH CDR1 (WT)

<400> 21

Gly Tyr Thr Phe Thr Arg Tyr Thr Met His
1 5 10

<210> 22
<211> 17
<212> PRT
<213> Anti -CD3 VH CDR2 (WT)

<400> 22

Tyr Ile Asn Pro Ser Arg Gly Tyr Thr Asn Tyr Asn Gln Lys Phe Lys
1 5 10 15

Asp

<210> 23
<211> 10
<212> PRT
<213> Anti -CD3 VH CDR3 (WT)

<400> 23

Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr
1 5 10

<210> 24
<211> 10
<212> PRT
<213> Anti -CD3 VK CDR1 (WT)

<400> 24

Arg Ala Ser Ser Ser Val Ser Tyr Met Asn
1 5 10

<210> 25
<211> 7
<212> PRT
<213> Anti -CD3 VK CDR2 (WT)

<400> 25

Asp Thr Ser Lys Val Ala Ser
1 5

<210> 26
<211> 9
<212> PRT
<213> Anti -CD3 VK CDR3 (WT)

<400> 26

eol f-seql . txt

Gl n Gl n Trp Ser Ser Asn Pro Leu Thr
1 5

<210> 27
<211> 10
<212> PRT
<213> Anti -CD3 VH CDR1 (UCHT-1)

<400> 27

Gl y Tyr Ser Phe Thr Gl y Tyr Thr Met Asn
1 5 10

<210> 28
<211> 17
<212> PRT
<213> Anti -CD3 VH CDR2 (UCHT-1)

<400> 28

Leu Ile Asn Pro Tyr Lys Gl y Val Ser Thr Tyr Asn Gl n Lys Phe Lys
1 5 10 15

Asp

<210> 29
<211> 11
<212> PRT
<213> Anti -CD3 VH CDR3 (UCHT-1)

<400> 29

Tyr Tyr Gl y Asp Ser Asp Trp Tyr Phe Asp Val
1 5 10

<210> 30
<211> 11
<212> PRT
<213> Anti -CD3 VL CDR1 (UCHT-1)

<400> 30

Arg Ala Ser Gl n Asp Ile Arg Asn Tyr Leu Asn
1 5 10

<210> 31
<211> 7
<212> PRT
<213> Anti -CD3 VL CDR2 (UCHT-1)

<400> 31

Tyr Thr Ser Arg Leu Gl u Ser
1 5

<210> 32
<211> 9
<212> PRT
<213> Anti -CD3 VL CDR3 (UCHT-1)

eol f-seql . txt

<400> 32

Gl n Gl n Gl y Asn Thr Leu Pro Trp Thr
1 5

<210> 33

<211> 8

<212> PRT

<213> Ani t-CD3 VH CDR 1 (L2K)

<400> 33

Gl y Tyr Thr Phe Thr Arg Tyr Thr
1 5

<210> 34

<211> 8

<212> PRT

<213> Anti -CD3 VH CDR 2 (L2K)

<400> 34

Ile Asn Pro Ser Arg Gl y Tyr Thr
1 5

<210> 35

<211> 12

<212> PRT

<213> Anti -CD3 VH CDR 3 (L2K)

<400> 35

Al a Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr
1 5 10

<210> 36

<211> 5

<212> PRT

<213> Anti -CD3 VL CDR 1 (L2K)

<400> 36

Ser Ser Val Ser Tyr
1 5

<210> 37

<211> 9

<212> PRT

<213> Anti -CD3 VL CDR 3 (L2K)

<400> 37

Gl n Gl n Trp Ser Ser Asn Pro Leu Thr
1 5

<210> 38

<211> 8

<212> PRT

<213> Anti -CD3 VH CDR 1 (145-2C11)

<400> 38

eol f-seql . txt

Gly Phe Thr Phe Ser Gly Tyr Gly
1 5

<210> 39
<211> 8
<212> PRT
<213> Anti -CD3 VH CDR 2 (145-2C11)

Ile Thr Ser Ser Ser Ile Asn Ile
1 5

<210> 40
<211> 9
<212> PRT
<213> Anti -CD3 VH CDR 3 (145-2C11)

<400> 40

Ala Arg Phe Asp Trp Asp Lys Asn Tyr
1 5

<210> 41
<211> 6
<212> PRT
<213> Anti -CD3 VL CDR 1 (145-2C11)

<400> 41

Gln Asp Ile Ser Asn Tyr
1 5

<210> 42
<211> 9
<212> PRT
<213> Anti -CD3 VL CDR 3 (145-2C11)

<400> 42

Gln Gln Tyr Tyr Asn Tyr Pro Trp Thr
1 5

<210> 43
<211> 8
<212> PRT
<213> Anti -HIS VH CDR1

<400> 43

Gly Tyr Thr Phe Thr Asp Tyr Tyr
1 5

<210> 44
<211> 8
<212> PRT
<213> Anti -HIS VH CDR2

<400> 44

Ile Asn Pro Asn Asn Gly Gly Thr

eol f-seql . txt

1 5

<210> 45
<211> 7
<212> PRT
<213> Anti -HIS VH CDR3

<400> 45

Gl u Ser Gl n Ser Gl y Al a Tyr
1 5

<210> 46
<211> 11
<212> PRT
<213> Anti -HIS VL CDR1

<400> 46

Gl n Ser Ile Val His Ser Asn Gl y Asn Thr Tyr
1 5 10

<210> 47
<211> 9
<212> PRT
<213> Anti -HIS VL CDR3

<400> 47

Phe Gl n Gl y Ser His Val Pro Phe Thr
1 5

<210> 48
<211> 8
<212> PRT
<213> Anti -DIG VH CDR1

<400> 48

Gl y Phe Thr Phe Ser Asp Tyr Al a
1 5

<210> 49
<211> 8
<212> PRT
<213> Anti -DIG VH CDR2

<400> 49

Ile Asn Ile Gl y Al a Thr Tyr Al a
1 5

<210> 50
<211> 6
<212> PRT
<213> Anti -DIG VL CDR1

<400> 50

Gl n Asp Ile Lys Asn Tyr
1 5

eol f-seql . txt

<210> 51
<211> 123
<212> PRT
<213> Anti -HLA-A2 VH

<400> 51

Gl n Val Gl n Leu Val Gl n Ser Gl y Gl y Gl y Val Val Gl n Pro Gl y Gl y
1 5 10 15

Ser Leu Arg Val Ser Cys Al a Al a Ser Gl y Val Thr Leu Ser Asp Tyr
20 25 30

Gl y Met His Trp Val Arg Gl n Al a Pro Gl y Lys Gl y Leu Gl u Trp Met
35 40 45

Al a Phe Ile Arg Asn Asp Gl y Ser Asp Lys Tyr Tyr Al a Asp Ser Val
50 55 60

Lys Gl y Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Val Ser
65 70 75 80

Leu Gl n Met Ser Ser Leu Arg Al a Gl u Asp Thr Al a Val Tyr Tyr Cys
85 90 95

Al a Lys Asn Gl y Gl u Ser Gl y Pro Leu Asp Tyr Trp Tyr Phe Asp Leu
100 105 110

Trp Gl y Arg Gl y Thr Leu Val Thr Val Ser Ser
115 120

<210> 52
<211> 108
<212> PRT
<213> Anti -HLA-A2 VL

<400> 52

Asp Val Val Met Thr Gl n Ser Pro Ser Ser Leu Ser Al a Ser Val Gl y
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gl n Al a Ser Gl n Asp Ile Ser Asn Tyr
20 25 30

Leu Asn Trp Tyr Gl n Gl n Lys Pro Gl y Lys Al a Pro Lys Leu Leu Ile
35 40 45

Tyr Asp Al a Ser Asn Leu Gl u Thr Gl y Val Pro Ser Arg Phe Ser Gl y
50 55 60

Ser Gl y Ser Gl y Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gl n Pro
65 70 75 80

Gl u Asp Phe Al a Thr Tyr Tyr Cys Gl n Gl n Tyr Ser Ser Phe Pro Leu

Thr Phe Gly Gly Thr Lys Val Asp Ile Lys Arg
 100 105

<210> 53
 <211> 118
 <212> PRT
 <213> Anti -HLA-Cw6 VH

<400> 53

Gl u Val Gl n Leu Val Gl u Ser Gly Gly Leu Val Gl n Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Al a Al a Ser Gly Phe Thr Phe Ser Ser Tyr
 20 25 30

Al a Met Ser Trp Val Arg Gl n Al a Pro Gly Lys Gly Leu Gl u Trp Val
 35 40 45

Ser Al a Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Al a Asp Ser Val
 50 55 60

Lys Gl y Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
 65 70 75 80

Leu Gl n Met Asn Ser Leu Arg Al a Gl u Asp Thr Al a Val Tyr Tyr Cys
 85 90 95

Al a Arg Tyr Ser Phe Ser Trp Phe Asp Val Trp Gly Gl n Gl y Thr Leu
 100 105 110

Val Thr Val Ser Ser Al a
 115

<210> 54
 <211> 108
 <212> PRT
 <213> Anti -HLA-Cw6 VL

<400> 54

Asp Ile Gl u Leu Thr Gl n Pro Pro Ser Val Ser Val Al a Pro Gly Gl n
 1 5 10 15

Thr Al a Arg Ile Ser Cys Ser Gly Asp Al a Leu Gl y Asp Lys Tyr Al a
 20 25 30

Ser Trp Tyr Gl n Gl n Lys Pro Gly Gl n Al a Pro Val Leu Val Ile Tyr
 35 40 45

Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Gl u Arg Phe Ser Gly Ser
 50 55 60

eol f-seql . txt

Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Glu Ala Glu
65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Glu Ser Tyr Asp Asn Phe Asp Ser Pro
85 90 95

Val Phe Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105

<210> 55

<211> 120

<212> PRT

<213> Anti -EpCAM VH

<400> 55

Glu Val Glu Leu Leu Glu Glu Ser Gly Ala Glu Leu Val Arg Pro Gly
1 5 10 15

Thr Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn
20 25 30

Tyr Trp Leu Gly Trp Val Lys Glu Arg Pro Gly His Gly Leu Glu Trp
35 40 45

Ile Gly Asp Ile Phe Pro Gly Ser Gly Asn Ile His Tyr Asn Glu Lys
50 55 60

Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
65 70 75 80

Tyr Met Glu Leu Ser Ser Leu Thr Phe Glu Asp Ser Ala Val Tyr Phe
85 90 95

Cys Ala Arg Leu Arg Asn Trp Asp Glu Pro Met Asp Tyr Trp Gly Glu
100 105 110

Gly Thr Thr Val Thr Val Ser Ser
115 120

<210> 56

<211> 113

<212> PRT

<213> Anti -EpCAM VL

<400> 56

Glu Leu Val Met Thr Glu Ser Pro Ser Ser Leu Thr Val Thr Ala Glu
1 5 10 15

Glu Lys Val Thr Met Ser Cys Lys Ser Ser Glu Ser Leu Leu Asn Ser
20 25 30

Gly Asn Glu Lys Asn Tyr Leu Thr Trp Tyr Glu Glu Lys Pro Gly Glu
Page 17

35 40 45
eol f-seql . txt

Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn
85 90 95

Asp Tyr Ser Tyr Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile
100 105 110

Lys

<210> 57

<211> 120

<212> PRT

<213> Anti -HER2 VH

<400> 57

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr
20 25 30

Tyr Ile His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Arg Ile Tyr Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 58

<211> 107

<212> PRT

<213> Anti -HER2 VL

<400> 58

eol f-seql . txt

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gln
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Val Asn Thr Ala
20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gln Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Ala Ser Phe Leu Tyr Ser Gln Val Pro Ser Arg Phe Ser Gln
50 55 60

Ser Arg Ser Gln Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Gl u Asp Phe Ala Thr Tyr Tyr Cys Gln Gln His Tyr Thr Thr Pro Pro
85 90 95

Thr Phe Gln Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 59

<211> 119

<212> PRT

<213> Anti -EGFR-1 VH

<400> 59

Gln Val Gln Leu Gln Glu Ser Gln Pro Gln Leu Val Lys Pro Ser Glu
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gln Gln Ser Val Ser Ser Gln
20 25 30

Asp Tyr Tyr Trp Thr Trp Ile Arg Gln Ser Pro Gln Lys Gln Leu Glu
35 40 45

Trp Ile Gln His Ile Tyr Tyr Ser Gln Asn Thr Asn Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Leu Thr Ile Ser Ile Asp Thr Ser Lys Thr Gln Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr
85 90 95

Cys Val Arg Asp Arg Val Thr Gln Ala Phe Asp Ile Trp Gln Gln Gln
100 105 110

Thr Met Val Thr Val Ser Ser
115

eol f-seql . txt

<210> 60
<211> 107
<212> PRT
<213> Anti -EGFR-1 VL

<400> 60

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Gl u Asp Ile Ala Thr Tyr Phe Cys Gln His Phe Asp His Leu Pro Leu
85 90 95

Ala Phe Gly Gly Thr Lys Val Glu Ile Lys
100 105

<210> 61
<211> 127
<212> PRT
<213> Anti -CEA VH

<400> 61

Ser Arg Val Ala Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala
1 5 10 15

Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr
20 25 30

Phe Thr Thr Tyr Thr Ile His Trp Val Arg Gln Arg Pro Gly His Asp
35 40 45

Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Ser Gly Tyr Ser Asp Tyr
50 55 60

Asn Gln Asn Phe Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser
65 70 75 80

Asn Thr Ala Tyr Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala
85 90 95

Val Tyr Tyr Cys Ala Arg Arg Ala Asp Tyr Gly Asn Tyr Glu Tyr Thr
100 105 110

eol f-seql . txt

Trp Phe Al a Tyr Trp Gl y Gl n Gl y Thr Thr Val Thr Val Ser Ser
115 120 125

<210> 62
<211> 110
<212> PRT
<213> Anti -CEA VL

<400> 62

Asp Ile Gl u Leu Thr Gl n Ser Pro Lys Phe Met Ser Thr Ser Val Gl y
1 5 10 15

Asp Arg Val Asn Val Thr Tyr Lys Al a Ser Gl n Asn Val Gl y Thr Asn
20 25 30

Val Al a Trp Phe Gl n Gl n Lys Pro Gl y Gl n Ser Pro Lys Val Leu Ile
35 40 45

Tyr Ser Al a Ser Tyr Arg Tyr Ser Gl y Val Pro Asp Arg Phe Thr Gl y
50 55 60

Ser Gl y Ser Gl y Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gl n Ser
65 70 75 80

Gl u Asp Leu Al a Gl u Tyr Phe Cys Gl n Gl n Tyr His Thr Tyr Pro Leu
85 90 95

Thr Phe Gl y Gl y Gl y Thr Lys Leu Gl u Ile Lys Arg Al a Asp
100 105 110

<210> 63
<211> 120
<212> PRT
<213> Anti -CD45 VH

<400> 63

Gl n Val Gl n Leu Val Gl u Ser Gl y Gl y Gl y Leu Val Gl n Pro Gl y Gl y
1 5 10 15

Ser Leu Lys Leu Ser Cys Al a Al a Ser Gl y Phe Asp Phe Ser Arg Tyr
20 25 30

Trp Met Ser Trp Val Arg Gl n Al a Pro Gl y Lys Gl y Leu Gl u Trp Ile
35 40 45

Gl y Gl u Ile Asn Pro Thr Ser Ser Thr Ile Asn Phe Thr Pro Ser Leu
50 55 60

Lys Asp Lys Val Phe Ile Ser Arg Asp Asn Al a Lys Asn Thr Leu Tyr
65 70 75 80

eol f-seql.txt

Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr Tyr Cys
85 90 95

Ala Arg Gly Asn Tyr Tyr Arg Tyr Gly Asp Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Ser Val Thr Val Ser
115 120

<210> 64
<211> 111
<212> PRT
<213> Anti -CD45 VL

<400> 64

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
20 25 30

Gly Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45

Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
65 70 75 80

Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg
85 90 95

Glu Leu Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> 65
<211> 121
<212> PRT
<213> VH anti -CD138

<400> 65

Gln Val Gln Leu Gln Gln Ser Gly Ser Glu Leu Met Pro Gly Ala Ser
1 5 10 15

Val Lys Ile Ser Cys Lys Ala Thr Gly Tyr Thr Phe Ser Asn Tyr Trp
20 25 30

Ile Glu Trp Val Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly
35 40 45

Glu Ile Leu Pro Gly Thr Gly Arg Thr Ile Tyr Asn Glu Lys Phe Lys
50 55 60

eol f-seql . txt

Gly Lys Ala Thr Phe Thr Ala Asp Ile Ser Ser Asn Thr Val Glu Met
65 70 75 80

Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala
85 90 95

Arg Glu Gln Tyr Tyr Gly Asn Phe Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110

Gln Gly Thr Ser Val Thr Val Ser Ser
115 120

<210> 66
<211> 110
<212> PRT
<213> VL anti -CD138

<400> 66

Asp Ile Gln Met Thr Gln Ser Thr Ser Ser Leu Ser Ala Ser Leu Gly
1 5 10 15

Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly Ile Asn Asn Tyr
20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Glu Leu Leu Ile
35 40 45

Tyr Tyr Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro
65 70 75 80

Glu Asp Ile Gly Thr Tyr Cys Gln Gln Tyr Ser Lys Leu Pro Arg
85 90 95

Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val
100 105 110

<210> 67
<211> 246
<212> PRT
<213> Anti -HLA-A2 scFv

<400> 67

Gln Val Gln Leu Val Gln Ser Gly Gly Val Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Val Ser Cys Ala Ala Ser Gly Val Thr Leu Ser Asp Tyr
20 25 30

eol f-seql . txt

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Met
35 40 45

Ala Phe Ile Arg Asn Asp Gly Ser Asp Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Lys Thr Val Ser
65 70 75 80

Leu Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Asn Gly Glu Ser Gly Pro Leu Asp Tyr Trp Tyr Phe Asp Leu
100 105 110

Trp Gly Arg Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Ser
115 120 125

Gly Gly Gly Ser Gly Gly Gly Ser Asp Val Val Met Thr Gln
130 135 140

Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr
145 150 155 160

Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln
165 170 175

Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu
180 185 190

Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
195 200 205

Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr
210 215 220

Tyr Cys Gln Gln Tyr Ser Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr
225 230 235 240

Lys Val Asp Ile Lys Arg
245

<210> 68

<211> 245

<212> PRT

<213> Anti -HLA-Cw6 scFv

<400> 68

Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
Page 24

eol f-seql . txt

20

25

30

Ala Met Ser Trp Val Arg Glu Ala Pro Gly Lys Glu Leu Glu Trp Val
35 40 45

Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Glu Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Glu Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Tyr Ser Phe Ser Trp Phe Asp Val Trp Glu Glu Glu Thr Leu
100 105 110

Val Thr Val Ser Ser Ala Glu Glu Glu Ser Glu Glu Glu Ser Glu
115 120 125

Gl y Gl y Gl y Ser Gl y Gl y Ser Asp Ile Glu Leu Thr Glu Pro
130 135 140

Pro Ser Val Ser Val Ala Pro Glu Glu Thr Ala Arg Ile Ser Cys Ser
145 150 155 160

Gl y Asp Ala Leu Gl y Asp Lys Tyr Ala Ser Trp Tyr Glu Glu Lys Pro
165 170 175

Gl y Glu Ala Pro Val Leu Val Ile Tyr Asp Asp Ser Asp Arg Pro Ser
180 185 190

Gl y Ile Pro Glu Arg Phe Ser Gl y Ser Asn Ser Gl y Asn Thr Ala Thr
195 200 205

Leu Thr Ile Ser Gl y Thr Glu Ala Glu Asp Glu Ala Asp Tyr Tyr Cys
210 215 220

Gl u Ser Tyr Asp Asn Phe Asp Ser Pro Val Phe Gl y Gl y Gl y Thr Lys
225 230 235 240

Leu Thr Val Leu Gl y
245

<210> 69

<211> 248

<212> PRT

<213> Anti -EpCAM scFv

<400> 69

Gl u Val Gl u Leu Leu Gl u Gl u Ser Gl y Ala Gl u Leu Val Arg Pro Gl y
1 5 10 15

eol f-seql . txt

Thr Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn
20 25 30

Tyr Trp Leu Gly Trp Val Lys Glu Arg Pro Gly His Gly Leu Glu Trp
35 40 45

Ile Gly Asp Ile Phe Pro Gly Ser Gly Asn Ile His Tyr Asn Glu Lys
50 55 60

Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala
65 70 75 80

Tyr Met Gln Leu Ser Ser Leu Thr Phe Glu Asp Ser Ala Val Tyr Phe
85 90 95

Cys Ala Arg Leu Arg Asn Trp Asp Glu Pro Met Asp Tyr Trp Gly Gln
100 105 110

Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly
115 120 125

Gly Ser Gly Gly Ser Glu Leu Val Met Thr Gln Ser Pro Ser
130 135 140

Ser Leu Thr Val Thr Ala Gly Glu Lys Val Thr Met Ser Cys Lys Ser
145 150 155 160

Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr Leu Thr Trp
165 170 175

Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Trp Ala
180 185 190

Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser
195 200 205

Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu
210 215 220

Ala Val Tyr Tyr Cys Gln Asn Asp Tyr Ser Tyr Pro Leu Thr Phe Gly
225 230 235 240

Ala Gly Thr Lys Leu Glu Ile Lys
245

<210> 70

<211> 242

<212> PRT

<213> Anti -HER2 scFv

<400> 70

eol f-seql . txt

Gl u Val Gl n Leu Val Gl u Ser Gl y Gl y Leu Val Gl n Pro Gl y Gl y
1 5 10 15

Ser Leu Arg Leu Ser Cys Al a Al a Ser Gl y Phe Asn Ile Lys Asp Thr
20 25 30

Tyr Ile His Trp Val Arg Gl n Al a Pro Gl y Lys Gl y Leu Gl u Trp Val
35 40 45

Al a Arg Ile Tyr Pro Thr Asn Gl y Tyr Thr Arg Tyr Al a Asp Ser Val
50 55 60

Lys Gl y Arg Phe Thr Ile Ser Al a Asp Thr Ser Lys Asn Thr Al a Tyr
65 70 75 80

Leu Gl n Met Asn Ser Leu Arg Al a Gl u Asp Thr Al a Val Tyr Tyr Cys
85 90 95

Ser Arg Trp Gl y Gl y Asp Gl y Phe Tyr Al a Met Asp Tyr Trp Gl y Gl n
100 105 110

Gl y Thr Leu Val Thr Val Ser Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y
115 120 125

Gl y Ser Gl y Gl y Gl y Ser Asp Ile Gl n Met Thr Gl n Ser Pro Ser
130 135 140

Ser Leu Ser Al a Ser Val Gl y Asp Arg Val Thr Ile Thr Cys Arg Al a
145 150 155 160

Ser Gl n Asp Val Asn Thr Al a Val Al a Trp Tyr Gl n Gl n Lys Pro Gl y
165 170 175

Lys Al a Pro Lys Leu Leu Ile Tyr Ser Al a Ser Phe Leu Tyr Ser Gl y
180 185 190

Val Pro Ser Arg Phe Ser Gl y Ser Arg Ser Gl y Thr Asp Phe Thr Leu
195 200 205

Thr Ile Ser Ser Leu Gl n Pro Gl u Asp Phe Al a Thr Tyr Tyr Cys Gl n
210 215 220

Gl n His Tyr Thr Thr Pro Pro Thr Phe Gl y Gl n Gl y Thr Lys Val Gl u
225 230 235 240

Ile Lys

<210> 71
<211> 241
<212> PRT

eol f-seql . txt

<213> Anti -EGFR(1) scFv

<400> 71

Gl n Val Gl n Leu Gl n Gl u Ser Gl y Pro Gl y Leu Val Lys Pro Ser Gl u
1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gl y Gl y Ser Val Ser Ser Gl y
20 25 30

Asp Tyr Tyr Trp Thr Trp Ile Arg Gl n Ser Pro Gl y Lys Gl y Leu Gl u
35 40 45

Trp Ile Gl y His Ile Tyr Tyr Ser Gl y Asn Thr Asn Tyr Asn Pro Ser
50 55 60

Leu Lys Ser Arg Leu Thr Ile Ser Ile Asp Thr Ser Lys Thr Gl n Phe
65 70 75 80

Ser Leu Lys Leu Ser Ser Val Thr Al a Al a Asp Thr Al a Ile Tyr Tyr
85 90 95

Cys Val Arg Asp Arg Val Thr Gl y Al a Phe Asp Ile Trp Gl y Gl n Gl y
100 105 110

Thr Met Val Thr Val Ser Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Gl y
115 120 125

Ser Gl y Gl y Gl y Gl y Ser Asp Ile Gl n Met Thr Gl n Ser Pro Ser Ser
130 135 140

Leu Ser Al a Ser Val Gl y Asp Arg Val Thr Ile Thr Cys Gl n Al a Ser
145 150 155 160

Gl n Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gl n Gl n Lys Pro Gl y Lys
165 170 175

Al a Pro Lys Leu Leu Ile Tyr Asp Al a Ser Asn Leu Gl u Thr Gl y Val
180 185 190

Pro Ser Arg Phe Ser Gl y Ser Gl y Thr Asp Phe Thr Phe Thr
195 200 205

Ile Ser Ser Leu Gl n Pro Gl u Asp Ile Al a Thr Tyr Phe Cys Gl n His
210 215 220

Phe Asp His Leu Pro Leu Al a Phe Gl y Gl y Gl y Thr Lys Val Gl u Ile
225 230 235 240

Lys

eol f-seql . txt

<210> 72
<211> 252
<212> PRT
<213> Anti -CEA scFv

<400> 72

Ser Arg Val Ala Glu Val Glu Leu Glu Glu Ser Gly Ala Glu Leu Ala
1 5 10 15

Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr
20 25 30

Phe Thr Thr Tyr Thr Ile His Trp Val Arg Glu Arg Pro Gly His Asp
35 40 45

Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Ser Gly Tyr Ser Asp Tyr
50 55 60

Asn Glu Asn Phe Lys Gly Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser
65 70 75 80

Asn Thr Ala Tyr Met Glu Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala
85 90 95

Val Tyr Tyr Cys Ala Arg Arg Ala Asp Tyr Gly Asn Tyr Glu Tyr Thr
100 105 110

Trp Phe Ala Tyr Trp Gly Glu Gly Thr Thr Val Thr Val Ser Ser Gly
115 120 125

Gly Gly Gly Ser Gly Gly Ser Gly Gly Gly Ser Asp Ile
130 135 140

Glu Leu Thr Glu Ser Pro Lys Phe Met Ser Thr Ser Val Gly Asp Arg
145 150 155 160

Val Asn Val Thr Tyr Lys Ala Ser Glu Asn Val Gly Thr Asn Val Ala
165 170 175

Trp Phe Glu Glu Lys Pro Gly Glu Ser Pro Lys Val Leu Ile Tyr Ser
180 185 190

Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly
195 200 205

Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Glu Ser Glu Asp
210 215 220

Leu Ala Glu Tyr Phe Cys Glu Glu Tyr His Thr Tyr Pro Leu Thr Phe
225 230 235 240

Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Ala Asp
Page 29

<210> 73
<211> 250
<212> PRT
<213> Anti -CD45 scFv

<400> 73

Asp Ile Val Leu Thr Glu Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser
20 25 30

Gly Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
35 40 45

Lys Leu Leu Ile Tyr Leu Ala Ser Asn Leu Glu Ser Gly Val Pro Ala
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
65 70 75 80

Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Arg
85 90 95

Gl u Leu Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys Lys
100 105 110

Ile Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly
115 120 125

Ser Ser Gln Val Gln Leu Val Glu Ser Gly Gly Leu Val Gln Pro
130 135 140

Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser
145 150 155 160

Arg Tyr Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
165 170 175

Trp Ile Gly Glu Ile Asn Pro Thr Ser Ser Thr Ile Asn Phe Thr Pro
180 185 190

Ser Leu Lys Asp Lys Val Phe Ile Ser Arg Asp Asn Ala Lys Asn Thr
195 200 205

Leu Tyr Leu Gln Met Ser Lys Val Arg Ser Glu Asp Thr Ala Leu Tyr
210 215 220

Tyr Cys Ala Arg Gly Asn Tyr Tyr Arg Tyr Gly Asp Ala Met Asp Tyr
225 230 235 240

eol f-seql . txt

Trp Gl y Gl n Gl y Thr Ser Val Thr Val Ser
245 250

<210> 74
<211> 246
<212> PRT
<213> Anti -CD138 scFv

<400> 74

Gl n Val Gl n Leu Gl n Gl n Ser Gl y Ser Gl u Leu Met Pro Gl y Ala Ser
1 5 10 15

Val Lys Ile Ser Cys Lys Ala Thr Gl y Tyr Thr Phe Ser Asn Tyr Trp
20 25 30

Ile Gl u Trp Val Lys Gl n Arg Pro Gl y His Gl y Leu Gl u Trp Ile Gl y
35 40 45

Gl u Ile Leu Pro Gl y Thr Gl y Arg Thr Ile Tyr Asn Gl u Lys Phe Lys
50 55 60

Gl y Lys Ala Thr Phe Thr Ala Asp Ile Ser Ser Asn Thr Val Gl n Met
65 70 75 80

Gl n Leu Ser Ser Leu Thr Ser Gl u Asp Ser Ala Val Tyr Tyr Cys Ala
85 90 95

Arg Gl u Gl n Tyr Tyr Gl y Asn Phe Tyr Tyr Ala Met Asp Tyr Trp Gl y
100 105 110

Gl n Gl y Thr Ser Val Thr Val Ser Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y
115 120 125

Gl y Gl y Ser Gl y Gl y Gl y Ser Asp Ile Gl n Met Thr Gl n Ser Thr
130 135 140

Ser Ser Leu Ser Ala Ser Leu Gl y Asp Arg Val Thr Ile Ser Cys Ser
145 150 155 160

Al a Ser Gl n Gl y Ile Asn Asn Tyr Leu Asn Trp Tyr Gl n Gl n Lys Pro
165 170 175

Asp Gl y Thr Val Gl u Leu Leu Ile Tyr Tyr Thr Ser Thr Leu Gl n Ser
180 185 190

Gl y Val Pro Ser Arg Phe Ser Gl y Ser Gl y Ser Gl y Thr Asp Tyr Ser
195 200 205

Leu Thr Ile Ser Asn Leu Gl u Pro Gl u Asp Ile Gl y Thr Tyr Tyr Cys
210 215 220

eol f-seql . txt

Gl n Gl n Tyr Ser Lys Leu Pro Arg Thr Phe Gl y Gl y Gl y Thr Lys Leu
225 230 235 240

Gl u Ile Lys Arg Thr Val
245

<210> 75
<211> 8
<212> PRT
<213> Anti -HLA-A2 VH CDR1

<400> 75

Gl y Val Thr Leu Ser Asp Tyr Gl y
1 5

<210> 76
<211> 8
<212> PRT
<213> Anti -HLA-A2 VH CDR2

<400> 76

Ile Arg Asn Asp Gl y Ser Asp Lys
1 5

<210> 77
<211> 16
<212> PRT
<213> Anti -HLA-A2 VH CDR3

<400> 77

Al a Lys Asn Gl y Gl u Ser Gl y Pro Leu Asp Tyr Trp Tyr Phe Asp Leu
1 5 10 15

<210> 78
<211> 6
<212> PRT
<213> Anti -HLA-A2 VL CDR1

<400> 78

Gl n Asp Ile Ser Asn Tyr
1 5

<210> 79
<211> 9
<212> PRT
<213> Anti -HLA-A2 VL CDR3

<400> 79

Gl n Gl n Tyr Ser Ser Phe Pro Leu Thr
1 5

<210> 80
<211> 8
<212> PRT
<213> Anti -HLA-Cw6 VH CDR1

eol f-seql . txt

<400> 80

Gl y Phe Thr Phe Ser Ser Tyr Al a
1 5

<210> 81

<211> 8

<212> PRT

<213> Anti -HLA-Cw6 VH CDR2

<400> 81

Ile Ser Gl y Ser Gl y Gl y Ser Thr
1 5

<210> 82

<211> 10

<212> PRT

<213> Anti -HLA-Cw6 VH CDR3

<400> 82

Al a Arg Tyr Ser Phe Ser Trp Phe Asp Val
1 5 10

<210> 83

<211> 6

<212> PRT

<213> Anti -HLA-Cw6 VL CDR1

<400> 83

Al a Leu Gl y Asp Lys Tyr
1 5

<210> 84

<211> 10

<212> PRT

<213> Anti -HLA-Cw6 VL CDR3

<400> 84

Gl n Ser Tyr Asp Asn Phe Asp Ser Pro Val
1 5 10

<210> 85

<211> 8

<212> PRT

<213> Anti -EpCAM CDR1 VH

<400> 85

Gl y Tyr Al a Phe Thr Asn Tyr Trp
1 5

<210> 86

<211> 8

<212> PRT

<213> Anti -EpCAM CDR2 VH

<400> 86

eol f-seql . txt

Ile Phe Pro Gly Ser Gly Asn Ile
1 5

<210> 87
<211> 12
<212> PRT
<213> Anti -EpCAM CDR3 VH

<400> 87

Ala Arg Leu Arg Asn Trp Asp Glu Pro Met Asp Tyr
1 5 10

<210> 88
<211> 12
<212> PRT
<213> Anti -EpCAM CDR1 VL

<400> 88

Gln Ser Leu Leu Asn Ser Gly Asn Gln Lys Asn Tyr
1 5 10

<210> 89
<211> 9
<212> PRT
<213> Anti -EpCAM CDR3 VL

<400> 89

Gln Asn Asp Tyr Ser Tyr Pro Leu Thr
1 5

<210> 90
<211> 8
<212> PRT
<213> Anti -HER2 VH CDR1

<400> 90

Gly Phe Asn Ile Lys Asp Thr Tyr
1 5

<210> 91
<211> 8
<212> PRT
<213> Anti -HER2 VH CDR2

<400> 91

Ile Tyr Pro Thr Asn Gly Tyr Thr
1 5

<210> 92
<211> 13
<212> PRT
<213> Anti -HER2 VH CDR3

<400> 92

Ser Arg Trp Gly Gly Asp Gly Phe Tyr Ala Met Asp Tyr

1 5 eol f-seql . txt
10

<210> 93
<211> 6
<212> PRT
<213> Anti -HER2 VL CDR1

<400> 93

Gln Asp Val Asn Thr Ala
1 5

<210> 94
<211> 9
<212> PRT
<213> Anti -HER2 VL CDR3

<400> 94

Gln Gln His Tyr Thr Thr Pro Pro Thr
1 5

<210> 95
<211> 10
<212> PRT
<213> Anti -EGFR-1 VH CDR1

<400> 95

Gly Gly Ser Val Ser Ser Gly Asp Tyr Tyr
1 5 10

<210> 96
<211> 7
<212> PRT
<213> Anti -EGFR-1 VH CDR2

<400> 96

Ile Tyr Tyr Ser Gly Asn Thr
1 5

<210> 97
<211> 11
<212> PRT
<213> Anti -EGFR-1 VH CDR3

<400> 97

Val Arg Asp Arg Val Thr Gly Ala Phe Asp Ile
1 5 10

<210> 98
<211> 6
<212> PRT
<213> Anti -EGFR-1 VL CDR1

<400> 98

Gln Asp Ile Ser Asn Tyr
1 5

eol f-seql . txt

<210> 99
<211> 9
<212> PRT
<213> Anti -EGFR-1 VL CDR3

<400> 99

Gl n His Phe Asp His Leu Pro Leu Al a
1 5

<210> 100
<211> 8
<212> PRT
<213> Anti -CEA VH CDR1

<400> 100

Gl y Tyr Thr Phe Thr Thr Tyr Thr
1 5

<210> 101
<211> 8
<212> PRT
<213> Anti -CEA VH CDR2

<400> 101

Ile Asn Pro Ser Ser Gl y Tyr Ser
1 5

<210> 102
<211> 16
<212> PRT
<213> Anti -CEA VH CDR3

<400> 102

Al a Arg Arg Al a Asp Tyr Gl y Asn Tyr Gl u Tyr Thr Trp Phe Al a Tyr
1 5 10 15

<210> 103
<211> 6
<212> PRT
<213> Anti -CEA VL CDR1

<400> 103

Gl n Asn Val Gl y Thr Asn
1 5

<210> 104
<211> 9
<212> PRT
<213> Anti -CEA VL CDR3

<400> 104

Gl n Gl n Tyr His Thr Tyr Pro Leu Thr
1 5

<210> 105

eol f-seql . txt

<211> 5
<212> PRT
<213> Anti -CD45 VH CDR 1

<400> 105

Gly Phe Asp Phe Ser
1 5

<210> 106
<211> 9
<212> PRT
<213> Anti -CD45 VH CDR 2

<400> 106

Glu Ile Asn Pro Thr Ser Ser Thr Ile
1 5

<210> 107
<211> 10
<212> PRT
<213> Anti -CD45 VL CDR 1

<400> 107

Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr
1 5 10

<210> 108
<211> 9
<212> PRT
<213> Anti -CD45 VL CDR 3

<400> 108

Gln His Ser Arg Glu Leu Pro Phe Thr
1 5

<210> 109
<211> 8
<212> PRT
<213> Anti -CD138 VH CDR1

<400> 109

Gly Tyr Thr Phe Ser Asn Tyr Trp
1 5

<210> 110
<211> 8
<212> PRT
<213> Anti -CD138 VH CDR2

<400> 110

Ile Leu Pro Gly Thr Gly Arg Thr
1 5

<210> 111
<211> 15
<212> PRT

eol f-seql . txt

<213> Anti -CD138 VH CDR3

<400> 111

Ala Arg Glu Gln Tyr Tyr Gly Asn Phe Tyr Tyr Ala Met Asp Tyr
1 5 10 15

<210> 112

<211> 6

<212> PRT

<213> Anti -CD138 VL CDR1

<400> 112

Gln Gly Ile Asn Asn Tyr
1 5

<210> 113

<211> 9

<212> PRT

<213> Anti -CD138 VL CDR3

<400> 113

Gln Gln Tyr Ser Lys Leu Pro Arg Thr
1 5

<210> 114

<211> 388

<212> PRT

<213> pel B-CD3VL-scFvEPCAM(VH-VL)-6Hi s

<400> 114

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
1 5 10 15

Ala Gln Pro Ala Met Ala Asp Ile Gln Leu Thr Gln Ser Pro Ala Ile
20 25 30

Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
35 40 45

Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser
50 55 60

Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly Val Pro
65 70 75 80

Tyr Arg Phe Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
85 90 95

Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
100 105 110

Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
115 120 125

eol f-seql . txt

Ser Gl y Gl y Gl y Gl y Ser Gl u Val Gl n Leu Leu Gl u Gl n Ser Gl y Al a
130 135 140

Gl u Leu Val Arg Pro Gl y Thr Ser Val Lys Ile Ser Cys Lys Al a Ser
145 150 155 160

Gl y Tyr Al a Phe Thr Asn Tyr Trp Leu Gl y Trp Val Lys Gl n Arg Pro
165 170 175

Gl y His Gl y Leu Gl u Trp Ile Gl y Asp Ile Phe Pro Gl y Ser Gl y Asn
180 185 190

Ile His Tyr Asn Gl u Lys Phe Lys Gl y Lys Al a Thr Leu Thr Al a Asp
195 200 205

Lys Ser Ser Ser Thr Al a Tyr Met Gl n Leu Ser Ser Leu Thr Phe Gl u
210 215 220

Asp Ser Al a Val Tyr Phe Cys Al a Arg Leu Arg Asn Trp Asp Gl u Pro
225 230 235 240

Met Asp Tyr Trp Gl y Gl n Gl y Thr Thr Val Thr Val Ser Ser Gl y Gl y
245 250 255

Gl y Gl y Ser Gl y Gl y Gl y Ser Gl y Gl y Gl y Ser Gl u Leu Val
260 265 270

Met Thr Gl n Ser Pro Ser Ser Leu Thr Val Thr Al a Gl y Gl u Lys Val
275 280 285

Thr Met Ser Cys Lys Ser Ser Gl n Ser Leu Leu Asn Ser Gl y Asn Gl n
290 295 300

Lys Asn Tyr Leu Thr Trp Tyr Gl n Gl n Lys Pro Gl y Gl n Pro Pro Lys
305 310 315 320

Leu Leu Ile Tyr Trp Al a Ser Thr Arg Gl u Ser Gl y Val Pro Asp Arg
325 330 335

Phe Thr Gl y Ser Gl y Ser Gl y Thr Asp Phe Thr Leu Thr Ile Ser Ser
340 345 350

Val Gl n Al a Gl u Asp Leu Al a Val Tyr Tyr Cys Gl n Asn Asp Tyr Ser
355 360 365

Tyr Pro Leu Thr Phe Gl y Al a Gl y Thr Lys Leu Gl u Ile Lys His His
370 375 380

His His His His
385

eol f-seql . txt

<210> 115

<211> 404

<212> PRT

<213> pel B-CD3VH-scFvHer2-6HI S

<400> 115

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
1 5 10 15

Ala Gln Pro Ala Met Ala Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu
20 25 30

Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Thr Ser Gly
35 40 45

Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys Gln Arg Pro Gly
50 55 60

Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr
65 70 75 80

Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys
85 90 95

Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp
100 105 110

Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu
115 120 125

Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly
130 135 140

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Gln Leu
145 150 155 160

Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Arg Leu
165 170 175

Ser Cys Ala Ala Ser Gly Phe Asn Ile Lys Asp Thr Tyr Ile His Trp
180 185 190

Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ala Arg Ile Tyr
195 200 205

Pro Thr Asn Gly Tyr Thr Arg Tyr Ala Asp Ser Val Lys Gly Arg Phe
210 215 220

Thr Ile Ser Ala Asp Thr Ser Lys Asn Thr Ala Tyr Leu Gln Met Asn
225 230 235 240

eol f-seql . txt

Ser Leu Arg Al a Gl u Asp Thr Al a Val Tyr Tyr Cys Ser Arg Trp Gl y
245 250 255

Gl y Asp Gl y Phe Tyr Al a Met Asp Tyr Trp Gl y Gl n Gl y Thr Leu Val
260 265 270

Thr Val Ser Ser Gl y Gl y Gl y Ser Gl y Gl y Gl y Ser Gl y Gl y
275 280 285

Gl y Gl y Ser Asp Ile Gl n Met Thr Gl n Ser Pro Ser Ser Leu Ser Al a
290 295 300

Ser Val Gl y Asp Arg Val Thr Ile Thr Cys Arg Al a Ser Gl n Asp Val
305 310 315 320

Asn Thr Al a Val Al a Trp Tyr Gl n Gl n Lys Pro Gl y Lys Al a Pro Lys
325 330 335

Leu Leu Ile Tyr Ser Al a Ser Phe Leu Tyr Ser Gl y Val Pro Ser Arg
340 345 350

Phe Ser Gl y Ser Arg Ser Gl y Thr Asp Phe Thr Leu Thr Ile Ser Ser
355 360 365

Leu Gl n Pro Gl u Asp Phe Al a Thr Tyr Tyr Cys Gl n Gl n His Tyr Thr
370 375 380

Thr Pro Pro Thr Phe Gl y Gl n Gl y Thr Lys Val Gl u Ile Lys His His
385 390 395 400

His His His His

<210> 116

<211> 403

<212> PRT

<213> pel B-CD3VH-scFvEGFR(1)-6HIS

<400> 116

Met Lys Tyr Leu Leu Pro Thr Al a Al a Al a Gl y Leu Leu Leu Leu Al a
1 5 10 15

Al a Gl n Pro Al a Met Al a Asp Ile Lys Leu Gl n Gl n Ser Gl y Al a Gl u
20 25 30

Leu Al a Arg Pro Gl y Al a Ser Val Lys Met Ser Cys Lys Thr Ser Gl y
35 40 45

Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys Gl n Arg Pro Gl y
50 55 60

Gl n Gl y Leu Gl u Trp Ile Gl y Tyr Ile Asn Pro Ser Arg Gl y Tyr Thr
Page 41

eol f-seql . txt

65

70

75

80

Asn Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys
 85 90 95

Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp
 100 105 110

Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu
 115 120 125

Asp Tyr Trp Gly Glu Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly
 130 135 140

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu Val Glu Leu
 145 150 155 160

Glu Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu
 165 170 175

Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Gly Asp Tyr Tyr Trp
 180 185 190

Thr Trp Ile Arg Glu Ser Pro Gly Lys Gly Leu Glu Trp Ile Gly His
 195 200 205

Ile Tyr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg
 210 215 220

Leu Thr Ile Ser Ile Asp Thr Ser Lys Thr Glu Phe Ser Leu Lys Leu
 225 230 235 240

Ser Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys Val Arg Asp
 245 250 255

Arg Val Thr Gly Ala Phe Asp Ile Trp Gly Glu Gly Thr Met Val Thr
 260 265 270

Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly
 275 280 285

Gly Ser Asp Ile Glu Met Thr Glu Ser Pro Ser Ser Leu Ser Ala Ser
 290 295 300

Val Gly Asp Arg Val Thr Ile Thr Cys Glu Ala Ser Glu Asp Ile Ser
 305 310 315 320

Asn Tyr Leu Asn Trp Tyr Glu Glu Lys Pro Gly Lys Ala Pro Lys Leu
 325 330 335

Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe
 Page 42

eol f-seql . txt

340

345

350

Ser Gl y Ser Gl y Ser Gl y Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu
355 360 365

Gl n Pro Gl u Asp Ile Ala Thr Tyr Phe Cys Gl n His Phe Asp His Leu
370 375 380

Pro Leu Ala Phe Gl y Gl y Gl y Thr Lys Val Gl u Ile Lys His His His
385 390 395 400

His His His

<210> 117

<211> 414

<212> PRT

<213> pel B-CD3VH-scFvCEA-6HIS

<400> 117

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gl y Leu Leu Leu Leu Ala
1 5 10 15

Al a Gl n Pro Al a Met Al a Asp Ile Lys Leu Gl n Gl n Ser Gl y Al a Gl u
20 25 30

Leu Al a Arg Pro Gl y Al a Ser Val Lys Met Ser Cys Lys Thr Ser Gl y
35 40 45

Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys Gl n Arg Pro Gl y
50 55 60

Gl n Gl y Leu Gl u Trp Ile Gl y Tyr Ile Asn Pro Ser Arg Gl y Tyr Thr
65 70 75 80

Asn Tyr Asn Gl n Lys Phe Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys
85 90 95

Ser Ser Ser Thr Ala Tyr Met Gl n Leu Ser Ser Leu Thr Ser Gl u Asp
100 105 110

Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu
115 120 125

Asp Tyr Trp Gl y Gl n Gl y Thr Thr Leu Thr Val Ser Ser Gl y Gl y Gl y
130 135 140

Gl y Ser Gl y Gl y Gl y Ser Gl y Gl y Gl y Ser Ser Arg Val Ala
145 150 155 160

Gl n Val Gl n Leu Gl n Gl n Ser Gl y Ala Gl u Leu Ala Arg Pro Gl y Ala
165 170 175

eol f-seql . txt

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
180 185 190

Thr Ile His Trp Val Arg Gln Arg Pro Gly His Asp Leu Glu Trp Ile
195 200 205

Gly Tyr Ile Asn Pro Ser Ser Gly Tyr Ser Asp Tyr Asn Gln Asn Phe
210 215 220

Lys Glu Lys Thr Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr
225 230 235 240

Met Gln Leu Asn Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
245 250 255

Ala Arg Arg Ala Asp Tyr Gly Asn Tyr Glu Tyr Thr Trp Phe Ala Tyr
260 265 270

Trp Glu Gln Gly Thr Thr Val Thr Val Ser Ser Gly Glu Glu Glu Ser
275 280 285

Gly Glu Gly Ser Gly Glu Gly Ser Asp Ile Glu Leu Thr Gln
290 295 300

Ser Pro Lys Phe Met Ser Thr Ser Val Gly Asp Arg Val Asn Val Thr
305 310 315 320

Tyr Lys Ala Ser Gln Asn Val Gly Thr Asn Val Ala Trp Phe Gln Gln
325 330 335

Lys Pro Glu Gln Ser Pro Lys Val Leu Ile Tyr Ser Ala Ser Tyr Arg
340 345 350

Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp
355 360 365

Phe Thr Leu Thr Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Glu Tyr
370 375 380

Phe Cys Gln Gln Tyr His Thr Tyr Pro Leu Thr Phe Gly Gly Gly Thr
385 390 395 400

Lys Leu Glu Ile Lys Arg Ala Asp His His His His His
405 410

<210> 118
<211> 392
<212> PRT
<213> pel B-CD3VL-scFvCEA-6HIS

<400> 118

eol f-seql . txt

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
1 5 10 15

Ala Glu Pro Ala Met Ala Asp Ile Glu Leu Thr Glu Ser Pro Ala Ile
20 25 30

Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
35 40 45

Ser Ser Val Ser Tyr Met Asn Trp Tyr Glu Glu Lys Ser Gly Thr Ser
50 55 60

Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly Val Pro
65 70 75 80

Tyr Arg Phe Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
85 90 95

Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Glu Glu Trp
100 105 110

Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
115 120 125

Ser Gly Gly Gly Ser Ser Arg Val Ala Glu Val Glu Leu Glu Glu
130 135 140

Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys
145 150 155 160

Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr Thr Ile His Trp Val Arg
165 170 175

Glu Arg Pro Gly His Asp Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser
180 185 190

Ser Gly Tyr Ser Asp Tyr Asn Glu Asn Phe Lys Gly Lys Thr Thr Leu
195 200 205

Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr Met Glu Leu Asn Ser Leu
210 215 220

Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Arg Ala Asp Tyr
225 230 235 240

Gly Asn Tyr Glu Tyr Thr Trp Phe Ala Tyr Trp Gly Glu Glu Thr Thr
245 250 255

Val Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly
260 265 270

eol f-seql . txt

Gly Gly Gly Ser Asp Ile Glu Leu Thr Glu Ser Pro Lys Phe Met Ser
275 280 285

Thr Ser Val Gly Asp Arg Val Asn Val Thr Tyr Lys Ala Ser Glu Asn
290 295 300

Val Gly Thr Asn Val Ala Trp Phe Glu Glu Lys Pro Gly Glu Ser Pro
305 310 315 320

Lys Val Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp
325 330 335

Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
340 345 350

Asn Val Glu Ser Glu Asp Leu Ala Glu Tyr Phe Cys Glu Glu Tyr His
355 360 365

Thr Tyr Pro Leu Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys Arg
370 375 380

Ala Asp His His His His His
385 390

<210> 119
<211> 414
<212> PRT
<213> pel B-(aCD3)VH-scFvHLA-Cw6-myc-6His

<400> 119

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
1 5 10 15

Ala Glu Pro Ala Met Ala Asp Ile Lys Leu Glu Glu Ser Gly Ala Glu
20 25 30

Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Thr Ser Gly
35 40 45

Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys Glu Arg Pro Gly
50 55 60

Glu Glu Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr
65 70 75 80

Asn Tyr Asn Glu Lys Phe Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys
85 90 95

Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp
100 105 110

eol f-seql . txt

Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu
115 120 125

Asp Tyr Trp Gly Glu Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly
130 135 140

Gly Ser Gly Gly Gly Ser Gly Glu Val Glu Leu Val Glu Ser
145 150 155 160

Gly Gly Gly Leu Val Glu Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala
165 170 175

Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser Trp Val Arg Glu
180 185 190

Ala Pro Gly Lys Gly Leu Glu Trp Val Ser Ala Ile Ser Gly Ser Gly
195 200 205

Gly Ser Thr Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
210 215 220

Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu Glu Met Asn Ser Leu Arg
225 230 235 240

Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg Tyr Ser Phe Ser Trp
245 250 255

Phe Asp Val Trp Gly Glu Gly Thr Leu Val Thr Val Ser Ser Ala Gly
260 265 270

Gly Gly Ser Gly Gly Gly Ser Gly Glu Gly Ser Gly Gly Gly
275 280 285

Gly Ser Asp Ile Glu Leu Thr Glu Pro Pro Ser Val Ser Val Ala Pro
290 295 300

Gly Glu Thr Ala Arg Ile Ser Cys Ser Gly Asp Ala Leu Gly Asp Lys
305 310 315 320

Tyr Ala Ser Trp Tyr Glu Glu Lys Pro Gly Glu Ala Pro Val Leu Val
325 330 335

Ile Tyr Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser
340 345 350

Gly Ser Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Gly Thr Glu
355 360 365

Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Glu Ser Tyr Asp Asn Phe Asp
370 375 380

eof f-seql.txt

Ser Pro Val Phe Gly Gly Thr Lys Leu Thr Val Leu Gly Glu Gln
385 390 395 400

Lys Leu Ile Ser Glu Glu Asp Leu His His His His His His
405 410

<210> 120

<211> 391

<212> PRT

<213> pel B-CD3VL-scFvCD138-6His

<400> 120

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
1 5 10 15

Ala Gln Pro Ala Met Ala Asp Ile Gln Leu Thr Gln Ser Pro Ala Ile
20 25 30

Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
35 40 45

Ser Ser Val Ser Tyr Met Asn Trp Tyr Gln Gln Lys Ser Gly Thr Ser
50 55 60

Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly Val Pro
65 70 75 80

Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
85 90 95

Ser Ser Met Gln Ala Gln Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp
100 105 110

Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Gln Leu Lys
115 120 125

Ser Gln Gln Gln Gln Ser Gln Gln Gln Ser Gln Val Gln Leu Gln
130 135 140

Gln Ser Gly Ser Gln Leu Met Pro Gly Ala Ser Val Lys Ile Ser Cys
145 150 155 160

Lys Ala Thr Gly Tyr Thr Phe Ser Asn Tyr Trp Ile Glu Trp Val Lys
165 170 175

Gln Arg Pro Gly His Gly Leu Gln Trp Ile Gly Glu Ile Leu Pro Gly
180 185 190

Thr Gly Arg Thr Ile Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Phe
195 200 205

Thr Ala Asp Ile Ser Ser Asn Thr Val Gln Met Gln Leu Ser Ser Leu
Page 48

eol f-seql . txt

210 215 220

Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Glu Glu Tyr Tyr
225 230 235 240

Gl y Asn Phe Tyr Tyr Ala Met Asp Tyr Trp Gl y Gl n Gl y Thr Ser Val
245 250 255

Thr Val Ser Ser Gl y Gl y Gl y Ser Gl y Gl y Gl y Ser Gl y Gl y
260 265 270

Gl y Gl y Ser Asp Ile Gl n Met Thr Gl n Ser Thr Ser Ser Leu Ser Ala
275 280 285

Ser Leu Gl y Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gl n Gl y Ile
290 295 300

Asn Asn Tyr Leu Asn Trp Tyr Gl n Gl n Lys Pro Asp Gl y Thr Val Gl u
305 310 315 320

Leu Leu Ile Tyr Tyr Thr Ser Thr Leu Gl n Ser Gl y Val Pro Ser Arg
325 330 335

Phe Ser Gl y Ser Gl y Ser Gl y Thr Asp Tyr Ser Leu Thr Ile Ser Asn
340 345 350

Leu Gl u Pro Gl u Asp Ile Gl y Thr Tyr Tyr Cys Gl n Gl n Tyr Ser Lys
355 360 365

Leu Pro Arg Thr Phe Gl y Gl y Gl y Thr Lys Leu Gl u Ile Lys Arg Thr
370 375 380

Val His His His His His
385 390

<210> 121
<211> 408
<212> PRT
<213> pel B-CD3VH-scFvCD138-6His

<400> 121

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gl y Leu Leu Leu Leu Ala
1 5 10 15

Al a Gl n Pro Ala Met Ala Asp Ile Lys Leu Gl n Gl n Ser Gl y Ala Gl u
20 25 30

Leu Ala Arg Pro Gl y Ala Ser Val Lys Met Ser Cys Lys Thr Ser Gl y
35 40 45

Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys Gl n Arg Pro Gl y
50 55 60

eol f-seql . txt

Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr
65 70 75 80

Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys
85 90 95

Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp
100 105 110

Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu
115 120 125

Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly
130 135 140

Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Gln Val Gln Leu
145 150 155 160

Gln Gln Ser Gly Ser Glu Leu Met Pro Gly Ala Ser Val Lys Ile Ser
165 170 175

Cys Lys Ala Thr Gly Tyr Thr Phe Ser Asn Tyr Trp Ile Glu Trp Val
180 185 190

Lys Gln Arg Pro Gly His Gly Leu Glu Trp Ile Gly Glu Ile Leu Pro
195 200 205

Gly Thr Gly Arg Thr Ile Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr
210 215 220

Phe Thr Ala Asp Ile Ser Ser Asn Thr Val Gln Met Gln Leu Ser Ser
225 230 235 240

Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Glu Gln Tyr
245 250 255

Tyr Gly Asn Phe Tyr Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser
260 265 270

Val Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly
275 280 285

Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Thr Ser Ser Leu Ser
290 295 300

Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Ser Ala Ser Gln Gly
305 310 315 320

Ile Asn Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val
325 330 335

eol f-seql . txt

Gl u Leu Leu Ile Tyr Tyr Thr Ser Thr Leu Gl n Ser Gl y Val Pro Ser
340 345 350

Arg Phe Ser Gl y Ser Gl y Ser Gl y Thr Asp Tyr Ser Leu Thr Ile Ser
355 360 365

Asn Leu Gl u Pro Gl u Asp Ile Gl y Thr Tyr Tyr Cys Gl n Gl n Tyr Ser
370 375 380

Lys Leu Pro Arg Thr Phe Gl y Gl y Gl y Thr Lys Leu Gl u Ile Lys Arg
385 390 395 400

Thr Val His His His His His His
405

<210> 122

<211> 404

<212> PRT

<213> pel B-(aHis)VH-scFvHLA-A2(VH-VL)-myc

<400> 122

Met Lys Tyr Leu Leu Pro Thr Al a Al a Al a Gl y Leu Leu Leu Leu Al a
1 5 10 15

Al a Gl n Pro Al a Met Al a Gl n Val Gl n Leu Gl n Gl n Ser Gl y Pro Gl u
20 25 30

Asp Val Lys Pro Gl y Al a Ser Val Lys Ile Ser Cys Lys Al a Ser Gl y
35 40 45

Tyr Thr Phe Thr Asp Tyr Tyr Met Asn Trp Val Lys Gl n Ser Pro Gl y
50 55 60

Lys Gl y Leu Gl u Trp Ile Gl y Asp Ile Asn Pro Asn Asn Gl y Gl y Thr
65 70 75 80

Ser Tyr Asn Gl n Lys Phe Lys Gl y Arg Al a Thr Leu Thr Val Asp Lys
85 90 95

Ser Ser Ser Thr Al a Tyr Met Gl u Leu Arg Ser Leu Thr Ser Gl u Asp
100 105 110

Ser Ser Val Tyr Tyr Cys Gl u Ser Gl n Ser Gl y Al a Tyr Trp Gl y Gl n
115 120 125

Gl y Thr Thr Val Thr Val Ser Al a Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y
130 135 140

Gl y Ser Gl y Gl y Gl n Val Gl n Leu Val Gl n Ser Gl y Gl y Gl y Val Val
145 150 155 160

eol f-seql . txt

Gl n Pro Gl y Gl y Ser Leu Arg Val Ser Cys Ala Ala Ser Gl y Val Thr
165 170 175

Leu Ser Asp Tyr Gl y Met His Trp Val Arg Gl n Ala Pro Gl y Lys Gl y
180 185 190

Leu Gl u Trp Met Ala Phe Ile Arg Asn Asp Gl y Ser Asp Lys Tyr Tyr
195 200 205

Al a Asp Ser Val Lys Gl y Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
210 215 220

Lys Thr Val Ser Leu Gl n Met Ser Ser Leu Arg Ala Gl u Asp Thr Al a
225 230 235 240

Val Tyr Tyr Cys Al a Lys Asn Gl y Gl u Ser Gl y Pro Leu Asp Tyr Trp
245 250 255

Tyr Phe Asp Leu Trp Gl y Arg Gl y Thr Leu Val Thr Val Ser Ser Gl y
260 265 270

Gl y Gl y Gl y Ser Gl y Gl y Gl y Ser Gl y Gl y Gl y Ser Asp Val
275 280 285

Val Met Thr Gl n Ser Pro Ser Ser Leu Ser Al a Ser Val Gl y Asp Arg
290 295 300

Val Thr Ile Thr Cys Gl n Ala Ser Gl n Asp Ile Ser Asn Tyr Leu Asn
305 310 315 320

Trp Tyr Gl n Gl n Lys Pro Gl y Lys Al a Pro Lys Leu Leu Ile Tyr Asp
325 330 335

Al a Ser Asn Leu Gl u Thr Gl y Val Pro Ser Arg Phe Ser Gl y Ser Gl y
340 345 350

Ser Gl y Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gl n Pro Gl u Asp
355 360 365

Phe Al a Thr Tyr Tyr Cys Gl n Gl n Tyr Ser Ser Phe Pro Leu Thr Phe
370 375 380

Gl y Gl y Gl y Thr Lys Val Asp Ile Lys Arg Gl u Gl n Lys Leu Ile Ser
385 390 395 400

Gl u Gl u Asp Leu

<210> 123

<211> 410

<212> PRT

eol f-seql . txt

<213> pel B-(aHi s)VL-scFvCD45(VL-VH)-myc

<400> 123

Met Lys Tyr Leu Leu Pro Thr Al a Al a Al a Gl y Leu Leu Leu Leu Al a
1 5 10 15

Al a Gl n Pro Al a Met Al a Asp Tyr Lys Asp Ile Leu Met Thr Gl n Thr
20 25 30

Pro Ser Ser Leu Pro Val Ser Leu Gl y Asp Gl n Al a Ser Ile Ser Cys
35 40 45

Arg Ser Ser Gl n Ser Ile Val His Ser Asn Gl y Asn Thr Tyr Leu Gl u
50 55 60

Trp Tyr Leu Gl n Lys Pro Gl y Gl n Ser Pro Lys Leu Leu Ile Tyr Lys
65 70 75 80

Val Ser Asn Arg Phe Ser Gl y Val Pro Asp Arg Phe Ser Gl y Ser Gl y
85 90 95

Ser Gl y Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Gl u Al a Gl u Asp
100 105 110

Leu Gl y Val Tyr Tyr Cys Phe Gl n Gl y Ser His Val Pro Phe Thr Phe
115 120 125

Gl y Ser Gl y Thr Lys Leu Gl u Ile Lys Arg Gl y Gl y Gl y Ser Gl y
130 135 140

Gl y Gl y Gl y Ser Gl y Gl y Asp Ile Val Leu Thr Gl n Ser Pro Al a Ser
145 150 155 160

Leu Al a Val Ser Leu Gl y Gl n Arg Al a Thr Ile Ser Cys Arg Al a Ser
165 170 175

Lys Ser Val Ser Thr Ser Gl y Tyr Ser Tyr Leu His Trp Tyr Gl n Gl n
180 185 190

Lys Pro Gl y Gl n Pro Pro Lys Leu Leu Ile Tyr Leu Al a Ser Asn Leu
195 200 205

Gl u Ser Gl y Val Pro Al a Arg Phe Ser Gl y Ser Gl y Thr Asp
210 215 220

Phe Thr Leu Asn Ile His Pro Val Gl u Gl u Gl u Asp Al a Al a Thr Tyr
225 230 235 240

Tyr Cys Gl n His Ser Arg Gl u Leu Pro Phe Thr Phe Gl y Ser Gl y Thr
245 250 255

eol f-seql.txt

Lys Leu Glu Ile Lys Lys Ile Ser Gly Gly Gly Gly Ser Gly Gly Gly
260 265 270

Gly Ser Gly Gly Gly Ser Ser Gln Val Gln Leu Val Glu Ser Gly
275 280 285

Gly Gly Leu Val Gln Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Ala
290 295 300

Ser Gly Phe Asp Phe Ser Arg Tyr Trp Met Ser Trp Val Arg Gln Ala
305 310 315 320

Pro Gly Lys Gly Leu Glu Trp Ile Gly Glu Ile Asn Pro Thr Ser Ser
325 330 335

Thr Ile Asn Phe Thr Pro Ser Leu Lys Asp Lys Val Phe Ile Ser Arg
340 345 350

Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln Met Ser Lys Val Arg Ser
355 360 365

Glu Asp Thr Ala Leu Tyr Tyr Cys Ala Arg Gly Asn Tyr Tyr Arg Tyr
370 375 380

Gly Asp Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser
385 390 395 400

Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
405 410

<210> 124

<211> 415

<212> PRT

<213> pel B-(aCD3)VH-scFvHLA-A2(VH-VL)-myc-6His

<400> 124

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
1 5 10 15

Ala Gln Pro Ala Met Ala Asp Ile Lys Leu Gln Gln Ser Gly Ala Glu
20 25 30

Leu Ala Arg Pro Gly Ala Ser Val Lys Met Ser Cys Lys Thr Ser Gly
35 40 45

Tyr Thr Phe Thr Arg Tyr Thr Met His Trp Val Lys Gln Arg Pro Gly
50 55 60

Gln Gly Leu Glu Trp Ile Gly Tyr Ile Asn Pro Ser Arg Gly Tyr Thr
65 70 75 80

Asn Tyr Asn Gln Lys Phe Lys Asp Lys Ala Thr Leu Thr Thr Asp Lys
Page 54

eol f-seql . txt

85

90

95

Ser Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp
 100 105 110

Ser Ala Val Tyr Tyr Cys Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu
 115 120 125

Asp Tyr Trp Gly Glu Gly Thr Thr Leu Thr Val Ser Ser Gly Gly Gly
 130 135 140

Gly Ser Gly Gly Gly Ser Gly Gly Glu Val Glu Leu Val Glu Ser
 145 150 155 160

Gly Gly Gly Val Val Glu Pro Gly Ser Leu Arg Val Ser Cys Ala
 165 170 175

Ala Ser Gly Val Thr Leu Ser Asp Tyr Gly Met His Trp Val Arg Glu
 180 185 190

Ala Pro Gly Lys Gly Leu Glu Trp Met Ala Phe Ile Arg Asn Asp Gly
 195 200 205

Ser Asp Lys Tyr Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser
 210 215 220

Arg Asp Asn Ser Lys Lys Thr Val Ser Leu Glu Met Ser Ser Leu Arg
 225 230 235 240

Ala Glu Asp Thr Ala Val Tyr Tyr Cys Ala Lys Asn Gly Glu Ser Gly
 245 250 255

Pro Leu Asp Tyr Trp Tyr Phe Asp Leu Trp Gly Arg Gly Thr Leu Val
 260 265 270

Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly
 275 280 285

Gly Gly Ser Asp Val Val Met Thr Glu Ser Pro Ser Ser Leu Ser Ala
 290 295 300

Ser Val Gly Asp Arg Val Thr Ile Thr Cys Glu Ala Ser Glu Asp Ile
 305 310 315 320

Ser Asn Tyr Leu Asn Trp Tyr Glu Glu Lys Pro Gly Lys Ala Pro Lys
 325 330 335

Leu Leu Ile Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg
 340 345 350

Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser
 Page 55

eol f-seql . txt

355	360	365
Leu Glu Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Glu Glu Tyr Ser Ser		
370	375	380
Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Asp Ile Lys Arg Glu		
385	390	395
Glut Lys Leu Ile Ser Glu Glu Asp Leu His His His His His His		
405	410	415
<210> 125		
<211> 406		
<212> PRT		
<213> peptide B-(aCD3)VL-scFvCD45(VL-VH)-myc-6His		
<400> 125		
Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Glu Leu Leu Leu Leu Ala		
1	5	10
Ala Glu Pro Ala Met Ala Asp Ile Glu Leu Thr Glu Ser Pro Ala Ile		
20	25	30
Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser		
35	40	45
Ser Ser Val Ser Tyr Met Asn Trp Tyr Glu Glu Lys Ser Gly Thr Ser		
50	55	60
Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly Val Pro		
65	70	75
Tyr Arg Phe Ser Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile		
85	90	95
Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Glu Glu Trp		
100	105	110
Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys		
115	120	125
Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Asp Ile Val Leu		
130	135	140
Thr Glu Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr		
145	150	155
Ile Ser Cys Arg Ala Ser Lys Ser Val Ser Thr Ser Gly Tyr Ser Tyr		
165	170	175
Leu His Trp Tyr Glu Glu Lys Pro Gly Glu Pro Pro Lys Leu Leu Ile		
180	185	190

eol f-seql . txt

Tyr Leu Al a Ser Asn Leu Gl u Ser Gl y Val Pro Al a Arg Phe Ser Gl y
195 200 205

Ser Gl y Ser Gl y Thr Asp Phe Thr Leu Asn Ile His Pro Val Gl u Gl u
210 215 220

Gl u Asp Al a Al a Thr Tyr Tyr Cys Gl n His Ser Arg Gl u Leu Pro Phe
225 230 235 240

Thr Phe Gl y Ser Gl y Thr Lys Leu Gl u Ile Lys Lys Ile Ser Gl y Gl y
245 250 255

Gl y Gl y Ser Gl y Gl y Gl y Ser Gl y Gl y Gl y Ser Ser Gl n Val
260 265 270

Gl n Leu Val Gl u Ser Gl y Gl y Gl y Leu Val Gl n Pro Gl y Gl y Ser Leu
275 280 285

Lys Leu Ser Cys Al a Al a Ser Gl y Phe Asp Phe Ser Arg Tyr Trp Met
290 295 300

Ser Trp Val Arg Gl n Al a Pro Gl y Lys Gl y Leu Gl u Trp Ile Gl y Gl u
305 310 315 320

Ile Asn Pro Thr Ser Ser Thr Ile Asn Phe Thr Pro Ser Leu Lys Asp
325 330 335

Lys Val Phe Ile Ser Arg Asp Asn Al a Lys Asn Thr Leu Tyr Leu Gl n
340 345 350

Met Ser Lys Val Arg Ser Gl u Asp Thr Al a Leu Tyr Tyr Cys Al a Arg
355 360 365

Gl y Asn Tyr Tyr Arg Tyr Gl y Asp Al a Met Asp Tyr Trp Gl y Gl n Gl y
370 375 380

Thr Ser Val Thr Val Ser Gl u Gl n Lys Leu Ile Ser Gl u Gl u Asp Leu
385 390 395 400

His His His His His
405

<210> 126

<211> 415

<212> PRT

<213> pel B-VHaDI G-scFvEGFR-FLAG-6HI S

<400> 126

Met Lys Tyr Leu Leu Pro Thr Al a Al a Al a Gl y Leu Leu Leu Leu Al a
1 5 10 15

eol f-seql . txt

Ala Glu Pro Ala Met Ala Glu Val Glu Leu Val Glu Ser Gly Gly Gly
20 25 30

Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Val Ser Gly
35 40 45

Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Ile Arg Glu Thr Pro Glu
50 55 60

Asn Arg Leu Glu Trp Val Ala Ser Ile Asn Ile Gly Ala Thr Tyr Ala
65 70 75 80

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
85 90 95

Ala Lys Asn Thr Leu Phe Leu Glu Met Ser Ser Leu Gly Ser Glu Asp
100 105 110

Thr Ala Met Tyr Tyr Cys Ala Arg Pro Gly Ser Pro Tyr Glu Tyr Asp
115 120 125

Lys Ala Tyr Tyr Ser Met Ala Tyr Trp Gly Pro Gly Thr Ser Val Thr
130 135 140

Val Ser Ser Ala Lys Thr Gly Gly Gly Ser Gly Gly Gly Ser
145 150 155 160

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu
165 170 175

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Val Ser Ser Gly
180 185 190

Asp Tyr Tyr Trp Thr Trp Ile Arg Gln Ser Pro Gly Lys Gly Leu Glu
195 200 205

Trp Ile Gly His Ile Tyr Tyr Ser Gly Asn Thr Asn Tyr Asn Pro Ser
210 215 220

Leu Lys Ser Arg Leu Thr Ile Ser Ile Asp Thr Ser Lys Thr Gln Phe
225 230 235 240

Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Ile Tyr Tyr
245 250 255

Cys Val Arg Asp Arg Val Thr Gly Ala Phe Asp Ile Trp Gly Gln Gly
260 265 270

Thr Met Val Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Gly
275 280 285

eol f-seql . txt

Ser Gl y Gl y Gl y Gl y Ser Asp Ile Gl n Met Thr Gl n Ser Pro Ser Ser
290 295 300

Leu Ser Al a Ser Val Gl y Asp Arg Val Thr Ile Thr Cys Gl n Al a Ser
305 310 315 320

Gl n Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gl n Gl n Lys Pro Gl y Lys
325 330 335

Al a Pro Lys Leu Leu Ile Tyr Asp Al a Ser Asn Leu Gl u Thr Gl y Val
340 345 350

Pro Ser Arg Phe Ser Gl y Ser Gl y Thr Asp Phe Thr Phe Thr
355 360 365

Ile Ser Ser Leu Gl n Pro Gl u Asp Ile Al a Thr Tyr Phe Cys Gl n His
370 375 380

Phe Asp His Leu Pro Leu Al a Phe Gl y Gl y Gl y Thr Lys Val Gl u Ile
385 390 395 400

Lys Asp Tyr Lys Asp Asp Asp Lys His His His His His His
405 410 415

<210> 127

<211> 412

<212> PRT

<213> pel B-VLaDI G-scFvEpCAM-myc-6HI S

<400> 127

Met Lys Tyr Leu Leu Pro Thr Al a Al a Al a Gl y Leu Leu Leu Leu Al a
1 5 10 15

Al a Gl n Pro Al a Met Al a Asp Val Gl n Met Thr Gl n Ser Thr Ser Ser
20 25 30

Leu Ser Al a Ser Leu Gl y Asp Arg Val Thr Ile Ser Cys Arg Al a Ser
35 40 45

Gl n Asp Ile Lys Asn Tyr Leu Asn Trp Tyr Gl n Gl n Lys Pro Gl y Gl y
50 55 60

Thr Val Lys Leu Leu Ile Tyr Tyr Ser Ser Thr Leu Leu Ser Gl y Val
65 70 75 80

Pro Ser Arg Phe Ser Gl y Arg Gl y Ser Gl y Thr Asp Phe Ser Leu Thr
85 90 95

Ile Thr Asn Leu Gl u Arg Gl u Asp Ile Al a Thr Tyr Phe Cys Gl n Gl n
100 105 110

eol f-seql.txt

Ser Ile Thr Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
115 120 125

Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Gly Gly Ser Gly
130 135 140

Gly Gly Gly Ser Glu Val Glu Leu Leu Glu Glu Ser Gly Ala Glu Leu
145 150 155 160

Val Arg Pro Gly Thr Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr
165 170 175

Ala Phe Thr Asn Tyr Trp Leu Gly Trp Val Lys Glu Arg Pro Gly His
180 185 190

Gly Leu Glu Trp Ile Gly Asp Ile Phe Pro Gly Ser Gly Asn Ile His
195 200 205

Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser
210 215 220

Ser Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Phe Glu Asp Ser
225 230 235 240

Ala Val Tyr Phe Cys Ala Arg Leu Arg Asn Trp Asp Glu Pro Met Asp
245 250 255

Tyr Trp Gly Glu Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly
260 265 270

Ser Gly Gly Gly Ser Gly Glu Gly Ser Glu Leu Val Met Thr
275 280 285

Gl n Ser Pro Ser Ser Leu Thr Val Thr Ala Gly Glu Lys Val Thr Met
290 295 300

Ser Cys Lys Ser Ser Glu Ser Leu Leu Asn Ser Gly Asn Glu Lys Asn
305 310 315 320

Tyr Leu Thr Trp Tyr Glu Glu Lys Pro Gly Glu Pro Pro Lys Leu Leu
325 330 335

Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr
340 345 350

Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Glu
355 360 365

Ala Glu Asp Leu Ala Val Tyr Tyr Cys Glu Asn Asp Tyr Ser Tyr Pro
370 375 380

eof f-seql.txt

Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys Glu Glu Lys Leu
385 390 395 400

Ile Ser Glu Glu Asp Leu His His His His His
405 410

<210> 128

<211> 400

<212> PRT

<213> pel B-muri neCD3VH-scFvEpCAM-6His

<400> 128

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
1 5 10 15

Ala Glu Pro Ala Met Ala Glu Val Glu Leu Val Glu Ser Gly Gly Gly
20 25 30

Leu Val Glu Pro Gly Lys Ser Leu Lys Leu Ser Cys Glu Ala Ser Gly
35 40 45

Phe Thr Phe Ser Gly Tyr Gly Met His Trp Val Arg Glu Ala Pro Gly
50 55 60

Arg Gly Leu Glu Ser Val Ala Tyr Ile Thr Ser Ser Ser Ile Asn Ile
65 70 75 80

Lys Tyr Ala Asp Ala Val Lys Gly Arg Phe Thr Val Ser Arg Asp Asn
85 90 95

Ala Lys Asn Leu Leu Phe Leu Glu Met Asn Ile Leu Lys Ser Glu Asp
100 105 110

Thr Ala Met Tyr Tyr Cys Ala Arg Phe Asp Trp Asp Lys Asn Tyr Trp
115 120 125

Gly Glu Gly Thr Met Val Thr Val Ser Ser Ala Lys Thr Ser Ser Gly
130 135 140

Gly Glu Glu Val Glu Leu Leu Glu Glu Ser Gly Ala Glu Leu Val Arg
145 150 155 160

Pro Gly Thr Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe
165 170 175

Thr Asn Tyr Trp Leu Gly Trp Val Lys Glu Arg Pro Gly His Gly Leu
180 185 190

Glu Trp Ile Gly Asp Ile Phe Pro Gly Ser Gly Asn Ile His Tyr Asn
195 200 205

Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser
Page 61

eol f-seql . txt

210 215 220

Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Phe Glu Asp Ser Ala Val
225 230 235 240

Tyr Phe Cys Ala Arg Leu Arg Asn Trp Asp Glu Pro Met Asp Tyr Trp
245 250 255

Gly Glu Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly
260 265 270

Gly Gly Gly Ser Gly Gly Gly Ser Glu Leu Val Met Thr Glu Ser
275 280 285

Pro Ser Ser Leu Thr Val Thr Ala Gly Glu Lys Val Thr Met Ser Cys
290 295 300

Lys Ser Ser Glu Ser Leu Leu Asn Ser Gly Asn Glu Lys Asn Tyr Leu
305 310 315 320

Thr Trp Tyr Glu Glu Lys Pro Gly Glu Pro Pro Lys Leu Leu Ile Tyr
325 330 335

Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Thr Gly Ser
340 345 350

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Glu Ala Glu
355 360 365

Asp Leu Ala Val Tyr Tyr Cys Glu Asn Asp Tyr Ser Tyr Pro Leu Thr
370 375 380

Phe Glu Ala Glu Thr Lys Leu Glu Ile Lys His His His His His His
385 390 395 400

<210> 129
<211> 384
<212> PRT
<213> pel B-muri neCD3VL-scFvEGFR1-6His

<400> 129

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
1 5 10 15

Ala Glu Pro Ala Met Ala Asp Ile Glu Met Thr Glu Ser Pro Ser Ser
20 25 30

Leu Pro Ala Ser Leu Glu Asp Arg Val Thr Ile Asn Cys Glu Ala Ser
35 40 45

Glu Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Glu Glu Lys Pro Glu Lys
50 55 60

eol f-seql . txt

Ala Pro Lys Leu Leu Ile Tyr Tyr Thr Asn Lys Leu Ala Asp Gly Val
65 70 75 80

Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Arg Asp Ser Ser Phe Thr
85 90 95

Ile Ser Ser Leu Glu Ser Glu Asp Ile Gly Ser Tyr Tyr Cys Gln Gln
100 105 110

Tyr Tyr Asn Tyr Pro Trp Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile
115 120 125

Lys Arg Ala Asp Ser Ser Gly Gly Gln Val Gln Leu Gln Glu Ser
130 135 140

Gly Pro Gly Leu Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr
145 150 155 160

Val Ser Gly Gly Ser Val Ser Ser Gly Asp Tyr Tyr Trp Thr Trp Ile
165 170 175

Arg Gln Ser Pro Gly Lys Gly Leu Glu Trp Ile Gly His Ile Tyr Tyr
180 185 190

Ser Gly Asn Thr Asn Tyr Asn Pro Ser Leu Lys Ser Arg Leu Thr Ile
195 200 205

Ser Ile Asp Thr Ser Lys Thr Gln Phe Ser Leu Lys Leu Ser Ser Val
210 215 220

Thr Ala Ala Asp Thr Ala Ile Tyr Tyr Cys Val Arg Asp Arg Val Thr
225 230 235 240

Gly Ala Phe Asp Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
245 250 255

Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Asp
260 265 270

Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly Asp
275 280 285

Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr Leu
290 295 300

Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
305 310 315 320

Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly Ser
325 330 335

eol f-seql . txt

Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro Glu
340 345 350

Asp Ile Ala Thr Tyr Phe Cys Gln His Phe Asp His Leu Pro Leu Ala
355 360 365

Phe Gly Gly Thr Lys Val Glu Ile Lys His His His His His
370 375 380

<210> 130

<211> 558

<212> PRT

<213> pel B-ta(DIG*EpCAM)-Myc-6HIS

<400> 130

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala
1 5 10 15

Ala Gln Pro Ala Met Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly
20 25 30

Leu Val Lys Pro Gly Gly Ser Leu Lys Leu Ser Cys Ala Val Ser Gly
35 40 45

Phe Thr Phe Ser Asp Tyr Ala Met Ser Trp Ile Arg Gln Thr Pro Glu
50 55 60

Asn Arg Leu Glu Trp Val Ala Ser Ile Asn Ile Gly Ala Thr Tyr Ala
65 70 75 80

Tyr Tyr Pro Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
85 90 95

Ala Lys Asn Thr Leu Phe Leu Gln Met Ser Ser Leu Gly Ser Glu Asp
100 105 110

Thr Ala Met Tyr Tyr Cys Ala Arg Pro Gly Ser Pro Tyr Glu Tyr Asp
115 120 125

Lys Ala Tyr Tyr Ser Met Ala Tyr Trp Gly Pro Gly Thr Ser Val Thr
130 135 140

Val Ser Ser Ala Lys Thr Ser Ser Gly Gly Gly Ser Gly Gly Gly
145 150 155 160

Gly Ser Gly Gly Gly Ser Gly Asp Val Gln Met Thr Gln Ser Thr
165 170 175

Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser Cys Arg
180 185 190

eol f-seql . txt

Ala Ser Gln Asp Ile Lys Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro
195 200 205

Gly Gly Thr Val Lys Leu Leu Ile Tyr Tyr Ser Ser Thr Leu Leu Ser
210 215 220

Gly Val Pro Ser Arg Phe Ser Gly Arg Gly Ser Gly Thr Asp Phe Ser
225 230 235 240

Leu Thr Ile Thr Asn Leu Glu Arg Glu Asp Ile Ala Thr Tyr Phe Cys
245 250 255

Gln Gln Ser Ile Thr Leu Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu
260 265 270

Glut Ile Lys Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Gly Gly
275 280 285

Ser Gly Gly Gly Ser Glu Val Gln Leu Leu Glu Gln Ser Gly Ala
290 295 300

Glut Leu Val Arg Pro Gly Thr Ser Val Lys Ile Ser Cys Lys Ala Ser
305 310 315 320

Gly Tyr Ala Phe Thr Asn Tyr Trp Leu Gly Trp Val Lys Gln Arg Pro
325 330 335

Gly His Gly Leu Glu Trp Ile Gly Asp Ile Phe Pro Gly Ser Gly Asn
340 345 350

Ile His Tyr Asn Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp
355 360 365

Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Phe Glu
370 375 380

Asp Ser Ala Val Tyr Phe Cys Ala Arg Leu Arg Asn Trp Asp Glu Pro
385 390 395 400

Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly
405 410 415

Gly Gly Ser Gly Gly Gly Ser Glu Gly Gly Ser Glu Leu Val
420 425 430

Met Thr Gln Ser Pro Ser Ser Leu Thr Val Thr Ala Gly Glu Lys Val
435 440 445

Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Asn Ser Gly Asn Gln
450 455 460

eol f-seql . txt

Lys Asn Tyr Leu Thr Trp Tyr Gln Gln Lys Pro Gln Gln Pro Pro Lys
465 470 475 480

Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gln Val Pro Asp Arg
485 490 495

Phe Thr Gln Ser Gln Ser Gln Thr Asp Phe Thr Leu Thr Ile Ser Ser
500 505 510

Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln Asn Asp Tyr Ser
515 520 525

Tyr Pro Leu Thr Phe Gln Ala Gln Thr Lys Leu Glu Ile Lys Glu Gln
530 535 540

Lys Leu Ile Ser Glu Glu Asp Leu His His His His His His
545 550 555

<210> 131

<211> 9

<212> PRT

<213> Anti -DIG VL CDR3

<400> 131

Gln Gln Ser Ile Thr Leu Pro Pro Thr
1 5

<210> 132

<211> 8

<212> PRT

<213> Anti -CD45 VH CDR1

<400> 132

Gln Phe Asp Phe Ser Arg Tyr Trp
1 5

<210> 133

<211> 8

<212> PRT

<213> Anti -CD45 VH CDR2

<400> 133

Ile Asn Pro Thr Ser Ser Thr Ile
1 5

<210> 134

<211> 14

<212> PRT

<213> Anti -CD45 VH CDR3

<400> 134

Ala Arg Gln Asn Tyr Tyr Arg Tyr Gln Asp Ala Met Asp Tyr
1 5 10

eol f-seql . txt

<210> 135
<211> 1167
<212> DNA
<213> Nucl eot i de sequence encodi ng pel B-CD3VL-scFvEPCAM(VH-VL)-6Hi s

<400> 135
atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60
atggccgaca ttcagctgac ccagtctcca gcaatcatgt ctgcacatctcc aggggagaag 120
gtcaccatga cctgcagagc cagttcaagt gtaagttaca tgaactggta ccagcagaag 180
tcagggcacct cccccaaaag atggatttat gacacatcca aagtggcttc tggagtccct 240
tatcgcttca gtggcagtgg gtctgggacc tcatactctc tcacaatcag cagcatggag 300
gctgaagatg ctgccactta ttactgccaa cagtggagta gtaacccgct cacgttcggt 360
gctgggacca agctggagct gaaatccgga ggtgggtggat ccgaggtgca gctgctcgag 420
cagtctggag ctgagctgggt aaggcctggg acttcagtga agatatcctg caaggcttct 480
ggatacgcct tcactaacta ctggcttaggt tgggtaaagc agaggcctgg acatggactt 540
gagtggattg gagatatttt cccttggaaat ggttaatatcc actacaatga gaagttcaag 600
ggcaaagcca cactgactgc agacaaatct tcgagcacag cctatatgca gctcagtagc 660
ctgacatttg aggactctgc tgtctatttc tgtcaagac tgaggaactg ggacgagcct 720
atggactact gggccaagg gaccacggc accgtctcct caggtggtgg tgggtctggc 780
ggcggcggct ccgggtggtgg tgggtctgag ctcgtatga cacagtctcc atcctccctg 840
actgtgacag caggagagaa ggtcactatg agctgcaagt ccagtcagag tctgttaaac 900
agtggaaatc aaaagaacta cttgacctgg taccagcaga aaccaggca gcctccaaa 960
ctgttcatct actgggcatc cactaggaa tctgggtcc ctgatcgctt cacaggcagt 1020
ggatctggaa cagatttcac tctcaccatc agcagtgtgc aggctgaaga cctggcagtt 1080
tattactgtc agaatgatta tagttatccg ctcacgttcg gtgctgggac caagctttag 1140
atcaaacatc atcaccatca tcattag 1167

<210> 136
<211> 1215
<212> DNA
<213> Nucl eot i de sequence encodi ng pel B-CD3VH-scFvHer2/neu-6HI S

<400> 136
atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60
atggccgata tcaaactgca gcagtcaggg gctgaactgg caagacctgg ggcctcagtg 120
aagatgtcct gcaagacttc tggctacacc tttacttaggt acacgatgca ctgggtaaaa 180
cagaggcctg gacagggctt ggaatggatt ggatacatta atcctagccg tggttatact 240
aattacaatc agaagttcaa ggacaaggcc acattgacta cagacaaatc ctccagcaca 300
gcctacatgc aactgagcag cctgacatct gaggactctg cagtcttatta ctgtgcaaga 360
tattatgtatc atcattactg ctttgactac tggggccaag gcaccactct cacagtctcc 420

eol f-seql . txt

tcaggtggtg	gtggttctgg	cggcggcggc	tccgggtggtg	gtggttctga	ggttcagctg	480
gtggagtctg	gcggtgtgcct	ggtgcagcca	gggggctcac	tccgtttgtc	ctgtcagct	540
tctggcttca	acattaaaga	cacctatata	cactgggtgc	gtcaggcccc	ggtaagggc	600
ctggaatggg	ttgcaaggat	ttatcctacg	aatggttata	ctagatatgc	cgatagcgtc	660
aagggccgtt	tcactataag	cgcagacaca	tccaaaaaca	cagcctacct	gcagatgaac	720
agcctgcgtg	ctgaggacac	tgccgtctat	tattgttcta	ggtggggagg	ggacggcttc	780
tatgctatgg	actattgggg	tcaaggaacc	ctggtcactg	tctcctccgg	tggtggtggt	840
tctggcggcg	gcggctccgg	tggtggtggt	tctgatatcc	agatgaccca	gtcccccggc	900
tccctgtccg	cctctgtggg	cgatagggtc	accatcacct	gccgtgccag	tcaggatgtg	960
aatactgctg	tagcctggta	tcaacagaaa	ccagggaaaag	ctccgaaact	actgatttac	1020
tcggcatcct	tcctctactc	tggagtcct	tctcgcttct	ctggatccag	atctgggacg	1080
gatttcactc	tgaccatcag	cagtctgcag	ccggaagact	tcgcaactta	ttactgtcag	1140
caacattata	ctactccctcc	cacgttcgg	cagggtacca	aggtggagat	caaacatcat	1200
caccatcatc	attag					1215

<210> 137
 <211> 1212
 <212> DNA
 <213> Nucl eotide sequence encoding the B-CD3VH-scFvEGFR (1) -6HIS

<400> 137	atgaaatacc	tgctgccgac	cgctgctgct	ggtctgctgc	tcctcgctgc	ccagccggcg	60
	atggccgata	tcaaactgca	gcagtcaggg	gctgaactgg	caagacctgg	ggcctcagtg	120
	aagatgtcct	gcaagacttc	tggctacacc	tttacttaggt	acacgatgca	ctgggtaaaa	180
	cagaggcctg	gacagggct	ggaatggatt	ggatacatta	atcctagccg	tggttatact	240
	aattacaatc	agaagttcaa	ggacaaggcc	acattgacta	cagacaaatc	ctccagcaca	300
	gcctacatgc	aactgagcag	cctgacatct	gaggactctg	cagtctatta	ctgtgcaaga	360
	tattatgatg	atcattactg	ccttgactac	tggggccaag	gcaccactct	cacagtctcc	420
	tcaggtggtg	gtggttctgg	cggcggcggc	tccgggtgg	gtggttctca	ggtgcagctg	480
	caggagtccg	gcccaggact	ggtgaagct	tcggagaccc	tgtccctcac	ctgcactgtc	540
	tctggtggt	ccgtcagcag	tggtgattac	tactggacct	ggatccggca	gtcccccagg	600
	aaggactgg	agtggattgg	acacatctat	tacagtggga	acaccaatta	taaccctcc	660
	ctcaagagcc	gactcaccat	atcaattgac	acgtccaaga	ctcagttctc	cctgaagctg	720
	agttctgtga	ccgctgcgga	cacggccatt	tattactgtg	tgcgagatcg	agtgactgg	780
	gcttttata	tctggggcca	aggacaatg	gtcaccgtct	cttccgggtgg	tggtggttct	840
	ggcggcggcg	gctccgggtgg	tggtggttct	gacatccaga	tgacccagtc	tccatccctcc	900
	ctgtctgcat	ctgtcggaga	cagagtacc	atcaactgcc	aggcgagtca	ggacatcagc	960
	aactatataa	attggatatac	gcagaaacca	gggaaagccc	ctaaactcct	gatctacgat	1020

eol f-seql . txt

gcatccaatt	tggaaacagg	ggtccatca	aggtcagtg	gaagtggatc	tgggacagat	1080
tttactttca	ccatcagcag	cctgcagcct	gaagatattt	caacatattt	ctgtcaacac	1140
tttgcatcatc	tcccgctcgc	tttcggcgg	gggaccaagg	tggagatcaa	acatcatcac	1200
catcatcatt	ag					1212

<210> 138

<211> 1245

<212> DNA

<213> Nucl eot i de sequence encoding pel B-CD3VH-scFvCEA-6H1 S

<400> 138	atgaaatacc	tgctgccgac	cgctgctgct	ggtctgctgc	tcctcgctgc	ccagccggcg	60
	atggccgata	tcaaactgca	gcagtcaggg	gctgaactgg	caagacctgg	ggcctcagtg	120
	aagatgtcct	gcaagacttc	tggctacacc	tttacttaggt	acacgatgca	ctgggtaaaa	180
	cagaggcctg	gacagggct	ggaatggatt	ggatacatta	atcctagccg	tggttatact	240
	aattacaatc	agaagttcaa	ggacaaggcc	acattgacta	cagacaaatc	ctccagcaca	300
	gcctacatgc	aactgagcag	cctgacatct	gaggactctg	cagtctatta	ctgtgcaaga	360
	tattatgtg	atcattactg	ctttgactac	tggggccaag	gcaccactct	cacagtctcc	420
	tcaggtggtg	gtggttctgg	cggccggcggc	tccgggttg	gtggttcttc	tagtgtggcc	480
	caggtgcaac	tgcagcagtc	aggggctgag	ctggctagac	ctggggcttc	agtgaagatg	540
	tcctgcaagg	cttctggcta	cacccttact	acctacacaa	tacactgggt	aagacagagg	600
	cctggacacg	atctggaatg	gattggatac	attaatccta	gcagtggata	ttctgactac	660
	aatcaaaaact	tcaagggcaa	gaccacattt	actgcagaca	agtcctccaa	cacagcctac	720
	atgcaactga	acagcctgac	atctgaggac	tctgcggct	attactgtgc	aagaagagcg	780
	gactatggta	actacgaata	tacctggtti	gcttactggg	gccaaggggac	cacggtcacc	840
	gtctccctcag	gtggaggcgg	ttcaggcgg	ggtggctctg	gcgggtggcgg	atcggacatc	900
	gagctcactc	agtctccaaa	attcatgtcc	acatcagtag	gagacagggt	caacgtcacc	960
	tacaaggcca	gtcagaatgt	gggtactaat	gtagcctggt	ttcaacaaaa	accaggcCAA	1020
	tctcctaaag	ttctgattt	ctcggcatct	taccgataca	gtggagtccc	tgatcgcttc	1080
	acaggcagtg	gatctggaac	agatttact	ctcaccatca	gcaatgtgca	gtctgaagac	1140
	ttggcagagt	atttctgtca	gcaatatcac	acctatcctc	tcacgttcgg	agggggcacc	1200
	aagctggaaa	tcaaacgggc	ggatcatcat	caccatcatc	attag		1245

<210> 139

<211> 1179

<212> DNA

<213> Nucl eot i de sequence encoding pel B-CD3VL-scFvCEA-6H1 S

<400> 139

atgaaatacc	tgctgccgac	cgctgctgct	ggtctgctgc	tcctcgctgc	ccagccggcg	60
atggccgaca	ttcagctgac	ccagtctcca	gcaatcatgt	ctgcacatctcc	aggggagaag	120

eol f-seql . txt

gtcaccatga	cctgcagagc	cagttcaagt	gtaagttaca	tgaactggta	ccagcagaag	180
tcagggacct	cccccaaaag	atggatttat	gacacatcca	aagtggcttc	tggagtcct	240
tatcgcttca	gtggcagtgg	gtctgggacc	tcatactctc	tcacaatcag	cagcatggag	300
gctgaagatg	ctgccactta	ttactgccaa	cagtggagta	gtaacccgct	cacgttcggt	360
gctgggacca	agctggagct	gaaatccgga	ggtggtgat	cctctagagt	ggcccaggt	420
caactgcagc	agtcaaaaa	tgagctggct	agacctgggg	cttcagtgaa	gatgtcctgc	480
aaggcttctg	gctacaccct	tactacctac	acaatacact	ggtaagaca	gaggcctgga	540
cacgatctgg	aatggattgg	atacattaat	cctagcagt	gatattctga	ctacaatcaa	600
aacttcaagg	gcaagaccac	atttactgca	gacaagtctt	ccaacacagc	ctacatgcaa	660
ctgaacagcc	tgacatctga	ggactctgcg	gtctattact	gtgcaagaag	agcggactat	720
ggtaactacg	aatatacctg	gtttgcttac	tggggccaag	ggaccacggt	caccgtctcc	780
tcaggtggag	gcgggatcagg	cgagggtggc	tctggcggtg	gcggatcgga	catcgagctc	840
actcagtctc	caaaattcat	gtccacatca	gtaggagaca	gggtcaacgt	cacctacaag	900
gccagtcaga	atgtgggtac	taatgttagcc	tggttcaac	aaaaaccagg	gcaatctcct	960
aaagttctga	tttactcgcc	atcttaccga	tacagtggag	tccctgatcg	cttcacaggc	1020
agtggatctg	gaacagattt	cacttcacc	atcagcaatg	tgcagtctga	agacttggca	1080
gagtatttct	gtcagcaata	tcacacctat	cctctcacgt	tcggaggggg	caccaagctg	1140
gaaatcaaac	gggcggatca	tcatcaccat	catcattag			1179

<210> 140

<211> 1245

<212> DNA

<213> Nucl eotid e sequence encoding pel B-(aCD3)VH-scFvHLA-Cw6-myc-6Hi s

<400> 140

atgaaatacc	tgctgccgac	cgctgctgct	ggtctgctgc	tcctcgctgc	ccagccggcg	60
atggccgata	tcaaactgca	gcagtcaggg	gctgaactgg	caagacctgg	ggcctcagtg	120
aagatgtcct	gcaagacttc	tggctacacc	tttacttaggt	acacgatgca	ctgggtaaaa	180
cagaggcctg	gacagggct	ggaatggatt	ggatacatta	atcctagccg	tggttatact	240
aattacaatc	agaagttcaa	ggacaaggcc	acattgacta	cagacaaatc	ctccagcaca	300
gcctacatgc	aactgagcag	cctgacatct	gaggactctg	cagtctatta	ctgtgcaaga	360
tattatgatg	atcattactg	ccttgactac	tggggccaag	gcaccactct	cacagtctcc	420
tcagggcg	gcggcagcgg	cggcgccggc	agcggcgccg	aagtgcagct	ggtggaaagc	480
ggcggcggcc	tggcagcc	ggcggcagc	ctgcgcctga	gctgcgcggc	gagcggcttt	540
acctttagca	gctatgcgt	gagctgggt	cgccaggcgc	cggccaaagg	cctggaatgg	600
gtgagcgcga	ttagcggcag	cggcgccagc	acctattatg	cggatagcgt	gaaaggccgc	660
tttaccatta	gccgcataa	cagaaaaac	accctgtatc	tgcagatgaa	cagcctgcgc	720

	eol f-seql . txt	
gcggaagata ccgcgggtga ttattgcgcg	cgctatacgct ttagctggtt tgatgtgtgg	780
ggccaggca ccctggtgac cgtgagcagc	gcgggcccgc gcagcggcgg cggcggcagc	840
ggcggcggcg gcagcggcgg cggcggcagc	gatattgaac tgacccagcc gccgagcgtg	900
agcgtggcgc cggccagac cgccgcatt	agctgcagcg gcgatgcgc gggcgataaa	960
tatgcgagct ggtatcagca	gaaaccgggc caggcccg tgctggtgat ttatgtatgt	1020
agcgatcgcc cgagcggcat	tccggaacgc ttagcggca gcaacagcgg caacaccgcg	1080
accctgacca ttagcggcac ccaggcggaa	gatgaagcgg attattattt ccagagctat	1140
gataactttg atagcccggt gttggcggc	ggcaccaaac tgaccgtgct gggcgaacaa	1200
aaactcatct cagaagagga tctgcatcat	caccatcatc attag	1245

<210> 141
 <211> 1176
 <212> DNA

<213> Nucl eot i de sequence encodi ng pel B-CD3VL-scFvCD138-6Hi s

<400> 141		
atgaaatacc tgctgccgac	cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg	60
atggccgaca ttcagctgac	ccagtctcca gcaatcatgt ctgcattctcc aggggagaag	120
gtcaccatga cctgcagagc	cagttcaagt gtaagttaca tgaactggta ccagcagaag	180
tcagggaccc ccccaaaaag	atggatttat gacacatcca aagtggcttc tggagtcct	240
tatcgcttca gtggcagtgg	gtctgggacc tcatactctc tcacaatcag cagcatggag	300
gctgaagatg ctgccactta	ttactgccaa cagtggagta gtaacccgct cacgttcggt	360
gctgggacca agctggagct	gaaatccgga ggtgggtggat ccggaggtgg tggatcccag	420
gtgcagctgc agcagagcgg	cagcgaactg atgccggcg cgagcgtgaa aattagctgc	480
aaagcgaccg gctatacctt	tagcaactat tggattgaat gggtaaca ggcggccggc	540
catggcctgg aatggattgg	cgaaattctg ccgggcaccg gccgcaccat ttataacgaa	600
aaatttaag gcaaagcgac	cttaccgcg gatattagca gcaacaccgt gcagatgcag	660
ctgagcagcc tgaccagcga	agatagcgcg gtgtattatt gcgcgcgcga acagtattat	720
ggcaactttt attatgcgt	ggattattgg ggccaggca ccagcgtgac cgtgagcagc	780
ggcggcggcg gcagcggcgg	cggcggcagc ggcggcggcg gcagcgatat tcagatgacc	840
cagagcacca gcagcctgag	cgcgagcctg ggcgatgcgc tgaccattag ctgcagcgcg	900
agccagggca ttaacaacta	tctgaactgg tatcagcaga aaccggatgg caccgtggaa	960
ctgctgattt attataccag	caccctgcag agcggcgtgc cgagccgctt tagcggcagc	1020
ggcagcggca ccgattatag	cctgaccatt agcaacctgg aaccggaaga tattggcacc	1080
tattattgcc agcagtata	caaactgccc cgcaccttg gccggcggcac caaactggaa	1140
attaaacgca ccgtgcatca	tcaccatcat cattag	1176

<210> 142
 <211> 1227

eol f-seql . txt

<212> DNA

<213> Nucl eoti de sequence encodi ng pel B-CD3VH-scFvCD138-6Hi s

<400> 142		
atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg	60	
atggccgata tcaaactgca gcagtcaggg gctgaactgg caagacctgg ggcctcagtg	120	
aagatgtcct gcaagacttc tggctacacc tttacttagt acacgatgca ctgggtaaaa	180	
cagaggcctg gacagggctt ggaatggatt ggatacatta atcctagccg tggttatact	240	
aattacaatc agaagttcaa ggacaaggcc acattgacta cagacaaatc ctccagcaca	300	
gcctacatgc aactgagcag cctgacatct gaggactctg cagtctatta ctgtgcaaga	360	
tattatgatg atcattactg ccttgactac tggggccaag gcaccactct cacagtctcc	420	
tcaggtggtg gtggttctgg cggcgccggc tccgggtggt gtggttctca ggtgcagctg	480	
cagcagagcg gcagcgaact gatgccgggc gcgagcgtga aaattagctg caaagcgacc	540	
ggctatacct ttagcaacta ttggattgaa tgggtgaaac agcgcccgaa ccatggcctg	600	
gaatggattt gcgaaattct gccggcacc ggccgcacca ttataacga aaaatttaaa	660	
ggcaaagcga cctttaccgc ggtatttagc agcaacaccg tgcagatgca gctgagcagc	720	
ctgaccagcg aagatagcgc ggttattat tgcgcgcgcg aacagtatta tggcaacttt	780	
tattatgcga tggattattt gggccaggc accagcgtga ccgtgagcag cggcgccggc	840	
ggcagcggcg gcggcgccag cggcgccggc ggcagcgata ttcatgac ccagagcacc	900	
agcagcctga gcgcgagcct gggcgatcgc gtgaccatta gctgcagcgc gagccaggc	960	
attaacaact atctgaactg gtatcagcag aaaccggatg gcaccgtgaa actgctgatt	1020	
tattatacca gcaccctgca gagcggcgtg ccgagccgct ttagcggcag cggcagcggc	1080	
accgattata gcctgaccat tagcaacctg gaaccgaaag atattggcac ctattattgc	1140	
cagcgtata gcaaactgcc gcgcacctt ggcggccggca ccaaactgga aattaaacgc	1200	
accgtgcatac atcaccatca tcattag	1227	

<210> 143

<211> 1212

<212> DNA

<213> Nucl eoti de sequence encodi ng pel B- (aHi s)VH-scFvHLA-A2(VH-VL)-myc

<400> 143		
atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg	60	
atggcccagg tgcagctgca gcagagcgcc ccggaaatgt taaaaccggg cgcgagcgtg	120	
aaaattagct gcaaagcgag cggctatacc tttaccgatt attatatgaa ctgggtgaaa	180	
cagagcccg gcaaaggcct ggaatggatt ggcgatatta acccgaaacaa cggcgccacc	240	
agctataacc agaaattaa aggcgcgcg accctgaccg tggataaaag cagcagcacc	300	
gcgtatatgg aactgcgcag cctgaccagc gaagatagca gcgtgttatta ttgcgaaagc	360	
cagagcggcg cgtattgggg ccagggcacc accgtgaccg tgagcgcggg cggcgccggc	420	
agcggcgccg gcggcagcgg cggccaggtg cagctggtgc agtctggggg aggcgtggtc	480	

eol f-seql . txt

cagcctgggg	ggtccctgag	agtctcctgt	gcagcgtctg	gggtcaccct	cagtgattat	540
ggcatgcatt	gggtccgcca	ggctccaggc	aaggggctgg	agtggatggc	ttttatacgg	600
aatgatggaa	gtgataaata	ttatgcagac	tccgtgaagg	gccgattcac	catctccaga	660
gacaactcca	agaaaacagt	gtctctgcaa	atgagcagtc	tcagagctga	agacacggct	720
gtgtattact	gtgcgaaaaa	tggcgaatct	gggccttgg	actactggta	cttcgatctc	780
tggggccgtg	gcaccctggt	caccgtgtcg	agtggtgag	gcggttcagg	cggaggtggc	840
tctggcgtg	gcggatcgga	tgttgtgatg	actcagtctc	catcctccct	gtctgcatct	900
taggagaca	gagtcaccat	cacttgccag	gcgagtcagg	acattagcaa	ctatttaat	960
tggtatcagc	agaaaccagg	gaaagcccct	aagctcctga	tctacgatgc	atccaatttg	1020
gaaacagggg	tcccatcaag	gttcagtgga	agtggatctg	ggacagattt	tactttcacc	1080
atcagcagcc	tgcagcctga	ggattttgca	acttattact	gccaacaata	tagtagttt	1140
ccgctcactt	tcggcggagg	gaccaaagtg	gatatacaaac	gtgaacaaaaa	actcatctca	1200
gaagaggatc	tg					1212

<210> 144

<211> 1230

<212> DNA

<213> Nucl eotide sequence encoding the B- (aHis) VL-scFvCD45 (VL-VH) -myc

<400> 144

atgaaatacc	tgctgccgac	cgctgctgct	ggtctgctgc	tcctcgctgc	ccagccggcg	60
atggccgatt	ataaaagatat	tctgatgacc	cagaccccgaa	gcagcctgccc	ggtgagcctg	120
ggcgatcagg	cgagcattag	ctggccgcagc	agccagagca	tttgtcatag	caacggcaac	180
acctatctgg	aatggtatct	gcagaaaccg	ggccagagcc	cgaaactgct	gatttataaa	240
gtgagcaacc	gctttagcgg	cgtgcccggat	cgctttagcg	gcagcggcag	cggcaccgat	300
tttaccctga	aaatttagccg	cgtggaagcg	gaagatctgg	gcgtgttatta	ttgctttcag	360
ggcagccatg	tgccgttac	cttggcagc	ggcaccaaac	tggaaattaa	acgcggcggc	420
ggcggcagcg	gcggcggcgg	cagcggcggc	gatatttttc	tgacccagag	ccggcgcgac	480
ctggcggta	gcctgggtca	gcgtgccacc	attagctgcc	gtgcgagcaa	aagcgtgagc	540
accagcggct	atagctatct	gcattggat	cagcagaaac	cgggccagcc	tccaaaactg	600
ctgatttatac	tggccagcaa	cctggaaagc	ggtgtccgg	cccgttttag	cggcagcggc	660
agcggtaccg	attttaccct	gaacattcat	ccgggtggaaag	aagaagatgc	ggcgacctat	720
tattgccagc	atagccgtga	actgccgttt	acctttggca	gccccaccaa	actggaaatt	780
aaaaagatct	ctgggtggcgg	cggctcggt	ggtgtgggt	cgggcggcgg	cggtcgagc	840
caggtgcagc	tggtggaaag	cggtgccgg	ctgggtgcagc	cgggcggcag	cctgaaactg	900
agctgtgccg	ccagcggtt	tgatttttagc	cgtttattgga	tgagctgggt	gcgtcaggcg	960
ccgggcaaag	gcctggaaatg	gattggcga	attaaccga	ccagcagcac	cattaacttt	1020

eol f-seql . txt

accccgagcc	tgaaagataa	agtgttatt	agccgtgata	acgcgaaaaaa	caccctgtat	1080
ctgcagatga	gcaaagtgcg	tagcgaagat	accgcgtgt	attattgcgc	gcgtggcaac	1140
tattatcggtt	atggcgatgc	gatggattat	tggggccagg	gcaccagcgt	gaccgtgagc	1200
gaacaaaaac	tcatctcaga	agaggatctg				1230
<210> 145						
<211> 1248						
<212> DNA						
<213> Nucl eot i de sequence encodi ng pel B- (aCD3)VH-scFvHLA-A2(VH-VL)-myc-6Hi s						
<400> 145						
atgaaatacc	tgctgccgac	cgctgctgct	ggtctgctgc	tcctcgctgc	ccagccggcg	60
atggccgata	tcaaactgca	gcagtcaggg	gctgaactgg	caagacctgg	ggcctcagtg	120
aagatgtcct	gcaagacttc	tggctacacc	tttacttaggt	acacgatgca	ctgggtaaaa	180
cagaggcctg	gacagggct	ggaatggatt	ggatacatta	atcctagccg	tggttatact	240
aattacaatc	agaagttcaa	ggacaaggcc	acattgacta	cagacaaatc	ctccagcaca	300
gcctacatgc	aactgagcag	cctgacatct	gaggactctg	cagtctatta	ctgtgcaaga	360
tattatgatg	atcattactg	ccttgactac	tggggccaag	gcaccactct	cacagtctcc	420
tcaggcggcg	gcggcagcgg	cggcggcggc	agcggcggcc	aggtgcagct	ggtgcagtct	480
gggggaggcg	tggtccagcc	tgggggtcc	ctgagagtct	cctgtgcagc	gtctgggtc	540
accctcagtg	attatggcat	gcattgggtc	cggcaggctc	caggcaaggg	gctggagtgg	600
atggctttta	tacggaatga	tggaagtgtat	aaatattatg	cagactccgt	gaagggccga	660
ttcaccatct	ccagagacaa	ctccaagaaa	acagtgtctc	tgcaaatgag	cagtctcaga	720
gctgaagaca	cggctgtgta	ttactgtgcg	aaaaatggcg	aatctggcc	tttggactac	780
tggtacttcg	atctctgggg	ccgtggcacc	ctggtcaccg	tgtcgagtgg	tggaggcgggt	840
tcaggcggag	gtggctctgg	cggtggcgg	tcggatgttg	tgtgactca	gtctccatcc	900
tccctgtctg	catctgtagg	agacagagtc	accatcaatt	gccaggcgg	tcaggacatt	960
agcaactatt	taaattggta	tcagcagaaa	ccagggaaag	cccctaagct	cctgatctac	1020
gatgcatcca	atttggaaac	aggggtccca	tcaaggtca	gtggaagtgg	atctggaca	1080
gattttactt	tcaccatcg	cagcctgcag	cctgaggatt	ttgcaactta	ttactgccaa	1140
caatataatgt	gttttccgct	cactttcggc	ggagggacca	aagtggatat	caaacgtgaa	1200
caaaaaactca	tctcagaaga	ggatctgcat	catcaccatc	atcattag		1248
<210> 146						
<211> 1221						
<212> DNA						
<213> Nucl eot i de sequence encodi ng pel B- (aCD3)VL-scFvCD45(VL-VH)-myc-6Hi s						
<400> 146						
atgaaatacc	tgctgccgac	cgctgctgct	ggtctgctgc	tcctcgctgc	ccagccggcg	60
atggccgaca	ttcagctgac	ccagtctcca	gcaatcatgt	ctgcattctcc	aggggagaag	120

eol f-seql . txt

gtcaccatga	cctgcagagc	cagttcaagt	gtaagttaca	tgaactggta	ccagcagaag	180
tcagggacct	cccccaaaag	atggatttat	gacacatcca	aagtggcttc	tggagtcct	240
tatcgcttca	gtggcagttgg	gtctgggacc	tcatactctc	tcacaatca	cagcatggag	300
gctgaagatg	ctgccactta	ttactgcca	cagtggagta	gtaacccgct	cacgttcggt	360
gctgggacca	agctggagct	gaaaggcggc	ggcggcagcg	gcccggcgg	cagcggcggc	420
gatattgttc	tgacccagag	cccgccgagc	ctggcggta	gcctgggtca	gcgtgccacc	480
attagctgcc	gtgcgagcaa	aagcgtgagc	accagcgct	atagctatct	gcattggat	540
cagcagaaac	cgggccagcc	tccaaaactg	ctgatttac	tggccagcaa	cctggaaagc	600
ggtgtgccgg	cccgtttag	cgccagcggc	agcggtaccg	attttaccct	gaacattcat	660
ccggtgtgaag	aagaagatgc	ggcgcacat	tattgccagc	atagccgtga	actgccgtt	720
accttggca	cgggcaccaa	actggaaatt	aaaaagatct	ctggtgtgg	cggctcgggt	780
ggtggtgggt	cgggcggcgg	cggctcgagc	caggtgcagc	tggtgaaag	cggtgtgg	840
ctgggtgcagc	cgggcggcag	cctgaaactg	agctgtgccg	ccagcggtt	tgattttagc	900
cgttatttgg	tgagctgggt	gcgtcaggcg	ccgggcaaag	gcctggaaatg	gattggcgaa	960
attaaccga	ccagcagcac	cattaactt	accccgagcc	tgaagataa	agtgtttatt	1020
agccgtata	acgcgaaaaa	caccctgtat	ctgcagatga	gcaaagtgcg	tagcaagat	1080
accgcgctgt	attattgcgc	gcgtggcaac	tattatcg	atggcgatgc	gatggattat	1140
tggggccagg	gcaccagcgt	gaccgtgagc	gaacaaaaac	tcatctcaga	agaggatctg	1200
catcatcacc	atcatcatta	g				1221

<210> 147
 <211> 1248
 <212> DNA
 <213> Nucl eot i de sequence encoding pel B-VHaDI G-scFvEGFR-FLAG-6HI S

<400> 147	atgaaatacc	tgctgccgac	cgctgctgct	ggtctgctgc	tcctcgctgc	ccagccggcg	60
	atggccgaag	tgcagctgg	gaaagcggc	ggcggcctgg	tgaaacggg	cgccagcctg	120
	aaactgagct	gcgcggtgag	cggcttacc	tttagcgatt	atgcgatgag	ctggattcgc	180
	cagaccccg	aaaaccgcct	ggaatgggtg	gcgagcatta	acattggcgc	gacctatgc	240
	tattatccgg	atagcgtgaa	aggccgctt	accattagcc	gcgataacgc	aaaaaacacc	300
	ctgtttctgc	agatgagcag	cctggcagc	gaagataccg	cgtatgtatta	ttgcgcgcgc	360
	ccgggcagcc	cgtatgaata	tgataaagcg	tattatagca	tggcgtattt	gggcccgggc	420
	accagcgtga	ccgtgagcag	cgcggaaacc	ggtgggttg	gttctggcgg	cggcggctcc	480
	caggtgcagc	tgcaggagtc	ggcccccagga	ctggtgaaagc	cttcggagac	cctgtccctc	540
	acctgcactg	tctctggtgg	ctccgtcagc	agtggtgatt	actactggac	ctggatccgg	600
	cagtccccag	ggaaggact	ggagtgatt	ggacacatct	attacagtgg	gaacaccaat	660
	tataaccct	ccctcaagag	ccgactcacc	atatcaattt	acacgtccaa	gactcagttc	720

eol f-seql . txt

tccctgaagc	tgagttctgt	gaccgctgcg	gacacggcca	tttattactg	tgtgcagat	780
cgagtgactg	gtgctttga	tatctggggc	caagggacaa	tggtcaccgt	ctcttccgggt	840
ggtgggtggtt	ctggcggcg	cggctccgg	ggtgggtggtt	ctgacatcca	gatgacccag	900
tctccatcct	ccctgtctgc	atctgtcgga	gacagagtca	ccatcacttg	ccagggcgagt	960
caggacatca	gcaactat	aaattgtat	cagcagaac	cagggaaagc	ccctaaactc	1020
ctgatctacg	atgcatccaa	tttggaaaca	ggggtccc	caaggttcag	tggaagtgg	1080
tctggacag	atttacttt	caccatcagc	agcctgcagc	ctgaagat	tgcaacat	1140
ttctgtcaac	actttgatca	tctccgctc	gctttcg	gagggacaa	ggtggagatc	1200
aaagactaca	aggatgacga	tgacaaacat	catcaccatc	atcattag		1248

<210> 148
 <211> 1239
 <212> DNA
 <213> Nucl eoti de sequence encodi ng pel B-VLaDI G-scFvEpCAM-myc-6HI S

<400> 148	atgaaatacc	tgctgccgac	cgctgctgct	ggtctgctgc	tcctcgctgc	ccagccggcg	60
	atggccgatg	tgcagatgac	ccagagcacc	agcagcctga	gcgcgagcct	gggcgatcgc	120
	gtgaccatta	gctgccgcgc	gagccaggat	attaaaaact	atctgaactg	gtatcagcag	180
	aaaccgggcg	gcaccgtgaa	actgctgatt	tattatagca	gcaccctgct	gagcggcgt	240
	ccgagccgct	ttagcggccg	cgccagcggc	accgattta	gcctgaccat	taccaac	300
	gaacgcgaag	atattgcac	ctattttgc	cagcagagca	ttaccctgccc	gccgacc	360
	ggcggcggca	ccaaactgga	aattaaacgc	gcggatgcgg	cgccgaccgt	gagcatttt	420
	ggtggttccg	gaggtggtgg	atccgaggtg	cagctgctcg	agcagtctgg	agctgagctg	480
	gtaaggcctg	ggacttcagt	gaagatatcc	tgcaaggctt	ctggatacgc	cttca	540
	tactggctag	gttgggtaaa	gcagaggcct	ggacatggac	ttgagtggat	tggagatatt	600
	ttccctggaa	gtggtat	ccactacaat	gagaagttca	aggc	aaagc	660
	gcagacaat	cttcgagcac	agcctat	cagctcagta	gcctgacatt	tgaggact	720
	gctgtctatt	tctgtcaag	actgaggaac	tggacgagc	ctatggacta	ctggggccaa	780
	gggaccacgg	tcaccgtctc	ctcagggtgt	ggtggttctg	gcccggcgg	ctccgggt	840
	ggtggttctg	agctcgtat	gacacagtct	ccatcctccc	tgactgtgac	agcaggagag	900
	aaggtcacta	tgagctgcaa	gtccagtcag	agtctttaa	acagtggaaa	tcaaaagaac	960
	tacttgacct	ggtaccagca	gaaaccaggg	cagcctccta	aactgtt	gatctactggca	1020
	tccactaggg	aatctgggtt	ccctgatcgc	ttcacaggca	gtggatctgg	aacagatttc	1080
	actctcacca	tcagcgtgt	gcaggctgaa	gacctggcag	tttattactg	tcagaatgat	1140
	tatagttatc	cgctcacgtt	cggtgctgg	accaagttg	agatcaaaga	acagaaactg	1200
	atctctgaag	aagacctgca	tcatcaccat	catcattag			1239

eol f-seql . txt

<210> 149
 <211> 1203
 <212> DNA
 <213> Nucl eoti de sequence encodi ng pel B-muri neCD3VH-scFvEpCaAM-6Hi s

<400> 149
 atgaaatatac tgctgccgac cgccggcg ggcctgctgc tgctggcg gcagccggcg 60
 atggcggaaag tgcagctggt ggaaagcg gc ggcggcctgg tgcagccggg caaaagcctg 120
 aaactgagct gcgaagcgag cggcttacc tttagcggt atggcatgca ttgggtgcgc 180
 caggcgccgg gccgcccgt ggaaagcggt gcgtatatta ccagcagcag cattaaacatt 240
 aaatatgcgg atgcggtgaa agggcgtt accgtgagcc gcgataacgc gaaaaacctg 300
 ctgtttctgc agatgaacat tctgaaaagc gaagataccg cgtatgttta ttgcgcgc 360
 tttgattggg ataaaaacta ttggggccag ggcaccatgg tgaccgtgag cagcgcgaaa 420
 accagcagcg gccggcgca ggtgcagctg ctcgagcagt ctggagctga gctggtaagg 480
 cctggactt cagtgaagat atcctgcaag gcttctggat acgccttcac taactactgg 540
 cttagttggg taaagcagag gcctggacat ggacttgagt ggattggaga tattttccct 600
 ggaagtggta atatccacta caatgagaag ttcaaggca aagccacact gactgcagac 660
 aaatcttcga gcacagccca tatgcagctc agtagcctga catttgagga ctctgctgtc 720
 tatttctgtg caagactgag gaactggac gaggctatgg actactggg ccaaggacc 780
 acggtcaccg tctcctcagg tggtggtggt tctggcgcg gccgcctccgg tggtggtggt 840
 tctgagctcg ttagtgcacaca gtctccatcc tccctgactg tgacagcagg agagaaggc 900
 actatgagct gcaagtccag tcagagtctg ttaaacagtg gaaatcaaaa gaactacttg 960
 acctggtacc agcagaaacc agggcagcct cctaaactgt ttagtctactg ggcattccact 1020
 agggaatctg gggccctga tcgcttcaca ggcagtggat ctggAACAGA tttcactctc 1080
 accatcagca gtgtgcaggc tgaagacctg gcagtttatt actgtcagaa tgattatagt 1140
 tatccgctca cggtcggtgc tgggaccaag cttgagatca aacatcatca ccatcatcat 1200
 tag 1203

<210> 150
 <211> 1155
 <212> DNA
 <213> Nucl eoti de sequence encodi ng pel B-muri neCD3VL-scFvEGFR-6Hi s

<400> 150
 atgaaatatac tgctgccgac cgccggcg ggcctgctgc tgctggcg gcagccggcg 60
 atggcggata tttagatgac ccagagcccg agcagctgc cggcagcgc gggcgatcgc 120
 gtgaccatta actgccaggc gagccaggat attagcaact atctgaactg gtatcagcag 180
 aaaccggca aagcgccaa actgctgatt tattatacca acaaactggc ggtatggcgtg 240
 ccgagccgct ttagcggcag cggcagcgc cgccatagca gctttaccat tagcagcctg 300
 gaaagcgaag atattggcag ctattattgc cagcgttatt ataactatcc gtggacccctt 360

eol f-seql . txt

ggcccgggca	ccaaactgga	aattaaacgc	gcggatagca	gcggcggcgg	ccaggtgcag	420
ctgcaggagt	cgggcccagg	actggtgaag	ccttcggaga	ccctgtccct	cacctgcact	480
gtctctggtg	gctccgtcag	cagtggtgat	tactactgga	cctggatccg	gcagtcggca	540
ggaaggac	tggagtggat	tggacacatc	tattacagtg	ggaacacccaa	ttataacccc	600
tccctcaaga	gccgactcac	cataatcaatt	gacacgtcca	agactcagtt	ctccctgaag	660
ctgagttctg	tgaccgctgc	ggacacggcc	atttattact	gtgtgcgaga	tcgagtgact	720
ggtgctttt	atatctgggg	ccaaggaca	atggtcaccg	tctcttccgg	tggtggtgg	780
tctggcggcg	gcggctccgg	tggtggtgg	tctgacatcc	agatgacccaa	gtctccatcc	840
tccctgtctg	catctgtcgg	agacagagtc	accatcaatt	gccaggcgag	tcaggacatc	900
agcaactatt	taaattggta	tcagcagaaa	ccagggaaag	cccctaaact	cctgatctac	960
gatgcatcca	atttggaaac	aggggtccca	tcaaggttca	gtggaagtgg	atctggaca	1020
gattttactt	tcaccatcag	cagcctgcag	cctgaagata	ttgcaacata	tttctgtcaa	1080
cactttgatc	atctccgct	cgcttcggc	ggagggacca	aggtggagat	caaacatcat	1140
caccatcatc	attag					1155

<210> 151
 <211> 1677
 <212> DNA
 <213> Nucl eotide sequence encoding the B-ta(DIG*EpCAM)-Myc-6H1 S

<400> 151	atgaaatacc	tgctgccgac	cgctgctgct	ggtctgctgc	tcctcgctgc	ccagccggcg	60
	atggccgaag	tgcagctgg	gaaagcggc	ggcggcctgg	tgaaccggg	cggcagcctg	120
	aaactgagct	gcgcggtgag	cggcttacc	tttagcgatt	atgcgatgag	ctggattcgc	180
	cagaccccg	aaaaccgcct	ggaatgggt	gcgagcatta	acattggcgc	gacctatgcg	240
	tattatccgg	atagcgtgaa	aggccgttt	accattagcc	gcgataacgc	aaaaaacacc	300
	ctgtttctgc	agatgagcag	cctggcagc	gaagataccg	cgtgttatt	ttgcgcgcgc	360
	ccggcagcc	cgtatgaata	tgataaagcg	tattatagca	tggcgtattt	ggcccccggc	420
	accagcgtga	ccgtgagcag	cgcggaaacc	tcctcagggt	gtggtggttc	tggcggcgcc	480
	ggctccgg	gtggtggttc	tggtgatgt	cagatgaccc	agagcaccag	cagcctgagc	540
	gcgagcctgg	gcgatcgcgt	gaccattagc	tgccgcgcga	gccaggatata	taaaaactat	600
	ctgaactgg	atcagcagaa	accggcggc	accgtgaaac	tgctgattt	ttatagcagc	660
	accctgctga	gcggcgtgcc	gagccgttt	agcggccgc	gcagcggcac	cgattttagc	720
	ctgaccatta	ccaaccttgg	acgcaagat	attgcgaccc	attttgc	gcagagcatt	780
	accctgccc	cgacccttgg	cggccgcacc	aaactggaaa	ttaaacgcgc	ggatgcggcg	840
	ccgaccgtga	gcattttgg	tggccgg	ggtggtgat	ccgaggtgca	gctgctcgag	900
	cagtctggag	ctgagctgg	aaggcctgg	acttcagtga	agatatcctg	caaggcttct	960
	ggatacgcct	tcactaacta	ctggcttaggt	tggtaaagc	agaggcctgg	acatggactt	1020

eol f-seql . txt

gagtgattt	gagatattt	cccttggaa	gttatatcc	actacaatga	gaagttcaag	1080
ggcaaaagcc	caactgactgc	agacaaatct	tcgagcacag	cctatatgca	gctcagtagc	1140
ctgacattt	aggactctgc	tgtctattt	tgtgcaagac	tgaggaactg	ggacgaggct	1200
atggactact	ggggccaagg	gaccacggtc	accgtctcct	caggtggtgg	tggttctggc	1260
ggcggcggct	ccgggtggtgg	tggttctgag	ctcgtatga	cacagtctcc	atcctccctg	1320
actgtgacag	caggagagaa	ggtcactatg	agctgcaagt	ccagtcagag	tctgttaaac	1380
agtggaaatc	aaaagaacta	cttgacctgg	taccagcaga	aaccaggcga	gcctcctaaa	1440
ctgttgcatc	actgggcatc	cactaggaa	tctgggtcc	ctgatcgctt	cacaggcagt	1500
ggatctggaa	cagatttcac	tctcaccatc	agcagtgatc	aggctgaaga	cctggcagtt	1560
tattactgtc	agaatgatta	tagttatccg	ctcacgttcg	gtgctggac	caagctttag	1620
atcaaagaac	agaaactgat	ctctgaagaa	gacctgcac	atcaccatca	tcattag	1677

<210> 152

<211> 124

<212> PRT

<213> Anti -CD19 VH

<400> 152

Gln	Val	Gln	Leu	Gln	Gln	Ser	Gly	Ala	Gl u	Leu	Val	Arg	Pro	Gly	Ser
1				5					10					15	

Ser	Val	Lys	Ile	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Ala	Phe	Ser	Ser	Tyr
		20				25							30		

Trp	Met	Asn	Trp	Val	Lys	Gln	Arg	Pro	Gly	Gln	Gly	Leu	Gl u	Trp	Ile
		35			40							45			

Gly	Gln	Ile	Trp	Pro	Gly	Asp	Gly	Asp	Thr	Asn	Tyr	Asn	Gly	Lys	Phe
		50			55						60				

Lys	Gly	Lys	Ala	Thr	Leu	Thr	Ala	Asp	Gl u	Ser	Ser	Ser	Thr	Ala	Tyr
65				70					75					80	

Met	Gln	Leu	Ser	Ser	Leu	Ala	Ser	Gl u	Asp	Ser	Ala	Val	Tyr	Phe	Cys
			85					90					95		

Ala	Arg	Arg	Gl u	Thr	Thr	Val	Gly	Arg	Tyr	Tyr	Tyr	Ala	Met	Asp
			100			105						110		

Tyr	Trp	Gly	Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser
		115									

<210> 153

<211> 112

<212> PRT

<213> Anti -CD19 VL

eol f-seql . txt

<400> 153

Asp Ile Gln Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Gln Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
20 25 30

Gly Asp Ser Tyr Leu Asn Trp Tyr Gln Gln Ile Pro Gly Gln Pro Pro
35 40 45

Lys Leu Leu Ile Tyr Asp Ala Ser Asn Leu Val Ser Gly Ile Pro Pro
50 55 60

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His
65 70 75 80

Pro Val Glu Lys Val Asp Ala Ala Thr Tyr His Cys Gln Gln Ser Thr
85 90 95

Gl u Asp Pro Trp Thr Phe Gl y Gl y Gl y Thr Lys Leu Gl u Ile Lys Ser
100 105 110

<210> 154

<211> 251

<212> PRT

<213> scFv anti CD19 (VH-Linker-VL)

<400> 154

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ser
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Tyr
20 25 30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Gln Ile Trp Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe
50 55 60

Lys Gl y Lys Ala Thr Leu Thr Ala Asp Glu Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95

Ala Arg Arg Glu Thr Thr Thr Val Gly Arg Tyr Tyr Tyr Ala Met Asp
100 105 110

Tyr Trp Gl y Gln Gl y Thr Thr Val Gl y Thr Val Ser Ser Gl y Gl y Gl y
115 120 125

eol f-seql . txt

Ser Gl y Gl y Gl y Gl y Ser Gl y Gl y Gl y Ser Asp Ile Gl n Leu Thr
130 135 140

Gl n Ser Pro Ala Ser Leu Ala Val Ser Leu Gl y Gl n Arg Ala Thr Ile
145 150 155 160

Ser Cys Lys Ala Ser Gl n Ser Val Asp Tyr Asp Gl y Asp Ser Tyr Leu
165 170 175

Asn Trp Tyr Gl n Gl n Ile Pro Gl y Gl n Pro Pro Lys Leu Leu Ile Tyr
180 185 190

Asp Ala Ser Asn Leu Val Ser Gl y Ile Pro Pro Arg Phe Ser Gl y Ser
195 200 205

Gl y Ser Gl y Thr Asp Phe Thr Leu Asn Ile His Pro Val Gl u Lys Val
210 215 220

Asp Ala Ala Thr Tyr His Cys Gl n Gl n Ser Thr Gl u Asp Pro Trp Thr
225 230 235 240

Phe Gl y Gl y Gl y Thr Lys Leu Gl u Ile Lys Ser
245 250

<210> 155

<211> 8

<212> PRT

<213> Anti -CD19 VH CDR1

<400> 155

Gl y Tyr Ala Phe Ser Ser Tyr Trp
1 5

<210> 156

<211> 8

<212> PRT

<213> Anti -CD19 VH CDR2

<400> 156

Ile Trp Pro Gl y Asp Gl y Asp Thr
1 5

<210> 157

<211> 17

<212> PRT

<213> Anti -CD19 VH CDR3

<400> 157

Al a Arg Arg Gl u Thr Thr Thr Val Gl y Arg Tyr Tyr Tyr Tyr Ala Met Asp
1 5 10 15

Tyr

eol f-seql . txt

<210> 158
<211> 10
<212> PRT
<213> Anti -CD19 VL CDR1

<400> 158

Gln Ser Val Asp Tyr Asp Gly Asp Ser Tyr
1 5 10

<210> 159
<211> 9
<212> PRT
<213> Anti -CD19 VL CDR3

<400> 159

Gln Gln Ser Thr Glu Asp Pro Trp Thr
1 5

<210> 160
<211> 451
<212> PRT
<213> Clostridium perfringens iota toxin component Ia (a.a. 23-454) 6x histidine tag two protease cleavage sites

<400> 160

Met Ala Ser Thr Thr His His His His His Asp Thr Asp Ile Pro
1 5 10 15

Thr Thr Gly Gly Ser Arg Pro Asp Asp Asp Asp Lys Glu Asn Leu
20 25 30

Tyr Phe Gln Gly His Met Ala Phe Ile Glu Arg Pro Glu Asp Phe Leu
35 40 45

Lys Asp Lys Glu Asn Ala Ile Gln Trp Glu Lys Lys Glu Ala Glu Arg
50 55 60

Val Glu Lys Asn Leu Asp Thr Leu Glu Lys Glu Ala Leu Glu Leu Tyr
65 70 75 80

Lys Lys Asp Ser Glu Gln Ile Ser Asn Tyr Ser Gln Thr Arg Gln Tyr
85 90 95

Phe Tyr Asp Tyr Gln Ile Glu Ser Asn Pro Arg Glu Lys Glu Tyr Lys
100 105 110

Asn Leu Arg Asn Ala Ile Ser Lys Asn Lys Ile Asp Lys Pro Ile Asn
115 120 125

Val Tyr Tyr Phe Glu Ser Pro Glu Lys Phe Ala Phe Asn Lys Glu Ile
130 135 140

eol f-seql.txt

Arg Thr Glu Asn Glu Asn Glu Ile Ser Leu Glu Lys Phe Asn Glu Leu
145 150 155 160

Lys Glu Thr Ile Glu Asp Lys Leu Phe Lys Glu Asp Glu Phe Lys Asp
165 170 175

Val Ser Leu Tyr Glu Pro Glu Asn Glu Asp Glu Lys Pro Thr Pro Leu
180 185 190

Leu Ile His Leu Lys Leu Pro Lys Asn Thr Glu Met Leu Pro Tyr Ile
195 200 205

Asn Ser Asn Asp Val Lys Thr Leu Ile Glu Glu Asp Tyr Ser Ile Lys
210 215 220

Ile Asp Lys Ile Val Arg Ile Val Ile Glu Glu Lys Glu Tyr Ile Lys
225 230 235 240

Ala Glu Ala Ser Ile Val Asn Ser Leu Asp Phe Lys Asp Asp Val Ser
245 250 255

Lys Glu Asp Leu Trp Glu Lys Glu Asn Tyr Ser Asp Trp Ser Asn Lys
260 265 270

Leu Thr Pro Asn Glu Leu Ala Asp Val Asn Asp Tyr Met Arg Glu Glu
275 280 285

Tyr Thr Ala Ile Asn Asn Tyr Leu Ile Ser Asn Glu Pro Leu Asn Asn
290 295 300

Pro Asn Pro Glu Leu Asp Ser Lys Val Asn Asn Ile Glu Asn Ala Leu
305 310 315 320

Lys Leu Thr Pro Ile Pro Ser Asn Leu Ile Val Tyr Arg Arg Ser Glu
325 330 335

Pro Glu Glu Phe Glu Leu Thr Leu Thr Ser Pro Glu Tyr Asp Phe Asn
340 345 350

Lys Ile Glu Asn Ile Asp Ala Phe Lys Glu Lys Trp Glu Glu Lys Val
355 360 365

Ile Thr Tyr Pro Asn Phe Ile Ser Thr Ser Ile Glu Ser Val Asn Met
370 375 380

Ser Ala Phe Ala Lys Arg Lys Ile Ile Leu Arg Ile Asn Ile Pro Lys
385 390 395 400

Asp Ser Pro Glu Ala Tyr Leu Ser Ala Ile Pro Glu Tyr Ala Glu Glu
405 410 415

eol f-seql . txt

Tyr Glu Val Leu Leu Asn His Gly Ser Lys Phe Lys Ile Asn Lys Val
420 425 430

Asp Ser Tyr Lys Asp Gly Thr Val Thr Lys Leu Ile Leu Asp Ala Thr
435 440 445

Leu Ile Asn
450

<210> 161

<211> 300

<212> PRT

<213> Burkholderia sp. CCGE1002 Shiga toxin subunit A (a.a. 24-285) 6x histidine tag two protease cleavage sites

<400> 161

Met Ala Ser Thr Thr His His His His His Asp Thr Asp Ile Pro
1 5 10 15

Thr Thr Gly Gly Ser Arg Pro Asp Asp Asp Asp Lys Glu Asn Leu
20 25 30

Tyr Phe Gln Gly His Met Glu Phe Ser Val Asp Phe Thr Ser Pro Gln
35 40 45

Lys Tyr Val Gln Ser Leu Gly Ala Ile Arg Ala Ala Met Gly Asp Ala
50 55 60

Met Ser Leu Thr Asn Ile Pro Gly Asn Lys Ile Leu Tyr Gln Leu Arg
65 70 75 80

Pro Asp Ala Ser Asn Ile Val Glu Gly Val Thr Ile Glu Ile Ile Gly
85 90 95

Val Gly Arg Asn Asn Ser Pro Ser Asn Arg Asp Val Arg Phe Val Ile
100 105 110

Asn Pro Ser Asp Leu Tyr Leu Thr Gly Phe Ile Val Gly Arg Ile Phe
115 120 125

Tyr Arg Phe Ser Asp Phe Ser Asp Thr Ala Ser Gly Arg Val Gln Val
130 135 140

Asn Ala Pro Arg His Leu Val Asp Phe Thr Ile Asp Met Thr Val Asp
145 150 155 160

Ser Ser Tyr Leu Ser Leu Ala Arg Ser Ala Gly Val Ser Ala Asp Arg
165 170 175

Thr Asp Leu Ser Ile Asp Arg Tyr Ser Leu Met Lys Gly Tyr Arg Asp
180 185 190

eof f-seql.txt

Leu Ile Asn His Val Ser Ser Thr Arg Thr Ile Asn Gly Ala Glu Ala
195 200 205

Arg Ala Leu Leu Ser Tyr Ala Thr Val Leu Ser Glu Ala Val Arg Phe
210 215 220

Arg Ser Ile Gln Gly Asn Phe Ala Ser Thr Ala Leu Gly Asp Asp Ala
225 230 235 240

Phe Thr Pro Tyr Arg Leu Ser Leu Glu Asp Ser Asn Arg Thr Thr Arg
245 250 255

Trp Asp Arg Leu Ser Asp Glu Ile Arg Lys Ala His Tyr Gly Ala Ile
260 265 270

Lys Ile Ala Thr His Gln Ala Ala Pro Ile Leu Leu Ala Asn Val Arg
275 280 285

Asp Val Phe Gln Met Thr Thr Cys Thr Ser Lys Lys
290 295 300

<210> 162

<211> 521

<212> PRT

<213> Anthrax lethal factor endopeptidase no PA-binding region (34-295) 6x histidine tag

<400> 162

Gln Arg Met Leu Ala Arg Tyr Glu Lys Trp Glu Lys Ile Lys Gln His
1 5 10 15

Tyr Gln His Trp Ser Asp Ser Leu Ser Glu Glu Gln Arg Gln Leu Leu
20 25 30

Lys Lys Leu Gln Ile Pro Ile Glu Pro Lys Lys Asp Asp Ile Ile His
35 40 45

Ser Leu Ser Gln Glu Glu Lys Glu Leu Leu Lys Arg Ile Gln Ile Asp
50 55 60

Ser Ser Asp Phe Leu Ser Thr Glu Glu Lys Glu Phe Leu Lys Lys Leu
65 70 75 80

Gln Ile Asp Ile Arg Asp Ser Leu Ser Glu Glu Glu Lys Glu Leu Leu
85 90 95

Asn Arg Ile Gln Val Asp Ser Ser Asn Pro Leu Ser Glu Lys Glu Lys
100 105 110

Glu Phe Leu Lys Lys Leu Lys Leu Asp Ile Gln Pro Tyr Asp Ile Asn
115 120 125

eol f-seql . txt

Gln Arg Leu Gln Asp Thr Gly Gly Leu Ile Asp Ser Pro Ser Ile Asn
130 135 140

Leu Asp Val Arg Lys Gln Tyr Lys Arg Asp Ile Gln Asn Ile Asp Ala
145 150 155 160

Leu Leu His Gln Ser Ile Gly Ser Thr Leu Tyr Asn Lys Ile Tyr Leu
165 170 175

Tyr Glu Asn Met Asn Ile Asn Asn Leu Thr Ala Thr Leu Gly Ala Asp
180 185 190

Leu Val Asp Ser Thr Asp Asn Thr Lys Ile Asn Arg Gly Ile Phe Asn
195 200 205

Gl u Phe Lys Lys Asn Phe Lys Tyr Ser Ile Ser Ser Asn Tyr Met Ile
210 215 220

Val Asp Ile Asn Glu Arg Pro Ala Leu Asp Asn Glu Arg Leu Lys Trp
225 230 235 240

Arg Ile Gln Leu Ser Pro Asp Thr Arg Ala Gly Tyr Leu Glu Asn Gly
245 250 255

Lys Leu Ile Leu Gln Arg Asn Ile Gly Leu Glu Ile Lys Asp Val Gln
260 265 270

Ile Ile Lys Gln Ser Glu Lys Glu Tyr Ile Arg Ile Asp Ala Lys Val
275 280 285

Val Pro Lys Ser Lys Ile Asp Thr Lys Ile Gln Glu Ala Gln Leu Asn
290 295 300

Ile Asn Gln Glu Trp Asn Lys Ala Leu Gly Leu Pro Lys Tyr Thr Lys
305 310 315 320

Leu Ile Thr Phe Asn Val His Asn Arg Tyr Ala Ser Asn Ile Val Glu
325 330 335

Ser Ala Tyr Leu Ile Leu Asn Glu Trp Lys Asn Asn Ile Gln Ser Asp
340 345 350

Leu Ile Lys Lys Val Thr Asn Tyr Leu Val Asp Gly Asn Gly Arg Phe
355 360 365

Val Phe Thr Asp Ile Thr Leu Pro Asn Ile Ala Glu Gln Tyr Thr His
370 375 380

Gln Asp Glu Ile Tyr Glu Gln Val His Ser Lys Gly Leu Tyr Val Pro
385 390 395 400

eol f-seql . txt

Gl u Ser Arg Ser Ile Leu Leu His Gl y Pro Ser Lys Gl y Val Gl u Leu
405 410 415

Arg Asn Asp Ser Gl u Gl y Phe Ile His Gl u Phe Gl y His Al a Val Asp
420 425 430

Asp Tyr Al a Gl y Tyr Leu Leu Asp Lys Asn Gl n Ser Asp Leu Val Thr
435 440 445

Asn Ser Lys Lys Phe Ile Asp Ile Phe Lys Gl u Gl u Gl y Ser Asn Leu
450 455 460

Thr Ser Tyr Gl y Arg Thr Asn Gl u Al a Gl u Phe Phe Al a Gl u Al a Phe
465 470 475 480

Arg Leu Met His Ser Thr Asp His Al a Gl u Arg Leu Lys Val Gl n Lys
485 490 495

Asn Al a Pro Lys Thr Phe Gl n Phe Ile Asn Asp Gl n Ile Lys Phe Ile
500 505 510

Ile Asn Ser His His His His His
515 520

<210> 163

<211> 389

<212> PRT

<213> Corynebacterium diphtheriae toxin 6x histidine tag

<400> 163

Met Gl y Al a Asp Asp Val Val Asp Ser Ser Lys Ser Phe Val Met Gl u
1 5 10 15

Asn Phe Ser Ser Tyr His Gl y Thr Lys Pro Gl y Tyr Val Asp Ser Ile
20 25 30

Gl n Lys Gl y Ile Gl n Lys Pro Lys Ser Gl y Thr Gl n Gl y Asn Tyr Asp
35 40 45

Asp Asp Trp Lys Gl y Phe Tyr Ser Thr Asp Asn Lys Tyr Asp Al a Al a
50 55 60

Gl y Tyr Ser Val Asp Asn Gl u Asn Pro Leu Ser Gl y Lys Al a Gl y Gl y
65 70 75 80

Val Val Lys Val Thr Tyr Pro Gl y Leu Thr Lys Val Leu Al a Leu Lys
85 90 95

Val Asp Asn Al a Gl u Thr Phe Lys Lys Gl u Leu Gl y Leu Ser Leu Thr
100 105 110

Gl u Pro Leu Met Gl u Gl n Val Gl y Thr Gl u Gl u Phe Ile Lys Arg Phe
Page 87

115

120

125

Gly Asp Gly Ala Ser Arg Val Val Leu Ser Leu Pro Phe Ala Glu Gly
 130 135 140

Ser Ser Ser Val Glu Tyr Ile Asn Asn Trp Glu Gln Ala Lys Ala Leu
 145 150 155 160

Ser Val Glu Leu Glu Ile Asn Phe Glu Thr Arg Gly Lys Arg Gly Gln
 165 170 175

Asp Ala Met Tyr Glu Tyr Met Ala Gln Ala Cys Ala Gly Asn Arg Val
 180 185 190

Arg Arg Ser Val Gly Ser Ser Leu Ser Cys Ile Asn Leu Asp Trp Asp
 195 200 205

Val Ile Arg Asp Lys Thr Lys Thr Lys Ile Glu Ser Leu Lys Glu His
 210 215 220

Gly Pro Ile Lys Asn Lys Met Ser Glu Ser Pro Asn Lys Thr Val Ser
 225 230 235 240

Gl u Gl u Lys Ala Lys Gln Tyr Leu Gl u Gl u Phe His Gln Thr Ala Leu
 245 250 255

Gl u His Pro Gl u Leu Ser Gl u Leu Lys Thr Val Thr Gly Thr Asn Pro
 260 265 270

Val Phe Ala Gly Ala Asn Tyr Ala Ala Trp Ala Val Asn Val Ala Gln
 275 280 285

Val Ile Asp Ser Glu Thr Ala Asp Asn Leu Gl u Lys Thr Thr Ala Ala
 290 295 300

Leu Ser Ile Leu Pro Gly Ile Gly Ser Val Met Gly Ile Ala Asp Gly
 305 310 315 320

Ala Val His His Asn Thr Glu Glu Ile Val Ala Gln Ser Ile Ala Leu
 325 330 335

Ser Ser Leu Met Val Ala Gln Ala Ile Pro Leu Val Gly Glu Leu Val
 340 345 350

Asp Ile Gly Phe Ala Ala Tyr Asn Phe Val Glu Asp Ser Ile Ile Arg
 355 360 365

Thr Gly Phe Gln Gly Glu Ser Gly His Lys Thr Gln Pro His Met His
 370 375 380

His His His His His

<210> 164
 <211> 506
 <212> PRT
 <213> Clostridium perfringens str. 13 pfoA perfringolysin 0 6x histidine tag
 <400> 164

 Met Ile Arg Phe Lys Lys Thr Lys Leu Ile Ala Ser Ile Ala Met Ala
 1 5 10 15

 Leu Cys Leu Phe Ser Gln Pro Val Ile Ser Phe Ser Lys Asp Ile Thr
 20 25 30

 Asp Lys Asn Gln Ser Ile Asp Ser Gly Ile Ser Ser Leu Ser Tyr Asn
 35 40 45

 Arg Asn Glu Val Leu Ala Ser Asn Gly Asp Lys Ile Glu Ser Phe Val
 50 55 60

 Pro Lys Glu Gly Lys Lys Thr Gly Asn Lys Phe Ile Val Val Glu Arg
 65 70 75 80

 Gln Lys Arg Ser Leu Thr Thr Ser Pro Val Asp Ile Ser Ile Ile Asp
 85 90 95

 Ser Val Asn Asp Arg Thr Tyr Pro Gly Ala Leu Gln Leu Ala Asp Lys
 100 105 110

 Ala Phe Val Glu Asn Arg Pro Thr Ile Leu Met Val Lys Arg Lys Pro
 115 120 125

 Ile Asn Ile Asn Ile Asp Leu Pro Gly Leu Lys Gly Glu Asn Ser Ile
 130 135 140

 Lys Val Asp Asp Pro Thr Tyr Gly Lys Val Ser Gly Ala Ile Asp Glu
 145 150 155 160

 Leu Val Ser Lys Trp Asn Glu Lys Tyr Ser Ser Thr His Thr Leu Pro
 165 170 175

 Ala Arg Thr Gln Tyr Ser Glu Ser Met Val Tyr Ser Lys Ser Gln Ile
 180 185 190

 Ser Ser Ala Leu Asn Val Asn Ala Lys Val Leu Glu Asn Ser Leu Glu
 195 200 205

 Val Asp Phe Asn Ala Val Ala Asn Asn Glu Lys Lys Val Met Ile Leu
 210 215 220

 Ala Tyr Lys Gln Ile Phe Tyr Thr Val Ser Ala Asp Leu Pro Lys Asn
 225 230 235 240

eol f-seql . txt

Pro Ser Asp Leu Phe Asp Asp Ser Val Thr Phe Asn Asp Leu Lys Glu
245 250 255

Lys Glu Val Ser Asn Glu Ala Pro Pro Leu Met Val Ser Asn Val Ala
260 265 270

Tyr Glu Arg Thr Ile Tyr Val Lys Leu Glu Thr Thr Ser Ser Ser Lys
275 280 285

Asp Val Glu Ala Ala Phe Lys Ala Leu Ile Lys Asn Thr Asp Ile Lys
290 295 300

Asn Ser Glu Glu Tyr Lys Asp Ile Tyr Glu Asn Ser Ser Phe Thr Ala
305 310 315 320

Val Val Leu Glu Gly Asp Ala Glu Glu His Asn Lys Val Val Thr Lys
325 330 335

Asp Phe Asp Glu Ile Arg Lys Val Ile Lys Asp Asn Ala Thr Phe Ser
340 345 350

Thr Lys Asn Pro Ala Tyr Pro Ile Ser Tyr Thr Ser Val Phe Leu Lys
355 360 365

Asp Asn Ser Val Ala Ala Val His Asn Lys Thr Asp Tyr Ile Glu Thr
370 375 380

Thr Ser Thr Glu Tyr Ser Lys Glu Lys Ile Asn Leu Asp His Ser Glu
385 390 395 400

Ala Tyr Val Ala Glu Phe Glu Val Ala Trp Asp Glu Val Ser Tyr Asp
405 410 415

Lys Glu Glu Asn Glu Val Leu Thr His Lys Thr Trp Asp Glu Asn Tyr
420 425 430

Glu Asp Lys Thr Ala His Tyr Ser Thr Val Ile Pro Leu Glu Ala Asn
435 440 445

Ala Arg Asn Ile Arg Ile Lys Ala Arg Glu Cys Thr Glu Leu Ala Trp
450 455 460

Glu Trp Trp Arg Asp Val Ile Ser Glu Tyr Asp Val Pro Leu Thr Asn
465 470 475 480

Asn Ile Asn Val Ser Ile Trp Glu Thr Thr Leu Tyr Pro Glu Ser Ser
485 490 495

Ile Thr Tyr Asn His His His His His
500 505

eol f-seql . txt

<210> 165
<211> 273
<212> PRT
<213> Ricin A chain 6x histidine tag

<400> 165

Ile Phe Pro Lys Glu Tyr Pro Ile Ile Asn Phe Thr Thr Ala Gly Ala
1 5 10 15

Thr Val Glu Ser Tyr Thr Asn Phe Ile Arg Ala Val Arg Gly Arg Leu
20 25 30

Thr Thr Gly Ala Asp Val Arg His Glu Ile Pro Val Leu Pro Asn Arg
35 40 45

Val Glu Leu Pro Ile Asn Glu Arg Phe Ile Leu Val Glu Leu Ser Asn
50 55 60

His Ala Glu Leu Ser Val Thr Leu Ala Leu Asp Val Thr Asn Ala Tyr
65 70 75 80

Val Val Glu Tyr Arg Ala Glu Asn Ser Ala Tyr Phe Phe His Pro Asp
85 90 95

Ala Glu Glu Asp Ala Glu Ala Ile Thr His Leu Phe Thr Asp Val Glu
100 105 110

Asn Arg Tyr Thr Phe Ala Phe Glu Glu Asn Tyr Asp Arg Leu Glu Glu
115 120 125

Leu Ala Glu Asn Leu Arg Glu Asn Ile Glu Leu Glu Asn Glu Pro Leu
130 135 140

Glu Glu Ala Ile Ser Ala Leu Tyr Tyr Tyr Ser Thr Glu Glu Thr Glu
145 150 155 160

Leu Pro Thr Leu Ala Arg Ser Phe Ile Ile Cys Ile Glu Met Ile Ser
165 170 175

Glu Ala Ala Arg Phe Glu Tyr Ile Glu Glu Glu Met Arg Thr Arg Ile
180 185 190

Arg Tyr Asn Arg Arg Ser Ala Pro Asp Pro Ser Val Ile Thr Leu Glu
195 200 205

Asn Ser Trp Glu Arg Leu Ser Thr Ala Ile Glu Glu Ser Asn Glu Glu
210 215 220

Ala Phe Ala Ser Pro Ile Glu Leu Glu Arg Arg Asn Glu Ser Lys Phe
225 230 235 240

eol f-seql . txt

Ser Val Tyr Asp Val Ser Ile Leu Ile Pro Ile Ile Ala Leu Met Val
245 250 255

Tyr Arg Cys Ala Pro Pro Pro Ser Ser Gln Phe His His His His His
260 265 270

His

<210> 166

<211> 285

<212> PRT

<213> Ricin A chain linker peptide 6x histidine tag

<400> 166

Ile Phe Pro Lys Gln Tyr Pro Ile Ile Asn Phe Thr Thr Ala Gly Ala
1 5 10 15

Thr Val Gln Ser Tyr Thr Asn Phe Ile Arg Ala Val Arg Gly Arg Leu
20 25 30

Thr Thr Gly Ala Asp Val Arg His Glu Ile Pro Val Leu Pro Asn Arg
35 40 45

Val Gly Leu Pro Ile Asn Gln Arg Phe Ile Leu Val Glu Leu Ser Asn
50 55 60

His Ala Glu Leu Ser Val Thr Leu Ala Leu Asp Val Thr Asn Ala Tyr
65 70 75 80

Val Val Gly Tyr Arg Ala Gly Asn Ser Ala Tyr Phe Phe His Pro Asp
85 90 95

Ala Gln Glu Asp Ala Glu Ala Ile Thr His Leu Phe Thr Asp Val Gln
100 105 110

Asn Arg Tyr Thr Phe Ala Phe Gly Gly Asn Tyr Asp Arg Leu Glu Gln
115 120 125

Leu Ala Gly Asn Leu Arg Glu Asn Ile Glu Leu Gly Asn Gly Pro Leu
130 135 140

Glu Glu Ala Ile Ser Ala Leu Tyr Tyr Tyr Ser Thr Gly Gly Thr Gln
145 150 155 160

Leu Pro Thr Leu Ala Arg Ser Phe Ile Ile Cys Ile Gln Met Ile Ser
165 170 175

Glu Ala Ala Arg Phe Gln Tyr Ile Glu Gly Glu Met Arg Thr Arg Ile
180 185 190

Arg Tyr Asn Arg Arg Ser Ala Pro Asp Pro Ser Val Ile Thr Leu Glu
 195 200 205

Asn Ser Trp Glu Arg Leu Ser Thr Ala Ile Glu Glu Ser Asn Glu Glu
 210 215 220

Ala Phe Ala Ser Pro Ile Glu Leu Glu Arg Arg Asn Glu Ser Lys Phe
 225 230 235 240

Ser Val Tyr Asp Val Ser Ile Leu Ile Pro Ile Ile Ala Leu Met Val
 245 250 255

Tyr Arg Cys Ala Pro Pro Pro Ser Ser Glu Phe Ser Leu Leu Ile Arg
 260 265 270

Pro Val Val Pro Asn Phe Asn His His His His His His
 275 280 285

<210> 167

<211> 256

<212> PRT

<213> Plant RIP bougainvillea with reduced immunogenic potential 6x histidine tag

<400> 167

Tyr Asn Thr Val Ser Phe Asn Leu Glu Glu Ala Tyr Glu Tyr Pro Thr
 1 5 10 15

Phe Ile Glu Asp Leu Arg Asn Glu Leu Ala Lys Glu Thr Pro Val Cys
 20 25 30

Glu Leu Pro Val Thr Leu Glu Thr Ile Ala Asp Asp Lys Arg Phe Val
 35 40 45

Leu Val Asp Ile Thr Thr Ser Lys Lys Thr Val Lys Val Ala Ile
 50 55 60

Asp Val Thr Asp Val Tyr Val Val Glu Tyr Glu Asp Lys Trp Asp Glu
 65 70 75 80

Lys Asp Arg Ala Val Phe Leu Asp Lys Val Pro Thr Val Ala Thr Ser
 85 90 95

Lys Leu Phe Pro Glu Val Thr Asn Arg Val Thr Leu Thr Phe Asp Glu
 100 105 110

Ser Tyr Glu Lys Leu Val Asn Ala Ala Lys Ala Asp Arg Lys Ala Leu
 115 120 125

Glu Leu Glu Val Asn Lys Leu Glu Phe Ser Ile Glu Ala Ile His Glu
 130 135 140

Lys Thr Ile Asn Glu Glu Glu Ala Ala Lys Phe Phe Leu Ile Val Ile

eol f-seql . txt

145

150

155

160

Gl n Met Val Ser Gl u Al a Al a Arg Phe Lys Tyr Ile Gl u Thr Gl u Val
165 170 175

Val Asp Arg Gl y Leu Tyr Gl y Ser Phe Lys Pro Asn Phe Lys Val Leu
180 185 190

Asn Leu Gl u Asn Asn Trp Gl y Asp Ile Ser Asp Al a Ile His Lys Ser
195 200 205

Ser Pro Gl n Cys Thr Thr Ile Asn Pro Al a Leu Gl n Leu Ile Ser Pro
210 215 220

Ser Asn Asp Pro Trp Val Val Asn Lys Val Ser Gl n Ile Ser Pro Asp
225 230 235 240

Met Gl y Ile Leu Lys Phe Lys Ser Ser Lys His His His His His His
245 250 255

<210> 168

<211> 149

<212> PRT

<213> Human RNASE3 ribonuclease (RNase A family, 3) protein without N-terminal signal peptide but with a N-terminal nuclear localization sequence 6x histidine tag

<400> 168

Pro Lys Lys Lys Arg Lys Val Gl u Al a Ser Arg Pro Pro Gl n Phe Thr
1 5 10 15

Arg Al a Gl n Trp Phe Al a Ile Gl n His Ile Ser Leu Asn Pro Pro Arg
20 25 30

Cys Thr Ile Al a Met Arg Al a Ile Asn Asn Tyr Arg Trp Arg Cys Lys
35 40 45

Asn Gl n Asn Thr Phe Leu Arg Thr Thr Phe Al a Asn Val Val Asn Val
50 55 60

Cys Gl y Asn Gl n Ser Ile Arg Cys Pro His Asn Arg Thr Leu Asn Asn
65 70 75 80

Cys His Arg Ser Arg Phe Arg Val Pro Leu Leu His Cys Asp Leu Ile
85 90 95

Asn Pro Gl y Al a Gl n Asn Ile Ser Asn Cys Thr Tyr Al a Asp Arg Pro
100 105 110

Gl y Arg Arg Phe Tyr Val Val Al a Cys Asp Asn Arg Asp Pro Arg Asp
115 120 125

Ser Pro Arg Tyr Pro Val Val Pro Val His Leu Asp Thr Thr Ile His
 130 135 140

His His His His His
 145

<210> 169

<211> 18

<212> PRT

<213> Antigen for human myeloma cell line U266 antibody IgE-ND

<400> 169

Leu Ser Pro His Leu Leu Trp Asp Leu Phe Arg Val Gly Leu Pro Gly
 1 5 10 15

Ala Ala

<210> 170

<211> 146

<212> PRT

<213> Dermatophagoides farinae

<400> 170

Met Ile Ser Lys Ile Leu Cys Leu Ser Leu Leu Val Ala Ala Val Val
 1 5 10 15

Ala Asp Gln Val Asp Val Lys Asp Cys Ala Asn Asn Glu Ile Lys Lys
 20 25 30

Val Met Val Asp Gly Cys His Gly Ser Asp Pro Cys Ile Ile His Arg
 35 40 45

Gly Lys Pro Phe Thr Leu Glu Ala Leu Phe Asp Ala Asn Gln Asn Thr
 50 55 60

Lys Thr Ala Lys Ile Glu Ile Lys Ala Ser Leu Asp Gly Leu Glu Ile
 65 70 75 80

Asp Val Pro Gly Ile Asp Thr Asn Ala Cys His Phe Met Lys Cys Pro
 85 90 95

Leu Val Lys Gly Gln Gln Tyr Asp Ile Lys Tyr Thr Trp Asn Val Pro
 100 105 110

Lys Ile Ala Pro Lys Ser Glu Asn Val Val Val Thr Val Lys Leu Ile
 115 120 125

Gly Asp Asn Gly Val Leu Ala Cys Ala Ile Ala Thr His Gly Lys Ile
 130 135 140

Arg Asp
 145

eol f-seql . txt

<210> 171
<211> 320
<212> PRT
<213> Dermatophagoi des pteronyssi nus

<400> 171

Met Lys Ile Val Leu Ala Ile Ala Ser Leu Leu Ala Leu Ser Ala Val
1 5 10 15

Tyr Ala Arg Pro Ser Ser Ile Lys Thr Phe Glu Glu Tyr Lys Lys Ala
20 25 30

Phe Asn Lys Ser Tyr Ala Thr Phe Glu Asp Glu Glu Ala Ala Arg Lys
35 40 45

Asn Phe Leu Glu Ser Val Lys Tyr Val Glu Ser Asn Glu Glu Ala Ile
50 55 60

Asn His Leu Ser Asp Leu Ser Leu Asp Glu Phe Lys Asn Arg Phe Leu
65 70 75 80

Met Ser Ala Glu Ala Phe Glu His Leu Lys Thr Glu Phe Asp Leu Asn
85 90 95

Ala Glu Thr Asn Ala Cys Ser Ile Asn Glu Asn Ala Pro Ala Glu Ile
100 105 110

Asp Leu Arg Glu Met Arg Thr Val Thr Pro Ile Arg Met Glu Glu Glu
115 120 125

Cys Glu Ser Cys Trp Ala Phe Ser Glu Val Ala Ala Thr Glu Ser Ala
130 135 140

Tyr Leu Ala Tyr Arg Asn Glu Ser Leu Asp Leu Ala Glu Glu Glu Leu
145 150 155 160

Val Asp Cys Ala Ser Glu His Glu Cys His Glu Asp Thr Ile Pro Arg
165 170 175

Glu Ile Glu Tyr Ile Glu His Asn Glu Val Val Glu Glu Ser Tyr Tyr
180 185 190

Arg Tyr Val Ala Arg Glu Glu Ser Cys Arg Arg Pro Asn Ala Glu Arg
195 200 205

Phe Glu Ile Ser Asn Tyr Cys Glu Ile Tyr Pro Pro Asn Val Asn Lys
210 215 220

Ile Arg Glu Ala Leu Ala Glu Thr His Ser Ala Ile Ala Val Ile Ile
225 230 235 240

eol f-seql . txt

Gly Ile Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile
245 250 255

Ile Gln Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn Ile
260 265 270

Val Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr Trp Ile Val Arg Asn
275 280 285

Ser Trp Asp Thr Asn Trp Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala
290 295 300

Asn Ile Asp Leu Met Met Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
305 310 315 320

<210> 172

<211> 141

<212> PRT

<213> Tyrophagus putrescentiae

<400> 172

Met Lys Phe Leu Ile Leu Phe Ala Leu Val Ala Val Ala Ala Ala Gly
1 5 10 15

Gln Val Lys Phe Thr Asp Cys Gly Lys Lys Glu Ile Ala Ser Val Ala
20 25 30

Val Asp Gly Cys Glu Gly Asp Leu Cys Val Ile His Lys Ser Lys Pro
35 40 45

Val His Val Ile Ala Glu Phe Thr Ala Asn Gln Asp Thr Cys Lys Ile
50 55 60

Gl u Val Lys Val Thr Gly Gln Leu Asn Gly Leu Gl u Val Pro Ile Pro
65 70 75 80

Gly Ile Glu Thr Asp Gly Cys Lys Val Leu Lys Cys Pro Leu Lys Lys
85 90 95

Gly Thr Lys Tyr Thr Met Asn Tyr Ser Val Asn Val Pro Ser Val Val
100 105 110

Pro Asn Ile Lys Thr Val Val Lys Leu Leu Ala Thr Gly Glu His Gly
115 120 125

Val Leu Ala Cys Gly Ala Val Asn Thr Asp Val Lys Pro
130 135 140

<210> 173

<211> 109

<212> PRT

<213> Felis catus

eol f-seql . txt

<400> 173

Met Arg Gly Ala Leu Leu Val Leu Ala Leu Leu Val Thr Glu Ala Leu
1 5 10 15

Gly Val Lys Met Ala Glu Thr Cys Pro Ile Phe Tyr Asp Val Phe Phe
20 25 30

Ala Val Ala Asn Gly Asn Glu Leu Leu Leu Asp Leu Ser Leu Thr Lys
35 40 45

Val Asn Ala Thr Glu Pro Glu Arg Thr Ala Met Lys Lys Ile Glu Asp
50 55 60

Cys Tyr Val Glu Asn Gly Leu Ile Ser Arg Val Leu Asp Gly Leu Val
65 70 75 80

Met Thr Thr Ile Ser Ser Ser Lys Asp Cys Met Gly Glu Ala Val Glu
85 90 95

Asn Thr Val Glu Asp Leu Lys Leu Asn Thr Leu Gly Arg
100 105

<210> 174

<211> 92

<212> PRT

<213> Felis catus

<400> 174

Met Lys Gly Ala Cys Val Leu Val Leu Leu Trp Ala Ala Leu Leu Leu
1 5 10 15

Ile Ser Gly Gly Asn Cys Glu Ile Cys Pro Ala Val Lys Arg Asp Val
20 25 30

Asp Leu Phe Leu Thr Gly Thr Pro Asp Glu Tyr Val Glu Glu Val Ala
35 40 45

Glu Tyr Lys Ala Leu Pro Val Val Leu Glu Asn Ala Arg Ile Leu Lys
50 55 60

Asn Cys Val Asp Ala Lys Met Thr Glu Glu Asp Lys Glu Asn Ala Leu
65 70 75 80

Ser Val Leu Asp Lys Ile Tyr Thr Ser Pro Leu Cys
85 90

<210> 175

<211> 146

<212> PRT

<213> Felis catus

<400> 175

eol f-seql . txt

Gl u Ile Cys Pro Al a Val Lys Arg Asp Val Asp Leu Phe Leu Thr Gl y
1 5 10 15

Thr Pro Asp Gl u Tyr Val Gl u Gl n Val Al a Gl n Tyr Lys Al a Leu Pro
20 25 30

Val Val Leu Gl u Asn Al a Arg Ile Leu Lys Asn Cys Val Asp Al a Lys
35 40 45

Met Thr Gl u Gl u Asp Lys Gl u Asn Al a Leu Ser Leu Leu Asp Lys Ile
50 55 60

Tyr Thr Ser Pro Leu Cys Val Lys Met Al a Gl u Thr Cys Pro Ile Phe
65 70 75 80

Tyr Asp Val Phe Phe Al a Val Al a Asn Gl y Asn Gl u Leu Leu Leu Asp
85 90 95

Leu Ser Leu Thr Lys Val Asn Al a Thr Gl u Pro Gl u Arg Thr Al a Met
100 105 110

Lys Lys Ile Gl n Asp Cys Tyr Val Gl u Asn Gl y Leu Ile Ser Arg Val
115 120 125

Leu Asp Gl y Leu Val Met Thr Thr Ile Ser Ser Ser Lys Asp Cys Met
130 135 140

Gl y Gl u
145

<210> 176

<211> 172

<212> PRT

<213> Arachis hypogaea

<400> 176

Met Al a Lys Leu Thr Ile Leu Val Al a Leu Al a Leu Phe Leu Leu Al a
1 5 10 15

Al a His Al a Ser Al a Arg Gl n Gl n Trp Gl u Leu Gl n Gl y Asp Arg Arg
20 25 30

Cys Gl n Ser Gl n Leu Gl u Arg Al a Asn Leu Arg Pro Cys Gl u Gl n His
35 40 45

Leu Met Gl n Lys Ile Gl n Arg Asp Gl u Asp Ser Tyr Gl y Arg Asp Pro
50 55 60

Tyr Ser Pro Ser Gl n Asp Pro Tyr Ser Pro Ser Gl n Asp Pro Asp Arg
65 70 75 80

eol f-seql . txt

Arg Asp Pro Tyr Ser Pro Ser Pro Tyr Asp Arg Arg Gly Ala Gly Ser
85 90 95

Ser Glu His Glu Glu Arg Cys Cys Asn Glu Leu Asn Glu Phe Glu Asn
100 105 110

Asn Glu Arg Cys Met Cys Glu Ala Leu Glu Glu Glu Ile Met Glu Asn Glu
115 120 125

Ser Asp Arg Leu Glu Gly Arg Glu Glu Glu Glu Glu Phe Lys Arg Glu
130 135 140

Leu Arg Asn Leu Pro Glu Glu Cys Gly Leu Arg Ala Pro Glu Arg Cys
145 150 155 160

Asp Leu Glu Val Glu Ser Glu Gly Arg Asp Arg Tyr
165 170

<210> 177

<211> 157

<212> PRT
212 AL+

<213> Al ternaria al ternata (Al ternaria rot fungus)

<400> 177

Met Gln Phe Thr Thr Ile Ala Ser Leu Phe Ala Ala Ala Gly Leu Ala
1 5 10 15

Al a Al a Al a Pro Leu Glu Ser Arg Gl n Asp Thr Al a Ser Cys Pro Val
20 25 30

Thr Thr Glu Glu Asp Tyr Val Trp Lys Ile Ser Glu Phe Tyr Glu Arg
35 40 45

Lys Pro Glu Gly Thr Tyr Tyr Asn Ser Leu Glu Phe Asn Ile Lys Ala
50 55 60

Thr Asn Gl y Gl y Thr 70 Leu Asp Phe Thr Cys 75 Ser 65 Al a Gln 80 Al a Asp Lys 80

Leu Glu Asp His Lys Trp Tyr Ser Cys Glu Asn Ser Phe Met Asp
85 90 95

Phe Ser Phe Asp Ser Asp Arg Ser Gl y Leu Leu Leu Lys Gl n Lys Val
100 105 110

Ser Asp Asp Ile Thr Tyr Val Ala Thr Ala Thr Leu Pro Asn Tyr Cys
115 120 125

Arg 130 Ala 130 Gly 130 Gly 130 Asn 130 Gly 130 Pro 135 Lys 135 Asp 135 Phe 135 Val 135 Cys 140 Glu 140 Gly 140 Val 140 Ala 140

Asp Ala Tyr Ile Thr Leu Val Thr Leu Pro Lys Ser Ser
Page 100

eol f-seql . txt

145

150

155

<210> 178
 <211> 174
 <212> PRT
 <213> Canis familiaris

<400> 178

Met Lys Thr Leu Leu Leu Thr Ile Gly Phe Ser Leu Ile Ala Ile Leu
 1 5 10 15

Gln Ala Gln Asp Thr Pro Ala Leu Gly Lys Asp Thr Val Ala Val Ser
 20 25 30

Gly Lys Trp Tyr Leu Lys Ala Met Thr Ala Asp Gln Glu Val Pro Glu
 35 40 45

Lys Pro Asp Ser Val Thr Pro Met Ile Leu Lys Ala Gln Lys Gly Gly
 50 55 60

Asn Leu Glu Ala Lys Ile Thr Met Leu Thr Asn Gly Gln Cys Gln Asn
 65 70 75 80

Ile Thr Val Val Leu His Lys Thr Ser Glu Pro Gly Lys Tyr Thr Ala
 85 90 95

Tyr Glu Gly Gln Arg Val Val Phe Ile Gln Pro Ser Pro Val Arg Asp
 100 105 110

His Tyr Ile Leu Tyr Cys Glu Gly Glu Leu His Gly Arg Gln Ile Arg
 115 120 125

Met Ala Lys Leu Leu Gly Arg Asp Pro Glu Gln Ser Gln Glu Ala Leu
 130 135 140

Gl u Asp Phe Arg Gl u Phe Ser Arg Ala Lys Gly Leu Asn Gln Gl u Ile
 145 150 155 160

Leu Gl u Leu Ala Gln Ser Gl u Thr Cys Ser Pro Gly Gly Gln
 165 170

<210> 179
 <211> 286
 <212> PRT
 <213> Triticum aestivum

<400> 179

Met Lys Thr Phe Leu Ile Leu Val Leu Leu Ala Ile Val Ala Thr Thr
 1 5 10 15

Ala Thr Thr Ala Val Arg Phe Pro Val Pro Gln Leu Gln Pro Gln Asn
 20 25 30

eol f-seql . txt

Pro Ser Glu Glu Glu Pro Glu Glu Val Pro Leu Val Glu Glu Glu
35 40 45

Glu Phe Leu Glu Glu Glu Pro Phe Pro Pro Glu Glu Pro Tyr Pro
50 55 60

Glu Pro Glu Pro Phe Pro Ser Glu Leu Pro Tyr Leu Glu Leu Glu Pro
65 70 75 80

Phe Pro Glu Pro Glu Leu Pro Tyr Ser Glu Pro Glu Pro Phe Arg Pro
85 90 95

Glu Glu Pro Tyr Pro Glu Pro Glu Tyr Ser Glu Pro Glu Glu
100 105 110

Pro Ile Ser Glu
115 120 125

Glu Glu Glu Glu Glu Ile Leu Glu Glu Ile Leu Glu Glu Glu Leu Ile
130 135 140

Pro Cys Met Asp Val Val Leu Glu Glu His Asn Ile Ala His Glu Arg
145 150 155 160

Ser Glu Val Leu Glu Glu Ser Thr Tyr Glu Leu Leu Glu Glu Leu Cys
165 170 175

Cys Glu His Leu Trp Glu Ile Pro Glu Glu Ser Glu Cys Glu Ala Ile
180 185 190

His Asn Val Val His Ala Ile Ile Leu His Glu Glu Glu Lys Glu Glu
195 200 205

Glu Glu Pro Ser Ser Glu Val Ser Phe Glu Glu Pro Leu Glu Glu Tyr
210 215 220

Pro Leu Glu Glu Glu Ser Phe Arg Pro Ser Glu Glu Asn Pro Glu Ala
225 230 235 240

Glu Glu Ser Val Glu Pro Glu Glu Leu Pro Glu Phe Glu Glu Ile Arg
245 250 255

Asn Leu Ala Leu Glu Thr Leu Pro Ala Met Cys Asn Val Tyr Ile Pro
260 265 270

Pro Tyr Cys Thr Ile Ala Pro Phe Glu Ile Phe Glu Thr Asn
275 280 285

<210> 180

<211> 491

<212> PRT

eol f-seql . txt

<213> Blattella germanica

<400> 180

Ala Ile Glu Phe Leu Asn Asn Ile His Asp Leu Leu Gly Ile Pro His
1 5 10 15

Ile Pro Val Thr Ala Arg Lys His His Arg Arg Gly Val Gly Ile Thr
20 25 30

Gly Leu Ile Asp Asp Ile Ile Ala Ile Leu Pro Val Asp Asp Leu Tyr
35 40 45

Ala Leu Phe Gln Glu Lys Leu Glu Thr Ser Pro Glu Phe Lys Ala Leu
50 55 60

Tyr Asp Ala Ile Arg Ser Pro Glu Phe Gln Ser Ile Val Gly Thr Leu
65 70 75 80

Gl u Ala Met Pro Glu Tyr Gln Asn Leu Ile Gln Lys Leu Lys Asp Lys
85 90 95

Gly Val Asp Val Asp His Ile Ile Glu Leu Ile His Gln Ile Phe Asn
100 105 110

Ile Val Arg Asp Thr Arg Gly Leu Pro Glu Asp Leu Gln Asp Phe Leu
115 120 125

Ala Leu Ile Pro Thr Asp Gln Val Leu Ala Ile Ala Ala Asp Tyr Leu
130 135 140

Ala Asn Asp Ala Glu Val Lys Ala Ala Val Glu Tyr Leu Lys Ser Asp
145 150 155 160

Gl u Phe Glu Thr Ile Val Val Thr Val Asp Ser Leu Pro Glu Phe Lys
165 170 175

Asn Phe Leu Asn Phe Leu Gln Thr Asn Gly Leu Asn Ala Ile Glu Phe
180 185 190

Leu Asn Asn Ile His Asp Leu Leu Gly Ile Pro His Ile Pro Val Thr
195 200 205

Ala Arg Lys His Leu Arg Arg Gly Val Gly Ile Thr Gly Leu Ile Asp
210 215 220

Asp Ile Ile Ala Ile Leu Pro Val Asp Asp Leu Tyr Ala Leu Phe Gln
225 230 235 240

Gl u Lys Leu Gl u Thr Ser Pro Gl u Phe Lys Ala Leu Tyr Asp Ala Ile
245 250 255

eol f-seql . txt

Arg Ser Pro Glu Phe Gln Ser Ile Val Glu Thr Leu Lys Ala Met Pro
260 265 270

Gl u Tyr Gl n Ser Leu Ile Gl n Lys Leu Lys Asp Lys Gl y Val Asp Val
275 280 285

Asp His Ile Ile Glu Leu Ile His Gl n Ile Phe Asn Ile Val Arg Asp
290 295 300

Thr Arg Gl y Leu Pro Gl u Asp Leu Gl n Asp Phe Leu Ala Leu Ile Pro
305 310 315 320

Ile Asp Gl n Ile Leu Ala Ile Ala Ala Asp Tyr Leu Ala Asn Asp Ala
325 330 335

Gl u Val Gl n Ala Ala Val Gl u Tyr Leu Lys Ser Asp Gl u Phe Gl u Thr
340 345 350

Ile Val Val Thr Val Asp Ser Leu Pro Gl u Phe Lys Asn Phe Leu Asn
355 360 365

Phe Leu Gl n Thr Asn Gl y Leu Asn Ala Ile Gl u Phe Ile Asn Asn Ile
370 375 380

His Asp Leu Leu Gl y Ile Pro His Ile Pro Ala Thr Gl y Arg Lys His
385 390 395 400

Val Arg Arg Gl y Val Gl y Ile Asn Gl y Leu Ile Asp Asp Val Ile Ala
405 410 415

Ile Leu Pro Val Asp Gl u Leu Tyr Ala Leu Phe Gl n Gl u Lys Leu Gl u
420 425 430

Ser Ser Pro Gl u Phe Lys Ala Leu Tyr Asp Ala Ile Arg Ser Pro Gl u
435 440 445

Phe Gl n Ser Ile Val Gl n Thr Leu Lys Ala Met Pro Gl u Tyr Gl n Asp
450 455 460

Leu Ile Gl n Arg Leu Lys Asp Lys Gl y Val Asp Val Asp His Phe Ile
465 470 475 480

Gl u Leu Ile Lys Lys Leu Phe Gl y Leu Ser His
485 490

<210> 181

<211> 160

<212> PRT

<213> Betula pendula (Betula verrucosa)

<400> 181

Met Gl y Val Phe Asn Tyr Gl u Thr Gl u Thr Thr Ser Val Ile Pro Ala

eol f-seql . txt

1

5

10

15

Ala Arg Leu Phe Lys Ala Phe Ile Leu Asp Gly Asp Asn Leu Phe Pro
 20 25 30

Lys Val Ala Pro Glu Ala Ile Ser Ser Val Glu Asn Ile Glu Gly Asn
 35 40 45

Gly Gly Pro Gly Thr Ile Lys Lys Ile Ser Phe Pro Glu Gly Phe Pro
 50 55 60

Phe Lys Tyr Val Lys Asp Arg Val Asp Glu Val Asp His Thr Asn Phe
 65 70 75 80

Lys Tyr Asn Tyr Ser Val Ile Glu Gly Gly Pro Ile Gly Asp Thr Leu
 85 90 95

Glu Lys Ile Ser Asn Glu Ile Lys Ile Val Ala Thr Pro Asp Gly Gly
 100 105 110

Ser Ile Leu Lys Ile Ser Asn Lys Tyr His Thr Lys Gly Asp His Glu
 115 120 125

Val Lys Ala Glu Glu Val Lys Ala Ser Lys Glu Met Gly Glu Thr Leu
 130 135 140

Leu Arg Ala Val Glu Ser Tyr Leu Leu Ala His Ser Asp Ala Tyr Asn
 145 150 155 160

<210> 182

<211> 160

<212> PRT

<213> Betula pendula (Betula verrucosa)

<400> 182

Met Gly Val Phe Asn Tyr Glu Thr Glu Ala Thr Ser Val Ile Pro Ala
 1 5 10 15

Ala Arg Met Phe Lys Ala Phe Ile Leu Asp Gly Asp Lys Leu Val Pro
 20 25 30

Lys Val Ala Pro Glu Ala Ile Ser Ser Val Glu Asn Ile Glu Gly Asn
 35 40 45

Gly Gly Pro Gly Thr Ile Lys Lys Ile Asn Phe Pro Glu Gly Phe Pro
 50 55 60

Phe Lys Tyr Val Lys Asp Arg Val Asp Glu Val Asp His Thr Asn Phe
 65 70 75 80

Lys Tyr Asn Tyr Ser Val Ile Glu Gly Gly Pro Val Gly Asp Thr Leu
 85 90 95

eol f-seql . txt

Gl u Lys Ile Ser Asn Gl u Ile Lys Ile Val Ala Thr Pro Asp Gl y Gl y
100 105 110

Cys Val Leu Lys Ile Ser Asn Lys Tyr His Thr Lys Gl y Asn His Gl u
115 120 125

Val Lys Ala Gl u Gl n Val Lys Ala Ser Lys Gl u Met Gl y Gl u Thr Leu
130 135 140

Leu Arg Ala Val Gl u Ser Tyr Leu Leu Ala His Ser Asp Ala Tyr Asn
145 150 155 160

<210> 183

<211> 133

<212> PRT

<213> Betula pendula (Betula verrucosa)

<400> 183

Met Ser Trp Gl n Thr Tyr Val Asp Gl u His Leu Met Cys Asp Ile Asp
1 5 10 15

Gl y Gl n Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gl y His Asp Gl y
20 25 30

Ser Val Trp Ala Gl n Ser Ser Phe Pro Gl n Phe Lys Pro Gl n Gl u
35 40 45

Ile Thr Gl y Ile Met Lys Asp Phe Gl u Gl u Pro Gl y His Leu Ala Pro
50 55 60

Thr Gl y Leu His Leu Gl y Gl y Ile Lys Tyr Met Val Ile Gl n Gl y Gl u
65 70 75 80

Al a Gl y Ala Val Ile Arg Gl y Lys Lys Gl y Ser Gl y Gl y Ile Thr Ile
85 90 95

Lys Lys Thr Gl y Gl n Ala Leu Val Phe Gl y Ile Tyr Gl u Gl u Pro Val
100 105 110

Thr Pro Gl y Gl n Cys Asn Met Val Val Gl u Arg Leu Gl y Asp Tyr Leu
115 120 125

Ile Asp Gl n Gl y Leu
130

<210> 184

<211> 263

<212> PRT

<213> Phleum pratense

<400> 184

eof f-seql.txt

Met Ala Ser Ser Ser Ser Val Leu Leu Val Val Val Leu Phe Ala Val
1 5 10 15

Phe Leu Gly Ser Ala Tyr Gly Ile Pro Lys Val Pro Pro Gly Pro Asn
20 25 30

Ile Thr Ala Thr Tyr Gly Asp Lys Trp Leu Asp Ala Lys Ser Thr Trp
35 40 45

Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys Asp Asn Gly Gly Ala Cys
50 55 60

Gly Tyr Lys Asp Val Asp Lys Pro Pro Phe Ser Gly Met Thr Gly Cys
65 70 75 80

Gly Asn Thr Pro Ile Phe Lys Ser Gly Arg Gly Cys Gly Ser Cys Phe
85 90 95

Gl u Ile Lys Cys Thr Lys Pro Gl u Ala Cys Ser Gly Gl u Pro Val Val
100 105 110

Val His Ile Thr Asp Asp Asn Gl u Gl u Pro Ile Ala Pro Tyr His Phe
115 120 125

Asp Leu Ser Gly His Ala Phe Gly Ala Met Ala Lys Lys Gly Asp Gl u
130 135 140

Gl n Lys Leu Arg Ser Ala Gl y Gl u Leu Gl u Leu Gl n Phe Arg Arg Val
145 150 155 160

Lys Cys Lys Tyr Pro Gl u Gl y Thr Lys Val Thr Phe His Val Gl u Lys
165 170 175

Gly Ser Asn Pro Asn Tyr Leu Ala Leu Leu Val Lys Tyr Val Asn Gly
180 185 190

Asp Gly Asp Val Val Ala Val Asp Ile Lys Gl u Lys Gl y Lys Asp Lys
195 200 205

Trp Ile Gl u Leu Lys Gl u Ser Trp Gl y Ala Ile Trp Arg Ile Asp Thr
210 215 220

Pro Asp Lys Leu Thr Gl y Pro Phe Thr Val Arg Tyr Thr Thr Gl u Gly
225 230 235 240

Gly Thr Lys Thr Gl u Ala Gl u Asp Val Ile Pro Gl u Gl y Trp Lys Ala
245 250 255

Asp Thr Ser Tyr Gl u Ser Lys
260

eol f-seql . txt

<210> 185
<211> 122
<212> PRT
<213> Phl eum pratense

<400> 185

Met Ser Met Ala Ser Ser Ser Ser Ser Leu Leu Ala Met Ala Val
1 5 10 15

Leu Ala Ala Leu Phe Ala Gly Ala Trp Cys Val Pro Lys Val Thr Phe
20 25 30

Thr Val Glu Lys Gly Ser Asn Glu Lys His Leu Ala Val Leu Val Lys
35 40 45

Tyr Glu Gly Asp Thr Met Ala Glu Val Glu Leu Arg Glu His Gly Ser
50 55 60

Asp Glu Trp Val Ala Met Thr Lys Gly Glu Gly Glu Val Trp Thr Phe
65 70 75 80

Asp Ser Glu Glu Pro Leu Glu Gly Pro Phe Asn Phe Arg Phe Leu Thr
85 90 95

Glu Lys Gly Met Lys Asn Val Phe Asp Asp Val Val Pro Glu Lys Tyr
100 105 110

Thr Ile Gly Ala Thr Tyr Ala Pro Glu Glu
115 120

<210> 186
<211> 159
<212> PRT
<213> Malus domestica

<400> 186

Met Gly Val Tyr Thr Phe Glu Asn Glu Phe Thr Ser Glu Ile Pro Pro
1 5 10 15

Ser Arg Leu Phe Lys Ala Phe Val Leu Asp Ala Asp Asn Leu Ile Pro
20 25 30

Lys Ile Ala Pro Glu Ala Ile Lys Glu Ala Glu Ile Leu Glu Gly Asn
35 40 45

Gly Gly Pro Gly Thr Ile Lys Lys Ile Thr Phe Gly Glu Gly Ser Glu
50 55 60

Tyr Glu Tyr Val Lys His Arg Ile Asp Ser Ile Asp Glu Ala Ser Tyr
65 70 75 80

Ser Tyr Ser Tyr Thr Leu Ile Glu Gly Asp Ala Leu Thr Asp Thr Ile
85 90 95

eol f-seql . txt

Gl u Lys Ile Ser Tyr Gl u Thr Lys Leu Val Ala Cys Gl y Ser Gl y Ser
100 105 110

Thr Ile Lys Ser Ile Ser His Tyr His Thr Lys Gl y Asn Ile Gl u Ile
115 120 125

Lys Gl u Gl u His Val Lys Val Gl y Lys Gl u Lys Ala His Gl y Leu Phe
130 135 140

Lys Leu Ile Gl u Ser Tyr Leu Lys Asp His Pro Asp Ala Tyr Asn
145 150 155

<210> 187

<211> 96

<212> PRT

<213> Dactylis glomerata

<400> 187

Val Lys Val Thr Phe Lys Val Gl u Lys Gl y Ser Asp Pro Lys Lys Leu
1 5 10 15

Val Leu Asp Ile Lys Tyr Thr Arg Pro Gl y Asp Thr Leu Ala Gl u Val
20 25 30

Gl u Leu Arg Gl n His Gl y Ser Gl u Gl u Trp Gl u Pro Leu Thr Lys Lys
35 40 45

Gl y Asn Leu Trp Gl u Val Lys Ser Ser Lys Pro Leu Thr Gl y Pro Phe
50 55 60

Asn Phe Arg Phe Met Ser Lys Gl y Gl y Met Arg Asn Val Phe Asp Gl u
65 70 75 80

Val Ile Pro Thr Ala Phe Lys Ile Gl y Thr Thr Tyr Thr Pro Gl u Gl u
85 90 95

<210> 188

<211> 269

<212> PRT

<213> Phalaris aquatica

<400> 188

Met Met Lys Met Val Cys Ser Ser Ser Ser Ser Leu Leu Val Val
1 5 10 15

Al a Al a Leu Leu Al a Val Phe Val Gl y Ser Al a Gl n Gl y Ile Al a Lys
20 25 30

Val Pro Pro Gl y Pro Asn Ile Thr Ala Gl u Tyr Gl y Asp Lys Trp Leu
35 40 45

eof f-seql.txt

Asp Ala Lys Ser Thr Trp Tyr Gly Lys Pro Thr Gly Ala Gly Pro Lys
50 55 60

Asp Asn Gly Gly Ala Cys Gly Tyr Lys Asp Val Asp Lys Ala Pro Phe
65 70 75 80

Asn Gly Met Thr Gly Cys Gly Asn Thr Pro Ile Phe Lys Asp Gly Arg
85 90 95

Gly Cys Gly Ser Cys Phe Glu Leu Lys Cys Ser Lys Pro Glu Ser Cys
100 105 110

Ser Gly Glu Pro Ile Thr Val His Ile Thr Asp Asp Asn Glu Glu Pro
115 120 125

Ile Ala Pro Tyr His Phe Asp Leu Ser Gly His Ala Phe Gly Ser Met
130 135 140

Ala Lys Lys Gly Glu Glu Glu Asn Val Arg Gly Ala Gly Glu Leu Glu
145 150 155 160

Leu Gln Phe Arg Arg Val Lys Cys Lys Tyr Pro Asp Gly Thr Lys Pro
165 170 175

Thr Phe His Val Glu Lys Gly Ser Asn Pro Asn Tyr Leu Ala Leu Leu
180 185 190

Val Lys Tyr Val Asp Gly Asp Gly Asp Val Val Ala Val Asp Ile Lys
195 200 205

Glu Lys Gly Lys Asp Lys Trp Ile Glu Leu Lys Glu Ser Trp Gly Ala
210 215 220

Ile Trp Arg Ile Asp Thr Pro Asp Lys Leu Thr Gly Pro Phe Thr Val
225 230 235 240

Arg Tyr Thr Thr Glu Gly Gly Thr Lys Ala Glu Phe Glu Asp Val Ile
245 250 255

Pro Glu Gly Trp Lys Ala Asp Thr His Asp Ala Ser Lys
260 265

<210> 189

<211> 246

<212> PRT

<213> Cynodon dactylon

<400> 189

Ala Ile Gly Asp Lys Pro Gly Pro Asn Ile Thr Ala Thr Tyr Gly Ser
1 5 10 15

Lys Trp Leu Glu Ala Arg Ala Thr Phe Tyr Gly Ser Asn Pro Arg Gly
Page 110

eol f-seql . txt

20

25

30

Al a Al a Pro Asp Asp His Gl y Gl y Al a Cys Gl y Tyr Lys Asp Val Asp
 35 40 45

Lys Pro Pro Phe Asp Gl y Met Thr Al a Cys Gl y Asn Gl u Pro Ile Phe
 50 55 60

Lys Asp Gl y Leu Gl y Cys Arg Al a Cys Tyr Gl u Ile Lys Cys Lys Gl u
 65 70 75 80

Pro Val Gl u Cys Ser Gl y Gl u Pro Val Leu Val Lys Ile Thr Asp Lys
 85 90 95

Asn Tyr Gl u His Ile Al a Al a Tyr His Phe Asp Leu Ser Gl y Lys Al a
 100 105 110

Phe Gl y Al a Met Al a Lys Lys Gl y Gl n Gl u Asp Lys Leu Arg Lys Al a
 115 120 125

Gl y Gl u Leu Thr Leu Gl n Phe Arg Arg Val Lys Cys Lys Tyr Pro Ser
 130 135 140

Gl y Thr Lys Ile Thr Phe His Ile Gl u Lys Gl y Ser Asn Asp His Tyr
 145 150 155 160

Leu Al a Leu Leu Val Lys Tyr Al a Al a Gl y Asp Gl y Asn Ile Val Al a
 165 170 175

Val Asp Ile Lys Pro Arg Asp Ser Asp Gl u Phe Ile Pro Met Lys Ser
 180 185 190

Ser Trp Gl y Al a Ile Trp Arg Ile Asp Pro Lys Lys Pro Leu Lys Gl y
 195 200 205

Pro Phe Ser Ile Arg Leu Thr Ser Gl u Gl y Gl y Al a His Leu Val Gl n
 210 215 220

Asp Asp Val Ile Pro Al a Asn Trp Lys Pro Asp Thr Val Tyr Thr Ser
 225 230 235 240

Lys Leu Gl n Phe Gl y Al a
 245

<210> 190

<211> 214

<212> PRT

<213> Bos pri mi geni us

<400> 190

Met Lys Leu Leu Ile Leu Thr Cys Leu Val Al a Val Al a Leu Al a Arg
 1 5 10 15

eol f-seql . txt

Pro Lys His Pro Ile Lys His Glu Glu Leu Pro Glu Glu Val Leu Asn
20 25 30

Gl u Asn Leu Leu Arg Phe Phe Val Ala Pro Phe Pro Glu Val Phe Gl y
35 40 45

Lys Gl u Lys Val Asn Gl u Leu Ser Lys Asp Ile Gl y Ser Gl u Ser Thr
50 55 60

Gl u Asp Gl n Ala Met Gl u Asp Ile Lys Gl n Met Gl u Ala Gl u Ser Ile
65 70 75 80

Ser Ser Ser Gl u Gl u Ile Val Pro Asn Ser Val Gl u Gl n Lys His Ile
85 90 95

Gl n Lys Gl u Asp Val Pro Ser Gl u Arg Tyr Leu Gl y Tyr Leu Gl u Gl n
100 105 110

Leu Leu Arg Leu Lys Lys Tyr Lys Val Pro Gl n Leu Gl u Ile Val Pro
115 120 125

Asn Ser Ala Gl u Gl u Arg Leu His Ser Met Lys Gl u Gl y Ile His Ala
130 135 140

Gl n Gl n Lys Gl u Pro Met Ile Gl y Val Asn Gl n Gl u Leu Ala Tyr Phe
145 150 155 160

Tyr Pro Gl u Leu Phe Arg Gl n Phe Tyr Gl n Leu Asp Ala Tyr Pro Ser
165 170 175

Gl y Ala Trp Tyr Tyr Val Pro Leu Gl y Thr Gl n Tyr Thr Asp Ala Pro
180 185 190

Ser Phe Ser Asp Ile Pro Asn Pro Ile Gl y Ser Gl u Asn Ser Gl u Lys
195 200 205

Thr Thr Met Pro Leu Trp
210

<210> 191

<211> 142

<212> PRT

<213> Bos primigenius

<400> 191

Met Met Ser Phe Val Ser Leu Leu Leu Val Gl y Ile Leu Phe His Ala
1 5 10 15

Thr Gl n Ala Gl u Gl n Leu Thr Lys Cys Gl u Val Phe Arg Gl u Leu Lys
20 25 30

eol f-seql . txt

Asp Leu Lys Gl y Tyr Gl y Gl y Val Ser Leu Pro Gl u Trp Val Cys Thr
35 40 45

Thr Phe His Thr Ser Gl y Tyr Asp Thr Gl n Ala Ile Val Gl n Asn Asn
50 55 60

Asp Ser Thr Gl u Tyr Gl y Leu Phe Gl n Ile Asn Asn Lys Ile Trp Cys
65 70 75 80

Lys Asp Asp Gl n Asn Pro His Ser Ser Asn Ile Cys Asn Ile Ser Cys
85 90 95

Asp Lys Phe Leu Asp Asp Asp Leu Thr Asp Asp Ile Met Cys Val Lys
100 105 110

Lys Ile Leu Asp Lys Val Gl y Ile Asn Tyr Trp Leu Ala His Lys Ala
115 120 125

Leu Cys Ser Gl u Lys Leu Asp Gl n Trp Leu Cys Gl u Lys Leu
130 135 140

<210> 192

<211> 386

<212> PRT

<213> Gal Ius gal Ius

<400> 192

Met Gl y Ser Ile Gl y Ala Ala Ser Met Gl u Phe Cys Phe Asp Val Phe
1 5 10 15

Lys Gl u Leu Lys Val His His Ala Asn Gl u Asn Ile Phe Tyr Cys Pro
20 25 30

Ile Ala Ile Met Ser Ala Leu Ala Met Val Tyr Leu Gl y Ala Lys Asp
35 40 45

Ser Thr Arg Thr Gl n Ile Asn Lys Val Val Arg Phe Asp Lys Leu Pro
50 55 60

Gl y Phe Gl y Asp Ser Ile Gl u Ala Gl n Cys Gl y Thr Ser Val Asn Val
65 70 75 80

His Ser Ser Leu Arg Asp Ile Leu Asn Gl n Ile Thr Lys Pro Asn Asp
85 90 95

Val Tyr Ser Phe Ser Leu Ala Ser Arg Leu Tyr Ala Gl u Gl u Arg Tyr
100 105 110

Pro Ile Leu Pro Gl u Tyr Leu Gl n Cys Val Lys Gl u Leu Tyr Arg Gl y
115 120 125

eol f-seql . txt

Gly Leu Glu Pro Ile Asn Phe Gln Thr Ala Ala Asp Gln Ala Arg Glu
130 135 140

Leu Ile Asn Ser Trp Val Glu Ser Gln Thr Asn Gly Ile Ile Arg Asn
145 150 155 160

Val Leu Gln Pro Ser Ser Val Asp Ser Gln Thr Ala Met Val Leu Val
165 170 175

Asn Ala Ile Val Phe Lys Gly Leu Trp Glu Lys Ala Phe Lys Asp Glu
180 185 190

Asp Thr Gln Ala Met Pro Phe Arg Val Thr Glu Gln Glu Ser Lys Pro
195 200 205

Val Gln Met Met Tyr Gln Ile Gly Leu Phe Arg Val Ala Ser Met Ala
210 215 220

Ser Glu Lys Met Lys Ile Leu Glu Leu Pro Phe Ala Ser Gly Thr Met
225 230 235 240

Ser Met Leu Val Leu Leu Pro Asp Glu Val Ser Gly Leu Glu Gln Leu
245 250 255

Gl u Ser Ile Ile Asn Phe Glu Lys Leu Thr Glu Trp Thr Ser Ser Asn
260 265 270

Val Met Glu Glu Arg Lys Ile Lys Val Tyr Leu Pro Arg Met Lys Met
275 280 285

Gl u Glu Lys Tyr Asn Leu Thr Ser Val Leu Met Ala Met Gly Ile Thr
290 295 300

Asp Val Phe Ser Ser Ser Ala Asn Leu Ser Gly Ile Ser Ser Ala Glu
305 310 315 320

Ser Leu Lys Ile Ser Gln Ala Val His Ala Ala His Ala Glu Ile Asn
325 330 335

Gl u Ala Gly Arg Glu Val Val Gly Ser Ala Glu Ala Gly Val Asp Ala
340 345 350

Ala Ser Val Ser Glu Glu Phe Arg Ala Asp His Pro Phe Leu Phe Cys
355 360 365

Ile Lys His Ile Ala Thr Asn Ala Val Leu Phe Phe Gly Arg Cys Val
370 375 380

Ser Pro
385

eol f-seql . txt

<210> 193
<211> 147
<212> PRT
<213> Gallus gallus

<400> 193

Met Arg Ser Leu Leu Ile Leu Val Leu Cys Phe Leu Pro Leu Ala Ala
1 5 10 15

Leu Glu Lys Val Phe Gly Arg Cys Glu Leu Ala Ala Ala Met Lys Arg
20 25 30

His Glu Leu Asp Asn Tyr Arg Gly Tyr Ser Leu Glu Asn Trp Val Cys
35 40 45

Ala Ala Lys Phe Glu Ser Asn Phe Asn Thr Glu Ala Thr Asn Arg Asn
50 55 60

Thr Asp Glu Ser Thr Asp Tyr Gly Ile Leu Glu Ile Asn Ser Arg Trp
65 70 75 80

Trp Cys Asn Asp Glu Arg Thr Pro Glu Ser Arg Asn Leu Cys Asn Ile
85 90 95

Pro Cys Ser Ala Leu Leu Ser Ser Asp Ile Thr Ala Ser Val Asn Cys
100 105 110

Ala Lys Lys Ile Val Ser Asp Glu Asn Gly Met Asn Ala Trp Val Ala
115 120 125

Trp Arg Asn Arg Cys Lys Glu Thr Asp Val Glu Ala Trp Ile Arg Glu
130 135 140

Cys Arg Leu
145

<210> 194
<211> 187
<212> PRT
<213> Equus caballus

<400> 194

Met Lys Leu Leu Leu Cys Leu Glu Leu Ile Leu Val Cys Ala Glu
1 5 10 15

Glu Glu Glu Asn Ser Asp Val Ala Ile Arg Asn Phe Asp Ile Ser Lys
20 25 30

Ile Ser Glu Glu Trp Tyr Ser Ile Phe Leu Ala Ser Asp Val Lys Glu
35 40 45

Lys Ile Glu Glu Asn Glu Ser Met Arg Val Phe Val Asp Val Ile Arg
50 55 60

eol f-seql . txt

Ala Leu Asp Asn Ser Ser Leu Tyr Ala Glu Tyr Glu Thr Lys Val Asn
65 70 75 80

Gl y Gl u Cys Thr Gl u Phe Pro Met Val Phe Asp Lys Thr Gl u Gl u Asp
85 90 95

Gl y Val Tyr Ser Leu Asn Tyr Asp Gl y Tyr Asn Val Phe Arg Ile Ser
100 105 110

Gl u Phe Gl u Asn Asp Gl u His Ile Ile Leu Tyr Leu Val Asn Phe Asp
115 120 125

Lys Asp Arg Pro Phe Gl n Leu Phe Gl u Phe Tyr Ala Arg Gl u Pro Asp
130 135 140

Val Ser Pro Gl u Ile Lys Gl u Gl u Phe Val Lys Ile Val Gl n Lys Arg
145 150 155 160

Gl y Ile Val Lys Gl u Asn Ile Ile Asp Leu Thr Lys Ile Asp Arg Cys
165 170 175

Phe Gl n Leu Arg Gl y Asn Gl y Val Ala Gl n Ala
180 185

<210> 195

<211> 228

<212> PRT

<213> Equus caballus

<400> 195

Met Leu Lys Val Ser Cys Leu Phe Val Leu Leu Cys Gl y Leu Leu Val
1 5 10 15

Pro Ser Ser Ala Gl n Gl n Ile Pro Pro Gl u Val Ser Ser Gl n Ile Thr
20 25 30

Asp Ala Leu Thr Gl n Gl y Leu Leu Asp Gl y Asn Phe Leu Ser Leu Leu
35 40 45

Asn Ala Ile Asn Leu Gl u Gl y Leu Leu Asn Thr Ile Leu Asp Gl n Val
50 55 60

Thr Gl y Leu Leu Asn Ile Leu Val Gl y Pro Leu Leu Gl y Pro Ser Asp
65 70 75 80

Ala Gl u Ile Lys Leu Gl n Asp Thr Arg Leu Leu Gl n Leu Ser Leu Gl u
85 90 95

Phe Ser Pro Asp Ser Lys Gl y Ile Asp Ile Trp Ile Pro Leu Gl u Leu
100 105 110

eol f-seql . txt

Ser Val Tyr Leu Lys Leu Leu Ile Leu Glu Pro Leu Thr Leu Tyr Val
115 120 125

Arg Thr Asp Ile Arg Val Glu Leu Arg Leu Glu Ser Asp Glu Asp Glu
130 135 140

Lys Tyr Arg Leu Ala Phe Glu His Cys Ser Leu Leu Pro Arg Ala Ile
145 150 155 160

Gl u Leu Glu Ser Glu Asn Pro Leu Ser Leu Pro Val Asn Ala Val Leu
165 170 175

Gl y Thr Ile Glu Asn Ala Leu Glu Asn Phe Ile Thr Glu Asp Leu Glu
180 185 190

Ala Glu Leu Cys Pro Thr Leu Asn Ser Leu Val Ser Asn Leu Asp Leu
195 200 205

Gl n Leu Val Asn Asn Leu Ile Asn Leu Ile Leu Asp Arg Ala Asn Val
210 215 220

Asp Leu Ser Val
225

<210> 196
<211> 558
<212> DNA
<213> Nucl eotide sequence encoding the B-CD3(VL) - FLAG-Bi rA-U266Ant-6His

<400> 196
atgaaatacc tgctgccgac cgctgctgct ggtctgctgc tcctcgctgc ccagccggcg 60
atggccgaca ttcagctgac ccagtctcca gcaatcatgt ctgcacatctcc aggggagaag 120
gtcaccatga cctgcagagc cagttcaagt gtaagttaca tgaactggta ccagcagaag 180
tcaggcacct cccccaataag atggatttat gacacatcca aagtggcttc tggagtcct 240
tatcgcttca gtggcagtgg gtctgggacc tcatactctc tcacaatcag cagcatggag 300
gctgaagatg ctgccactta ttactgcca cagtggagta gtaacccgct cacgttcgg 360
gctgggacca agctggagct gaaatccgga ggtggatccgactacaa ggtgacgat 420
gacaaaggcg gcggcctgaa cgtatttttt gaagcgcaga aaattgaatg gcatctgagc 480
ccgcatctgc tgtggatct gtttcgcgtg ggcctgccgg ggcggcggg cggcgccat 540
catcaccatc atcattag 558

<210> 197
<211> 185
<212> PRT
<213> the B-CD3(VL) - FLAG-Bi rA-U266Ant-6His

<400> 197

Met Lys Tyr Leu Leu Pro Thr Ala Ala Ala Glu Leu Leu Leu Leu Ala
Page 117

eol f-seql . txt

1

5

10

15

Ala Glu Pro Ala Met Ala Asp Ile Glu Leu Thr Glu Ser Pro Ala Ile
 20 25 30

Met Ser Ala Ser Pro Gly Glu Lys Val Thr Met Thr Cys Arg Ala Ser
 35 40 45

Ser Ser Val Ser Tyr Met Asn Trp Tyr Glu Glu Lys Ser Gly Thr Ser
 50 55 60

Pro Lys Arg Trp Ile Tyr Asp Thr Ser Lys Val Ala Ser Gly Val Pro
 65 70 75 80

Tyr Arg Phe Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile
 85 90 95

Ser Ser Met Glu Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Glu Glu Trp
 100 105 110

Ser Ser Asn Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
 115 120 125

Ser Gly Gly Gly Ser Asp Tyr Lys Asp Asp Asp Lys Gly Gly
 130 135 140

Gly Leu Asn Asp Ile Phe Glu Ala Glu Lys Ile Glu Trp His Leu Ser
 145 150 155 160

Pro His Leu Leu Trp Asp Leu Phe Arg Val Gly Leu Pro Gly Ala Ala
 165 170 175

Gly Gly Gly His His His His His
 180 185

<210> 198

<211> 18

<212> PRT

<213> Alternative linker

<400> 198

Gly Glu Gly Thr Ser Thr Gly Ser Gly Gly Ser Gly Ser Gly Gly
 1 5 10 15

Ala Asp